-DOCSTART- -X- O O

Eltrombopag NNP N
for IN N
management NN N
of IN N
chronic JJ 4_p
immune NN 4_p
thrombocytopenia NN 4_p
RAISE NNP N
a DT N
6-month JJ N
randomised VBN N
phase VB N
3 CD N
study NN N
BACKGROUND NNP N
Eltrombopag NNP N
is VBZ N
an DT N
oral JJ N
thrombopoietin NN N
receptor NN N
agonist NN N
for IN N
the DT N
treatment NN N
of IN N
thrombocytopenia NN N
We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
response NN N
to TO N
once RB N
daily JJ N
eltrombopag NNS N
versus VBP N
placebo NN N
in IN N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
immune JJ 4_p
thrombocytopenia NN 4_p
during IN N
a DT N
6-month JJ N
period NN N
METHODS NNP N
We PRP N
undertook VBD N
a DT N
phase NN N
3 CD N
double-blind NN N
placebo-controlled JJ N
study NN N
in IN N
adults NNS 1_p
with IN N
previously RB 4_p
treated VBN 4_p
immune JJ 4_p
thrombocytopenia NN 4_p
of IN 4_p
more JJR 4_p
than IN 4_p
6 CD 4_p
months NNS 4_p
duration NN 4_p
who WP N
had VBD N
baseline NN 4_p
platelet NN 4_p
counts VBZ 4_p
lower JJR 4_p
than IN 4_p
30,000 CD 4_p
per IN 4_p
μL NN 4_p
Patients NNS N
were VBD N
randomly RB N
allocated VBN N
in IN N
a DT N
2:1 CD N
ratio NN N
treatment NN N
with IN N
local JJ N
standard NN N
of IN N
care NN N
plus CC N
50 CD N
mg NN N
eltrombopag NN N
or CC N
matching VBG N
placebo JJ N
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
Randomisation NN N
was VBD N
done VBN N
centrally RB N
with IN N
a DT N
computer-generated JJ N
randomisation NN N
schedule NN N
and CC N
was VBD N
stratified VBN N
by IN N
baseline JJ N
platelet NN N
count NN N
≤ JJ N
15,000 CD N
per IN N
μL NN N
use NN N
of IN N
treatment NN N
for IN N
immune JJ N
thrombocytopenia NN N
and CC N
splenectomy JJ N
status NN N
Patients NNS N
investigators NNS N
and CC N
those DT N
assessing VBG N
data NNS N
were VBD N
masked VBN N
to TO N
allocation NN N
Dose JJ N
modifications NNS N
were VBD N
made VBN N
on IN N
the DT N
basis NN N
of IN N
platelet NN N
response NN N
Patients NNS N
were VBD N
assessed VBN N
for IN N
response NN N
to TO N
treatment NN N
defined VBN N
as IN N
a DT N
platelet NN N
count NN N
of IN N
50,000-400,000 CD N
per IN N
μL NN N
weekly NN N
during IN N
the DT N
first JJ N
6 CD N
weeks NNS N
and CC N
at IN N
least JJS N
once RB N
every DT N
4 CD N
weeks NNS N
thereafter RB N
the DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
odds NNS N
of IN N
response NN N
to TO N
eltrombopag VB N
versus NN N
placebo NN N
Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
This DT N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
number NN N
NCT00370331 NNP N
FINDINGS NNP N
Between NNP N
Nov NNP N
22 CD N
2006 CD N
and CC N
July NNP N
31 CD N
2007 CD N
197 CD 3_p
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
groups NNS N
and CC N
were VBD N
included VBN N
in IN N
the DT N
intention-to-treat JJ N
analysis NN N
135 CD N
eltrombopag NN N
62 CD N
placebo NN N
106 CD N
79 CD N
patients NNS N
in IN N
the DT N
eltrombopag NN N
group NN N
responded VBD N
to TO N
treatment NN N
at IN N
least JJS N
once RB N
during IN N
the DT N
study NN N
compared VBN N
with IN N
17 CD N
28 CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
The DT N
odds NNS N
of IN N
responding VBG N
were VBD N
greater JJR N
in IN N
patients NNS N
in IN N
the DT N
eltrombopag NN N
group NN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
throughout IN N
the DT N
6-month JJ N
treatment NN N
period NN N
odds NNS N
ratio VBP N
8·2 CD N
99 CD N
CI NNP N
3·59-18·73 CD N
p CC N
0·0001 CD N
37 CD N
59 CD N
patients NNS N
receiving VBG N
eltrombopag NN N
reduced VBD N
concomitant JJ N
treatment NN N
versus NN N
ten NN N
32 CD N
patients NNS N
receiving VBG N
placebo NN N
p=0·016 NN N
24 CD N
18 CD N
patients NNS N
receiving VBG N
eltrombopag NN N
needed VBN N
rescue NN N
treatment NN N
compared VBN N
with IN N
25 CD N
40 CD N
patients NNS N
receiving VBG N
placebo NN N
p=0·001 NN N
Three NNP N
2 CD N
patients NNS N
receiving VBG N
eltrombopag NN N
had VBD N
thromboembolic JJ N
events NNS N
compared VBN N
with IN N
none NN N
in IN N
patients NNS N
on IN N
placebo NN N
Nine NNP N
7 CD N
eltrombopag-treated JJ N
patients NNS N
and CC N
two CD N
3 CD N
in IN N
the DT N
placebo NN N
group NN N
had VBD N
mild VBN N
increases NNS N
in IN N
alanine JJ N
aminotransferase NN N
concentration NN N
and CC N
five CD N
4 CD N
eltrombopag-treated JJ N
patients NNS N
vs IN N
none NN N
allocated VBN N
to TO N
placebo VB N
had VBD N
increases NNS N
in IN N
total JJ N
bilirubin NN N
Four CD N
7 CD N
patients NNS N
taking VBG N
placebo NN N
had VBD N
serious JJ N
bleeding VBG N
events NNS N
compared VBN N
with IN N
one CD N
1 CD N
patient NN N
treated VBN N
with IN N
eltrombopag NN N
INTERPRETATION NNP N
Eltrombopag NNP N
is VBZ N
effective JJ N
for IN N
management NN N
of IN N
chronic JJ N
immune NN N
thrombocytopenia NN N
and CC N
could MD N
be VB N
particularly RB N
beneficial JJ N
for IN N
patients NNS N
who WP N
have VBP N
not RB N
responded VBN N
to TO N
splenectomy VB N
or CC N
previous JJ N
treatment NN N
These DT N
benefits NNS N
should MD N
be VB N
balanced VBN N
with IN N
the DT N
potential JJ N
risks NNS N
associated VBN N
with IN N
eltrombopag JJ N
treatment NN N
FUNDING NN N
GlaxoSmithKline NNP N
-DOCSTART- -X- O O

To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
nifedipine NN N
sustained VBN N
release NN N
with IN N
Ginkgo NNP N
biloba NN N
extract NN N
to TO N
treat VB N
patients NNS 4_p
with IN 4_p
primary JJ 4_p
Raynaud NNP 4_p
's POS 4_p
phenomenon NN 4_p
in IN 4_p
South NNP 4_p
Korea NNP 4_p
Korean NNP N
Raynaud NNP N
study NN N
KOARA NNP N
study NN N
This DT N
study NN N
examined VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
nifedipine NN N
sustained VBN N
release NN N
nifedipine JJ N
SR NNP N
compared VBN N
with IN N
Ginkgo NNP N
biloba NN N
extract NN N
as IN N
treatment NN N
for IN N
primary JJ N
Raynaud NNP N
's POS N
phenomenon NN N
RP NNP N
in IN N
Korea NNP N
Primary NNP N
RP NNP N
were VBD N
screened VBN N
and CC N
assigned VBN N
to TO N
either CC N
the DT N
nifedipine JJ N
SR NNP N
group NN N
Group NNP N
N NNP N
or CC N
the DT N
Ginkgo NNP N
biloba NN N
extract NN N
group NN N
Group NNP N
G NNP N
in IN N
the DT N
ratio NN N
of IN N
2:1 CD N
After IN N
a DT N
run-in JJ N
period NN N
of IN N
2 CD N
weeks NNS N
patients NNS N
received VBD N
treatment NN N
for IN N
8 CD N
weeks NNS N
We PRP N
observed VBD N
the DT N
percent NN N
improvement NN N
of IN N
the DT N
RP NNP N
attack NN N
rate NN N
between IN N
before IN N
and CC N
after IN N
the DT N
8-week JJ N
treatment NN N
Ninety-three JJ 3_p
subjects NNS 3_p
were VBD N
randomly RB N
assigned VBN N
The DT N
percent NN N
improvement NN N
in IN N
Group NNP N
N NNP N
was VBD N
50.1 CD N
at IN N
8 CD N
weeks NNS N
after IN N
treatment NN N
while IN N
it PRP N
was VBD N
31.0 CD N
in IN N
Group NNP N
G NNP N
p JJ N
0.03 CD N
No DT N
serious JJ N
adverse JJ N
events NNS N
occurred VBD N
and CC N
almost RB N
adverse JJ N
events NNS N
were VBD N
mild JJ N
and CC N
improved VBN N
without IN N
specific JJ N
treatment NN N
nifedipine JJ N
SR NNP N
was VBD N
more RBR N
effective JJ N
than IN N
Ginkgo NNP N
biloba NN N
extract NN N
for IN N
treatment NN N
of IN N
primary JJ N
RP NNP N
in IN N
Korean JJ 4_p
patients NNS 4_p
Both DT N
drugs NNS N
were VBD N
tolerable JJ N
with IN N
primary JJ N
RP NNP 4_p
patients NNS 4_p
-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
a DT N
social JJ N
skills NNS N
training VBG N
for IN N
preadolescent JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
generalization NN N
of IN N
skills NNS N
by IN N
training VBG N
parents NNS N
and CC N
teachers NNS N
BACKGROUND NNP N
Social NNP N
skills NNS N
training VBG N
SST NNP N
is VBZ N
a DT N
common JJ N
intervention NN N
for IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
ASDs NNP 4_p
to TO N
improve VB N
their PRP$ N
social JJ N
and CC N
communication NN N
skills NNS N
Despite IN N
the DT N
fact NN N
that IN N
SSTs NNP N
are VBP N
often RB N
applied VBN N
in IN N
clinical JJ N
practice NN N
the DT N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
these DT N
trainings NNS N
for IN N
children NNS 4_p
with IN 4_p
ASD NNP 4_p
is VBZ N
inconclusive JJ N
Moreover RB N
long JJ N
term NN N
outcome NN N
and CC N
generalization NN N
of IN N
learned JJ N
skills NNS N
are VBP N
little JJ N
evaluated JJ N
Additionally RB N
there EX N
is VBZ N
no DT N
research NN N
on IN N
the DT N
influence NN N
of IN N
involvement NN N
of IN N
parents NNS N
and CC N
teachers NNS N
on IN N
effectiveness NN N
of IN N
SST NNP N
and CC N
on IN N
the DT N
generalization NN N
of IN N
learned VBN N
social JJ N
skills NNS N
to TO N
daily JJ N
life NN N
We PRP N
expect VBP N
parent NN N
and CC N
teacher NN N
involvement NN N
in IN N
SST NNP N
to TO N
enhance VB N
treatment NN N
efficacy NN N
and CC N
to TO N
facilitate VB N
generalization NN N
of IN N
learned JJ N
skills NNS N
to TO N
daily JJ N
life NN N
METHOD/DESIGN NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
RCT NNP N
with IN N
three CD N
conditions NNS N
120 CD 3_p
participants NNS 4_p
with IN 4_p
ASD NNP 4_p
at IN 4_p
the DT 4_p
end NN 4_p
of IN 4_p
primary JJ 4_p
school NN 4_p
10-12 CD 1_p
years NNS 1_p
of IN 1_p
calendar NN 1_p
age NN 1_p
have VBP N
been VBN N
randomized VBN N
to TO N
SST NNP N
SST-PTI NNP N
SST NNP N
with IN N
Parent NNP N
Teacher NNP N
Involvement NNP N
or CC N
care-as-usual JJ N
The DT N
SST NNP N
consists VBZ N
of IN N
18 CD N
group NN N
sessions NNS N
of IN N
1.5 CD N
hours NNS N
for IN N
the DT N
children NNS N
In IN N
the DT N
SST-PTI JJ N
condition NN N
parents NNS N
additionally RB N
participate VBP N
in IN N
8 CD N
parent NN N
sessions NNS N
and CC N
parents NNS N
and CC N
teachers NNS N
are VBP N
actively RB N
involved VBN N
in IN N
homework NN N
assignments NNS N
Assessment NNP N
takes VBZ N
place NN N
at IN N
three CD N
moments NNS N
before RB N
and CC N
immediately RB N
after IN N
the DT N
intervention NN N
period NN N
and CC N
at IN N
6 CD N
months NNS N
follow-up RB N
Primary JJ N
outcome NN N
is VBZ N
socialization NN N
as IN N
an DT N
aspect NN N
of IN N
adaptive JJ N
functioning NN N
Secondary JJ N
outcomes NNS N
focus VBP N
on IN N
specific JJ N
social JJ N
skills NNS N
children NNS N
learn VBP N
during IN N
SST NNP N
and CC N
on IN N
more JJR N
general JJ N
social JJ N
skills NNS N
pertaining VBG N
to TO N
home NN N
and CC N
community NN N
settings NNS N
from IN N
a DT N
multi-informant JJ N
perspective NN N
Additionally RB N
possible JJ N
predictors NNS N
of IN N
treatment NN N
outcome NN N
will MD N
be VB N
assessed VBN N
DISCUSSION VB N
The DT N
current JJ N
study NN N
is VBZ N
an DT N
RCT NNP N
study NN N
evaluating VBG N
SST NNP N
in IN N
a DT N
large JJ N
sample NN N
of IN N
Dutch NNP 4_p
children NNS 1_p
with IN 4_p
ASD NNP 4_p
in IN 4_p
a DT 4_p
specific JJ 1_p
age NN 1_p
range NN 1_p
10-12 CD 1_p
years NNS 1_p
Strengths NNP N
of IN N
the DT N
study NN N
are VBP N
the DT N
use NN N
of IN N
one CD N
manualized VBN N
protocol NN N
application NN N
of IN N
standardized JJ N
and CC N
internationally RB N
used VBD N
rating NN N
instruments NNS N
use NN N
of IN N
multiple JJ N
raters NNS N
investigation NN N
of IN N
generalization NN N
of IN N
learned JJ N
skills NNS N
to TO N
daily JJ N
life NN N
and CC N
the DT N
evaluation NN N
of IN N
efficacy NN N
in IN N
the DT N
longer JJR N
term NN N
by IN N
follow-up JJ N
measures NNS N
at IN N
6 CD N
months NNS N
after IN N
the DT N
end NN N
of IN N
training NN N
TRIAL NNP N
REGISTRATION NNP N
NTR2405 NNP N
-DOCSTART- -X- O O

Language NNP N
outcome NN N
in IN N
autism NN 4_p
randomized JJ N
comparison NN N
of IN N
joint JJ N
attention NN N
and CC N
play NN N
interventions NNS N
This DT N
study NN N
reports VBZ N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
aimed VBN N
at IN N
joint JJ N
attention NN N
JA NNP N
and CC N
symbolic JJ N
play NN N
SP NNP N
in IN N
preschool NN 1_p
children NNS 1_p
with IN 4_p
autism NN 4_p
with IN N
prediction NN N
to TO N
language NN N
outcome RB N
12 CD N
months NNS N
later RB N
Participants NNS N
were VBD N
58 CD 3_p
children NNS 1_p
46 CD 3_p
boys NNS N
with IN N
autism NN 4_p
between IN 1_p
3 CD 1_p
and CC 1_p
4 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
Children NNP N
were VBD N
randomized VBN N
to TO N
a DT N
JA NNP N
intervention NN N
an DT N
SP NNP N
intervention NN N
or CC N
control NN N
group NN N
Interventions NNS N
were VBD N
conducted VBN N
30 CD N
min JJ N
daily JJ N
for IN N
5-6 JJ N
weeks NNS N
Assessments NNS N
of IN N
JA NNP N
skills NNS N
SP NNP N
skills NNS N
mother-child JJ N
interactions NNS N
and CC N
language NN N
development NN N
were VBD N
collected VBN N
at IN N
4 CD N
time NN N
points NNS N
pre- NN N
and CC N
postintervention NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
postintervention NN N
by IN N
independent JJ N
testers NNS N
Results NNS N
indicate VBP N
that IN N
expressive JJ N
language NN N
gains NNS N
were VBD N
greater JJR N
for IN N
both DT N
treatment NN N
groups NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
results NNS N
could MD N
not RB N
be VB N
explained VBN N
by IN N
differences NNS N
in IN N
other JJ N
interventions NNS N
in IN N
which WDT N
children NNS N
participated VBD N
For IN N
children NNS N
beginning VBG N
treatment NN N
with IN N
the DT N
lowest JJS N
language NN N
levels NNS N
the DT N
JA NNP N
intervention NN N
improved VBD N
language NN N
outcome NN N
significantly RB N
more RBR N
than IN N
did VBD N
the DT N
SP NNP N
or CC N
control VB N
interventions NNS N
These DT N
findings NNS N
suggest VBP N
clinically RB N
significant JJ N
benefits NNS N
of IN N
actively RB N
treating VBG N
JA NNP N
and CC N
SP NNP N
skills NNS N
in IN N
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
-DOCSTART- -X- O O

Intermediate-term JJ N
mortality NN N
and CC N
cardiac JJ N
transplantation NN N
in IN N
infants NNS 1_p
with IN N
single-ventricle JJ 4_p
lesions NNS 4_p
risk NN N
factors NNS N
and CC N
their PRP$ N
interaction NN N
with IN N
shunt NN N
type NN N
OBJECTIVE CC N
The DT N
study NN N
objective NN N
was VBD N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
death NN N
and CC N
cardiac JJ N
transplantation NN N
in IN N
infants NNS 1_p
undergoing VBG 4_p
the DT 4_p
Norwood NNP 4_p
procedure NN 4_p
and CC N
to TO N
determine VB N
differences NNS N
in IN N
associations NNS N
that WDT N
might MD N
favor VB N
the DT N
modified JJ N
Blalock-Taussig NNP N
shunt NN N
or CC N
a DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
METHODS NNP N
We PRP N
used VBD N
competing VBG N
risks NNS N
methodology NN N
to TO N
analyze VB N
death NN N
without IN N
transplantation NN N
cardiac JJ N
transplantation NN N
and CC N
survival NN N
without IN N
transplantation NN N
Parametric NNP N
time-to-event JJ N
modeling NN N
and CC N
bootstrapping NN N
were VBD N
used VBN N
to TO N
identify VB N
independent JJ N
predictors NNS N
RESULTS NNP N
Data NNP N
from IN N
549 CD 3_p
subjects NNS N
follow-up JJ N
2.7 CD N
± JJ N
0.9 CD N
years NNS N
were VBD N
analyzed VBN N
Mortality NNP N
risk NN N
was VBD N
characterized VBN N
by IN N
early JJ N
and CC N
constant JJ N
phases NNS N
transplant NN N
was VBD N
characterized VBN N
by IN N
only RB N
a DT N
constant JJ N
phase NN N
Early JJ N
phase NN N
factors NNS N
associated VBN N
with IN N
death NN N
included VBD N
lower JJR N
socioeconomic JJ N
status NN N
P NNP N
.01 NNP N
obstructed VBD N
pulmonary JJ N
venous JJ N
return NN N
P NNP N
.001 NNP N
smaller JJR N
ascending VBG N
aorta NN N
P NNP N
.02 NNP N
and CC N
anatomic JJ N
subtype NN N
Constant JJ N
phase NN N
factors NNS N
associated VBN N
with IN N
death NN N
included VBD N
genetic JJ N
syndrome NN N
P NNP N
.001 NNP N
and CC N
lower JJR N
gestational JJ N
age NN N
P NNP N
.001 NNP N
The DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
demonstrated VBD N
better JJR N
survival NN N
in IN N
the DT N
51 CD N
of IN N
subjects NNS N
who WP N
were VBD N
full JJ N
term NN N
with IN N
aortic JJ N
atresia NN N
P NNP N
.001 NNP N
The DT N
modified JJ N
Blalock-Taussig NNP N
shunt NN N
was VBD N
better RBR N
among IN N
the DT N
4 CD N
of IN N
subjects NNS N
who WP N
were VBD N
preterm VBN N
with IN N
a DT N
patent NN N
aortic JJ N
valve NN N
P NNP N
.003 NNP N
Lower JJR N
pre-Norwood NN N
right JJ N
ventricular JJ N
fractional JJ N
area NN N
change NN N
pre-Norwood NN N
surgery NN N
and CC N
anatomy VBZ N
other JJ N
than IN N
hypoplastic JJ N
left JJ N
heart NN N
syndrome NN N
were VBD N
independently RB N
associated VBN N
with IN N
transplantation NN N
all DT N
P NNP N
.03 NNP N
but CC N
shunt NN N
type NN N
was VBD N
not RB N
P NNP N
.43 NNP N
CONCLUSIONS NNP N
Independent NNP N
risk NN N
factors NNS N
for IN N
intermediate-term JJ N
mortality NN N
include VBP N
lower JJR N
socioeconomic JJ N
status NN N
anatomy RB N
genetic JJ N
syndrome NN N
and CC N
lower JJR N
gestational JJ N
age NN N
Term JJ N
infants NNS N
with IN N
aortic JJ N
atresia NN N
benefited VBD N
from IN N
a DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
and CC N
preterm JJ N
infants NNS N
with IN N
a DT N
patent NN N
aortic JJ N
valve NN N
benefited VBD N
from IN N
a DT N
modified VBN N
Blalock-Taussig NNP N
shunt NN N
Right NNP N
ventricular JJ N
function NN N
and CC N
anatomy NN N
but CC N
not RB N
shunt VB N
type NN N
were VBD N
associated VBN N
with IN N
transplantation NN N
-DOCSTART- -X- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
acupuncture NN N
versus NN N
sham JJ N
acupuncture NN N
in IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
OBJECTIVE IN N
We PRP N
aim VBP N
to TO N
study VB N
the DT N
efficacy NN N
of IN N
acupuncture NN N
versus NN N
sham JJ N
acupuncture NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
METHODS VB N
A DT N
single-blind JJ N
randomized VBN N
control NN N
trial NN N
was VBD N
conducted VBN N
in IN N
50 CD 3_p
children NNS 1_p
These DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
group NN N
with IN N
tongue JJ N
acupuncture NN N
40 CD N
sessions NNS N
over IN N
8 CD N
weeks NNS N
or CC N
the DT N
control NN N
group NN N
sham JJ N
tongue NN N
acupuncture NN N
to TO N
nonacupoints NNS N
in IN N
the DT N
tongue NN N
RESULTS NNP N
There EX N
was VBD N
improvement NN N
in IN N
both CC N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
in IN N
all DT N
assessed JJ N
measures NNS N
but CC N
more JJR N
so RB N
in IN N
the DT N
treatment NN N
than IN N
in IN N
the DT N
control NN N
group NN N
1 CD N
eye-hand NN N
coordination NN N
performance NN N
and CC N
practical JJ N
reasoning NN N
of IN N
Griffiths NNP N
Mental NNP N
Developmental NNP N
Scale NNP N
2 CD N
sensory-motor NN N
social JJ N
affectual JJ N
language NN N
and CC N
total JJ N
score NN N
of IN N
Ritvo-Freeman NNP N
Real NNP N
Life NNP N
Scale NNP N
3 CD N
Comprehension NN N
Language NNP N
age NN N
in IN N
the DT N
Reynell NNP N
Language NNP N
Developmental NNP N
Scale NNP N
and CC N
4 CD N
Total NN N
Score NNP N
and CC N
Mental NNP N
Age NNP N
in IN N
Symbolic NNP N
Play NNP N
Test NNP N
The DT N
only JJ N
statistically RB N
significant JJ N
improvement NN N
in IN N
the DT N
treatment NN N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
was VBD N
seen VBN N
in IN N
self-care JJ N
and CC N
cognition NN N
domains NNS N
of IN N
the DT N
Functional NNP N
Independence NNP N
Measure NN N
for IN N
children NNS N
CONCLUSIONS NNP N
We PRP N
had VBD N
demonstrated VBN N
that IN N
a DT N
short JJ N
course NN N
of IN N
acupuncture NN N
had VBD N
efficacy NN N
in IN N
improving VBG N
various JJ N
developmental JJ N
and CC N
behavioral JJ N
aspects NNS N
of IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
The DT N
long-term JJ N
efficacy NN N
in IN N
functional JJ N
gain NN N
needs NNS N
to TO N
be VB N
further RB N
explored VBN N
-DOCSTART- -X- O O

Effects NNS N
of IN N
soy JJ N
intake NN N
on IN N
sex NN N
hormone NN N
metabolism NN N
in IN N
premenopausal JJ 4_p
women NNS 2_p
Studies NNS N
suggest VBP N
that IN N
phytoestrogens NNS N
in IN N
soy JJ N
products NNS N
may MD N
impart VB N
hormonal JJ N
effects NNS N
that WDT N
protect VBP N
women NNS N
against IN N
breast NN N
cancer NN N
Limited VBN N
research NN N
suggests VBZ N
that IN N
intake NN N
of IN N
soy NN N
products NNS N
high JJ N
in IN N
isoflavonoid JJ N
phytoestrogens NNS N
affects VBZ N
sex NN N
hormone NN N
metabolism NN N
but CC N
it PRP N
is VBZ N
unknown JJ N
whether IN N
phytoestrogens NNS N
in IN N
soy NNS N
have VBP N
any DT N
effect NN N
on IN N
menstrual JJ N
function NN N
or CC N
serum VB N
sex NN N
hormones NNS N
in IN N
women NNS N
on IN N
common JJ N
hormone NN N
therapies NNS N
such JJ N
as IN N
oral JJ N
contraceptives NNS N
OC NNP N
We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
soy NN N
in IN N
36 CD 3_p
premenopausal JJ 4_p
women NNS 2_p
20 CD 3_p
of IN N
whom WP N
used VBD 4_p
OC NNP 4_p
Subjects NNS N
consumed VBD N
their PRP$ N
normal JJ N
diet NNS N
for IN N
two CD N
menstrual JJ N
cycles NNS N
and CC N
added VBD N
a DT N
soy JJ N
beverage NN N
containing VBG N
20 CD N
g NN N
of IN N
protein NN N
and CC N
38 CD N
mg NN N
of IN N
total JJ N
isoflavones NNS N
to TO N
their PRP$ N
usual JJ N
diet NN N
for IN N
another DT N
two CD N
menstrual JJ N
cycles NNS N
No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
serum NN N
estrone NN N
estradiol NN N
sex NN N
hormone-binding JJ N
globulin NN N
dehydroepiandrosterone NN N
sulfate NN N
prolactin NN N
or CC N
progesterone NN N
concentrations NNS N
with IN N
soy JJ N
feeding NN N
in IN N
the DT N
non-OC JJ N
or CC N
the DT N
OC NNP N
group NN N
No DT N
changes NNS N
in IN N
menstrual JJ N
cycle NN N
length NN N
or CC N
the DT N
urinary JJ N
estrogen NN N
metabolite NNS N
ratio NN N
of IN N
2-hydroxyestrone CD N
to TO N
16 CD N
alpha-hydroxyestrone NN N
were VBD N
seen VBN N
with IN N
soy JJ N
feeding NN N
in IN N
the DT N
non-OC JJ N
or CC N
the DT N
OC NNP N
group NN N
Levels NNP N
of IN N
urinary JJ N
estrogen NN N
metabolites NNS N
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
non-OC JJ N
and CC N
the DT N
OC NNP N
group NN N
Thus RB N
soy JJ N
consumption NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
menstrual JJ N
cycle NN N
serum JJ N
sex NN N
hormones NNS N
or CC N
urinary JJ N
estrogen NN N
metabolite NN N
ratio NN N
in IN N
premenopausal NN 4_p
OC NNP 4_p
or CC N
non-OC JJ 4_p
users NNS 4_p
-DOCSTART- -X- O O

Teaching VBG N
emotion NN N
recognition NN N
skills NNS N
to TO N
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
an DT N
emotion NN N
training NN N
programme NN N
BACKGROUND NNP N
Children NNP N
with IN N
autism NN N
have VBP N
difficulties NNS N
in IN N
emotion NN N
recognition NN N
and CC N
a DT N
number NN N
of IN N
interventions NNS N
have VBP N
been VBN N
designed VBN N
to TO N
target VB N
these DT N
problems NNS N
However RB N
few JJ N
emotion NN N
training NN N
interventions NNS N
have VBP N
been VBN N
trialled VBN N
with IN N
young JJ N
children NNS N
with IN N
autism NN N
and CC N
co-morbid JJ N
ID NNP N
This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
an DT N
emotion NN N
training NN N
programme NN N
for IN N
a DT N
group NN N
of IN N
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
with IN 4_p
a DT 4_p
range NN 4_p
of IN 4_p
intellectual JJ 4_p
ability NN 4_p
METHODS NNP N
Participants NNPS N
were VBD N
55 CD 3_p
children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
aged VBN 1_p
4-7 CD 1_p
years NNS 1_p
FSIQ NNP N
42-107 CD N
Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
n JJ N
28 CD N
or CC N
control VB N
group NN N
n JJ N
27 CD N
Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
watched VBD N
a DT N
DVD NNP N
designed VBN N
to TO N
teach VB N
emotion NN N
recognition NN N
skills NNS N
to TO N
children NNS N
with IN N
autism NN N
the DT N
Transporters NNPS N
whereas IN N
the DT N
control NN N
group NN N
watched VBD N
a DT N
DVD NNP N
of IN N
Thomas NNP N
the DT N
Tank NNP N
Engine NNP N
Participants NNS N
were VBD N
assessed VBN N
on IN N
their PRP$ N
ability NN N
to TO N
complete VB N
basic JJ N
emotion NN N
recognition NN N
tasks NNS N
mindreading VBG N
and CC N
theory NN N
of IN N
mind NN N
TOM NNP N
tasks NNS N
before IN N
and CC N
after IN N
the DT N
4-week JJ N
intervention NN N
period NN N
and CC N
at IN N
3-month JJ N
follow-up NN N
RESULTS NNP N
Analyses NNP N
controlled VBD N
for IN N
the DT N
effect NN N
of IN N
chronological JJ N
age NN N
verbal JJ N
intelligence NN N
gender NN N
and CC N
DVD NNP N
viewing VBG N
time NN N
on IN N
outcomes NNS N
Children NNP N
in IN N
the DT N
intervention NN N
group NN N
showed VBD N
improved JJ N
performance NN N
in IN N
the DT N
recognition NN N
of IN N
anger NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
with IN N
few JJ N
improvements NNS N
maintained VBD N
at IN N
3-month JJ N
follow-up NN N
There EX N
was VBD N
no DT N
generalisation NN N
of IN N
skills NNS N
to TO N
TOM NNP N
or CC N
social JJ N
skills NNS N
CONCLUSIONS VB N
The DT N
Transporters NNP N
programme NN N
showed VBD N
limited JJ N
efficacy NN N
in IN N
teaching VBG N
basic JJ N
emotion NN N
recognition NN N
skills NNS N
to TO N
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
with IN N
a DT N
lower JJR N
range NN N
of IN N
cognitive JJ N
ability NN N
Improvements NNS N
were VBD N
limited VBN N
to TO N
the DT N
recognition NN N
of IN N
expressions NNS N
of IN N
anger NN N
with IN N
poor JJ N
maintenance NN N
of IN N
these DT N
skills NNS N
at IN N
follow-up NN N
These DT N
findings NNS N
provide VBP N
limited JJ N
support NN N
for IN N
the DT N
efficacy NN N
of IN N
the DT N
Transporters NNP N
programme NN N
for IN N
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
of IN N
a DT N
lower JJR N
cognitive JJ N
range NN N
-DOCSTART- -X- O O

Raising VBG N
high-density NN N
lipoprotein NN N
in IN N
humans NNS N
through IN N
inhibition NN N
of IN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
an DT N
initial JJ N
multidose NN N
study NN N
of IN N
torcetrapib NN N
OBJECTIVE CC N
The DT N
ability NN N
of IN N
the DT N
potent NN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
CETP NNP N
inhibitor NN N
torcetrapib NN N
CP-529,414 NNP N
to TO N
raise VB N
high-density NN N
lipoprotein NN N
cholesterol NN N
HDL-C NNP N
levels NNS N
in IN N
healthy JJ 4_p
young JJ 1_p
subjects NNS N
was VBD N
tested VBN N
in IN N
this DT N
initial JJ N
phase NN N
1 CD N
multidose NN N
study NN N
METHODS NNP N
AND CC N
RESULTS NNP N
Five NNP 3_p
groups NNS 3_p
of IN 3_p
8 CD 3_p
subjects NNS 3_p
each DT 3_p
were VBD N
randomized VBN N
to TO N
placebo VB N
n=2 NN N
or CC N
torcetrapib NN N
n=6 JJ N
at IN N
10 CD N
30 CD N
60 CD N
and CC N
120 CD N
mg NNS N
daily RB N
and CC N
120 CD N
mg NN N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
Torcetrapib NN N
was VBD N
well RB N
tolerated VBN N
with IN N
all DT N
treated JJ N
subjects NNS N
completing VBG N
the DT N
study NN N
The DT N
correlation NN N
of IN N
plasma JJ N
drug NN N
levels NNS N
with IN N
inhibition NN N
EC50=43 NNP N
nM RB N
was VBD N
as IN N
expected VBN N
based VBN N
on IN N
in IN N
vitro JJ N
potency NN N
IC50 NNP N
approximately RB N
50 CD N
nM NNS N
and CC N
increases VBZ N
in IN N
CETP NNP N
mass NN N
were VBD N
consistent JJ N
with IN N
the DT N
proposed VBN N
mechanism NN N
of IN N
inhibition NN N
CETP NNP N
inhibition NN N
increased VBD N
with IN N
escalating VBG N
dose NN N
leading VBG N
to TO N
elevations NNS N
of IN N
HDL-C NNP N
of IN N
16 CD N
to TO N
91 CD N
Total JJ N
plasma JJ N
cholesterol NN N
did VBD N
not RB N
change VB N
significantly RB N
because IN N
of IN N
a DT N
reduction NN N
in IN N
nonHDL-C JJ N
including VBG N
a DT N
21 CD N
to TO N
42 CD N
lowering NN N
of IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
at IN N
the DT N
higher JJR N
doses NNS N
Apolipoprotein NNP N
A-I NNP N
and CC N
E NNP N
were VBD N
elevated VBN N
27 CD N
and CC N
66 CD N
respectively RB N
and CC N
apoB NN N
was VBD N
reduced VBN N
26 CD N
with IN N
120 CD N
mg NNS N
twice RB N
daily RB N
Cholesteryl NNP N
ester NN N
content NN N
decreased VBN N
and CC N
triglyceride VB N
increased VBN N
in IN N
the DT N
nonHDL JJ N
plasma NN N
fraction NN N
with IN N
contrasting VBG N
changes NNS N
occurring VBG N
in IN N
HDL NNP N
CONCLUSIONS NNP N
These DT N
effects NNS N
of IN N
CETP NNP N
inhibition NN N
resemble VBP N
those DT N
observed VBN N
in IN N
partial JJ N
CETP NNP N
deficiency NN N
This DT N
work NN N
serves VBZ N
as IN N
a DT N
prelude NN N
to TO N
further JJ N
studies NNS N
in IN N
subjects NNS N
with IN N
low JJ N
HDL NNP N
or CC N
combinations NNS N
of IN N
dyslipidemia NN N
in IN N
assessing VBG N
the DT N
role NN N
of IN N
CETP NNP N
in IN N
atherosclerosis NN N
-DOCSTART- -X- O O

Necessary NNP N
but CC N
not RB N
sufficient JJ N
the DT N
effect NN N
of IN N
screening NN N
and CC N
feedback NN N
on IN N
outcomes NNS N
of IN N
primary JJ 4_p
care NN 4_p
patients NNS 4_p
with IN 4_p
untreated JJ 4_p
anxiety NN 4_p
OBJECTIVE UH N
To TO N
consider VB N
the DT N
impact NN N
on IN N
primary JJ N
care NN N
patient JJ N
outcomes NNS N
of IN N
using VBG N
both DT N
a DT N
screener NN N
to TO N
determine VB N
elevated VBN N
anxiety NN N
levels NNS N
among IN N
patients NNS 4_p
with IN 4_p
previously RB 4_p
undetected VBN 4_p
anxiety NN 4_p
and CC N
a DT N
physician JJ N
intervention NN N
to TO N
inform VB N
physicians NNS N
of IN N
their PRP$ N
patients NNS N
conditions NNS N
DESIGN NNP N
Participating VBG N
physicians NNS N
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
demonstration NN N
or CC N
the DT N
control NN N
arm NN N
and CC N
patients NNS N
were VBD N
assigned VBN N
to TO N
a DT N
study NN N
arm NN N
based VBN N
on IN N
the DT N
randomization NN N
of IN N
their PRP$ N
physicians NNS N
The DT N
patients NNS N
were VBD N
followed VBN N
for IN N
change NN N
in IN N
outcome JJ N
measures NNS N
during IN N
the DT N
five-month JJ N
study NN N
period NN N
SETTING VB N
A DT N
mixed-model JJ N
health NN N
maintenance NN N
organization NN N
serving VBG N
approximately RB N
110,000 CD N
enrollees NNS N
in IN N
central JJ N
Colorado NNP N
PATIENTS/PARTICIPANTS NNP N
573 CD 3_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
unrecognized VBN 4_p
and CC 4_p
untreated JJ 4_p
anxiety NN 4_p
identified VBN N
from IN N
the DT N
approximately RB N
8,000 CD N
patients NNS N
who WP N
completed VBD N
the DT N
waiting VBG N
room NN N
screening NN N
questionnaire NN N
INTERVENTIONS VBZ N
A DT N
physician JJ N
intervention NN N
served VBD N
the DT N
dual JJ N
function NN N
of IN N
1 CD N
providing VBG N
an DT N
educational JJ N
demonstration NN N
of IN N
anxiety NN N
in IN N
the DT N
primary JJ N
care NN N
setting VBG N
and CC N
2 CD N
providing VBG N
a DT N
reporting NN N
system NN N
for IN N
summarizing VBG N
the DT N
anxiety NN N
symptom NN N
levels NNS N
and CC N
functioning VBG N
status NN N
of IN N
the DT N
patients NNS N
enrolled VBN N
in IN N
the DT N
study NN N
MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Patient NNP N
outcomes NNS N
were VBD N
measured VBN N
as IN N
changes NNS N
in IN N
global JJ N
anxiety NN N
scores NNS N
functioning VBG N
and CC N
well-being JJ N
and CC N
patients NNS N
reports NNS N
of IN N
global JJ N
improvements NNS N
CONCLUSIONS VB N
The DT N
findings NNS N
indicate VBP N
that IN N
this DT N
method NN N
of IN N
reporting VBG N
symptoms NNS N
and CC N
functioning VBG N
status NN N
to TO N
primary VB N
care NN N
physicians NNS N
did VBD N
not RB N
significantly RB N
change VBP N
patient JJ N
outcomes NNS N
Improvement NN N
in IN N
outcomes NNS N
appeared VBD N
to TO N
be VB N
more RBR N
closely RB N
associated VBN N
with IN N
the DT N
patient NN N
's POS N
severity NN N
of IN N
psychological JJ N
distress NN N
-DOCSTART- -X- O O

Once-daily RB N
amoxicillin JJ N
versus IN N
twice-daily JJ N
penicillin NN N
V NNP N
in IN N
group NN N
A NNP N
beta-haemolytic JJ 4_p
streptococcal JJ 4_p
pharyngitis NN 4_p
BACKGROUND NNP N
Rheumatic NNP N
fever NN N
is VBZ N
a DT N
preventable JJ N
chronic JJ N
disease NN N
preceded VBN N
by IN N
group NN N
A NNP N
beta-haemolytic JJ N
streptococcal NN N
GABHS NNP N
pharyngitis NN N
OBJECTIVE UH N
To TO N
test VB N
the DT N
non-inferiority NN N
of IN N
once-daily JJ N
QD NNP N
oral JJ N
amoxicillin NN N
to TO N
the DT N
recommended VBN N
twice-daily RB N
BID NNP N
oral JJ N
penicillin NN N
V NNP N
in IN N
GABHS NNP N
pharyngitis NN N
METHODS NNP N
This DT N
was VBD N
a DT N
randomised JJ N
non-inferiority JJ N
trial NN N
carried VBD N
out RP N
in IN N
a DT N
school-based JJ 4_p
clinic NN 4_p
in IN 4_p
New NNP 4_p
Zealand NNP 4_p
Children NNP 1_p
presenting VBG N
with IN N
GABHS NNP 4_p
pharyngitis NN 4_p
were VBD N
randomised VBN N
to TO N
oral JJ N
amoxicillin NN N
1500 CD N
mg NN N
QD NNP N
or CC N
750 CD N
mg NN N
if IN N
bodyweight VBN N
was VBD N
or=30 JJ N
kg NN N
or CC N
to TO N
oral JJ N
penicillin NN N
V NNP N
500 CD N
mg NN N
BID NNP N
or CC N
250 CD N
mg NN N
if IN N
bodyweight VBN N
was VBD N
or=20 JJ N
kg NN N
for IN N
10 CD N
days NNS N
Observed VBN N
medication NN N
and CC N
weekend NN N
diary JJ N
cards NNS N
were VBD N
used VBN N
to TO N
monitor VB N
adherence NN N
OUTCOME NNP N
Eradication NNP N
of IN N
GABHS NNP N
determined VBD N
with IN N
follow-up JJ N
throat NN N
cultures NNS N
on IN N
days NNS N
3-6 CD N
12-16 CD N
and CC N
26-36 JJ N
GABHS NNP N
isolates NNS N
were VBD N
serotyped VBN N
to TO N
distinguish VB N
bacteriological JJ N
treatment NN N
failures NNS N
and CC N
relapses NNS N
from IN N
new JJ N
acquisitions NNS N
Non-inferiority NN N
was VBD N
defined VBN N
as IN N
an DT N
upper JJ N
95 CD N
confidence NN N
limit NN N
CL NNP N
for IN N
the DT N
difference NN N
in IN N
success NN N
of IN N
eradication NN N
in IN N
the DT N
amoxicillin NN N
and CC N
penicillin NN N
V NNP N
treatment NN N
groups NNS N
of IN N
or=10 FW N
RESULTS CC N
353 CD 3_p
children NNS 4_p
with IN 4_p
positive JJ 4_p
throat NN 4_p
swabs NN 4_p
for IN 4_p
GABHS NNP 4_p
were VBD N
randomised VBN N
to TO N
amoxicillin VB N
n JJ N
177 CD N
or CC N
penicillin JJ N
V NNP N
n JJ N
176 CD N
The DT N
upper JJ N
95 CD N
CL NNP N
for IN N
the DT N
differences NNS N
in IN N
positive JJ N
cultures NNS N
between IN N
the DT N
antibiotics NNS N
was VBD N
4.9 CD N
at IN N
days NNS N
3-6 CD N
6.5 CD N
at IN N
days NNS N
12-16 CD N
and CC N
8.5 CD N
at IN N
days NNS N
26-36 JJ N
Treatment NN N
failures NNS N
including VBG N
relapses NNS N
occurred VBD N
at IN N
each DT N
visit NN N
in IN N
5.8 CD N
12.7 CD N
and CC N
10.7 CD N
of IN N
amoxicillin NN N
recipients NNS N
and CC N
6.2 CD N
11.9 CD N
and CC N
11.3 CD N
of IN N
penicillin NN N
V NNP N
recipients NNS N
respectively RB N
No UH N
significant JJ N
differences NNS N
in IN N
resolution NN N
of IN N
symptoms NNS N
were VBD N
noted VBN N
between IN N
treatment NN N
groups NNS N
One CD N
case NN N
of IN N
unsubstantiated JJ N
acute JJ N
rheumatic JJ N
fever NN N
occurred VBD N
after IN N
7 CD N
days NNS N
of IN N
amoxicillin NN N
CONCLUSION NN N
In IN N
this DT N
adequately RB N
powered VBN N
study NN N
once-daily JJ N
oral JJ N
amoxicillin NN N
is VBZ N
not RB N
inferior JJ N
to TO N
twice-daily JJ N
penicillin NN N
V NNP N
for IN N
the DT N
treatment NN N
and CC N
eradication NN N
of IN N
GABHS NNP 4_p
in IN 4_p
children NNS 4_p
with IN 4_p
pharyngitis NN 4_p
-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
sevoflurane NN N
and CC N
isoflurane NN N
on IN N
recovery NN N
from IN N
outpatient JJ 4_p
surgery NN 4_p
This DT N
randomized JJ N
open-label JJ N
study NN N
compared VBN N
the DT N
investigational JJ N
inhalational JJ N
anesthetic JJ N
sevoflurane NN N
with IN N
isoflurane NN N
in IN N
47 CD 3_p
healthy JJ 4_p
women NNS 2_p
undergoing VBG 4_p
elective JJ 4_p
ambulatory NN 4_p
surgery NN 4_p
The DT N
women NNS 2_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
sevoflurane NN N
or CC N
isoflurane NN N
in IN N
60 CD N
nitrous JJ N
oxide-oxygen NN N
Induction NN N
with IN N
thiopental JJ N
3-6 JJ N
mg/kg NN N
was VBD N
followed VBN N
by IN N
vecuronium NN N
0.1 CD N
mg/kg NN N
and CC N
fentanyl JJ N
0-200 JJ N
micrograms NNS N
Duration NN N
of IN N
anesthesia NN N
time NN N
to TO N
emergence VB N
orientation NN N
length NN N
of IN N
stay NN N
in IN N
the DT N
surgical JJ N
unit NN N
and CC N
hospital JJ N
discharge NN N
were VBD N
recorded VBN N
The DT N
emergence NN N
length NN N
of IN N
stay NN N
and CC N
discharge NN N
times NNS N
after IN N
discontinuation NN N
of IN N
sevoflurane NN N
were VBD N
9.7 CD N
+/- JJ N
0.7 CD N
120.6 CD N
+/- JJ N
8.0 CD N
and CC N
244 CD N
+/- JJ N
15 CD N
minutes NNS N
respectively RB N
and CC N
for IN N
isoflurane NN N
were VBD N
11.9 CD N
+/- JJ N
1.4 CD N
106.8 CD N
+/- JJ N
7.1 CD N
and CC N
282 CD N
+/- JJ N
24 CD N
minutes NNS N
respectively RB N
NS NNP N
The DT N
isoflurane NN N
group NN N
had VBD N
a DT N
higher JJR N
frequency NN N
of IN N
postoperative JJ N
cough NN N
At IN N
the DT N
end NN N
of IN N
surgery NN N
the DT N
sevoflurane NN N
group NN N
received VBD N
a DT N
deeper JJR N
level NN N
of IN N
anesthesia NN N
minimum JJ N
alveolar JJ N
concentration NN N
1.5 CD N
vs NN N
1.3 CD N
however RB N
these DT N
patients NNS N
were VBD N
oriented VBN N
earlier RB N
13.6 CD N
+/- JJ N
1.1 CD N
min NN N
vs NN N
17.0 CD N
+/- JJ N
1.5 CD N
min NN N
isoflurane NN N
p CC N
0.02 CD N
after IN N
discontinuation NN N
of IN N
anesthesia NN N
although IN N
this DT N
difference NN N
is VBZ N
of IN N
little JJ N
clinical JJ N
significance NN N
-DOCSTART- -X- O O

Goal NNP N
attainment NN N
scaling NN N
as IN N
an DT N
outcome NN N
measure NN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
psychosocial JJ N
interventions NNS N
in IN N
autism NN 4_p
Goal NNP N
attainment JJ N
scaling NN N
GAS NNP N
holds VBZ N
promise NN N
as IN N
an DT N
idiographic JJ N
approach NN N
for IN N
measuring VBG N
outcomes NNS N
of IN N
psychosocial JJ N
interventions NNS N
in IN N
community NN N
settings NNS N
GAS NNP N
has VBZ N
been VBN N
criticized VBN N
for IN N
untested JJ N
assumptions NNS N
of IN N
scaling VBG N
level NN N
i.e. JJ N
interval JJ N
or CC N
ordinal JJ N
inter-individual JJ N
equivalence NN N
and CC N
comparability NN N
and CC N
reliability NN N
of IN N
coding VBG N
across IN N
different JJ N
behavioral JJ N
observation NN N
methods NNS N
We PRP N
tested VBD N
assumptions NNS N
of IN N
equality NN N
between IN N
GAS NNP N
descriptions NNS N
for IN N
outcome JJ N
measurement NN N
in IN N
a DT N
randomized JJ N
trial NN N
i.e. FW N
measurability NN N
equidistance NN N
level NN N
of IN N
difficulty NN N
comparability NN N
of IN N
behavior NN N
samples NNS N
collected VBN N
from IN N
teachers NNS N
vs. FW N
researchers NNS N
and CC N
live JJ N
vs. FW N
videotape NN N
Results NNP N
suggest VBP N
GAS NNP N
descriptions NNS N
can MD N
be VB N
evaluated VBN N
for IN N
equivalency NN N
that IN N
teacher RB N
collected VBN N
behavior NN N
samples NNS N
are VBP N
representative JJ N
and CC N
that IN N
varied JJ N
sources NNS N
of IN N
behavior NN N
samples NNS N
can MD N
be VB N
reliably RB N
coded VBN N
GAS NNP N
is VBZ N
a DT N
promising JJ N
measurement NN N
approach NN N
Recommendations NNS N
are VBP N
provided VBN N
to TO N
ensure VB N
methodological JJ N
quality NN N
-DOCSTART- -X- O O

Reduced VBN N
platelet NN N
thromboxane NN N
formation NN N
after IN N
long-term JJ N
administration NN N
of IN N
a DT N
dihydropyridine JJ N
calcium NN N
channel NN N
blocker NN N
a DT N
prospective JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
with IN N
nitrendipine NN N
in IN N
borderline JJ 4_p
hypertensive JJ 4_p
patients NNS 4_p
with IN 4_p
IDDM-type NNP 4_p
diabetes NNS 4_p
mellitus NN 4_p
Twenty-nine JJ 3_p
IDDM NNP 4_p
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
hypertension NN 4_p
were VBD N
randomly RB N
allocated VBN N
to TO N
placebo VB N
or CC N
nitrendipine VB N
treatment NN N
Nitrendipine NNP N
was VBD N
given VBN N
orally RB N
at IN N
a DT N
dosage NN N
of IN N
20 CD N
mg NNS N
once RB N
daily RB N
over IN N
4 CD N
weeks NNS N
Stimulated VBN N
platelet NN N
thromboxane NN N
formation NN N
at IN N
rest NN N
and CC N
after IN N
standardized VBN N
non JJ N
exhausting VBG N
exercise NN N
was VBD N
measured VBN N
by IN N
standard JJ N
methods NNS N
In IN N
addition NN N
plasma NN N
levels NNS N
of IN N
platelet NN N
factor NN N
4 CD N
and CC N
aggregation NN N
responses NNS N
to TO N
collagen VB N
and CC N
ADP NNP N
were VBD N
determined VBN N
In IN N
the DT N
treatment NN N
group NN N
thromboxane NN N
formation NN N
after IN N
stimulation NN N
with IN N
collagen NN N
0.3 CD N
and CC N
1.0 CD N
micrograms/ml NN N
and CC N
1 CD N
mM NN N
arachidonic JJ N
acid NN N
AA NNP N
was VBD N
reduced VBN N
in IN N
the DT N
resting NN N
state NN N
Exercise NN N
induced JJ N
change NN N
of IN N
thromboxane NN N
synthesis NN N
in IN N
response NN N
to TO N
1.0 CD N
micrograms/ml NNS N
collagen NN N
was VBD N
significantly RB N
lower JJR N
as IN N
compared VBN N
to TO N
placebo VB N
p JJ N
0.05 CD N
In IN N
parallel JJ N
PF4 NNP N
plasma NN N
levels NNS N
were VBD N
significantly RB N
lowered VBN N
p JJ N
0.05 CD N
Whole JJ N
blood NN N
aggregation NN N
after IN N
collagen NN N
stimulation NN N
1.0 CD N
micrograms/ml NN N
was VBD N
reduced VBN N
after IN N
4 CD N
weeks NNS N
of IN N
nitrendipine JJ N
treatment NN N
but CC N
ADP NNP N
5 CD N
microM NN N
induced VBD N
aggregation NN N
was VBD N
not RB N
These DT N
effects NNS N
of IN N
nitrendipine NN N
were VBD N
not RB N
seen VBN N
in IN N
platelet NN N
rich JJ N
plasma NN N
In IN N
conclusion NN N
long-term JJ N
nitrendipine JJ N
treatment NN N
may MD N
inhibit VB N
collagen NN N
dependent JJ N
platelet NN N
activation NN N
in IN N
the DT N
blood NN N
of IN N
diabetic JJ 4_p
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
hypertension NN 4_p
-DOCSTART- -X- O O

In IN N
school-aged JJ 1_p
children NNS 1_p
a DT N
combination NN N
of IN N
galacto-oligosaccharides NNS N
and CC N
Lactobacillus NNP N
GG NNP N
increases VBZ N
bifidobacteria RB N
more JJR N
than IN N
Lactobacillus NNP N
GG NNP N
on IN N
its PRP$ N
own JJ N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
combination NN N
of IN N
Lactobacillus NNP N
GG NNP N
LGG NNP N
and CC N
galacto-oligosaccharides NNS N
GOS NNP N
with IN N
LGG NNP N
on IN N
its PRP$ N
own JJ N
and CC N
their PRP$ N
effects NNS N
on IN N
the DT N
intestinal JJ N
microbiota NN N
in IN N
school-aged JJ N
children NNS N
The DT N
randomized JJ N
double-blinded JJ N
crossover NN N
study NN N
comprised VBD N
30 CD 3_p
healthy JJ 4_p
children NNS N
There EX N
were VBD N
two CD N
3-week JJ N
study NN N
periods NNS N
with IN N
a DT N
4-week JJ N
wash-out JJ N
period NN N
in IN N
between IN N
The DT N
children NNS N
ingested VBD N
daily RB N
65 CD N
ml NN N
of IN N
milk-based JJ N
fruit NN N
juice NN N
containing VBG N
either CC N
LGG NNP N
alone RB N
6.5 CD N
x RB N
10 CD N
9 CD N
CFU NNP N
or CC N
LGG NNP N
plus CC N
2 CD N
g NN N
of IN N
GOS NNP N
Symptom NNP N
diaries NNS N
were VBD N
filled VBN N
during IN N
the DT N
study NN N
periods NNS N
Fecal JJ N
samples NNS N
were VBD N
collected VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
both DT N
study NN N
periods NNS N
At IN N
the DT N
end NN N
of IN N
both DT N
study NN N
periods NNS N
the DT N
amount NN N
of IN N
bifidobacteria NN N
was VBD N
significantly RB N
greater JJR N
after IN N
the DT N
ingestion NN N
of IN N
LGG NNP N
GOS NNP N
compared VBN N
with IN N
LGG NNP N
alone RB N
geometric JJ N
mean VBP N
9.33 CD N
x $ N
10 CD N
9 CD N
vs. FW N
4.28 CD N
x $ N
10 CD N
9 CD N
CFU/g NNP N
p NN N
0.001 CD N
No DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
amount NN N
of IN N
lactobacilli NN N
or CC N
LGG NNP N
nor CC N
did VBD N
gastrointestinal JJ N
symptoms NNS N
defecation NN N
frequency NN N
consistency NN N
of IN N
stools NNS N
or CC N
ease NN N
of IN N
defecation NN N
differ NN N
between IN N
the DT N
two CD N
study NN N
periods NNS N
Ingestion NN N
of IN N
LGG NNP N
combined VBD N
with IN N
2 CD N
g NN N
of IN N
GOS NNP N
increased VBD N
the DT N
bifidobacteria NN N
more JJR N
than IN N
LGG NNP N
on IN N
its PRP$ N
own JJ N
and CC N
thus RB N
GOS NNP N
clearly RB N
has VBZ N
a DT N
prebiotic JJ N
effect NN N
in IN N
children NNS N
The DT N
children NNS N
tolerated VBN N
well RB N
a DT N
daily JJ N
intake NN N
of IN N
2 CD N
g NN N
of IN N
GOS NNP N
-DOCSTART- -X- O O

Low JJ N
doses NNS N
of IN N
ketazolam NN N
in IN N
anxiety NN 4_p
a DT N
double-blind NN N
placebo-controlled JJ N
study NN N
A DT N
multicenter NN N
double-blind JJ N
between-patient JJ N
trial NN N
comparing VBG N
two CD N
doses NNS N
of IN N
ketazolam NN N
15 CD N
and CC N
30 CD N
mg NN N
with IN N
placebo NN N
each DT N
given VBN N
once RB N
daily JJ N
in IN N
the DT N
evening NN N
to TO N
92 CD 3_p
outpatients NNS 4_p
affected VBN 4_p
by IN 4_p
generalized JJ 4_p
anxiety NN 4_p
disorders NNS 4_p
for IN N
at IN N
least JJS N
1 CD N
month NN N
was VBD N
carried VBN N
out RP N
After IN N
1-week JJ N
washout NN N
period NN N
47 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
ketazolam VB N
15 CD N
mg NN N
and CC N
45 CD N
to TO N
placebo VB N
for IN N
15 CD N
days NNS N
first JJ N
period NN N
At IN N
the DT N
end NN N
of IN N
this DT N
period NN N
if IN N
the DT N
patient NN N
experienced VBD N
a DT N
decrease NN N
on IN N
the DT N
total JJ N
Hamilton NNP N
Anxiety NNP N
Rating NNP N
Scale NNP N
HAM-A NNP N
of IN N
at IN N
least JJS N
25 CD N
of IN N
basal NN N
value NN N
the DT N
treatment NN N
was VBD N
kept VBN N
unchanged JJ N
for IN N
a DT N
further JJ N
15 CD N
days NNS N
otherwise RB N
15 CD N
mg NN N
of IN N
ketazolam NNS N
were VBD N
added VBN N
to TO N
the DT N
previous JJ N
treatment NN N
second JJ N
period NN N
Anxiety NN N
was VBD N
rated VBN N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
with IN N
the DT N
Italian JJ N
HAM-A NNP N
scale NN N
and CC N
with IN N
a DT N
4-point JJ N
scale NN N
patient NN N
's POS N
assessment NN N
Seventy-eight JJ 3_p
patients NNS N
completed VBD N
the DT N
first JJ N
period NN N
and CC N
75 CD 3_p
the DT N
whole NN N
study NN N
During IN N
the DT N
first JJ N
period NN N
the DT N
percentage NN N
of IN N
responders NNS N
was VBD N
almost RB N
identical JJ N
in IN N
both DT N
treatment NN N
groups NNS N
but CC N
during IN N
the DT N
second JJ N
period NN N
a DT N
further JJ N
slight NN N
improvement NN N
was VBD N
observed VBN N
in IN N
the DT N
early JJ N
placebo NN N
responders NNS N
while IN N
the DT N
HAM-A NNP N
score NN N
of IN N
patients NNS N
on IN N
ketazolam NNS N
continued VBN N
to TO N
improve VB N
significantly RB N
p NN N
less JJR N
than IN N
0.01 CD N
throughout IN N
the DT N
study NN N
Likewise VB N
a DT N
significant JJ N
p NN N
less JJR N
than IN N
0.001 CD N
difference NN N
between IN N
treatments NNS N
was VBD N
observed VBN N
on IN N
the DT N
4-point JJ N
scale NN N
in IN N
the DT N
population NN N
as IN N
a DT N
whole NN N
end NN N
of IN N
first JJ N
period NN N
as RB N
well RB N
as IN N
in IN N
responder NN N
patients NNS N
end JJ N
second JJ N
period NN N
Tolerability NN N
was VBD N
good JJ N
except IN N
in IN N
1 CD N
patient NN N
on IN N
placebo NN N
who WP N
was VBD N
withdrawn VBN N
from IN N
the DT N
study NN N
because IN N
of IN N
severe JJ N
headache NN N
-DOCSTART- -X- O O

Sensory NNP N
Adapted NNP N
Dental NNP N
Environments NNP N
to TO N
Enhance VB N
Oral NNP N
Care NNP N
for IN N
Children NNP 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNPS 4_p
A DT N
Randomized NNP N
Controlled NNP N
Pilot NNP N
Study NNP N
This DT N
pilot NN N
and CC N
feasibility NN N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
a DT N
sensory JJ N
adapted JJ N
dental NN N
environment NN N
SADE NNP N
to TO N
reduce VB N
distress NN N
sensory JJ N
discomfort NN N
and CC N
perception NN N
of IN N
pain NN N
during IN N
oral JJ N
prophylaxis NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
ASD NNP 4_p
Participants NNS N
were VBD N
44 CD 3_p
children NNS 1_p
ages VBZ 1_p
6-12 NN 1_p
n JJ 3_p
22 CD 3_p
typical JJ 3_p
n JJ 3_p
22 CD 3_p
ASD NNP 3_p
In IN N
an DT N
experimental JJ N
crossover NN N
design NN N
each DT N
participant JJ N
underwent JJ N
two CD N
professional JJ N
dental JJ N
cleanings NNS N
one CD N
in IN N
a DT N
regular JJ N
dental NN N
environment NN N
RDE NNP N
and CC N
one CD N
in IN N
a DT N
SADE NNP N
administered VBN N
in IN N
a DT N
randomized JJ N
and CC N
counterbalanced JJ N
order NN N
3-4 JJ N
months NNS N
apart RB N
Outcomes NNP N
included VBD N
measures NNS N
of IN N
physiological JJ N
anxiety NN N
behavioral JJ N
distress NN N
pain NN N
intensity NN N
and CC N
sensory JJ N
discomfort NN N
Both DT N
groups NNS N
exhibited VBD N
decreased JJ N
physiological JJ N
anxiety NN N
and CC N
reported VBD N
lower JJR N
pain NN N
and CC N
sensory JJ N
discomfort NN N
in IN N
the DT N
SADE NNP N
condition NN N
compared VBN N
to TO N
RDE NNP N
indicating VBG N
a DT N
beneficial JJ N
effect NN N
of IN N
the DT N
SADE NNP N
-DOCSTART- -X- O O

Role NNP N
of IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
in IN N
early JJ N
antihypertensive JJ N
treatment NN N
in IN N
non-insulin JJ 4_p
dependent NN 4_p
diabetes VBZ 4_p
mellitus NN 4_p
The DT N
effect NN N
of IN N
captopril NN N
monotherapy NN N
on IN N
blood NN N
pressure NN N
and CC N
metabolism NN N
was VBD N
investigated VBN N
in IN N
a DT N
placebo-controlled JJ N
study NN N
in IN N
30 CD 3_p
non-insulin JJ 4_p
dependent NN 4_p
Type NNP 4_p
II NNP 4_p
diabetic JJ 4_p
subjects NNS 4_p
during IN N
a DT N
3-week JJ N
observation NN N
period NN N
run-in/drug JJ N
placebo/wash-out NN N
on IN N
a DT N
metabolic JJ N
ward NN N
Captopril NNP N
significantly RB N
reduced VBD N
both DT N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
154/90 CD N
+/- JJ N
5/2 CD N
vs. FW N
144/86 CD N
+/- JJ N
4/3 CD N
mmHg NN N
without IN N
major JJ N
side NN N
effects NNS N
Mean JJ N
run-in JJ N
postprandial JJ N
blood NN N
glucose JJ N
concentrations NNS N
were VBD N
also RB N
reduced VBN N
upon IN N
ACE-inhibition NNP N
9 CD N
a.m. RB N
12.7 CD N
+/- JJ N
0.4 CD N
vs. FW N
11.1 CD N
+/- JJ N
0.4 CD N
mmol/l NN N
1 CD N
p.m. NN N
11.0 CD N
+/- JJ N
0.3 CD N
vs. FW N
8.9 CD N
+/- JJ N
0.3 CD N
mmol/l NN N
P NNP N
less JJR N
than IN N
0.05 CD N
while IN N
blood NN N
kinin NN N
concentrations NNS N
40.0 CD N
+/- JJ N
2.5 CD N
pmol/l NN N
were VBD N
approximately RB N
doubled VBN N
108.8 CD N
+/- JJ N
23.5 CD N
pmol/l NN N
P NNP N
less JJR N
than IN N
0.05 CD N
Body NNP N
mass NN N
index NN N
fasting VBG N
plasma JJ N
insulin NN N
serum JJ N
electrolyte NN N
pattern NN N
uric JJ N
acid NN N
white JJ N
blood NN N
count NN N
lipid JJ N
profile NN N
as RB N
well RB N
as IN N
hepatic JJ N
and CC N
renal JJ N
function NN N
parameters NNS N
remained VBD N
unaltered JJ N
throughout IN N
the DT N
observation NN N
period NN N
The DT N
data NNS N
are VBP N
in IN N
line NN N
with IN N
recent JJ N
experimental JJ N
studies NNS N
showing VBG N
a DT N
beneficial JJ N
metabolic JJ N
effect NN N
of IN N
captopril NN N
in IN N
Type NNP N
II NNP N
diabetes VBZ N
ACE NNP N
inhibitors NNS N
might MD N
therefore VB N
become JJ N
first-line JJ N
drugs NNS N
in IN N
early JJ N
antihypertensive JJ N
intervention NN N
in IN N
Type NNP 4_p
II NNP 4_p
diabetic JJ 4_p
patients NNS N
-DOCSTART- -X- O O

Intervention NN N
to TO N
lower VB N
household NN N
wood NN N
smoke NN N
exposure NN N
in IN N
Guatemala NNP N
reduces NNS N
ST-segment NNP N
depression NN N
on IN N
electrocardiograms NNS N
BACKGROUND VB N
A DT N
large JJ N
body NN N
of IN N
evidence NN N
suggests VBZ N
that IN N
fine JJ N
particulate NN N
matter NN N
PM NNP N
air NN N
pollution NN N
is VBZ N
a DT N
cause NN N
of IN N
cardiovascular JJ N
disease NN N
but CC N
little JJ N
is VBZ N
known VBN N
in IN N
particular JJ N
about IN N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
indoor JJ N
air NN N
pollution NN N
from IN N
household NN N
use NN N
of IN N
solid JJ N
fuels NNS N
in IN N
developing VBG N
countries NNS N
RESPIRE NNP N
Randomized NNP N
Exposure NNP N
Study NNP N
of IN N
Pollution NNP N
Indoors NNP N
and CC N
Respiratory NNP N
Effects NNP N
was VBD N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
chimney NN N
woodstove NN N
that WDT N
reduces VBZ N
wood NN N
smoke NN N
exposure NN N
OBJECTIVES IN N
We PRP N
tested VBD N
the DT N
hypotheses NNS N
that IN N
the DT N
stove NN N
intervention NN N
compared VBN N
with IN N
open JJ N
fire NN N
use NN N
would MD N
reduce VB N
ST-segment NNP N
depression NN N
and CC N
increase VB N
heart NN N
rate NN N
variability NN N
HRV NNP N
METHODS NNP N
We PRP N
used VBD N
two CD N
complementary JJ N
study NN N
designs NNS N
a DT N
between-groups NN N
comparisons NNS N
based VBN N
on IN N
randomized JJ N
stove NN N
assignment NN N
and CC N
b NN N
before-and-after NN N
comparisons NNS N
within IN N
control NN N
subjects NNS N
who WP N
used VBD N
open JJ N
fires NNS N
during IN N
the DT N
trial NN N
and CC N
received VBD N
chimney NN N
stoves NNS N
after IN N
the DT N
trial NN N
Electrocardiogram NNP N
sessions NNS N
that WDT N
lasted VBD N
20 CD N
hr NNS N
were VBD N
repeated VBN N
up RP N
to TO N
three CD N
times NNS N
among IN N
49 CD 3_p
intervention NN N
and CC N
70 CD 3_p
control NN N
women NNS N
38-84 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC N
55 CD 3_p
control NN N
subjects NNS N
were VBD N
also RB N
assessed VBN N
after IN N
receiving VBG N
stoves NNS N
HRV NNP N
and CC N
ST-segment JJ N
values NNS N
were VBD N
assessed VBN N
for IN N
each DT N
30-min JJ N
period NN N
ST-segment JJ N
depression NN N
was VBD N
defined VBN N
as IN N
an DT N
average JJ N
value NN N
below IN N
-1.00 NNP N
mm NN N
Personal JJ N
fine JJ N
PM NNP N
aerodynamic JJ N
diameter NN N
≤ VBD N
2.5 CD N
μm NNP N
PM₂.₅ NNP N
exposures NNS N
were VBD N
measured VBN N
for IN N
24 CD N
hr NN N
before IN N
each DT N
electrocardiogram NN N
RESULTS NNP N
PM₂.₅ NNP N
exposure NN N
means NNS N
were VBD N
266 CD N
and CC N
102 CD N
μg/m³ NN N
during IN N
the DT N
trial NN N
period NN N
in IN N
the DT N
control NN N
and CC N
intervention NN N
groups NNS N
respectively RB N
During IN N
the DT N
trial NN N
the DT N
stove NN N
intervention NN N
was VBD N
associated VBN N
with IN N
an DT N
odds NNS N
ratio NN N
of IN N
0.26 CD N
95 CD N
confidence NN N
interval NN N
0.08-0.90 NN N
for IN N
ST-segment JJ N
depression NN N
We PRP N
found VBD N
similar JJ N
associations NNS N
with IN N
the DT N
before-and-after JJ N
comparison NN N
The DT N
intervention NN N
was VBD N
not RB N
significantly RB N
associated VBN N
with IN N
HRV NNP N
CONCLUSIONS NNP N
The DT N
stove NN N
intervention NN N
was VBD N
associated VBN N
with IN N
reduced JJ N
occurrence NN N
of IN N
nonspecific JJ N
ST-segment JJ N
depression NN N
suggesting VBG N
that IN N
household NN N
wood NN N
smoke NN N
exposures NNS N
affect VBP N
ventricular JJ N
repolarization NN N
and CC N
potentially RB N
cardiovascular JJ N
health NN N
-DOCSTART- -X- O O

Experimental JJ N
hyaline NN N
membrane NN N
disease NN N
in IN N
the DT 4_p
premature NN 4_p
monkey NN 4_p
effects NNS N
of IN N
antenatal JJ N
dexamethasone NN N
A DT N
blind NN N
randomized VBN N
trial NN N
of IN N
antenatal JJ N
glucocorticoid NN N
treatment NN N
was VBD N
conducted VBN N
using VBG N
the DT N
premature NN 4_p
monkey NN 4_p
Macaca NNP 4_p
nemestrina RB 4_p
model NN 4_p
of IN 4_p
hyaline JJ 4_p
membrane NN 4_p
disease NN 4_p
HMD NNP 4_p
Twelve NNP 3_p
dams VBZ 3_p
received VBN N
dexamethasone NN N
2 CD N
mg/dose NN N
72 CD N
48 CD N
and CC N
24 CD N
h NN N
before IN N
abdominal JJ N
delivery NN N
at IN N
135 CD N
+/- JJ N
1 CD N
days NNS N
of IN N
gestation NN N
Twelve VB 3_p
control NN 3_p
animals NNS 3_p
received VBD N
saline JJ N
Infants NNS N
of IN N
dexamethasone-treated JJ N
dams NNS N
had VBD N
significantly RB N
lower JJR N
incidence NN N
and CC N
severity NN N
of IN N
HMD NNP N
than IN N
did VBD N
infants NNS N
of IN N
control NN N
animals NNS N
50 CD N
versus RB N
92 CD N
p NN N
less JJR N
than IN N
0.05 CD N
Improvement JJ N
with IN N
treatment NN N
was VBD N
markedly RB N
greater JJR N
for IN N
males NNS N
than IN N
for IN N
females NNS N
Differences NNS N
in IN N
volume-pressure JJ N
behavior NN N
of IN N
the DT N
excised JJ N
lungs NNS N
included VBD N
greater JJR N
distensibility NN N
in IN N
the DT N
infants NNS N
from IN N
dexamethasone-treated JJ N
dams NNS N
20.6 CD N
+/- JJ N
7.1 CD N
ml/g NN N
dry JJ N
lung NN N
versus IN N
14.7 CD N
+/- JJ N
6.1 CD N
p NN N
less JJR N
than IN N
0.05 CD N
and CC N
enhanced JJ N
deflation NN N
stability NN N
with IN N
treatment NN N
Accelerated JJ N
production NN N
of IN N
surface NN N
active JJ N
material NN N
SAM NNP N
phospholipids NNS N
in IN N
infants NNS N
from IN N
dexamethasone-treated JJ N
dams NNS N
was VBD N
indicated VBN N
by IN N
increases NNS N
in IN N
total JJ N
lung NN N
phospholipid NN N
84.5 CD N
+/- JJ N
8.1 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
75.1 CD N
+/- JJ N
9.9 CD N
p NN N
less JJR N
than IN N
0.025 CD N
alveolar JJ N
lavage NN N
fluid NN N
phospholipid NN N
5.65 CD N
+/- JJ N
3.33 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
3.01 CD N
+/- JJ N
1.84 CD N
p NN N
less JJR N
than IN N
0.05 CD N
and CC N
alveolar JJ N
lavage NN N
fluid NN N
disaturated VBN N
phosphatidylcholine NN N
DPC NNP N
2.47 CD N
+/- JJ N
1.84 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
1.06 CD N
+/- JJ N
1.05 CD N
p NN N
less JJR N
than IN N
0.05 CD N
Incorporation NN N
of IN N
14C-palmitate JJ N
into IN N
lung NN N
lipid NN N
was VBD N
not RB N
influenced VBN N
by IN N
dexamethasone NN N
but CC N
a DT N
significantly RB N
greater JJR N
portion NN N
of IN N
the DT N
label NN N
appeared VBD N
in IN N
the DT N
DPC NNP N
fraction NN N
with IN N
treatment NN N
Antenatal NNP N
dexamethasone NN N
treatment NN N
was VBD N
successful JJ N
in IN N
reducing VBG N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
experimental JJ N
HMD NNP N
in IN N
this DT N
animal JJ N
model NN N
the DT N
beneficial JJ N
effects NNS N
of IN N
treatment NN N
were VBD N
associated VBN N
with IN N
accelerated JJ N
maturation NN N
of IN N
fetal JJ N
pulmonary JJ N
functions NNS N
including VBG N
but CC N
not RB N
limited JJ N
to TO N
synthetic JJ N
metabolism NN N
of IN N
SAM NNP N
phospholipid NN N
-DOCSTART- -X- O O

Influence NN N
of IN N
lime NN N
juice NN N
on IN N
the DT N
severity NN N
of IN N
sickle NN 4_p
cell NN 4_p
anemia NN 4_p
BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
The DT N
pain NN N
in IN N
sickle NN N
cell NN N
anemia NN N
SCA NNP N
is VBZ N
often RB N
triggered VBN N
by IN N
dehydration NN N
acidosis NN N
and CC N
fever NN N
that WDT N
are VBP N
usually RB N
due JJ N
to TO N
malaria VB N
Intake NNP N
of IN N
lime JJ N
juice NN N
was VBD N
recently RB N
demonstrated VBN N
to TO N
facilitate VB N
clearance NN N
of IN N
the DT N
malaria NN N
parasite NN N
It PRP N
was VBD N
therefore RB N
sought VBN N
to TO N
determine VB N
whether IN N
regular JJ N
intake NN N
of IN N
lime JJ N
juice NN N
will MD N
ameliorate VB N
crisis NN N
especially RB N
recurrent JJ N
bone NN N
pain NN N
DESIGN NN N
In IN N
this DT N
preliminary JJ N
open-labeled JJ N
randomized JJ N
study NN N
the DT N
effects NNS N
of IN N
lime JJ N
juice NN N
on IN N
the DT N
clinical JJ N
and CC N
some DT N
laboratory JJ N
characteristics NNS N
of IN N
children NNS 1_p
with IN N
SCA NNP 4_p
were VBD N
tested VBN N
RESULTS NNP N
Among IN N
the DT N
113 CD 3_p
children NNS 1_p
with IN N
SCA NNP 4_p
studied VBN N
in IN N
two CD N
hospitals NNS N
the DT N
58 CD N
receiving NN N
lime NN N
treatment NN N
had VBD N
lower JJR N
rates NNS N
of IN N
significant JJ N
painful JJ N
episodes NNS N
than IN N
the DT N
55 CD N
without IN N
lime NN N
37 CD N
versus NN N
83 CD N
crises NNS N
in IN N
6 CD N
months NNS N
and CC N
0.64±0.11 CD N
versus NN N
1.51±0.34 CD N
average JJ N
rates NNS N
per IN N
child NN N
p JJ N
0.001 CD N
Also RB N
fewer JJR N
subjects NNS N
than IN N
the DT N
controls NNS N
had VBD N
significant JJ N
painful JJ N
episodes NNS N
50.0 CD N
versus IN N
92.7 CD N
febrile JJ N
illness NN N
46.6 CD N
versus IN N
87.3 CD N
and CC N
admission NN N
rate NN N
3.4 CD N
versus IN N
34.5 CD N
p JJ N
0.001 CD N
The DT N
mean JJ N
hematocrit NN N
of IN N
the DT N
subjects NNS N
26.23±2.03 CD N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
also RB N
higher JJR N
p JJ N
0.001 CD N
However RB N
transfusion NN N
rate NN N
presence NN N
of IN N
hepatomegaly NN N
splenomegaly NN N
and CC N
jaundice NN N
was VBD N
similar JJ N
Treatment NN N
with IN N
lime NN N
did VBD N
not RB N
cause VB N
any DT N
significant JJ N
side-effect JJ N
CONCLUSIONS NNP N
Regular NNP N
intake NN N
of IN N
lime JJ N
juice NN N
may MD N
be VB N
of IN N
great JJ N
therapeutic JJ N
and CC N
nutritional JJ N
relevance NN N
in IN N
children NNS 1_p
with IN N
SCA NNP 4_p
-DOCSTART- -X- O O

Serum NNP N
biochemical JJ N
characteristics NNS N
of IN N
Beluga NNP 4_p
Huso NNP 4_p
huso NN 4_p
L. NNP 4_p
in IN N
response NN N
to TO N
blood NN N
sampling NN N
after IN N
clove NN N
powder NN N
solution NN N
exposure NN N
In IN N
order NN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
anesthesia NN N
on IN N
serum NN N
parameters NNS N
Beluga NNP 4_p
Huso NNP 4_p
huso NN 4_p
L. NNP 4_p
were VBD N
blood-sampled JJ N
immediately RB N
without IN N
anesthesia NN N
control NN N
or CC N
subjected VBN N
to TO N
following VBG N
anesthesia JJ N
procedure NN N
40 CD N
120 CD N
and CC N
240 CD N
s NN N
exposure NN N
to TO N
3,000 CD N
700 CD N
and CC N
500 CD N
mg NN N
l⁻¹ NN N
clove NN N
solution NN N
respectively RB N
Blood NN N
samples NNS N
were VBD N
collected VBN N
after IN N
these DT N
periods NNS N
when WRB N
fish NN N
were VBD N
immobile JJ N
and CC N
reached VBD N
stage NN N
4 CD N
anesthesia NN N
Results NNS N
showed VBD N
that IN N
cortisol NN N
and CC N
glucose JJ N
levels NNS N
were VBD N
significantly RB N
high JJ N
in IN N
700 CD N
and CC N
500 CD N
but CC N
not RB N
3,000 CD N
mg NNS N
l⁻¹ JJ N
group NN N
compared VBN N
to TO N
control VB N
Serum NNP N
lactate NN N
levels NNS N
were VBD N
significantly RB N
high JJ N
in IN N
500 CD N
mg NNS N
l⁻¹ JJ N
group NN N
compared VBN N
to TO N
control VB N
group NN N
Lactate NNP N
levels NNS N
were VBD N
not RB N
significantly RB N
differed VBN N
between IN N
control NN N
3,000 CD N
and CC N
700 CD N
mg NN N
l⁻¹ NN N
groups NNS N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
serum NN N
levels NNS N
of IN N
cholesterol NN N
total JJ N
protein NN N
lactate JJ N
dehydrogenase NN N
aspartate JJ N
aminotransferase NN N
alanine JJ N
aminotransferase NN N
Na⁺ NNP N
Cl⁻ NNP N
K⁺ NNP N
and CC N
Ca²⁺ NNP N
Results NNP N
suggest VBP N
that IN N
rapid JJ N
anesthesia NN N
with IN N
higher JJR N
dose NN N
is VBZ N
better JJR N
than IN N
slow JJ N
anesthesia NN N
with IN N
lower JJR N
dose NN N
for IN N
blood NN N
sampling NN N
in IN N
Beluga NNP N
-DOCSTART- -X- O O

Training VBG N
referential JJ N
communicative JJ N
skills NNS N
to TO N
individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
a DT N
pilot NN N
study NN N
The DT N
present JJ N
study NN N
reports VBZ N
the DT N
effects NNS N
of IN N
referential JJ N
communication NN N
training NN N
in IN N
individuals NNS 4_p
formally RB 4_p
diagnosed VBN 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
ASD NNP 4_p
Participants NNS N
were VBD N
20 CD 3_p
children NNS 1_p
with IN N
ASD NNP 4_p
M NNP 1_p
age NN 1_p
14.3 CD 1_p
yr. NN 1_p
SD NNP 1_p
4.2 CD 1_p
6 CD 3_p
girls NNS N
14 CD 3_p
boys NNS N
in IN N
the DT N
role NN N
of IN N
speakers NNS N
and CC N
20 CD 3_p
control NN N
children NNS 1_p
who WP N
acted VBD N
as IN N
listeners NNS N
They PRP N
were VBD N
all DT N
enrolled VBN N
in IN N
mainstream JJ N
compulsory NN N
education NN N
Inclusion/exclusion NNP N
criteria NNS N
were VBD N
defined VBN N
according VBG N
to TO N
the DT N
clinical JJ N
diagnosis NN N
of IN N
ASD NNP N
the DT N
presence NN N
or CC N
absence NN N
of IN N
additional JJ N
or CC N
associated JJ N
disability NN N
previous JJ N
training NN N
in IN N
referential JJ N
communication NN N
and CC N
any DT N
drug NN N
treatment NN N
Speakers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
trained JJ N
vs NN N
untrained VBD N
Linguistic JJ N
age NN N
cognitive JJ N
level NN N
and CC N
autistic JJ N
symptoms NNS N
were VBD N
analyzed VBN N
respectively RB N
with IN N
the DT N
Peabody NNP N
Picture NNP N
Vocabulary NNP N
Test NNP N
PPVT NNP N
the DT N
Wechsler NNP N
Intelligence NNP N
Scale NNP N
WISC-R NNP N
or CC N
WAIS-III NNP N
and CC N
the DT N
Autistic NNP N
Behavior NNP N
Checklist NNP N
ABC NNP N
Communicative JJ N
abilities NNS N
were VBD N
analyzed VBN N
through IN N
two CD N
indexes NNS N
related VBN N
to TO N
message VB N
complexity NN N
and CC N
self-regulation NN N
The DT N
trained JJ N
group NN N
was VBD N
trained VBN N
in IN N
referential JJ N
communication NN N
tasks NNS N
task NN N
analysis NN N
role NN N
taking NN N
and CC N
task JJ N
evaluation NN N
while IN N
the DT N
untrained JJ N
group NN N
took VBD N
part NN N
in IN N
a DT N
communicative JJ N
game NN N
but CC N
without IN N
any DT N
specific JJ N
communicative JJ N
training NN N
The DT N
results NNS N
showed VBD N
that IN N
the DT N
complexity NN N
of IN N
emitted JJ N
messages NNS N
had VBD N
improved VBN N
statistically RB N
significantly RB N
in IN N
the DT N
trained JJ N
group NN N
as IN N
an DT N
effect NN N
of IN N
training NN N
Ecological JJ N
referential JJ N
communication NN N
is VBZ N
shown VBN N
to TO N
be VB N
an DT N
appropriate JJ N
paradigm NN N
for IN N
studying VBG N
the DT N
communicative JJ N
process NN N
and CC N
its PRP$ N
products NNS N
and CC N
could MD N
be VB N
used VBN N
to TO N
develop VB N
and CC N
implement VB N
a DT N
training NN N
program NN N
focused VBN N
on IN N
those DT N
skills NNS N
in IN N
which WDT N
individuals NNS 4_p
with IN 4_p
ASD NNP 4_p
are VBP N
most RBS N
deficient JJ N
-DOCSTART- -X- O O

Preschoolers NNS 1_p
acquire VB N
general JJ N
knowledge NN N
by IN N
sharing VBG N
in IN N
pretense NN N
Children NNP N
acquire VB N
general JJ N
knowledge NN N
about IN N
many JJ N
kinds NNS N
of IN N
things NNS N
but CC N
there EX N
are VBP N
few JJ N
known VBN N
means NNS N
by IN N
which WDT N
this DT N
knowledge NN N
is VBZ N
acquired VBN N
In IN N
this DT N
article NN N
it PRP N
is VBZ N
proposed VBN N
that IN N
children NNS N
acquire VB N
generic JJ N
knowledge NN N
by IN N
sharing VBG N
in IN N
pretend JJ N
play NN N
In IN N
Experiment JJ N
1 CD N
twenty-two JJ 3_p
3- JJ 1_p
to TO 1_p
4-year-olds NNS 1_p
watched VBN N
pretense NN N
in IN N
which WDT N
a DT N
puppet NN N
represented VBD N
a DT N
nerp NN N
an DT N
unfamiliar JJ N
kind NN N
of IN N
animal NN N
For IN N
instance NN N
in IN N
one CD N
scenario NN N
the DT N
nerp JJ N
ate NN N
and CC N
disliked VBD N
a DT N
carrot NN N
When WRB N
subsequently RB N
asked VBD N
generic JJ N
questions NNS N
about IN N
real JJ N
nerps NNS N
children NNS N
's POS N
responses NNS N
suggested VBD N
that IN N
they PRP N
had VBD N
learned VBN N
general JJ N
facts NNS N
e.g. NN N
nerps RB N
dislike JJ N
carrots NNS N
In IN N
Experiment JJ N
2 CD N
thirty-two JJ 3_p
4- JJ 1_p
to TO 1_p
5-year-olds NNS 1_p
learned VBN N
from IN N
scenarios NNS N
lacking VBG N
pretend JJ N
speech NN N
or CC N
sound JJ N
effects NNS N
The DT N
findings NNS N
reveal VBP N
a DT N
long JJ N
overlooked JJ N
means NNS N
by IN N
which WDT N
children NNS N
can MD N
acquire VB N
generic JJ N
knowledge NN N
-DOCSTART- -X- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
personalised JJ N
decision NN N
support NN N
delivered VBD N
via IN N
the DT N
internet NN N
for IN N
bowel NN N
cancer NN N
screening VBG N
with IN N
a DT N
faecal JJ N
occult NN N
blood NN N
test NN N
the DT N
effects NNS N
of IN N
tailoring NN N
of IN N
messages NNS N
according VBG N
to TO N
social JJ N
cognitive JJ N
variables NNS N
on IN N
participation NN N
BACKGROUND NNP N
In IN N
Australia NNP N
bowel NN N
cancer NN N
screening VBG N
participation NN N
using VBG N
faecal JJ N
occult NN N
blood NN N
testing NN N
FOBT NNP N
is VBZ N
low JJ N
Decision NN N
support NN N
tailored VBD N
to TO N
psychological JJ N
predictors NNS N
of IN N
participation NN N
may MD N
increase VB N
screening VBG N
The DT N
study NN N
compared VBN N
tailored VBD N
computerised JJ N
decision NN N
support NN N
to TO N
non-tailored JJ N
computer NN N
or CC N
paper NN N
information NN N
The DT N
primary JJ N
outcome NN N
was VBD N
FOBT NNP N
return NN N
within IN N
12 CD N
weeks NNS N
Additional JJ N
analyses NNS N
were VBD N
conducted VBN N
on IN N
movement NN N
in IN N
decision NN N
to TO N
screen NN N
and CC N
change NN N
on IN N
psychological JJ N
variables NNS N
METHODS NNP N
A NNP N
parallel NN N
randomised VBD N
controlled VBN N
trial NN N
invited VBD N
25,511 CD 3_p
people NNS N
aged VBN 1_p
50-74 JJ 1_p
years NNS N
to TO N
complete VB N
an DT N
eligibility NN N
questionnaire NN N
Eligible JJ N
respondents NNS N
n JJ N
3,408 CD N
were VBD N
assigned VBN N
to TO N
Tailored NNP N
Personalised VBD N
Decision NNP N
Support NNP N
TPDS NNP N
Non-Tailored JJ N
PDS NNP N
NTPDS NNP N
or CC N
Control NNP N
CG NNP N
intention-to-treat JJ N
ITT NNP N
sample NN N
TPDS NNP N
and CC N
NTPDS NNP N
groups NNS N
completed VBD N
an DT N
on-line JJ N
baseline NN N
survey NN N
BS NNP N
and CC N
accessed VBN N
generic JJ N
information NN N
The DT N
TPDS NNP N
group NN N
additionally RB N
received VBD N
a DT N
tailored VBN N
intervention NN N
CG JJ N
participants NNS N
completed VBD N
a DT N
paper NN N
BS NNP N
only RB N
Those DT N
completing VBG N
the DT N
BS NNP N
n JJ N
2270 CD N
were VBD N
mailed VBN N
an DT N
FOBT NNP N
and CC N
requested VBN N
to TO N
complete VB N
an DT N
endpoint NN N
survey NN N
ES NNP N
that IN N
re-measured JJ N
BS NNP N
variables NNS N
per-protocol NN N
PP NNP N
sample NN N
RESULTS NNP N
FOBT NNP N
return NN N
In IN N
the DT N
ITT NNP N
sample NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
any DT N
group NN N
χ NNP N
2 CD N
2 CD N
2.57 CD N
p NN N
.26 NNP N
TPDS NNP N
32.5 CD N
NTPDS NNP N
33 CD N
and CC N
CG NNP N
34.5 CD N
In IN N
the DT N
PP NNP N
sample NN N
FOBT NNP N
return NN N
in IN N
the DT N
internet NN N
groups NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
the DT N
paper NN N
group NN N
χ NNP N
2 CD N
2 CD N
17.01 CD N
p NN N
.001 NNP N
TPDS NNP N
80 CD N
NTPDS NNP N
83 CD N
and CC N
CG NNP N
74 CD N
FOBT NNP N
completion NN N
by IN N
TPDS NNP N
and CC N
NTPDS NNP N
did VBD N
not RB N
differ VB N
χ NNP N
2 CD N
1 CD N
2.23 CD N
p NN N
.13 NNP N
Age NNP N
was VBD N
positively RB N
associated VBN N
with IN N
kit JJ N
return NN N
Decision NN N
to TO N
screen NN N
2227/2270 CD N
of IN N
the DT N
PP NNP N
sample NN N
provided VBD N
complete JJ N
BS NNP N
data NN N
Participants NNS N
not RB N
wanting VBG N
to TO N
screen VB N
at IN N
baseline NN N
1083/2227 CD N
and CC N
allocated VBN N
to TO N
TPDS NNP N
and CC N
NTPDS NNP N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
decide VB N
to TO N
screen VB N
and CC N
return VB N
an DT N
FOBT NNP N
than IN N
those DT N
assigned VBN N
to TO N
the DT N
CG NNP N
FOBT NNP N
return NN N
by IN N
TPDS NNP N
and CC N
NTPDS NNP N
did VBD N
not RB N
differ VB N
from IN N
one CD N
another DT N
OR NNP N
1.16 CD N
p NN N
.42 NNP N
Change NN N
on IN N
psychosocial JJ N
predictors NNS N
Analysis NN N
of IN N
change NN N
indicated VBD N
that IN N
salience NN N
and CC N
coherence NN N
of IN N
screening VBG N
and CC N
self-efficacy NN N
were VBD N
improved VBN N
and CC N
faecal JJ N
aversion NN N
decreased VBN N
by IN N
tailored JJ N
messaging NN N
CONCLUSIONS NNP N
Online NNP N
information NN N
resources NNS N
may MD N
have VB N
a DT N
role NN N
in IN N
encouraging VBG N
internet-enabled JJ N
people NNS N
who WP N
are VBP N
uncommitted VBN N
to TO N
screening VBG N
to TO N
change VB N
their PRP$ N
attitudes NNS N
perceptions NNS N
and CC N
behaviour NN N
TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
ACTRN12610000095066 NNP N
-DOCSTART- -X- O O

Efficacy NN N
of IN N
intramuscular JJ N
oxytetracycline NN N
as IN N
a DT N
dry JJ N
cow NN N
treatment NN N
for IN N
Staphylococcus NNP N
aureus NN N
mastitis NN N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
intramuscular JJ N
oxytetracycline NN N
as IN N
a DT N
supplemental JJ N
dry JJ N
cow NN N
treatment NN N
for IN N
Staphylococcus NNP N
aureus NN N
mastitis NN N
37 CD 3_p
Holstein NNP 4_p
cows NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
treatment NN N
groups NNS N
intracisternal JJ N
infusion NN N
with IN N
a DT N
commercial JJ N
preparation NN N
of IN N
cephapirin JJ N
benzathine NN N
at IN N
drying VBG N
off RP N
20 CD N
cows NNS N
and CC N
infusion NN N
with IN N
cephapirin JJ N
benzathine NN N
at IN N
drying VBG N
off RP N
and CC N
intramuscular JJ N
oxytetracycline NN N
at IN N
11 CD N
mg/kg NNS N
once RB N
daily RB N
on IN N
d NN N
7 CD N
8 CD N
9 CD N
and CC N
10 CD N
after IN N
drying VBG N
off RB N
17 CD N
cows NNS N
Milk NN N
samples NNS N
collected VBD N
7 CD N
14 CD N
30 CD N
and CC N
60 CD N
d NN N
after IN N
calving VBG N
were VBD N
plated VBN N
for IN N
bacterial JJ N
isolation NN N
within IN N
24 CD N
h NN N
after IN N
collection NN N
and CC N
after IN N
24 CD N
to TO N
72 CD N
h NN N
of IN N
storage NN N
at IN N
-20 NNP N
degrees NNS N
C. NNP N
Quarters NNS N
were VBD N
defined VBN N
as IN N
infected JJ N
if IN N
S. NNP N
aureus NN N
was VBD N
isolated VBN N
from IN N
the DT N
fresh JJ N
and CC N
frozen JJ N
cultures NNS N
from IN N
any DT N
one CD N
sample NN N
collected VBD N
before IN N
drying VBG N
off RP N
An DT N
infected JJ N
quarter NN N
was VBD N
defined VBN N
as IN N
cured JJ N
if IN N
S. NNP N
aureus NN N
was VBD N
not RB N
isolated VBN N
from IN N
the DT N
fresh JJ N
or CC N
frozen JJ N
culture NN N
from IN N
milk NN N
samples NNS N
obtained VBD N
following VBG N
calving NN N
The DT N
rate NN N
of IN N
cure NN N
by IN N
30 CD N
d NN N
after IN N
calving VBG N
for IN N
systemic JJ N
oxytetracycline NN N
in IN N
combination NN N
with IN N
cephapirin JJ N
treatment NN N
was VBD N
29.4 CD N
for IN N
infected JJ N
quarters NNS N
and CC N
29.4 CD N
for IN N
infected JJ N
cows NNS N
compared VBN N
with IN N
27.5 CD N
and CC N
25.0 CD N
respectively RB N
for IN N
the DT N
cephapirin NN N
treatment NN N
only RB N
Results NNS N
including VBG N
the DT N
culture NN N
at IN N
60 CD N
d NN N
after IN N
calving VBG N
were VBD N
21.2 CD N
and CC N
22.5 CD N
respectively RB N
for IN N
combination NN N
therapy NN N
and CC N
cephapirin NN N
therapy NN N
only RB N
Systemic NNP N
oxytetracycline NN N
in IN N
combination NN N
with IN N
intramammary JJ N
dry JJ N
cow NN N
treatment NN N
did VBD N
not RB N
improve VB N
the DT N
rate NN N
of IN N
cure NN N
for IN N
S. NNP N
aureus JJ N
mastitis NN N
-DOCSTART- -X- O O

Recurrent JJ N
epithelial JJ N
ovarian JJ N
carcinoma NN N
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
of IN N
pegylated VBN N
liposomal JJ N
doxorubicin NN N
versus NN N
topotecan JJ N
PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
pegylated JJ N
liposomal JJ N
doxorubicin NN N
PLD NNP N
and CC N
topotecan JJ N
in IN N
patients NNS 4_p
with IN 4_p
epithelial JJ 4_p
ovarian JJ 4_p
carcinoma NN 4_p
that WDT 4_p
recurred VBD 4_p
after IN 4_p
or CC 4_p
did VBD 4_p
n't RB 4_p
respond VB 4_p
to TO 4_p
first-line JJ 4_p
platinum-based JJ 4_p
chemotherapy NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS 4_p
with IN 4_p
measurable JJ 4_p
and CC 4_p
assessable JJ 4_p
disease NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
PLD NNP N
50 CD N
mg/m NN N
2 CD N
as IN N
a DT N
1-hour JJ N
infusion NN N
every DT N
4 CD N
weeks NNS N
or CC N
topotecan JJ N
1.5 CD N
mg/m NN N
2 CD N
/d NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
3 CD N
weeks NNS N
Patients NNS N
were VBD N
stratified VBN N
prospectively RB N
for IN N
platinum NN N
sensitivity NN N
and CC N
for IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
bulky JJ N
disease NN N
RESULTS VB N
A DT N
total NN N
of IN N
474 CD 3_p
patients NNS N
were VBD N
treated VBN N
239 CD N
PLD NNP N
and CC N
235 CD N
topotecan JJ N
They PRP N
comprised VBD N
the DT N
intent-to-treat JJ N
population NN N
The DT N
overall JJ N
progression-free JJ N
survival NN N
rates NNS N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
arms NNS N
P NNP N
=.095 NNP N
The DT N
overall JJ N
response NN N
rates NNS N
for IN N
PLD NNP N
and CC N
topotecan JJ N
were VBD N
19.7 CD N
and CC N
17.0 CD N
respectively RB N
P NNP N
=.390 NNP N
Median JJ N
overall JJ N
survival NN N
times NNS N
were VBD N
60 CD N
weeks NNS N
for IN N
PLD NNP N
and CC N
56.7 CD N
weeks NNS N
for IN N
topotecan JJ N
Data NNP N
analyzed VBD N
in IN N
platinum-sensitive JJ N
patients NNS N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
PLD NNP N
for IN N
progression-free JJ N
survival NN N
P NNP N
=.037 NNP N
with IN N
medians NNS N
of IN N
28.9 CD N
for IN N
PLD NNP N
versus FW N
23.3 CD N
weeks NNS N
for IN N
topotecan JJ N
For IN N
overall JJ N
survival NN N
PLD NNP N
was VBD N
significantly RB N
superior JJ N
to TO N
topotecan VB N
P NNP N
=.008 NNP N
with IN N
a DT N
median NN N
of IN N
108 CD N
weeks NNS N
versus RB N
71.1 CD N
weeks NNS N
The DT N
platinum-refractory JJ N
subgroup NN N
demonstrated VBD N
a DT N
nonstatistically RB N
significant JJ N
survival JJ N
trend NN N
in IN N
favor NN N
of IN N
topotecan JJ N
P NNP N
=.455 NNP N
Severe JJ N
hematologic JJ N
toxicity NN N
was VBD N
more RBR N
common JJ N
with IN N
topotecan JJ N
and CC N
was VBD N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
dosage NN N
modification NN N
or CC N
growth NN N
factor NN N
or CC N
blood NN N
product NN N
utilization NN N
CONCLUSION VB N
The DT N
comparable JJ N
efficacy NN N
favorable JJ N
safety NN N
profile NN N
and CC N
convenient NN N
dosing VBG N
support NN N
the DT N
role NN N
of IN N
PLD NNP N
as IN N
a DT N
valuable JJ N
treatment NN N
option NN N
in IN N
this DT N
patient JJ N
population NN N
-DOCSTART- -X- O O

Bolus NNP N
injection NN N
of IN N
contrast NN N
agents NNS N
with IN N
various JJ N
iodine JJ N
concentrations NNS N
and CC N
delivery NN N
rates NNS N
for IN N
intracranial JJ N
three-dimensional JJ N
CT NNP N
angiography NN N
evaluation NN N
of IN N
intracranial JJ N
arteriovenous JJ N
contrast NN N
using VBG N
a DT N
multidetector-row JJ N
CT NNP N
scanner NN N
PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
difference NN N
in IN N
computed JJ N
tomography NN N
CT NNP N
attenuation NN N
values NNS N
of IN N
the DT N
intracranial JJ N
arterial NN N
and CC N
venous JJ N
systems NNS N
among IN N
the DT N
various JJ N
contrast NN N
injection NN N
protocols NNS N
higher JJR N
iodine NN N
delivery NN N
rate NN N
or CC N
higher JJR N
concentration NN N
of IN N
the DT N
agent NN N
on IN N
the DT N
source NN N
images NNS N
of IN N
intracranial JJ N
three-dimensional JJ N
CT NNP N
angiography NN N
3D-CTA JJ N
using VBG N
a DT N
multidetector-row JJ N
CT NNP N
MDCT NNP N
scanner NN N
MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
used VBD N
100 CD N
ml NN N
of IN N
iopamidol JJ N
300 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.0 CD N
ml/s NNS N
100 CD N
ml NN N
of IN N
iopamidol JJ N
300 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.7 CD N
ml/s NN N
and CC N
80 CD N
ml NN N
of IN N
iopamidol JJ N
370 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.0 CD N
ml/s NN N
There EX N
were VBD N
10 CD 3_p
patients NNS 3_p
in IN 3_p
each DT 3_p
group NN 3_p
Attenuation NNP N
values NNS N
of IN N
the DT N
bilateral JJ N
internal JJ N
carotid NN N
arteries NNS N
ICAs NNP N
basilar JJ N
artery NN N
trunk NN N
bilateral JJ N
cavernous JJ N
sinuses NNS N
CSs NNP N
and CC N
Galenic NNP N
vein NNS N
were VBD N
measured VBN N
quantitatively RB N
on IN N
the DT N
axial JJ N
CT NNP N
angiographic JJ N
source NN N
images NNS N
obtained VBN N
by IN N
four-channel JJ N
MDCT NNP N
RESULTS NNP N
Injection NNP N
of IN N
the DT N
high-concentration NN N
contrast NN N
with IN N
a DT N
higher JJR N
iodine-delivery JJ N
rate NN N
achieved VBN N
good JJ N
arteriovenous JJ N
contrast NN N
at IN N
the DT N
cavernous JJ N
portion NN N
With IN N
the DT N
same JJ N
rate NN N
of IN N
iodine NN N
delivery NN N
injection NN N
of IN N
the DT N
intermediate JJ N
concentrate NN N
agent NN N
increased VBD N
the DT N
CT NNP N
value NN N
of IN N
not RB N
only RB N
the DT N
ICAs NNP N
but CC N
also RB N
the DT N
CSs NNP N
CONCLUSION NNP N
High-concentration NNP N
contrast NN N
could MD N
increase VB N
ICA NNP N
attenuation NN N
without IN N
intracavernous JJ N
attenuation NN N
gain NN N
during IN N
the DT N
first-pass NN N
phase NN N
-DOCSTART- -X- O O

A DT N
randomized JJ N
comparison NN N
of IN N
alternative JJ N
techniques NNS N
to TO N
achieve VB N
coronary JJ N
sinus NN N
cannulation NN N
during IN N
biventricular JJ 4_p
implantation NN 4_p
procedures NNS N
INTRODUCTION NNP N
Biventricular NNP N
pacing VBG N
system NN N
implantation NN N
is VBZ N
a DT N
time-consuming JJ N
and CC N
challenging JJ N
procedure NN N
A DT N
critical JJ N
step NN N
in IN N
biventricular JJ N
pacemaker NN N
implantation NN N
is VBZ N
coronary JJ N
sinus NN N
CS NNP N
cannulation NN N
CS NNP N
cannulation NN N
can MD N
be VB N
achieved VBN N
either DT N
using VBG N
dedicated JJ N
guiding NN N
catheters NNS N
guiding VBG N
catheter NN N
alone RB N
positioning VBG N
strategy NN N
GCA NNP N
or CC N
with IN N
the DT N
aid NN N
of IN N
an DT N
electrophysiology NN N
catheter NN N
advanced VBD N
inside IN N
the DT N
guiding NN N
catheter NN N
electrophysiology JJ N
catheter NN N
aided VBD N
positioning VBG N
strategy NN N
EPA NNP N
AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
evaluate VB N
whether IN N
the DT N
EPA NNP N
technique NN N
is VBZ N
useful JJ N
for IN N
reducing VBG N
CS NNP N
cannulation NN N
time NN N
compared VBN N
to TO N
a DT N
conventional JJ N
GCA NNP N
technique NN N
METHODS NNP N
Thirty-four JJ 3_p
consecutive JJ 4_p
patients NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
GCA NNP N
18 CD N
patients NNS N
or CC N
EPA NNP N
16 CD N
patients NNS N
CS NNP N
cannulation NN N
strategy NN N
RESULTS JJ N
Time NNP N
to TO N
successful JJ N
catheterization NN N
of IN N
CS NNP N
was VBD N
5.0 CD N
+/- JJ N
2.4 CD N
min NN N
in IN N
the DT N
EPA NNP N
group NN N
versus VBD N
10.1 CD N
+/- JJ N
5.4 CD N
min NN N
in IN N
the DT N
GCA NNP N
group NN N
p VBD N
0.004 CD N
Fluoroscopy NN N
time NN N
was VBD N
4.6 CD N
+/- JJ N
2.3 CD N
min NN N
in IN N
the DT N
EPA NNP N
group NN N
versus VBD N
9.2 CD N
+/- JJ N
4.9 CD N
min NN N
in IN N
the DT N
GCA NNP N
group NN N
p VBD N
0.004 CD N
Total JJ N
contrast NN N
dye NN N
volume NN N
to TO N
search NN N
and CC N
engage VB N
the DT N
CS NNP N
ostium NN N
was VBD N
0.0 CD N
ml NN N
in IN N
the DT N
EPA NNP N
group NN N
versus VBD N
14.3 CD N
+/- JJ N
3.4 CD N
ml NN N
in IN N
the DT N
GCA NNP N
group NN N
p VBD N
0.001 CD N
CONCLUSIONS NNP N
Cannulation NNP N
of IN N
CS NNP N
with IN N
the DT N
adjunct NN N
of IN N
an DT N
electrophysiology NN N
catheter NN N
to TO N
dedicated VBN N
delivery NN N
systems NNS N
significantly RB N
reduces VBZ N
procedural JJ N
time NN N
fluoroscopy JJ N
time NN N
and CC N
contrast NN N
dye NN N
volume NN N
compared VBN N
to TO N
a DT N
conventional JJ N
strategy NN N
-DOCSTART- -X- O O

Effect NN N
of IN N
different JJ N
rates NNS N
of IN N
infusion NN N
of IN N
propofol NN N
for IN N
induction NN N
of IN N
anaesthesia NN N
in IN N
elderly JJ 1_p
patients NNS 1_p
The DT N
effect NN N
of IN N
changing VBG N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
propofol NN N
for IN N
induction NN N
of IN N
anaesthesia NN N
was VBD N
studied VBN N
in IN N
60 CD 3_p
elderly JJ 1_p
patients NNS 1_p
Propofol NNP N
was VBD N
administered VBN N
at IN N
300 CD N
600 CD N
or CC N
1200 CD N
ml JJ N
h-1 JJ N
until IN N
loss NN N
of IN N
consciousness NN N
as IN N
judged VBN N
by IN N
loss NN N
of IN N
verbal JJ N
contact NN N
with IN N
the DT N
patient NN N
had VBD N
been VBN N
achieved VBN N
The DT N
duration NN N
of IN N
induction NN N
was VBD N
significantly RB N
longer JJR N
P NNP N
less JJR N
than IN N
0.001 CD N
with IN N
the DT N
slower JJR N
infusion NN N
rates NNS N
104 CD N
68 CD N
and CC N
51 CD N
s NN N
but CC N
the DT N
total JJ N
dose NN N
used VBN N
was VBD N
significantly RB N
less JJR N
P NNP N
less JJR N
than IN N
0.001 CD N
in IN N
these DT N
patients NNS N
1.2 CD N
1.6 CD N
and CC N
2.5 CD N
mg NN N
kg-1 NN N
respectively RB N
The DT N
decrease NN N
in IN N
systolic JJ N
and CC N
diastolic JJ N
arterial JJ N
pressure NN N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
300-ml JJ N
h-1 JJ N
group NN N
at IN N
the DT N
end NN N
of IN N
induction NN N
and CC N
immediately RB N
after IN N
induction NN N
P NNP N
less JJR N
than IN N
0.01 CD N
The DT N
incidence NN N
of IN N
apnoea NN N
was VBD N
also RB N
significantly RB N
less RBR N
in IN N
the DT N
slower JJR N
infusion NN N
group NN N
-DOCSTART- -X- O O

A DT N
pooled JJ N
analysis NN N
of IN N
eastern JJ N
cooperative JJ N
oncology NN N
group NN N
and CC N
intergroup NN N
trials NNS N
of IN N
adjuvant JJ N
high-dose JJ N
interferon NN N
for IN N
melanoma NN N
PURPOSE NNP N
Nearly RB 3_p
2000 CD 3_p
patients NNS 4_p
with IN 4_p
stage NN 4_p
IIB NNP 4_p
and CC 4_p
III NNP 4_p
melanoma NNS 4_p
have VBP N
participated VBN N
in IN N
four CD N
multicenter NN N
randomized VBN N
trials NNS N
conducted VBN N
by IN N
the DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
and CC N
the DT N
Intergroup NNP N
investigating VBG N
adjuvant JJ N
high-dose JJ N
IFN-alpha JJ N
2b CD N
therapy NN N
The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
update VB N
the DT N
analyses NNS N
of IN N
each DT N
individual JJ N
trial NN N
and CC N
to TO N
analyze VB N
prognostic JJ N
factors NNS N
and CC N
treatment NN N
effects NNS N
based VBN N
on IN N
pooled JJ N
data NNS N
EXPERIMENTAL NNP N
DESIGN NNP N
Survival NNP N
and CC N
disease NN N
status NN N
were VBD N
updated VBN N
to TO N
April NNP N
2001 CD N
Analysis NN N
of IN N
prognostic JJ N
factors NNS N
using VBG N
optimized JJ N
statistical JJ N
models NNS N
was VBD N
based VBN N
on IN N
data NNS N
from IN N
patients NNS N
in IN N
E1684 NNP N
E1690 NNP N
E1694 NNP N
and CC N
E2696 NNP N
Analysis NN N
of IN N
treatment NN N
effects NNS N
versus VBP N
observation NN N
Obs NNP N
was VBD N
based VBN N
on IN N
data NNS N
from IN N
713 CD N
patients NNS N
randomized VBN N
to TO N
high-dose JJ N
IFN-alpha JJ N
2b CD N
HDI NNP N
or CC N
Obs NNP N
in IN N
Trials NNP N
E1684 NNP N
and CC N
E1690 NNP N
RESULTS NNP N
Updated VBD N
analysis NN N
of IN N
E1684 NNP N
E1690 NNP N
and CC N
E1694 NNP N
confirmed VBD N
their PRP$ N
original JJ N
conclusions NNS N
now RB N
at IN N
median JJ N
follow-up JJ N
intervals NNS N
of IN N
2.1-12.6 JJ N
years NNS N
Based VBN N
on IN N
two-sided JJ N
univariate JJ N
log-rank JJ N
analysis NN N
of IN N
pooled VBN N
data NNS N
from IN N
E1684 NNP N
and CC N
E1690 NNP N
median JJ N
follow-up NN N
7.2 CD N
years NNS N
relapse-free JJ N
survival NN N
RFS NNP N
-but VBZ N
not RB N
overall JJ N
survival NN N
OS NNP N
-was VBP N
significantly RB N
prolonged VBN N
two-sided JJ N
log-rank NN N
P NNP N
value NN N
0.006 CD N
for IN N
patients NNS N
treated VBN N
with IN N
HDI NNP N
versus NN N
Obs NNP N
Among IN N
all DT N
patients NNS N
prognostic JJ N
factors NNS N
that WDT N
significantly RB N
negatively RB N
impacted JJ N
RFS NNP N
and CC N
OS NNP N
included VBD N
ulceration NN N
recurrent JJ N
disease NN N
at IN N
entry NN N
enrollment NN N
in IN N
E1684 NNP N
and CC N
age NN N
49 CD N
years NNS N
Multivariate NNP N
statistical JJ N
models NNS N
adjusting VBG N
for IN N
these DT N
factors NNS N
confirmed VBD N
the DT N
statistically RB N
significant JJ N
RFS NNP N
benefit NN N
of IN N
HDI NNP N
versus NN N
Obs NNP N
but CC N
did VBD N
not RB N
demonstrate VB N
a DT N
significant JJ N
OS NNP N
benefit NN N
in IN N
the DT N
pooled JJ N
populations NNS N
CONCLUSIONS NNP N
In IN N
patients NNS 4_p
with IN 4_p
high-risk JJ 4_p
resected JJ 4_p
melanoma NN 4_p
HDI NNP N
is VBZ N
effective JJ N
adjuvant JJ N
therapy NN N
with IN N
strong JJ N
evidence NN N
for IN N
improved JJ N
RFS NNP N
and CC N
evidence NN N
for IN N
moderate JJ N
improvement NN N
in IN N
OS NNP N
based VBN N
on IN N
two CD N
prospective JJ N
randomized VBN N
studies NNS N
but CC N
not RB N
the DT N
pooled JJ N
analysis NN N
Analyses NNS N
of IN N
predictors NNS N
of IN N
relapse NN N
and CC N
response NN N
are VBP N
now RB N
needed VBN N
to TO N
improve VB N
the DT N
therapeutic JJ N
value NN N
of IN N
this DT N
modality NN N
-DOCSTART- -X- O O

Cryoprobe NNP N
biopsy NN N
increases VBZ N
the DT N
diagnostic JJ N
yield NN N
in IN N
endobronchial JJ 4_p
tumor NN 4_p
lesions NNS 4_p
OBJECTIVE NNP N
Forceps NNP N
biopsy NN N
is VBZ N
the DT N
standard JJ N
method NN N
to TO N
obtain VB N
specimens NNS N
in IN N
endoscopically RB N
visible JJ N
lesions NNS N
It PRP N
is VBZ N
common JJ N
to TO N
combine VB N
forceps NNS N
biopsy VB N
with IN N
cytology NN N
methods NNS N
to TO N
increase VB N
the DT N
diagnostic JJ N
yield NN N
Although IN N
the DT N
flexible JJ N
cryoprobe NN N
has VBZ N
been VBN N
established VBN N
for IN N
bronchoscopic NN N
interventions NNS N
in IN N
malignant JJ N
stenosis NN N
the DT N
obtained JJ N
biopsies NNS N
called VBN N
cryobiopsies NNS N
have VBP N
not RB N
been VBN N
investigated VBN N
in IN N
a DT N
large JJ N
cohort NN N
of IN N
patients NNS N
The DT N
aim NN N
of IN N
this DT N
feasibility NN N
study NN N
was VBD N
to TO N
prospectively RB N
evaluate VB N
the DT N
diagnostic JJ N
yield NN N
and CC N
safety NN N
of IN N
cryobiopsy NN N
and CC N
forceps JJ N
biopsy NN N
METHODS NNP N
During IN N
a DT N
6-year JJ N
period NN N
296 CD 3_p
patients NNS 4_p
with IN 4_p
visible JJ 4_p
endoluminal JJ 4_p
tumor NN 4_p
lesions NNS 4_p
were VBD 4_p
included VBN 4_p
in IN N
the DT N
study NN N
at IN N
the DT N
bronchoscopy NN 4_p
unit NN 4_p
of IN 4_p
a DT 4_p
university NN 4_p
hospital NN 4_p
In IN N
the DT N
first JJ N
consecutively RB N
conducted VBN N
55 CD N
cases NNS N
both DT N
techniques NNS N
forceps NNS N
biopsy NN N
and CC N
cryobiopsy NN N
were VBD N
applied VBN N
simultaneously RB N
Pathologic NNP N
and CC N
quantitative JJ N
image NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
size NN N
and CC N
quality NN N
of IN N
the DT N
obtained VBN N
specimens NNS N
We PRP N
evaluated VBD N
the DT N
safety NN N
and CC N
diagnostic JJ N
yield NN N
to TO N
describe VB N
the DT N
feasibility NN N
of IN N
cryobiopsy NN N
RESULTS NNP N
Comparative JJ N
analysis NN N
of IN N
the DT N
first JJ N
conducted VBN N
and CC N
randomly RB N
assigned VBD N
55 CD N
cases NNS N
revealed VBD N
a DT N
significantly RB N
higher RBR N
diagnostic JJ N
yield NN N
for IN N
cryobiopsy NN N
compared VBN N
with IN N
forceps NNS N
biopsy NNS N
89.1 CD N
vs JJ N
65.5 CD N
P NNP N
.05 NNP N
In IN N
this DT N
cohort NN N
quantitative JJ N
image NN N
analysis NN N
showed VBD N
significantly RB N
larger JJR N
biopsies NNS N
regarding VBG N
size NN N
and CC N
artifact-free JJ N
tissue NN N
sections NNS N
for IN N
cryobiopsy NN N
compared VBN N
with IN N
forceps NNS N
biopsy NN N
P NNP N
.0001 NNP N
The DT N
overall JJ N
diagnostic JJ N
yield NN N
of IN N
cryobiopsy NN N
was VBD N
89.5 CD N
Mild NNP N
bleeding VBG N
occurred VBD N
in IN N
11 CD N
cases NNS N
3.7 CD N
moderate JJ N
bleeding NN N
occurred VBD N
in IN N
3 CD N
cases NNS N
1.0 CD N
and CC N
severe JJ N
bleeding NN N
occurred VBD N
in IN N
1 CD N
case NN N
0.3 CD N
CONCLUSION NNP N
Cryobiopsy NNP N
is VBZ N
safe JJ N
and CC N
increases VBZ N
the DT N
diagnostic JJ N
yield NN N
in IN N
endobronchial JJ N
tumor NN N
lesions NNS N
The DT N
method NN N
also RB N
is VBZ N
feasible JJ N
under IN N
routine JJ N
conditions NNS N
-DOCSTART- -X- O O

Levobunolol NNP N
compared VBN N
with IN N
timolol NN N
a DT N
four-year JJ N
study NN N
Fifty-one CD 3_p
patients NNS 4_p
with IN N
raised VBN 4_p
intraocular JJ 4_p
pressure NN 4_p
IOP NNP 4_p
were VBD N
treated VBN N
for IN N
up IN N
to TO N
four CD N
years NNS N
with IN N
one CD N
of IN N
three CD N
ophthalmic JJ N
solutions NNS N
0.5 CD N
levobunolol NN N
1 CD N
levobunolol NN N
or CC N
0.5 CD N
timolol NN N
The DT N
study NN N
was VBD N
conducted VBN N
as IN N
a DT N
double-masked JJ N
randomised JJ N
trial NN N
in IN N
which WDT N
medications NNS N
were VBD N
administered VBN N
twice RB N
daily RB N
to TO N
both DT N
eyes NNS N
Levobunolol NNP N
and CC N
timolol NN N
were VBD N
equally RB N
effective JJ N
in IN N
reducing VBG N
overall JJ N
mean JJ N
IOP NNP N
reductions NNS N
were VBD N
greater JJR N
than IN N
8.8 CD N
mmHg NNS N
in IN N
all DT N
three CD N
treatment NN N
groups NNS N
The DT N
study NN N
showed VBD N
levobunolol NNS N
to TO N
be VB N
as IN N
safe JJ N
and CC N
effective JJ N
as IN N
timolol NN N
in IN N
the DT N
long-term JJ N
control NN N
of IN N
raised VBN N
IOP NNP N
-DOCSTART- -X- O O

Lowering VBG N
the DT N
triglyceride/high-density NN N
lipoprotein NN N
cholesterol NN N
ratio NN N
is VBZ N
associated VBN N
with IN N
the DT N
beneficial JJ N
impact NN N
of IN N
pioglitazone NN N
on IN N
progression NN N
of IN N
coronary JJ N
atherosclerosis NN N
in IN N
diabetic JJ 4_p
patients NNS 4_p
insights NNS N
from IN N
the DT N
PERISCOPE NNP N
Pioglitazone NNP N
Effect NNP N
on IN N
Regression NNP N
of IN N
Intravascular NNP N
Sonographic NNP N
Coronary NNP N
Obstruction NNP N
Prospective NNP N
Evaluation NNP N
study NN N
OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
factors NNS N
associated VBN N
with IN N
the DT N
favorable JJ N
effect NN N
of IN N
pioglitazone NN N
on IN N
atheroma JJ N
progression NN N
BACKGROUND NNP N
Diabetes NNP N
mellitus NN N
is VBZ N
associated VBN N
with IN N
accelerated JJ N
coronary JJ N
atheroma NN N
progression NN N
Pioglitazone NN N
slowed VBD N
progression NN N
compared VBN N
with IN N
glimepiride NN N
in IN N
this DT N
population NN N
METHODS NNP N
In IN N
all DT N
360 CD 3_p
diabetic JJ 4_p
patients NNS 4_p
with IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
were VBD N
treated VBN N
with IN N
pioglitazone NN N
or CC N
glimepiride NN N
for IN N
18 CD N
months NNS N
in IN N
the DT N
PERISCOPE NNP N
Pioglitazone NNP N
Effect NNP N
on IN N
Regression NNP N
of IN N
Intravascular NNP N
Sonographic NNP N
Coronary NNP N
Obstruction NNP N
Prospective NNP N
Evaluation NNP N
study NN N
Coronary NNP N
atheroma NN N
progression NN N
was VBD N
evaluated VBN N
by IN N
serial JJ N
intravascular JJ N
ultrasound NN N
The DT N
relationship NN N
between IN N
changes NNS N
in IN N
biochemical JJ N
parameters NNS N
percent JJ N
atheroma NN N
volume NN N
and CC N
total JJ N
atheroma NN N
volume NN N
was VBD N
investigated VBN N
RESULTS JJ N
Pioglitazone-treated JJ N
patients NNS N
demonstrated VBD N
greater JJR N
increases NNS N
in IN N
high-density NN N
lipoprotein NN N
cholesterol NN N
HDL-C NNP N
and CC N
reductions NNS N
in IN N
glycated JJ N
hemoglobin NN N
triglycerides NNS N
and CC N
C-reactive JJ N
protein NN N
Significant JJ N
correlations NNS N
were VBD N
observed VBN N
between IN N
changes NNS N
in IN N
percent NN N
atheroma NN N
volume NN N
and CC N
triglycerides NNS N
r VB N
0.15 CD N
p NN N
0.04 CD N
triglyceride/HDL-C JJ N
ratio NN N
r JJ N
0.16 CD N
p NN N
0.03 CD N
and CC N
glycated VBD N
hemoglobin NN N
r JJ N
0.16 CD N
p NN N
0.03 CD N
with IN N
pioglitazone NN N
and CC N
changes NNS N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
r JJ N
-0.15 NNP N
p NN N
0.05 CD N
apolipoprotein RB N
B NNP N
r NN N
-0.16 NNP N
p NN N
0.04 CD N
and CC N
apolipoprotein RB N
A-I NNP N
r NN N
-0.20 NNP N
p NN N
0.01 CD N
with IN N
glimepiride NN N
Substantial JJ N
atheroma JJ N
regression NN N
compared VBN N
to TO N
progression NN N
was VBD N
associated VBN N
with IN N
greater JJR N
relative JJ N
increases NNS N
in IN N
HDL-C NNP N
14.2 CD N
vs. FW N
7.8 CD N
p NN N
0.04 CD N
relative JJ N
decreases NNS N
in IN N
triglycerides NNS N
-13.3 CD N
vs. FW N
-1.9 CD N
p NN N
0.045 CD N
triglyceride/HDL-C JJ N
ratio NN N
-22.5 NNP N
vs. FW N
-9.9 NNP N
p NN N
0.05 CD N
and CC N
decrease NN N
in IN N
glycated JJ N
hemoglobin NN N
-0.6 CD N
vs. FW N
-0.3 CD N
p NN N
0.01 CD N
Multivariable JJ N
analysis NN N
revealed VBD N
that IN N
pioglitazone-induced JJ N
effects NNS N
on IN N
triglyceride/HDL-C NN N
were VBD N
associated VBN N
with IN N
changes NNS N
in IN N
percent NN N
atheroma NN N
volume NN N
p JJ N
0.03 CD N
and CC N
total JJ N
atheroma NN N
volume NN N
p JJ N
0.02 CD N
CONCLUSIONS NNP N
Favorable JJ N
effects NNS N
of IN N
pioglitazone NN N
on IN N
the DT N
triglyceride/HDL-C JJ N
ratio NN N
correlated VBN N
with IN N
delayed JJ N
atheroma NN N
progression NN N
in IN N
diabetic JJ 4_p
patients NNS 4_p
This DT N
finding NN N
highlights VBZ N
the DT N
potential JJ N
importance NN N
of IN N
targeting VBG N
atherogenic JJ N
dyslipidemia NN N
in IN N
diabetic JJ 4_p
patients NNS 4_p
with IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
-DOCSTART- -X- O O

Time-varying JJ N
smoking NN N
abstinence NN N
predicts VBZ N
lower JJR N
depressive JJ N
symptoms NNS N
following VBG N
smoking VBG N
cessation NN N
treatment NN N
INTRODUCTION NNP N
The DT N
question NN N
of IN N
whether IN N
abstinence NN N
during IN N
the DT N
months NNS N
following VBG N
a DT N
planned VBN N
quit NN N
attempt NN N
exacerbates VBZ N
or CC N
improves VBZ N
depressive JJ N
symptoms NNS N
is VBZ N
an DT N
important JJ N
clinical JJ N
issue NN N
Extant NNP N
research NN N
has VBZ N
primarily RB N
modeled VBN N
between-person JJ N
covariation NN N
between IN N
postquit NN N
abstinence NN N
and CC N
depressive JJ N
symptom NN N
trajectories NNS N
However RB N
this DT N
approach NN N
can MD N
not RB N
account VB N
for IN N
potential JJ N
third JJ N
variables NNS N
between IN N
participants NNS N
that WDT N
may MD N
affect VB N
both DT N
smoking NN N
and CC N
depression NN N
Accordingly RB N
the DT N
current JJ N
study NN N
examined VBD N
within-person JJ N
covariation NN N
between IN N
time-varying JJ N
abstinence NN N
and CC N
depressive JJ N
symptom NN N
in IN N
a DT N
multilevel NN N
model NN N
MLM NNP N
which WDT N
allowed VBD N
for IN N
transitions NNS N
between IN N
smoking VBG N
statuses NNS N
within IN N
a DT N
participant NN N
METHODS JJ N
Participants NNS N
were VBD N
236 CD 3_p
heavy JJ 4_p
drinking NN 4_p
smokers NNS 4_p
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
testing VBG N
the DT N
efficacy NN N
of IN N
incorporating VBG N
brief JJ N
alcohol NN N
intervention NN N
into IN N
smoking VBG N
cessation NN N
treatment NN N
Depressive NNP N
symptoms NNS N
and CC N
biochemically RB N
verified JJ N
abstinence NN N
were VBD N
assessed VBN N
1 CD N
week NN N
prior RB N
to TO N
and CC N
2 CD N
8 CD N
16 CD N
and CC N
26 CD N
weeks NNS N
after IN N
quit NN N
date NN N
RESULTS NNP N
MLMs NNP N
indicated VBD N
a DT N
slight JJ N
increase NN N
in IN N
depressive JJ N
symptoms NNS N
over IN N
time NN N
in IN N
the DT N
sample NN N
as IN N
a DT N
whole NN N
However RB N
there EX N
was VBD N
an DT N
inverse JJ N
relation NN N
between IN N
time-varying JJ N
abstinence NN N
vs. IN N
smoking NN N
and CC N
concurrent JJ N
level NN N
of IN N
depressive JJ N
symptoms NNS N
indicating VBG N
that IN N
transitions NNS N
from IN N
smoking VBG N
to TO N
abstinence VB N
within IN N
individuals NNS N
were VBD N
associated VBN N
with IN N
reductions NNS N
in IN N
depressive JJ N
symptoms NNS N
CONCLUSIONS NNP N
During IN N
the DT N
first JJ N
6 CD N
months NNS N
following VBG N
a DT N
planned VBN N
quit NN N
attempt NN N
being VBG N
abstinent NN N
in IN N
a DT N
particular JJ N
week NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
lower JJR N
levels NNS N
of IN N
concurrent NN N
depressive NN N
symptoms NNS N
These DT N
results NNS N
are VBP N
not RB N
concordant JJ N
with IN N
the DT N
view NN N
that IN N
intentional JJ N
smoking NN N
abstinence NN N
exacerbates VBZ N
depressive JJ N
symptoms NNS N
Efforts NNS N
to TO N
promote VB N
smoking VBG N
cessation NN N
should MD N
highlight VB N
that IN N
individuals NNS N
are VBP N
likely JJ N
to TO N
feel VB N
more RBR N
rather RB N
than IN N
less JJR N
psychologically RB N
healthy JJ N
when WRB N
they PRP N
successfully RB N
quit VBP N
smoking NN N
-DOCSTART- -X- O O

An DT N
open-label JJ N
extension NN N
study NN N
of IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
risperidone NN N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
long-term JJ N
safety NN N
and CC N
efficacy NN N
of IN N
risperidone NN N
in IN N
treating VBG N
irritability NN N
and CC N
related JJ N
behaviors NNS N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
autistic JJ 4_p
disorders NNS 4_p
METHODS NNP N
In IN N
this DT N
6 CD N
month NN N
26 CD N
week NN N
open-label NN N
extension NN N
OLE NNP N
study NN N
patients NNS N
5-17 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
who WP N
completed VBD N
the DT N
previous JJ N
fixed-dose JJ N
6 CD N
week NN N
double-blind JJ N
DB NNP N
phase NN N
were VBD N
flexibly RB N
dosed VBN N
with IN N
risperidone NN N
based VBN N
on IN N
body NN N
weight NN N
The DT N
maximum JJ N
allowed VBD N
dose NN N
was VBD N
1.25 CD N
mg/day NN N
for IN N
those DT N
weighing VBG N
20 CD N
to TO N
45 CD N
kg NN N
and CC N
1.75 CD N
mg/day NN N
for IN N
those DT N
weighing VBG N
≥ JJ N
45 CD N
kg NN N
The DT N
study NN N
primarily RB N
assessed VBD N
risperidone NN N
's POS N
safety NN N
efficacy NN N
was VBD N
assessed VBN N
as IN N
a DT N
secondary JJ N
end-point NN N
RESULTS VB N
Fifty-six NNP N
71 CD N
out IN N
of IN N
79 CD N
enrolled JJ N
patients NNS N
completed VBD N
the DT N
OLE NNP N
the DT N
most RBS N
common JJ N
discontinuations NNS N
were VBD N
for IN N
insufficient JJ N
response NN N
7 CD N
9 CD N
or CC N
adverse JJ N
events NNS N
AE NNP N
5 CD N
6 CD N
The DT N
most RBS N
common JJ N
≥ JJ N
5 CD N
frequency NN N
in IN N
the DT N
total JJ N
group NN N
AEs NNP N
were VBD N
increased VBN N
appetite RB N
11 CD N
n=9 JJ N
increased VBN N
weight NN N
and CC N
vomiting NN N
9 CD N
n=7 JJ N
each DT N
sedation NN N
pyrexia NN N
and CC N
upper JJ N
respiratory NN N
tract NN N
infection NN N
8 CD N
n=6 JJ N
each DT N
nasopharyngitis NN N
6 CD N
n=5 JJ N
and CC N
somnolence NN N
and CC N
fatigue NN N
5 CD N
n=4 JJ N
each DT N
Extrapyramidal JJ N
AEs NNP N
were VBD N
reported VBN N
in IN N
6 CD N
8 CD N
patients NNS N
Increase NNP N
in IN N
mean JJ N
weight NN N
11-15 CD N
and CC N
body NN N
mass NN N
index NN N
5-10 CD N
occurred VBD N
one CD N
patient NN N
discontinued VBN N
because IN N
of IN N
weight JJ N
increase NN N
One CD N
potentially RB N
prolactin-related JJ N
AE NNP N
irregular JJ N
menstruation NN N
was VBD N
reported VBN N
The DT N
risperidone NN N
high-dose JJ N
group NN N
had VBD N
the DT N
greatest JJS N
mean JJ N
improvement NN N
in IN N
sleep JJ N
visual JJ N
analog NN N
scale NN N
24.6 CD N
All DT N
groups NNS N
showed VBD N
additional JJ N
improvement NN N
in IN N
efficacy NN N
scale JJ N
scores NNS N
during IN N
the DT N
OLE NNP N
CONCLUSIONS NNP N
During IN N
this DT N
OLE NNP N
safety NN N
findings NNS N
with IN N
risperidone NN N
treatment NN N
maximum JJ N
weight-based JJ N
dose NN N
of IN N
1.25 CD N
mg/day NN N
or CC N
1.75 CD N
mg/day NN N
were VBD N
consistent JJ N
with IN N
those DT N
observed VBN N
in IN N
the DT N
DB NNP N
phase NN N
and CC N
with IN N
the DT N
current JJ N
safety NN N
information NN N
for IN N
risperidone NN N
in IN N
autistic JJ N
psychiatric JJ N
and CC N
behavioral JJ N
disorders NNS N
Patients NNS N
experienced VBD N
some DT N
additional JJ N
improvement NN N
in IN N
irritability NN N
and CC N
related JJ N
behaviors NNS N
CLINICAL JJ N
TRIALS NNP N
REGISTRY NNP N
This DT N
phase-4 JJ N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
NCT00576732 NNP N
-DOCSTART- -X- O O

Use NNP N
of IN N
hormonal JJ N
contraceptives NNS N
and CC N
risk NN N
of IN N
HIV-1 NNP N
transmission NN N
a DT N
prospective JJ N
cohort NN N
study NN N
BACKGROUND NNP N
Hormonal NNP N
contraceptives NNS N
are VBP N
used VBN N
widely RB N
but CC N
their PRP$ N
effects NNS N
on IN N
HIV-1 NNP N
risk NN N
are VBP N
unclear JJ N
We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
association NN N
between IN N
hormonal JJ N
contraceptive NN N
use NN N
and CC N
risk NN N
of IN N
HIV-1 NNP N
acquisition NN N
by IN N
women NNS N
and CC N
HIV-1 JJ N
transmission NN N
from IN N
HIV-1-infected JJ N
women NNS N
to TO N
their PRP$ N
male JJ N
partners NNS N
METHODS NNP N
In IN N
this DT N
prospective JJ N
study NN N
we PRP N
followed VBD N
up RP N
3790 CD 3_p
heterosexual JJ 4_p
HIV-1-serodiscordant JJ 4_p
couples NNS 4_p
participating VBG 4_p
in IN 4_p
two CD 4_p
longitudinal JJ 4_p
studies NNS 4_p
of IN 4_p
HIV-1 NNP 4_p
incidence NN 4_p
in IN 4_p
seven CD 4_p
African JJ 4_p
countries NNS 4_p
Among IN N
injectable JJ N
and CC N
oral JJ N
hormonal JJ N
contraceptive NN N
users NNS N
and CC N
non-users NNS N
we PRP N
compared VBN N
rates NNS N
of IN N
HIV-1 NNP N
acquisition NN N
by IN N
women NNS N
and CC N
HIV-1 JJ N
transmission NN N
from IN N
women NNS N
to TO N
men NNS N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
HIV-1 JJ N
seroconversion NN N
We PRP N
used VBD N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
and CC N
marginal JJ N
structural JJ N
modelling NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
contraceptive NN N
use NN N
on IN N
HIV-1 NNP N
risk NN N
FINDINGS NNP N
Among IN N
1314 CD 3_p
couples NNS 4_p
in IN 4_p
which WDT 4_p
the DT 4_p
HIV-1-seronegative JJ 4_p
partner NN 4_p
was VBD N
female JJ 2_p
median JJ N
follow-up NN N
18·0 CD N
IQR NNP N
12·6-24·2 JJ N
months NNS N
rates NNS N
of IN N
HIV-1 NNP N
acquisition NN N
were VBD N
6·61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
women NNS N
who WP N
used VBD N
hormonal JJ N
contraception NN N
and CC N
3·78 CD N
per IN N
100 CD N
person-years NNS N
in IN N
those DT N
who WP N
did VBD N
not RB N
adjusted VBN N
hazard RB N
ratio JJ N
1·98 CD N
95 CD N
CI NNP N
1·06-3·68 CD N
p=0·03 NN N
Among IN N
2476 CD N
couples NNS N
in IN N
which WDT N
the DT N
HIV-1-seronegative JJ N
partner NN N
was VBD N
male JJ N
median JJ N
follow-up NN N
18·7 CD N
IQR NNP N
12·8-24·2 JJ N
months NNS N
rates NNS N
of IN N
HIV-1 NNP N
transmission NN N
from IN N
women NNS N
to TO N
men NNS N
were VBD N
2·61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT N
women NNS N
used VBD N
hormonal JJ N
contraception NN N
and CC N
1·51 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT N
women NNS N
did VBD N
not RB N
use VB N
hormonal JJ N
contraception NN N
adjusted VBN N
hazard RB N
ratio JJ N
1·97 CD N
95 CD N
CI NNP N
1·12-3·45 CD N
p=0·02 NN N
Marginal JJ N
structural JJ N
model NN N
analyses NNS N
generated VBD N
much RB N
the DT N
same JJ N
results NNS N
to TO N
the DT N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
INTERPRETATION NNP N
Women NNP N
should MD N
be VB N
counselled VBN N
about IN N
potentially RB N
increased VBN N
risk NN N
of IN N
HIV-1 NNP N
acquisition NN N
and CC N
transmission NN N
with IN N
hormonal JJ N
contraception NN N
especially RB N
injectable JJ N
methods NNS N
and CC N
about IN N
the DT N
importance NN N
of IN N
dual JJ N
protection NN N
with IN N
condoms NNS N
to TO N
decrease VB N
HIV-1 NNP N
risk NN N
Non-hormonal JJ N
or CC N
low-dose JJ N
hormonal JJ N
contraceptive NN N
methods NNS N
should MD N
be VB N
considered VBN N
for IN N
women NNS N
with IN N
or CC N
at-risk JJ N
for IN N
HIV-1 NNP N
FUNDING NNP N
US NNP N
National NNP N
Institutes NNP N
of IN N
Health NNP N
and CC N
the DT N
Bill NNP N
Melinda NNP N
Gates NNP N
Foundation NNP N
-DOCSTART- -X- O O

Economic NNP N
burden NN N
of IN N
childhood NN 1_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
OBJECTIVE NNP N
To TO N
estimate VB N
the DT N
associations NNS N
between IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
ASD NNP 4_p
diagnoses NNS N
and CC N
service NN N
use NN N
caregiver NN N
time NN N
and CC N
cost NN N
outcomes NNS N
METHODS NNP N
We PRP N
used VBD N
national JJ N
data NNS N
from IN N
the DT N
Medical NNP N
Expenditure NNP N
Panel NNP N
Survey NNP N
linked VBD N
to TO N
the DT N
National NNP N
Health NNP N
Interview NNP N
Survey NNP N
and CC N
a DT N
study-specific JJ N
survey NN N
to TO N
estimate VB N
the DT N
annual JJ N
utilization NN N
and CC N
costs NNS N
for IN N
health NN N
care NN N
school NN N
ASD-related JJ N
therapy NN N
family-coordinated JJ N
services NNS N
as RB N
well RB N
as IN N
caregiver NN N
time NN N
in IN N
children NNS 1_p
aged VBD 1_p
3 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
with IN N
and CC N
without IN N
parent-reported JJ 4_p
ASD NNP 4_p
Regression NNP N
analyses VBZ N
estimated VBN N
the DT N
association NN N
between IN N
ASD NNP N
diagnosis NN N
and CC N
cost NN N
controlling VBG N
for IN N
child NN N
gender NN N
age NN N
race/ethnicity NN N
insurance NN N
status NN N
household JJ N
income NN N
country NN N
region NN N
and CC N
urban/rural JJ N
classification NN N
and CC N
non-ASD-related JJ N
illnesses NNS N
RESULTS NNP N
Children NNP 4_p
with IN 4_p
parent-reported JJ 4_p
ASD NNP 4_p
had VBD N
higher JJR N
levels NNS N
of IN N
health NN N
care NN N
office NN N
visits NNS N
and CC N
prescription NN N
drug NN N
use NN N
compared VBN N
with IN N
children NNS N
without IN N
ASD NNP N
P NNP N
.05 NNP N
A DT N
greater JJR N
proportion NN N
of IN N
children NNS N
in IN N
the DT N
ASD NNP N
group NN N
used VBD N
special JJ N
educational JJ N
services NNS N
76 CD N
vs. FW N
7 CD N
in IN N
the DT N
control NN N
group NN N
P NNP N
.05 NNP N
After IN N
adjusting VBG N
for IN N
child JJ N
demographic JJ N
characteristics NNS N
and CC N
non-ASD-associated JJ N
illnesses NNS N
ASD NNP N
was VBD N
associated VBN N
with IN N
3020 CD N
95 CD N
confidence NN N
interval NN N
CI NNP N
1017- CD N
4259 CD N
higher JJR N
health NN N
care NN N
costs NNS N
and CC N
14,061 CD N
95 CD N
CI NNP N
4390- JJ N
24,302 CD N
higher JJR N
aggregate JJ N
non-health NNS N
care NN N
costs NNS N
including VBG N
8610 CD N
95 CD N
CI NNP N
6595- JJ N
10,421 CD N
higher JJR N
school NN N
costs NNS N
In IN N
adjusted JJ N
analyses NNS N
parents NNS N
who WP N
reported VBD N
that IN N
their PRP$ N
child NN N
had VBD N
ASD NNP N
did VBD N
not RB N
have VB N
significantly RB N
higher JJR N
out-of-pocket NN N
costs NNS N
or CC N
spend VB N
more JJR N
time NN N
on IN N
caregiving VBG N
activities NNS N
compared VBN N
with IN N
control NN N
parents NNS N
CONCLUSIONS VB N
The DT N
economic JJ N
burden NN N
associated VBN N
with IN N
ASD NNP N
is VBZ N
substantial JJ N
and CC N
can MD N
be VB N
measured VBN N
across IN N
multiple JJ N
sectors NNS N
of IN N
our PRP$ N
society NN N
Previous JJ N
analyses NNS N
that WDT N
focused VBD N
on IN N
health NN N
care NN N
underestimated VBD N
this DT N
economic JJ N
burden NN N
particularly RB N
for IN N
school NN N
systems NNS N
-DOCSTART- -X- O O

Role NNP N
of IN N
posterior JJ N
tibial JJ N
nerve NN N
stimulation NN N
in IN N
the DT N
treatment NN N
of IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
a DT N
pilot NN N
study NN N
PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
early JJ N
clinical JJ N
and CC N
urodynamic JJ N
results NNS N
of IN N
posterior JJ N
tibial JJ N
nerve NN N
stimulation NN N
in IN N
patients NNS N
with IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
28 CD 3_p
patients NNS N
with IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
to TO N
2 CD N
equal JJ N
groups NNS N
Group NNP N
1 CD N
received VBD N
a DT N
weekly JJ N
session NN N
of IN N
posterior JJ N
tibial JJ N
nerve NN N
stimulation NN N
for IN N
12 CD N
weeks NNS N
and CC N
group NN N
2 CD N
was VBD N
the DT N
placebo NN N
group NN N
Evaluation NN N
was VBD N
performed VBN N
in IN N
each DT N
group NN N
at IN N
baseline NN N
and CC N
after IN N
posterior JJ N
tibial JJ N
nerve NN N
stimulation NN N
to TO N
compare VB N
clinical JJ N
and CC N
urodynamic JJ N
findings NNS N
Another DT N
clinical JJ N
assessment NN N
was VBD N
done VBN N
3 CD N
months NNS N
after IN N
the DT N
first JJ N
followup NN N
RESULTS VB N
The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
baseline JJ N
clinical JJ N
and CC N
urodynamic JJ N
data NNS N
Overall NNP N
13 CD N
patients NNS N
46.4 CD N
had VBD N
detrusor VBN N
overactivity NN N
and CC N
14 CD N
50 CD N
had VBD N
decreased VBN N
bladder NN N
capacity NN N
After IN N
treatment NN N
11 CD N
group NN N
1 CD N
patients NNS N
78.6 CD N
had VBD N
a DT N
partial JJ N
or CC N
full JJ N
response NN N
to TO N
posterior VB N
tibial JJ N
nerve NN N
stimulation NN N
but CC N
only RB N
2 CD N
14.3 CD N
in IN N
group NN N
2 CD N
had VBD N
a DT N
partial JJ N
response NN N
p JJ N
0.002 CD N
Also RB N
the DT N
average JJ N
number NN N
of IN N
wet JJ N
nights NNS N
in IN N
group NN N
1 CD N
was VBD N
significantly RB N
lower JJR N
than IN N
at IN N
baseline NN N
p JJ N
0.002 CD N
All DT N
urodynamic JJ N
parameters NNS N
significantly RB N
improved VBN N
in IN N
group NN N
1 CD N
In IN N
contrast NN N
the DT N
number NN N
of IN N
wet JJ N
nights NNS N
and CC N
urodynamic JJ N
parameters NNS N
did VBD N
not RB N
change VB N
significantly RB N
in IN N
group NN N
2 CD N
At IN N
3-month JJ N
followup NN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
a DT N
partial JJ N
or CC N
full JJ N
response NN N
in IN N
group NN N
1 CD N
had VBD N
decreased VBN N
from IN N
11 CD N
78.6 CD N
to TO N
6 CD N
42.9 CD N
No DT N
change NN N
was VBD N
evident JJ N
in IN N
group NN N
2 CD N
CONCLUSIONS NNP N
Posterior NNP N
tibial JJ N
nerve NN N
stimulation NN N
can MD N
be VB N
a DT N
viable JJ N
treatment NN N
option NN N
in IN N
some DT N
patients NNS N
with IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
However RB N
deterioration NN N
in IN N
some DT N
responders NNS N
with IN N
time NN N
suggests VBZ N
the DT N
need NN N
for IN N
maintenance NN N
protocols NNS N
-DOCSTART- -X- O O

Vibrotactile NNP N
-- : N
auditory JJ N
interactions NNS N
are VBP N
post-perceptual JJ N
Vibrotactile NNP N
stimuli NN N
can MD N
elicit VB N
compelling VBG N
auditory JJ N
sensations NNS N
even RB N
when WRB N
sound NN N
energy NN N
levels NNS N
are VBP N
minimal JJ N
and CC N
undetectable JJ N
It PRP N
has VBZ N
previously RB N
been VBN N
shown VBN N
that IN N
subjects NNS N
judge VBP N
auditory JJ N
tones NNS N
embedded VBN N
in IN N
white JJ N
noise NN N
to TO N
be VB N
louder VBN N
when WRB N
they PRP N
are VBP N
accompanied VBN N
by IN N
a DT N
vibrotactile JJ N
stimulus NN N
of IN N
the DT N
same JJ N
frequency NN N
A DT N
first JJ N
experiment NN N
replicated VBN N
this DT N
result NN N
at IN N
four CD N
different JJ N
levels NNS N
of IN N
auditory JJ N
stimulation NN N
no DT N
tone NN N
tone NN N
at IN N
detection NN N
threshold NN N
tone NN N
at IN N
5 CD N
dB NNS N
above IN N
threshold NN N
and CC N
tone NN N
at IN N
10 CD N
dB NNS N
above IN N
threshold NN N
The DT N
presence NN N
of IN N
a DT N
vibrotactile JJ N
stimulus NN N
induced VBD N
an DT N
increase NN N
in IN N
the DT N
perceived JJ N
loudness NN N
of IN N
auditory NN N
tones NNS N
at IN N
three CD N
of IN N
the DT N
four CD N
values NNS N
in IN N
this DT N
range NN N
In IN N
two CD N
further JJ N
experiments NNS N
a DT N
2-interval JJ N
forced-choice JJ N
procedure NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
nature NN N
of IN N
this DT N
cross-modal JJ N
interaction NN N
Subjects NNS 4_p
were VBD N
biased VBN N
when WRB N
vibrotaction NN N
was VBD N
applied VBN N
in IN N
one CD N
interval NN N
but CC N
applying VBG N
vibrotaction NN N
in IN N
both DT N
intervals NNS N
produced VBD N
performance NN N
comparable JJ N
to TO N
conditions NNS N
without IN N
vibrotactile NN N
stimuli NN N
This DT N
demonstrates VBZ N
that IN N
vibrotaction NN N
is VBZ N
sometimes RB N
ignored VBN N
when WRB N
judging VBG N
the DT N
presence NN N
of IN N
an DT N
auditory JJ N
tone NN N
Hence NNP N
the DT N
interaction NN N
between IN N
vibrotaction NN N
and CC N
audition NN N
does VBZ N
not RB N
appear VB N
to TO N
occur VB N
at IN N
an DT N
early JJ N
perceptual JJ N
level NN N
-DOCSTART- -X- O O

Effect NN N
of IN N
antipyretic JJ N
drugs NNS N
in IN N
children NNS 1_p
with IN N
malaria NN 4_p
A DT N
comparison NN N
of IN N
different JJ N
antipyretics NNS N
in IN N
children NNS 1_p
with IN N
malaria NN 4_p
showed VBD N
a DT N
small JJ N
effect NN N
of IN N
naproxen NN N
but CC N
not RB N
of IN N
metamizol NN N
on IN N
the DT N
reduction NN N
of IN N
fever NN N
peaks NNS N
Antipyretic JJ N
treatment NN N
had VBD N
no DT N
effect NN N
on IN N
fever NN N
clearance NN N
and CC N
therefore NN N
should MD N
be VB N
used VBN N
cautiously RB N
in IN N
the DT N
treatment NN N
of IN N
malaria NN 4_p
-DOCSTART- -X- O O

A DT N
novel JJ N
approach NN N
to TO N
the DT N
use NN N
of IN N
subgingival JJ N
controlled-release JJ N
chlorhexidine NN N
delivery NN N
in IN N
chronic JJ 4_p
periodontitis NN 4_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
BACKGROUND IN N
We PRP N
aimed VBD N
to TO N
analyze VB N
clinical JJ N
microbiologic JJ N
and CC N
serologic JJ N
effects NNS N
of IN N
chlorhexidine NN N
CHX NNP N
chips NNS N
used VBN N
as IN N
a DT N
subgingival JJ N
controlled-release JJ N
delivery NN N
device NN N
before IN N
and CC N
immediately RB N
after IN N
scaling VBG N
and CC N
root NN N
planing NN N
SRP NNP N
METHODS NNP N
Twenty-four JJ 3_p
patients NNS 4_p
presenting VBG N
with IN N
≥12 NNP N
teeth NNS N
with IN N
probing VBG N
depth NN N
PD NNP N
≥5 VBP N
mm NN N
and CC N
bleeding NN N
on IN N
probing VBG N
were VBD N
assigned VBN N
in IN N
test NN N
or CC N
control NN N
groups NNS N
After IN N
prophylaxis NN N
CHX NNP N
chips NNS N
test NN N
or CC N
placebo JJ N
chips NNS N
control NN N
were VBD N
placed VBN N
in IN N
pockets NNS N
with IN N
PD NNP N
≥5 NNP N
mm NN N
Ten CD N
days NNS N
later RB N
SRP NNP N
was VBD N
performed VBN N
in IN N
all DT N
teeth NNS N
with IN N
PD NNP N
≥4 NNP N
mm NN N
in IN N
a DT N
single JJ N
appointment NN N
Immediately RB N
after IN N
SRP NNP N
new JJ N
chips NNS N
were VBD N
inserted VBN N
in IN N
all DT N
pockets NNS N
with IN N
PD NNP N
≥5 NNP N
mm NN N
Parameters NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
beginning NN N
of IN N
SRP NNP N
and CC N
1 CD N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
treatment NN N
Subgingival JJ N
samples NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
beginning NN N
of IN N
SRP NNP N
and CC N
at IN N
1 CD N
month NN N
after IN N
treatment NN N
Periodontal JJ N
pathogens NNS N
Aggregatibacter NNP N
actinomycetemcomitans NNS N
Porphyromonas NNP N
gingivalis NN N
Prevotella NNP N
intermedia NN N
Tannerella NNP N
forsythia NN N
and CC N
Treponema NNP N
denticola NN N
were VBD N
analyzed VBN N
Serum NNP N
levels NNS N
of IN N
high JJ N
sensitive JJ N
C-reactive JJ N
and CC N
lipopolysaccharide-binding JJ N
proteins NNS N
were VBD N
measured VBN N
The DT N
changes NNS N
of IN N
the DT N
parameters NNS N
between IN N
and CC N
within IN N
the DT N
groups NNS N
were VBD N
tested VBN N
by IN N
Mann-Whitney NNP N
U NNP N
test NN N
P NNP N
0.05 CD N
RESULTS NNP N
All NNP N
clinical JJ N
and CC N
serologic JJ N
parameters NNS N
improved VBN N
in IN N
both DT N
groups NNS N
over IN N
time NN N
There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
clinical JJ N
attachment NN N
level NN N
CAL NNP N
gain NN N
from IN N
baseline NN N
to TO N
6 CD N
months NNS N
between IN N
groups NNS N
1.17 CD N
mm NN N
in IN N
the DT N
test NN N
group NN N
versus VBD N
0.79 CD N
mm NN N
in IN N
the DT N
placebo NN N
group NN N
P NNP N
0.05 CD N
The DT N
treatment NN N
with IN N
CHX NNP N
chips NNS N
showed VBD N
a DT N
greater JJR N
reduction NN N
of IN N
the DT N
microorganisms NN N
of IN N
the DT N
red VBD N
complex JJ N
after IN N
1 CD N
month NN N
P NNP N
0.02 CD N
CONCLUSION VB N
The DT N
use NN N
of IN N
CHX NNP N
chips NNS N
before IN N
and CC N
immediately RB N
after IN N
SRP NNP N
improved VBD N
CAL NNP N
and CC N
reduced VBD N
the DT N
subgingival JJ N
microorganisms NN N
of IN N
the DT N
red JJ N
complex NN N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ N
periodontitis NN N
-DOCSTART- -X- O O

Spotty JJ N
calcification NN N
as IN N
a DT N
marker NN N
of IN N
accelerated JJ N
progression NN N
of IN N
coronary JJ N
atherosclerosis NN N
insights NNS N
from IN N
serial JJ N
intravascular JJ N
ultrasound NN N
OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
atheroma JJ N
progression NN N
in IN N
patients NNS 4_p
with IN 4_p
spotty JJ 4_p
calcification NN 4_p
BACKGROUND NNP N
Although IN N
extensively RB N
calcified VBN N
atherosclerotic JJ N
lesions NNS N
have VBP N
been VBN N
proposed VBN N
to TO N
be VB N
clinically RB N
quiescent JJ N
the DT N
presence NN N
of IN N
spotty JJ N
calcification NN N
within IN N
plaque NN N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
ischemic JJ N
cardiovascular JJ N
events NNS N
The DT N
relationship NN N
between IN N
spotty JJ N
calcification NN N
and CC N
disease NN N
progression NN N
has VBZ N
not RB N
been VBN N
investigated VBN N
METHODS NNP N
A NNP N
total NN N
of IN N
1,347 CD 3_p
stable JJ 4_p
patients NNS 4_p
with IN 4_p
angiographic JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
underwent JJ N
serial JJ N
evaluation NN N
of IN N
atheroma JJ N
burden NN N
with IN N
intravascular JJ N
ultrasound NN N
imaging NN N
Patients NNS N
with IN N
spotty JJ N
calcification NN N
were VBD N
identified VBN N
based VBN N
on IN N
the DT N
presence NN N
of IN N
lesions NNS N
1 CD N
to TO N
4 CD N
mm NNS N
in IN N
length NN N
containing VBG N
an DT N
arc NN N
of IN N
calcification NN N
of IN N
90° CD N
Clinical JJ N
characteristics NNS N
and CC N
disease NN N
progression NN N
were VBD N
compared VBN N
between IN N
patients NNS N
with IN N
spotty JJ N
calcification NN N
n JJ N
922 CD N
and CC N
those DT N
with IN N
no DT N
calcification NN N
n JJ N
425 CD N
RESULTS JJ N
Patients NNS N
with IN N
spotty JJ N
calcification NN N
were VBD N
older JJR N
age NN N
56 CD N
years NNS N
vs. IN N
54 CD N
years NNS N
p VBZ N
0.001 CD N
more RBR N
likely JJ N
to TO N
be VB N
male JJ N
68 CD N
vs. FW N
54 CD N
p CC N
0.01 CD N
and CC N
have VBP N
a DT N
history NN N
of IN N
diabetes NNS N
mellitus NNS N
30 CD N
vs. FW N
24 CD N
p CC N
0.01 CD N
and CC N
myocardial JJ N
infarction NN N
28 CD N
vs. FW N
20 CD N
p CC N
0.004 CD N
and CC N
have VBP N
lower JJR N
on-treatment JJ N
high-density NN N
lipoprotein NN N
cholesterol NN N
levels NNS N
48 CD N
± RB N
16 CD N
mg/dl NNS N
vs. FW N
51 CD N
± $ N
17 CD N
mg/dl NN N
p CC N
0.001 CD N
Patients NNS N
with IN N
spotty JJ N
calcification NN N
demonstrated VBD N
a DT N
greater JJR N
percent JJ N
atheroma NN N
volume NN N
PAV NNP N
36.0 CD N
± RB N
7.6 CD N
vs. FW N
29.0 CD N
± $ N
8.5 CD N
p CC N
0.001 CD N
and CC N
total JJ N
atheroma NN N
volume NN N
174.6 CD N
± RB N
71.9 CD N
mm NN N
3 CD N
vs. FW N
133.9 CD N
± $ N
64.9 CD N
mm NN N
3 CD N
p CC N
0.001 CD N
On IN N
serial JJ N
evaluation NN N
spotty JJ N
calcification NN N
was VBD N
associated VBN N
with IN N
greater JJR N
progression NN N
of IN N
PAV NNP N
+0.43 NNP N
± RB N
0.07 CD N
vs. FW N
+0.02 NNP N
± VBD N
0.11 CD N
p CC N
0.002 CD N
Although IN N
intensive JJ N
low-density NN N
lipoprotein NN N
cholesterol NN N
and CC N
blood NN N
pressure NN N
lowering VBG N
therapy NN N
slowed VBD N
disease JJ N
progression NN N
these DT N
efficacies NNS N
were VBD N
attenuated VBN N
in IN N
patients NNS N
with IN N
spotty JJ N
calcification NN N
CONCLUSIONS VB N
The DT N
presence NN N
of IN N
spotty JJ N
calcification NN N
is VBZ N
associated VBN N
with IN N
more RBR N
extensive JJ N
and CC N
diffuse NN N
coronary JJ N
atherosclerosis NN N
and CC N
accelerated JJ N
disease NN N
progression NN N
despite IN N
use NN N
of IN N
medical JJ N
therapies NNS N
-DOCSTART- -X- O O

Therapeutic JJ N
effects NNS N
of IN N
combined JJ N
treatment NN N
using VBG N
tetracycline-immobilized JJ N
collagen NN N
film NN N
and CC N
root NN N
planing NN N
in IN N
periodontal JJ 4_p
furcation NN 4_p
pockets NNS 4_p
46 CD 4_p
upper JJ 4_p
and CC 4_p
lower JJR 4_p
molars NNS 4_p
with IN 4_p
furcation NN 4_p
grade NN 4_p
II NNP 4_p
involvement NN 4_p
were VBD N
selected VBN N
from IN N
16 CD 3_p
patients NNS 4_p
with IN 4_p
periodontal JJ 4_p
disease NN 4_p
The DT N
teeth NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
following VBG N
groups NNS N
according VBG N
to TO N
treatment NN N
1 CD N
4 CD N
consecutive JJ N
administrations NNS N
of IN N
tetracycline-immobilized JJ N
cross-linked JJ N
collagen NN N
film NN N
TC NNP N
film NN N
at IN N
intervals NNS N
of IN N
1 CD N
week NN N
TC NNP N
group NN N
2 CD N
1 CD N
root NN N
planing VBG N
treatment NN N
RP NNP N
group NN N
3 CD N
combination NN N
treatment NN N
TC NNP N
RP NNP N
group NN N
4 CD N
no DT N
treatment NN N
control VB N
group NN N
The DT N
therapeutic JJ N
effects NNS N
of IN N
each DT N
treatment NN N
were VBD N
compared VBN N
both DT N
clinically RB N
and CC N
microbiologically RB N
Records NNS N
of IN N
plaque NN N
index NN N
gingival NN N
index NN N
bleeding VBG N
on IN N
probing VBG N
probing VBG N
depth NN N
probing VBG N
attachment JJ N
level NN N
and CC N
microscopic NN N
counts NNS N
were VBD N
obtained VBN N
at IN N
0 CD N
4 CD N
6 CD N
and CC N
8 CD N
weeks NNS N
The DT N
results NNS N
showed VBD N
marked JJ N
decreases NNS N
in IN N
probing VBG N
depth NN N
and CC N
density NN N
of IN N
micro-organisms NN N
in IN N
both CC N
the DT N
RP NNP N
and CC N
TC NNP N
RP NNP N
groups NNS N
In IN N
particular JJ N
the DT N
TC NNP N
RP NNP N
group NN N
was VBD N
characterized VBN N
by IN N
a DT N
decreased JJ N
rate NN N
of IN N
bleeding VBG N
on IN N
pocket NN N
probing NN N
and CC N
an DT N
increased JJ N
probing NN N
attachment NN N
gain NN N
The DT N
above JJ N
findings NNS N
demonstrated VBD N
that IN N
root NN N
planning NN N
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
furcation NN N
involvement NN N
and CC N
that IN N
the DT N
effects NNS N
are VBP N
enhanced VBN N
by IN N
the DT N
local JJ N
administration NN N
of IN N
TC NNP N
films NNS N
-DOCSTART- -X- O O

Cancer NNP N
information NN N
and CC N
anxiety NN N
applying VBG N
the DT N
extended JJ N
parallel NN N
process NN N
model NN N
There EX N
is VBZ N
concern NN N
that IN N
public JJ N
education NN N
about IN N
testicular JJ N
cancer NN N
TC NNP N
may MD N
cause VB N
unnecessary JJ N
anxiety NN N
Psychological JJ N
theory NN N
suggests VBZ N
that IN N
if IN N
threat NN N
eg JJ N
TC NNP N
information NN N
is VBZ N
accompanied VBN N
with IN N
threat NN N
control NN N
strategies NNS N
eg NN N
testicular JJ N
self-examination NN N
TSE NNP N
anxiety NN N
is VBZ N
less RBR N
likely JJ N
Male JJ 2_p
students NNS 4_p
N=443 NNP 3_p
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
TC NNP N
or CC N
TC NNP N
+TSE NNP N
information NN N
group NN N
or CC N
a DT N
no DT N
information NN N
control NN N
group NN N
and CC N
assessed VBD N
at IN N
three CD N
time NN N
points NNS N
Anxiety NN N
levels NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
and CC N
exposure NN N
to TO N
TC+TSE NNP N
resulted VBD N
in IN N
greater JJR N
perceived JJ N
message NN N
benefit NN N
increased VBN N
intention NN N
to TO N
self-examine NN N
and CC N
lower JJR N
message NN N
denigration NN N
This DT N
suggests VBZ N
TC NNP N
information NN N
is VBZ N
not RB N
anxiogenic JJ N
but CC N
inclusion NN N
of IN N
TSE NNP N
information NN N
may MD N
improve VB N
acceptance NN N
of IN N
disease NN N
awareness NN N
information NN N
-DOCSTART- -X- O O

A DT N
double-blind NN N
randomized VBN N
controlled VBN N
multicenter NN N
study NN N
to TO N
assess VB N
the DT N
safety NN N
and CC N
cardiovascular JJ N
effects NNS N
of IN N
skeletal JJ N
myoblast NN N
implantation NN N
by IN N
catheter NN N
delivery NN N
in IN N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
after IN 4_p
myocardial JJ 4_p
infarction NN 4_p
BACKGROUND NNP N
We PRP N
sought VBD N
to TO N
determine VB N
the DT N
safety NN N
and CC N
preliminary JJ N
efficacy NN N
of IN N
transcatheter NN N
intramyocardial JJ N
administration NN N
of IN N
myoblasts NNS N
in IN N
patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
HF NNP 4_p
METHODS NNP N
MARVEL NNP N
is VBZ N
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
of IN N
image-guided JJ N
catheter-based JJ N
intramyocardial JJ N
injection NN N
of IN N
placebo NN N
or CC N
myoblasts NNS N
400 CD N
or CC N
800 CD N
million CD N
in IN N
patients NNS 4_p
with IN 4_p
class NN 4_p
II NNP 4_p
to TO 4_p
IV NNP 4_p
HF NNP 4_p
and CC 4_p
ejection NN 4_p
fraction NN 4_p
35 CD 4_p
Primary JJ N
end NN N
points NNS N
were VBD N
frequency NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
safety NN N
and CC N
changes NNS N
in IN N
6-minute JJ N
walk NN N
test NN N
and CC N
Minnesota NNP N
Living NNP N
With IN N
HF NNP N
score NN N
efficacy NN N
Of IN N
330 CD 3_p
patients NNS N
intended VBN N
for IN N
enrollment NN N
23 CD 3_p
were VBD N
randomized VBN N
MARVEL-1 NNP N
before IN N
stopping VBG N
the DT N
study NN N
for IN N
financial JJ N
reasons NNS N
RESULTS NNP N
At IN N
6 CD N
months NNS N
similar JJ N
numbers NNS N
of IN N
events NNS N
occurred VBN N
in IN N
each DT N
group NN N
8 CD N
placebo NN N
7 CD N
low JJ N
dose NN N
and CC N
8 CD N
high JJ N
dose NN N
without IN N
deaths NNS N
Ventricular JJ N
tachycardia NN N
responsive NN N
to TO N
amiodarone VB N
was VBD N
more RBR N
frequent JJ N
in IN N
myoblast-treated JJ N
patients NNS N
1 CD N
placebo NN N
3 CD N
low JJ N
dose NN N
and CC N
4 CD N
high JJ N
dose NN N
A DT N
trend NN N
toward IN N
improvement NN N
in IN N
functional JJ N
capacity NN N
was VBD N
noted VBN N
in IN N
myoblast-treated JJ N
groups NNS N
Δ6-minute JJ N
walk NN N
test NN N
of IN N
-3.6 NNP N
vs FW N
+95.6 NNP N
vs FW N
+85.5 NNP N
m FW N
placebo NN N
vs NN N
low JJ N
dose NN N
vs NN N
high JJ N
dose NN N
P NNP N
.50 NNP N
without IN N
significant JJ N
changes NNS N
in IN N
Minnesota NNP N
Living NNP N
With IN N
HF NNP N
scores NNS N
CONCLUSIONS NNP N
In IN N
HF NNP N
patients NNS N
with IN N
chronic JJ N
postinfarction NN N
cardiomyopathy NN N
transcatheter JJ N
administration NN N
of IN N
myoblasts NNS N
in IN N
doses NNS N
of IN N
400 CD N
to TO N
800 CD N
million CD N
cells NNS N
is VBZ N
feasible JJ N
and CC N
may MD N
lead VB N
to TO N
important JJ N
clinical JJ N
benefits NNS N
Ventricular JJ N
tachycardia NN N
may MD N
be VB N
provoked VBN N
by IN N
myoblast JJ N
injection NN N
but CC N
appears VBZ N
to TO N
be VB N
a DT N
transient NN N
and CC N
treatable JJ N
problem NN N
A DT N
large-scale JJ N
outcome JJ N
trial NN N
of IN N
myoblast JJ N
administration NN N
in IN N
HF NNP N
patients NNS N
with IN N
postinfarction NN N
cardiomyopathy NN N
is VBZ N
feasible JJ N
and CC N
warranted VBD N
-DOCSTART- -X- O O

Impact NNP N
of IN N
CCND1 NNP N
A870G NNP N
polymorphism NN N
on IN N
acute JJ N
adverse JJ N
events NNS N
in IN N
postoperative JJ 4_p
rectal JJ 4_p
cancer NN 4_p
patients NNS 4_p
treated VBN 4_p
with IN 4_p
adjuvant JJ 4_p
concurrent NN 4_p
chemoradiotherapy NN 4_p
OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
association NN N
between IN N
single JJ N
nucleotide JJ N
polymorphism NN N
SNP NNP N
of IN N
CCND1 NNP N
A870G NNP N
and CC N
acute JJ N
adverse JJ N
events NNS N
AEs NNP N
in IN N
postoperative JJ 4_p
rectal JJ 4_p
cancer NN 4_p
patients NNS 4_p
who WP 4_p
received VBD 4_p
capecitabine-based JJ 4_p
postoperative JJ 4_p
chemoradiotherapy NN 4_p
CRT NNP 4_p
METHODS NNP N
Four CD 3_p
hundred VBD 3_p
patients NNS 4_p
with IN 4_p
stage NN 4_p
II NNP 4_p
and CC 4_p
III NNP 4_p
rectal JJ 4_p
cancer NN 4_p
received VBD 4_p
postoperative JJ 4_p
CRT NNP 4_p
of IN N
capecitabine NN N
with IN N
or CC N
without IN N
oxaliplatin NNS N
were VBD N
accumulated VBN N
and CC N
prostectively RB N
studied VBN N
in IN N
this DT N
study NN N
The DT N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
Two CD N
hundred CD N
and CC N
twenty-eight JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
concurrent JJ N
capecitabine NN N
and CC N
radiotherapy NN N
Cap-CRT NNP N
and CC N
172 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
capecitabine NN N
and CC N
oxaliplatin JJ N
plus CC N
radiotherapy JJ N
Cap-Oxa-CRT NNP N
Adverse JJ N
events NNS N
were VBD N
graded VBN N
according VBG N
to TO N
the DT N
Common NNP N
Terminology NNP N
Criteria NNP N
for IN N
Adverse NNP N
Events NNP N
v. NN N
3.0 CD N
CTCAE NNP N
v3.0 NN N
The DT N
genotype NN N
of IN N
CCND1 NNP N
A870G NNP N
in IN N
the DT N
patients NNS N
was VBD N
detected VBN N
by IN N
polymerase NN N
chain NN N
reaction-based JJ N
restriction NN N
fragment NN N
length NN N
polymorphism NN N
PCR-RFLP NNP N
analysis NN N
The DT N
associations NNS N
between IN N
the DT N
SNP NNP N
and CC N
acute JJ N
AEs NNP N
were VBD N
indicated VBN N
by IN N
odds NNS N
ratios NNS N
ORs NNP N
and CC N
95 CD N
confidence NN N
intervals NNS N
CIs NNP N
which WDT N
were VBD N
computed VBN N
with IN N
logistic JJ N
regression NN N
model NN N
RESULTS VB N
A DT N
total NN N
of IN N
136 CD N
patients NNS N
presented VBN N
severe JJ N
AEs NNP N
Among IN N
them PRP N
the DT N
frequencies NNS N
of IN N
the DT N
three CD N
genotypes NNS N
GG NNP N
GA NNP N
and CC N
AA NNP N
were VBD N
16.9 CD N
50.7 CD N
and CC N
32.4 CD N
compared VBN N
with IN N
24.6 CD N
48.1 CD N
and CC N
27.3 CD N
respectively RB N
among IN N
the DT N
patients NNS N
without IN N
severe JJ N
AEs NNP N
Diarrhea NNP N
was VBD N
the DT N
most RBS N
common JJ N
AE NNP N
and CC N
severe JJ N
diarrhea NN N
occurred VBD N
in IN N
109 CD N
patients NNS N
The DT N
frequencies NNS N
of IN N
the DT N
three CD N
genotypes NNS N
GG NNP N
GA NNP N
and CC N
AA NNP N
were VBD N
15.6 CD N
47.7 CD N
and CC N
36.7 CD N
among IN N
these DT N
patients NNS N
compared VBN N
with IN N
24.4 CD N
49.5 CD N
and CC N
26.1 CD N
respectively RB N
among IN N
patients NNS N
without IN N
severe JJ N
diarrhea NN N
Multivariate NNP N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
a DT N
1.66-fold JJ N
increased JJ N
risk NN N
for IN N
severe JJ N
diarrhea NN N
in IN N
patients NNS N
with IN N
AA NNP N
genotype NN N
95 CD N
CI NNP N
1.03 CD N
2.67 CD N
P NNP N
0.038 CD N
compared VBN N
with IN N
the DT N
cases NNS N
with IN N
GG NNP N
or CC N
GA NNP N
genotypes NNS N
Stratified VBN N
analysis NN N
showed VBD N
that IN N
in IN N
the DT N
Cap-Oxa-CRT NNP N
group NN N
patients NNS N
with IN N
AA NNP N
genotype NN N
showed VBD N
a DT N
2.34-fold JJ N
increased JJ N
risk NN N
for IN N
severe JJ N
diarrhea NN N
95 CD N
CI NNP N
1.16 CD N
4.76 CD N
P NNP N
0.018 CD N
compared VBN N
with IN N
those DT N
with IN N
GG NNP N
or CC N
GA NNP N
genotypes NNS N
but CC N
in IN N
the DT N
Cap-CRT NNP N
group NN N
the DT N
SNP NNP N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
severe JJ N
diarrhea NN N
CONCLUSIONS VB N
The DT N
genetic JJ N
polymorphism NN N
of IN N
CCND1 NNP N
A870G NNP N
might MD N
be VB N
a DT N
potential JJ N
biomarker NN N
for IN N
predicting VBG N
acute JJ N
AEs NNP N
in IN N
postoperative JJ 4_p
stage NN 4_p
II NNP 4_p
and CC 4_p
III NNP 4_p
rectal JJ 4_p
cancer NN 4_p
patients NNS 4_p
treated VBN N
with IN N
adjuvant JJ N
concurrent JJ N
chemoradiotherapy NN N
of IN N
capecitabine NN N
and CC N
oxaliplatin NN N
-DOCSTART- -X- O O

Effect NN N
of IN N
indomethacin JJ N
phonophoresis NN N
on IN N
the DT N
relief NN N
of IN N
temporomandibular JJ 4_p
joint NN 4_p
pain NN 4_p
The DT N
pain-relieving JJ N
effect NN N
of IN N
indomethacin JJ N
phonophoresis NN N
on IN N
temporomandibular NN N
TMJ NNP N
joint NN N
pain NN N
was VBD N
evaluated VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
clinical JJ N
trial NN N
Twenty NNP 3_p
subjects NNS 4_p
who WP 4_p
have VBP 4_p
TMJ NNP 4_p
pain NN 4_p
were VBD N
included VBN N
for IN N
this DT N
study NN N
and CC N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
n JJ N
10 CD N
or CC N
the DT N
control NN N
group NN N
n JJ N
10 CD N
Each DT N
treatment NN N
consisted VBN N
of IN N
the DT N
application NN N
of IN N
ultrasound JJ N
massage NN N
1.0 CD N
MHz NNP N
0.8 CD N
to TO N
1.5 CD N
W/cm2 NNP N
continuous JJ N
output NN N
for IN N
15 CD N
minutes NNS N
to TO N
the DT N
painful JJ N
temporomandibular JJ N
joint NN N
As IN N
a DT N
conducting NN N
medium NN N
1 CD N
indomethacin JJ N
cream NN N
was VBD N
used VBN N
for IN N
the DT N
experimental JJ N
group NN N
and CC N
placebo NN N
cream NN N
for IN N
the DT N
control NN N
group NN N
respectively RB N
Pre- JJ N
and CC N
post-treatment JJ N
pain NN N
levels NNS N
and CC N
pain NN N
sensitivity NN N
were VBD N
assessed VBN N
with IN N
visual JJ N
analogue NN N
scales NNS N
VAS NNP N
and CC N
pressure NN N
pain NN N
threshold NN N
PPT NNP N
Mean NNP N
data NNS N
indicated VBD N
that IN N
post-treatment JJ N
VAS NNP N
was VBD N
significantly RB N
decreased VBN N
and CC N
post-treatment JJ N
PPT NNP N
was VBD N
significantly RB N
increased VBN N
in IN N
the DT N
experimental JJ N
group NN N
not RB N
in IN N
the DT N
control NN N
group NN N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
indomethacin JJ N
phonophoresis NN N
provides VBZ N
significant JJ N
pain NN N
relieving VBG N
effect NN N
over IN N
the DT N
TMJ NNP N
pain NN N
-DOCSTART- -X- O O

Systemic NNP N
hemodynamic NN N
neurohormonal JJ N
and CC N
renal JJ N
effects NNS N
of IN N
a DT N
steady-state JJ N
infusion NN N
of IN N
human JJ N
brain NN N
natriuretic JJ N
peptide NN N
in IN N
patients NNS 4_p
with IN 4_p
hemodynamically RB 4_p
decompensated VBN 4_p
heart NN 4_p
failure NN 4_p
BACKGROUND NNP N
Human NNP N
brain NN N
natriuretic JJ N
peptide NN N
hBNP NN N
is VBZ N
a DT N
promising JJ N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
decompensated JJ N
cardiac JJ N
failure NN N
However RB N
the DT N
systemic JJ N
hemodynamic NN N
neurohormonal JJ N
and CC N
renal JJ N
effects NNS N
of IN N
hBNP NNS N
have VBP N
been VBN N
incompletely RB N
studied VBN N
in IN N
human JJ N
heart NN N
failure NN N
METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
effects NNS N
of IN N
a DT N
continuous JJ N
4-hour JJ N
infusion NN N
of IN N
hBNP NN N
were VBD N
determined VBN N
in IN N
16 CD 3_p
decompensated JJ 4_p
heart NN 4_p
failure NN 4_p
patients NNS 4_p
in IN N
an DT N
invasive JJ N
randomized VBN N
double-blind JJ N
placebo-controlled JJ N
study NN N
Patients NNS N
were VBD N
evaluated VBN N
during IN N
three CD N
4-hour JJ N
study NN N
periods NNS N
baseline NN N
treatment NN N
placebo JJ N
n NN N
4 CD N
versus NN N
hBNP NN N
0.025 CD N
or CC N
0.05 CD N
microgram/kg/min NNS N
n JJ N
12 CD N
and CC N
post-treatment NN N
Urinary JJ N
volume NN N
losses NNS N
were VBD N
replaced VBN N
hourly RB N
to TO N
separate VB N
the DT N
vasodilatory NN N
and CC N
diuretic JJ N
effects NNS N
of IN N
hBNP NN N
Two CD N
patients NNS N
in IN N
the DT N
hBNP NN N
group NN N
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
because IN N
of IN N
adverse JJ N
events NNS N
hBNP NN N
significantly RB N
P NNP N
.001 NNP N
reduced VBD N
right JJ N
atrial JJ N
pressure NN N
and CC N
pulmonary JJ N
capillary JJ N
wedge NN N
pressure NN N
by IN N
approximately RB N
30 CD N
and CC N
40 CD N
respectively RB N
hBNP NN N
also RB N
significantly RB N
lowered VBN N
systemic JJ N
vascular JJ N
resistance NN N
from IN N
1722 CD N
+/- JJ N
139 CD N
to TO N
1101 CD N
+/- JJ N
83 CD N
dynes.s.cm-5 NN N
P NNP N
.05 NNP N
These DT N
unloading JJ N
effects NNS N
of IN N
hBNP NN N
produced VBD N
a DT N
28 CD N
increase NN N
in IN N
cardiac JJ N
index NN N
P NNP N
.05 NNP N
with IN N
no DT N
change NN N
in IN N
heart NN N
rate NN N
Compared VBN N
to TO N
placebo VB N
hBNP VB N
decreased VBN N
plasma JJ N
norepinephrine NN N
and CC N
aldosterone NN N
Renal JJ N
hemodynamics NNS N
were VBD N
unaffected VBN N
by IN N
hBNP NN N
however RB N
most JJS N
patients NNS N
were VBD N
resistant JJ N
to TO N
its PRP$ N
natriuretic JJ N
effect NN N
CONCLUSIONS NNP N
1 CD N
The DT N
predominant JJ N
hemodynamic JJ N
effects NNS N
of IN N
hBNP NN N
were VBD N
a DT N
decrease NN N
in IN N
cardiac JJ N
preload NN N
and CC N
systemic JJ N
vascular JJ N
resistance NN N
2 CD N
hBNP NN N
also RB N
improved VBD N
cardiac JJ N
output NN N
without IN N
increasing VBG N
heart NN N
rate NN N
3 CD N
Plasma NNP N
norepinephrine NN N
and CC N
aldosterone NN N
levels NNS N
decreased VBN N
during IN N
hBNP JJ N
infusion NN N
4 CD N
hBNP NN N
is VBZ N
pharmacologically RB N
active JJ N
and CC N
has VBZ N
potential VBN N
in IN N
the DT N
therapy NN N
for IN N
decompensated JJ N
heart NN N
failure NN N
-DOCSTART- -X- O O

Is VBZ N
a DT N
2-week JJ N
duration NN N
sufficient NN N
for IN N
stenting VBG N
in IN N
endopyelotomy NN N
PURPOSE NNP N
Internal NNP N
stenting NN N
is VBZ N
an DT N
integral JJ N
part NN N
of IN N
endopyelotomy NN N
Studies NNS N
in IN N
animals NNS N
show VBP N
good JJ N
healing NN N
after IN N
1 CD N
to TO N
2 CD N
weeks NNS N
of IN N
ureterotomy JJ N
Inherent JJ N
stent NN N
related VBN N
problems NNS N
warrant VBP N
a DT N
minimum JJ N
possible JJ N
duration NN N
of IN N
stenting VBG N
without IN N
compromising VBG N
the DT N
results NNS N
of IN N
endopyelotomy JJ N
We PRP N
performed VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
evaluate VB N
the DT N
optimum JJ N
duration NN N
of IN N
stenting VBG N
after IN N
endopyelotomy NN N
MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
57 CD 3_p
consecutive JJ N
patients NNS 4_p
with IN 4_p
primary JJ 4_p
ureteropelvic JJ 4_p
junction NN 4_p
obstruction NN 4_p
were VBD N
randomized VBN N
to TO N
undergo VB N
7/14Fr CD N
internal JJ N
endopyelotomy NN N
stent JJ N
placement NN N
for IN N
2 CD N
group NN N
1 CD N
and CC N
4 CD N
group NN N
2 CD N
weeks NNS N
A DT N
symptom NN N
based VBN N
questionnaire NN N
was VBD N
administered VBN N
to TO N
all DT N
patients NNS N
at IN N
stent JJ N
removal NN N
Followup NNP N
was VBD N
done VBN N
with IN N
diuretic JJ N
scanning NN N
at IN N
3 CD N
6 CD N
9 CD N
and CC N
12 CD N
months NNS N
and CC N
then RB N
yearly RB N
and CC N
thereafter RB N
with IN N
diuretic JJ N
renography NN N
RESULTS NNP N
In IN N
each DT N
group NN N
26 CD N
patients NNS N
were VBD N
available JJ N
for IN N
evaluation NN N
The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
age NN N
sex NN N
symptoms NNS N
and CC N
ipsilateral JJ N
glomerular JJ N
filtration NN N
rate NN N
Mean NNP N
followup NN N
was VBD N
22.3 CD N
range NN N
12 CD N
to TO N
36 CD N
and CC N
21.3 CD N
months NNS N
range VB N
12 CD N
to TO N
35 CD N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
respectively RB N
At IN N
the DT N
end NN N
of IN N
1 CD N
year NN N
24 CD N
group NN N
1 CD N
92.3 CD N
and CC N
23 CD N
group NN N
2 CD N
90.3 CD N
patients NNS N
had VBD N
an DT N
improved JJ N
drainage NN N
pattern NN N
This DT N
difference NN N
was VBD N
not RB N
significant JJ N
Stent NNP N
related JJ N
symptoms NNS N
were VBD N
present JJ N
in IN N
a DT N
good JJ N
proportion NN N
of IN N
patients NNS N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
but CC N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
urinary JJ N
tract NN N
infections NNS N
11.5 CD N
versus IN N
38.1 CD N
p NN N
0.04 CD N
Of IN N
the DT N
group NN N
2 CD N
patients NNS N
64 CD N
preferred JJ N
2 CD N
weeks NNS N
of IN N
stenting VBG N
CONCLUSIONS NNP N
Two CD N
weeks NNS N
seems VBZ N
to TO N
be VB N
a DT N
sufficient JJ N
duration NN N
to TO N
allow VB N
functional JJ N
restoration NN N
across IN N
the DT N
ureteropelvic JJ N
junction NN N
after IN N
endopyelotomy NN N
and CC N
decrease NN N
stent NN N
related JJ N
complications NNS N
-DOCSTART- -X- O O

Effects NNS N
of IN N
tryptophan JJ N
depletion NN N
in IN N
drug-free JJ 4_p
adults NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
BACKGROUND IN N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
behavioral JJ N
and CC N
biochemical JJ N
responses NNS N
to TO N
acute VB N
tryptophan JJ N
depletion NN N
in IN N
drug-free JJ 4_p
adult NN 4_p
patients NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
METHODS NNP N
Twenty NNP 3_p
drug-free JJ 4_p
adults NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
16 CD 3_p
men NNS 3_p
and CC 3_p
4 CD 3_p
women NNS 3_p
mean JJ 1_p
+/- NN 1_p
SD NNP 1_p
age NN 1_p
30.5 CD 1_p
+/- JJ 1_p
8.5 CD 1_p
years NNS 1_p
underwent JJ N
short-term JJ N
tryptophan NN N
depletion NN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
randomized JJ N
crossover NN N
design NN N
Patients NNS N
received VBD N
a DT N
24-hour JJ N
low-tryptophan JJ N
diet NN N
followed VBD N
the DT N
next JJ N
morning NN N
by IN N
an DT N
amino NN N
acid NN N
drink NN N
Behavioral JJ N
ratings NNS N
were VBD N
obtained VBN N
on IN N
the DT N
morning NN N
of IN N
the DT N
amino NN N
acid NN N
drink NN N
baseline NN N
and CC N
180 CD N
300 CD N
and CC N
420 CD N
minutes NNS N
after IN N
the DT N
drink NN N
Plasma NNP N
free JJ N
and CC N
total JJ N
tryptophan NN N
levels NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
5 CD N
hours NNS N
after IN N
the DT N
drink NN N
The DT N
active JJ N
and CC N
sham JJ N
testing NN N
sessions NNS N
were VBD N
separated VBN N
by IN N
7 CD N
days NNS N
RESULTS NNP N
Eleven NNP N
65 CD N
of IN N
the DT N
17 CD N
patients NNS N
who WP N
completed VBD N
both DT N
test NN N
days NNS N
showed VBD N
a DT N
significant JJ N
global JJ N
worsening NN N
of IN N
behavioral JJ N
symptoms NNS N
with IN N
short-term JJ N
tryptophan NN N
depletion NN N
but CC N
none NN N
of IN N
the DT N
17 CD N
patients NNS N
showed VBD N
any DT N
significant JJ N
change NN N
in IN N
clinical JJ N
status NN N
from IN N
baseline NN N
after IN N
sham JJ N
depletion NN N
P NNP N
.001 NNP N
Tryptophan NNP N
depletion NN N
led VBD N
to TO N
a DT N
significant JJ N
increase NN N
in IN N
behaviors NNS N
such JJ N
as IN N
whirling NN N
flapping NN N
pacing NN N
banging NN N
and CC N
hitting VBG N
self NN N
rocking NN N
and CC N
toe NN N
walking NN N
P NNP N
.05 NNP N
In IN N
addition NN N
patients NNS N
were VBD N
significantly RB N
less JJR N
calm JJ N
and CC N
happy JJ N
and CC N
more RBR N
anxious JJ N
No DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
social JJ N
relatedness NN N
or CC N
repetitive JJ N
thoughts NNS N
and CC N
behavior NN N
Plasma NNP N
total JJ N
and CC N
free JJ N
tryptophan NN N
levels NNS N
were VBD N
reduced VBN N
86 CD N
and CC N
69 CD N
respectively RB N
5 CD N
hours NNS N
after IN N
the DT N
tryptophan-deficient JJ N
amino NN N
acid NN N
drink NN N
Patients NNS N
who WP N
had VBD N
a DT N
significant JJ N
global JJ N
exacerbation NN N
of IN N
symptoms NNS N
had VBD N
significantly RB N
higher JJR N
baseline NN N
plasma IN N
total JJ N
tryptophan NN N
levels NNS N
P NNP N
.001 NNP N
and CC N
Autism NNP N
Behavior NNP N
Checklist NNP N
scores NNS N
P NNP N
.005 NNP N
than IN N
did VBD N
patients NNS N
who WP N
showed VBD N
no DT N
significant JJ N
change NN N
in IN N
symptoms NNS N
after IN N
tryptophan JJ N
depletion NN N
CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
that WDT N
has VBZ N
implicated VBN N
a DT N
dysregulation NN N
in IN N
serotonin JJ N
function NN N
in IN N
some DT N
patients NNS 4_p
with IN 4_p
autism NN 4_p
These DT N
data NNS N
suggest VBP N
that IN N
the DT N
short-term JJ N
reduction NN N
of IN N
serotonin NN N
precursor NN N
availability NN N
may MD N
exacerbate VB N
some DT N
symptoms NNS N
characteristic JJ N
of IN N
autism NN N
in IN N
some DT N
patients NNS N
Continued JJ N
investigation NN N
into IN N
the DT N
role NN N
of IN N
serotonin NN N
in IN N
the DT N
pathogenesis NN N
and CC N
treatment NN N
of IN N
autistic JJ N
disorder NN N
is VBZ N
warranted VBN N
-DOCSTART- -X- O O

The DT N
chemotherapy NN N
of IN N
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
A DT N
report NN N
on IN N
the DT N
first JJ N
600 CD 3_p
cases NNS 3_p
in IN N
a DT N
cooperative JJ N
programme NN N
to TO N
carry VB N
out RP N
a DT N
systematic JJ N
study NN N
1974-1977 JJ N
author NN N
's POS N
transl NN N
The DT N
authors NNS N
explain VBP N
the DT N
objectives NNS N
and CC N
the DT N
structure NN N
of IN N
a DT N
programme NN N
evolved VBN N
for IN N
the DT N
methodic JJ N
study NN N
of IN N
advanced JJ 4_p
breast NN 4_p
cancers NNS 4_p
which WDT N
they PRP N
have VBP N
worked VBN N
out RP N
and CC N
carried VBD N
out RP N
in IN N
cooperation NN N
with IN N
the DT N
departments NNS N
of IN N
medicine NN N
in IN 4_p
eight CD 4_p
French JJ 4_p
anticancer NN 4_p
centres NNS 4_p
They PRP N
analyse VBP N
the DT N
initial JJ N
phases NNS N
which WDT N
correspond NN N
to TO N
the DT N
three CD N
first JJ N
years NNS N
of IN N
work NN N
They PRP N
give VBP N
the DT N
state NN N
of IN N
the DT N
results NNS N
that WDT N
have VBP N
been VBN N
obtained VBN N
in IN N
603 CD 3_p
patients NNS 3_p
using VBG N
three CD N
protocols NNS N
for IN N
treatment NN N
These DT N
consisted VBN N
of IN N
the DT N
administration NN N
in IN N
interrupted JJ N
doses NNS N
of IN N
chemotherapy NN N
which WDT N
consisted VBD N
of IN N
vincristine NN N
associated VBN N
for IN N
the DT N
one CD N
part NN N
with IN N
cyclophosphamide NN N
and CC N
5-fluoro-uracil JJ N
and CC N
on IN N
the DT N
other JJ N
hand NN N
with IN N
doxorubicine NN N
or/and NN N
with IN N
methotrexate NN N
From IN N
this DT N
study NN N
there RB N
emerged VBD N
the DT N
value NN N
of IN N
combined JJ N
therapy NN N
using VBG N
doxorubicine NN N
as IN N
much JJ N
because IN N
of IN N
the DT N
frequency NN N
with IN N
which WDT N
results NNS N
better JJR N
than IN N
50 CD N
were VBD N
obtained VBN N
in IN N
a DT N
randomised JJ N
trial NN N
as IN N
by IN N
their PRP$ N
quality NN N
which WDT N
was VBD N
made VBN N
clear JJ N
in IN N
an DT N
important JJ N
series NN N
of IN N
240 CD N
cases NNS N
They PRP N
point VBP N
out RP N
the DT N
conditions NNS N
required VBN N
to TO N
initiate VB N
the DT N
place NN N
of IN N
such PDT N
a DT N
scheme NN N
in IN N
all DT N
complex JJ N
therapy NN N
which WDT N
aims VBZ N
as RB N
much JJ N
at IN N
palliation NN N
as IN N
at IN N
cure NN N
and CC N
point VB N
out RP N
how WRB N
important JJ N
it PRP N
is VBZ N
to TO N
be VB N
methodical JJ N
in IN N
the DT N
application NN N
of IN N
chemotherapy NN N
in IN N
order NN N
to TO N
ensure VB N
its PRP$ N
development NN N
as IN N
an DT N
anticancer NN N
therapy NN N
-DOCSTART- -X- O O

Clinical NNP N
study NN N
of IN N
the DT N
efficacy NN N
of IN N
and CC N
tolerance NN N
to TO N
nimesulide VB N
in IN N
suppository JJ N
formulation NN N
in IN N
pain-inflammatory JJ N
pathologies NNS N
of IN N
the DT N
ear NN N
nose RB N
and CC N
throat NN N
The DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
a DT N
new JJ N
pharmaceutical JJ N
form NN N
of IN N
the DT N
non-steroid JJ N
anti-inflammatory JJ N
drug NN N
Nimesulide NNP N
have VBP N
been VBN N
studied VBN N
in IN N
a DT N
double JJ N
blind NN N
study NN N
compared VBN N
with IN N
flurbiprofen NN N
in IN N
98 CD 3_p
patients NNS N
aged VBN 1_p
between IN 1_p
18 CD 1_p
and CC 1_p
75 CD 1_p
suffering VBG N
from IN N
pain-inflammatory JJ 4_p
pathologies NNS 4_p
of IN 4_p
ENT NNP 4_p
nature NN 4_p
Both DT N
drugs NNS N
administered VBN N
in IN N
a DT N
dose NN N
of IN N
one CD N
suppository NN N
twice RB N
a DT N
day NN N
for IN N
7 CD N
days NNS N
showed VBD N
marked JJ N
anti-inflammatory JJ N
analgesic JJ N
and CC N
antipyretic JJ N
activity NN N
and CC N
produced VBD N
a DT N
significant JJ N
progressive JJ N
improvement NN N
in IN N
the DT N
typical JJ N
symptoms NNS N
of IN N
the DT N
inflammatory NN N
state NN N
up IN N
to TO N
their PRP$ N
complete JJ N
remission NN N
Nimesulide NNP N
evidenced VBD N
greater JJR N
speed NN N
and CC N
duration NN N
of IN N
therapeutic JJ N
action NN N
Assessment NN N
on IN N
the DT N
effectiveness NN N
and CC N
tolerability NN N
as IN N
expressed VBN N
separately RB N
by IN N
the DT N
physician NN N
and CC N
patient NN N
were VBD N
positive JJ N
in IN N
almost RB N
all DT N
cases NNS N
of IN N
both DT N
treatments NNS N
-DOCSTART- -X- O O

Influence NN N
of IN N
diets NNS N
rich JJ N
in IN N
Maillard NNP N
reaction NN N
products NNS N
on IN N
calcium NN N
bioavailability NN N
Assays NNS N
in IN N
male JJ 2_p
adolescents NNS 2_p
and CC N
in IN N
Caco-2 NNP N
cells NNS N
The DT N
effects NNS N
of IN N
the DT N
high JJ N
intake NN N
of IN N
Maillard NNP N
reaction NN N
products NNS N
MRP NNP N
on IN N
calcium NN N
availability NN N
in IN N
adolescents NNS 1_p
and CC N
across IN N
Caco-2 NNP N
cell NN N
monolayers NNS N
were VBD N
examined VBN N
In IN N
a DT N
2 CD N
week NN N
randomized VBN N
two-period JJ N
crossover NN N
trial NN N
18 CD 3_p
male NN 2_p
adolescents NNS 1_p
consumed VBD N
two CD N
diets NNS N
named VBN N
white JJ N
diet NN N
WD NNP N
and CC N
brown JJ N
diet NN N
BD NNP N
which WDT N
were VBD N
poor JJ N
and CC N
rich JJ N
in IN N
MRP NNP N
respectively RB N
A DT N
3 CD N
day NN N
balance NN N
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
period NN N
and CC N
fasting VBG N
blood NN N
samples NNS N
were VBD N
collected VBN N
Calcium NNP N
solubility NN N
and CC N
absorption NN N
across IN N
Caco-2 NNP N
cells NNS N
were VBD N
studied VBN N
after IN N
the DT N
in IN N
vitro JJ N
digestion NN N
of IN N
the DT N
diets NNS N
The DT N
in IN N
vitro NN N
assay NN N
showed VBD N
similar JJ N
solubility NN N
after IN N
the DT N
in IN N
vitro JJ N
digestion NN N
and CC N
similar JJ N
transport NN N
across IN N
Caco-2 NNP N
cells NNS N
In IN N
accordance NN N
calcium NN N
bioavailability NN N
in IN N
adolescents NNS N
did VBD N
not RB N
vary JJ N
between IN N
the DT N
diets NNS N
WD NNP N
40.4 CD N
+/- JJ N
5.1 CD N
BD NNP N
38.2 CD N
+/- JJ N
3.6 CD N
Serum NNP N
and CC N
urine JJ N
biochemical JJ N
parameters NNS N
related VBN N
to TO N
calcium NN N
status NN N
and CC N
bone NN N
metabolism NN N
remained VBD N
unaltered JJ N
Only RB N
deoxypyridinoline JJ N
values NNS N
were VBD N
significantly RB N
lower JJR N
after IN N
consumption NN N
of IN N
the DT N
BD NNP N
13.0 CD N
+/- JJ N
1.1 CD N
compared VBN N
to TO N
18.3 CD N
+/- JJ N
2.1 CD N
nM/Mm JJ N
Cr NNP N
in IN N
the DT N
WD NNP N
possibly RB N
indicative JJ N
of IN N
less RBR N
efficient JJ N
bone NN N
turnover NN N
during IN N
this DT N
period NN N
As IN N
calcium NN N
acquired VBD N
during IN N
adolescence NN N
is VBZ N
essential JJ N
to TO N
maximize VB N
peak JJ N
bone NN N
mass NN N
and CC N
to TO N
prevent VB N
osteoporosis NN N
possible JJ N
long-term JJ N
effects NNS N
of IN N
excessive JJ N
MRP NNP N
intake NN N
during IN N
this DT N
period NN N
warrant JJ N
attention NN N
-DOCSTART- -X- O O

Inhaled VBN N
fluticasone NN N
reduces NNS N
sputum VBP N
inflammatory JJ N
indices NNS N
in IN N
severe JJ 4_p
bronchiectasis NN 4_p
Although IN N
corticosteroid JJ N
therapy NN N
might MD N
be VB N
clinically RB N
beneficial JJ N
for IN N
bronchiectasis NN N
very RB N
little JJ N
is VBZ N
known VBN N
of IN N
its PRP$ N
effects NNS N
on IN N
the DT N
inflammatory NN N
and CC N
infective JJ N
markers NNS N
in IN N
bronchiectasis NN N
We PRP N
have VBP N
therefore RB N
performed VBN N
a DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
4-wk JJ N
administration NN N
of IN N
inhaled JJ N
fluticasone NN N
in IN N
bronchiectasis NN N
Twenty-four CD 3_p
patients NNS N
12 CD 3_p
female NN N
mean JJ 1_p
age NN 1_p
51 CD 1_p
yr NN 1_p
were VBD N
randomized VBN N
into IN N
receiving VBG N
either CC N
inhaled JJ N
fluticasone NN N
500 CD N
microgram NN N
twice RB N
daily RB N
via IN N
the DT N
Accuhaler NNP N
device NN N
n JJ N
12 CD N
or CC N
placebo NN N
At IN N
each DT N
visit NN N
spirometry NN N
24-h JJ N
sputum NN N
volume NN N
sputum NN N
leukocyte NN N
density NN N
bacterial JJ N
densities NNS N
and CC N
concentrations NNS N
of IN N
interleukin NN N
IL NNP N
-1beta NN N
IL-8 NNP N
tumor NN N
necrosis NN N
factor-alpha JJ N
TNF-alpha NNP N
and CC N
leukotriene JJ N
B4 NNP N
LTB4 NNP N
were VBD N
determined VBN N
There EX N
was VBD N
a DT N
significant JJ N
p JJ N
0.05 CD N
decrease NN N
in IN N
sputum NN N
leukocyte NN N
density NN N
and CC N
IL-1beta NNP N
IL-8 NNP N
and CC N
LTB4 NNP N
after IN N
fluticasone NN N
treatment NN N
The DT N
fluticasone NN N
group NN N
had VBD N
one CD N
and CC N
the DT N
placebo NN N
group NN N
three CD N
episodes NNS N
of IN N
exacerbation NN N
There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
spirometry NN N
p JJ N
0.05 CD N
or CC N
any DT N
reported JJ N
adverse JJ N
reactions NNS N
in IN N
either DT N
group NN N
The DT N
results NNS N
of IN N
this DT N
study NN N
show VB N
that IN N
high-dose JJ N
fluticasone NN N
is VBZ N
effective JJ N
in IN N
reducing VBG N
the DT N
sputum NN N
inflammatory NN N
indices NNS N
in IN N
bronchiectasis NN N
Large-scale JJ N
and CC N
long-term JJ N
studies NNS N
are VBP N
indicated VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
inhaled JJ N
steroid JJ N
therapy NN N
on IN N
the DT N
inflammatory JJ N
components NNS N
in IN N
bronchiectasis NN 4_p
-DOCSTART- -X- O O

Neural JJ N
basis NN N
of IN N
self NN N
and CC N
other JJ N
representation NN N
in IN N
autism NN 4_p
an DT N
FMRI NNP N
study NN N
of IN N
self-face JJ N
recognition NN N
BACKGROUND NNP N
Autism NNP N
is VBZ N
a DT N
developmental JJ N
disorder NN N
characterized VBN N
by IN N
decreased JJ N
interest NN N
and CC N
engagement NN N
in IN N
social JJ N
interactions NNS N
and CC N
by IN N
enhanced JJ N
self-focus NN N
While IN N
previous JJ N
theoretical JJ N
approaches NNS N
to TO N
understanding VBG N
autism NN N
have VBP N
emphasized VBN N
social JJ N
impairments NNS N
and CC N
altered VBD N
interpersonal JJ N
interactions NNS N
there EX N
is VBZ N
a DT N
recent JJ N
shift NN N
towards NNS N
understanding VBG N
the DT N
nature NN N
of IN N
the DT N
representation NN N
of IN N
the DT N
self NN N
in IN N
individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
ASD NNP 4_p
Still RB N
the DT N
neural JJ N
mechanisms NNS N
subserving VBG N
self-representations NNS N
in IN N
ASD NNP N
are VBP N
relatively RB N
unexplored JJ N
METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
We PRP N
used VBD N
event-related JJ N
fMRI NN N
to TO N
investigate VB N
brain NN N
responsiveness NN N
to TO N
images NNS N
of IN N
the DT N
subjects NNS N
own JJ N
face NN N
and CC N
to TO N
faces VBZ N
of IN N
others NNS N
Children NNP 1_p
with IN N
ASD NNP 4_p
and CC 4_p
typically RB 4_p
developing VBG 4_p
TD NNP 4_p
children NNS 4_p
viewed VBD N
randomly RB N
presented VBN N
digital JJ N
morphs NN N
between IN N
their PRP$ N
own JJ N
face NN N
and CC N
a DT N
gender-matched JJ N
other JJ N
face NN N
and CC N
made VBD N
self/other CC N
judgments NNS N
Both DT N
groups NNS N
of IN N
children NNS N
activated VBD N
a DT N
right JJ N
premotor/prefrontal NN N
system NN N
when WRB N
identifying VBG N
images NNS N
containing VBG N
a DT N
greater JJR N
percentage NN N
of IN N
the DT N
self JJ N
face NN N
However RB N
while IN N
TD NNP N
children NNS N
showed VBD N
activation NN N
of IN N
this DT N
system NN N
during IN N
both DT N
self- JJ N
and CC N
other-processing JJ N
children NNS N
with IN N
ASD NNP N
only RB N
recruited VBD N
this DT N
system NN N
while IN N
viewing VBG N
images NNS N
containing VBG N
mostly RB N
their PRP$ N
own JJ N
face NN N
CONCLUSIONS/SIGNIFICANCE VB N
This DT N
functional JJ N
dissociation NN N
between IN N
the DT N
representation NN N
of IN N
self NN N
versus NN N
others NNS N
points NNS N
to TO N
a DT N
potential JJ N
neural JJ N
substrate NN N
for IN N
the DT N
characteristic JJ N
self-focus NN N
and CC N
decreased VBN N
social JJ N
understanding NN N
exhibited VBN N
by IN N
these DT N
individuals NNS N
and CC N
suggests VBZ N
that IN N
individuals NNS N
with IN N
ASD NNP N
lack VBP N
the DT N
shared JJ N
neural JJ N
representations NNS N
for IN N
self NN N
and CC N
others NNS N
that IN N
TD NNP N
children NNS N
and CC N
adults NNS N
possess NN N
and CC N
may MD N
use VB N
to TO N
understand VB N
others NNS N
-DOCSTART- -X- O O

Effects NNS N
of IN N
mild JJ N
physical JJ N
exercise NN N
on IN N
serum NN N
lipoproteins NNS N
and CC N
metabolites NNS N
of IN N
arachidonic JJ N
acid NN N
a DT N
controlled VBN N
randomised JJ N
trial NN N
in IN N
middle JJ 1_p
aged VBN 1_p
men NNS 1_p
To TO N
study VB N
the DT N
effects NNS N
of IN N
physical JJ N
exercise NN N
on IN N
biochemical JJ N
risk NN N
factors NNS N
for IN N
ischaemic JJ N
heart NN N
disease NN N
31 CD 3_p
healthy JJ 4_p
middle NNS 1_p
aged VBN 1_p
men NNS 1_p
undertook IN N
regular JJ N
physical JJ N
exercise NN N
for IN N
two CD N
months NNS N
and CC N
29 CD N
served VBD N
as IN N
controls NNS N
in IN N
a DT N
randomised JJ N
trial NN N
In IN N
the DT N
men NNS N
taking VBG N
regular JJ N
exercise NN N
serum NN N
cholesterol NN N
concentrations NNS N
increased VBD N
26 CD N
more JJR N
in IN N
the DT N
high JJ N
density NN N
lipoprotein VBP N
subfraction NN N
two CD N
HDL2 NNP N
and CC N
decreased VBD N
31 CD N
more JJR N
in IN N
the DT N
subfraction NN N
three CD N
HDL3 NNP N
and CC N
9 CD N
more JJR N
in IN N
the DT N
low JJ N
density NN N
lipoprotein NN N
fraction NN N
than IN N
in IN N
the DT N
control NN N
group NN N
A DT N
tendency NN N
towards NNS N
increased VBD N
plasma JJ N
6-keto-prostaglandin JJ N
F1 NNP N
alpha NN N
concentration NN N
and CC N
decreased VBD N
serum NN N
thromboxane NN N
B2 NNP N
concentration NN N
was VBD N
found VBN N
during IN N
the DT N
period NN N
of IN N
regular JJ N
exercise NN N
but CC N
prostaglandin VBP N
E2 NNP N
concentrations NNS N
remained VBD N
unchanged JJ N
The DT N
increase NN N
in IN N
plasma JJ N
6-keto-prostaglandin JJ N
F1 NNP N
alpha NN N
concentration NN N
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
serum JJ N
HDL2 NNP N
cholesterol NN N
concentration NN N
in IN N
the DT N
group NN N
taking VBG N
regular JJ N
exercise NN N
Our PRP$ N
data NNS N
suggest VBP N
that IN N
mild JJ N
regular JJ N
physical JJ N
exercise NN N
favourably RB N
influences VBZ N
cholesterol NN N
distribution NN N
in IN N
serum NN N
lipoproteins NNS N
in IN N
healthy JJ 4_p
middle NN 1_p
aged VBN 1_p
men NNS 1_p
and CC N
may MD N
have VB N
beneficial JJ N
effects NNS N
on IN N
circulating VBG N
metabolites NNS N
of IN N
arachidonic JJ N
acid NN N
-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
progressive JJ N
muscle NN N
relaxation NN N
training NN N
of IN N
patients NNS 4_p
after IN 4_p
stoma NN 4_p
surgery NN 4_p
Eighteen JJ 3_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
undergone JJ 4_p
stoma NN 4_p
surgery NN 4_p
were VBD N
assessed VBN N
with IN N
respect NN N
to TO N
their PRP$ N
anxiety NN N
level NN N
and CC N
self-reported JJ N
quality NN N
of IN N
life NN N
QoL NNP N
on IN N
three CD N
occasions NNS N
namely RB N
immediately RB N
after IN N
surgery NN N
5 CD N
weeks NNS N
after IN N
surgery NN N
and CC N
10 CD N
weeks NNS N
after IN N
surgery NN N
The DT N
patients NNS N
were VBD N
randomised VBN N
into IN N
a DT N
control NN N
group NN N
n JJ N
10 CD N
and CC N
an DT N
experimental JJ N
group NN N
n JJ N
8 CD N
A DT N
20-min JJ N
set NN N
of IN N
audiotaped JJ N
instructions NNS N
on IN N
progressive JJ N
muscle NN N
relaxation NN N
training NN N
PMRT NNP N
was VBD N
given VBN N
to TO N
the DT N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
for IN N
home NN N
practice NN N
Assessment NNP N
instructions NNS N
included VBD N
the DT N
Chinese JJ N
State-Trait NNP N
Anxiety NNP N
Inventory NNP N
C-STAI NNP N
the DT N
Quality NN N
of IN N
Life NNP N
Index NNP N
for IN N
Colostomy NNP N
QoL-Colostomy NNP N
and CC N
the DT N
Hong NNP N
Kong NNP N
Chinese JJ N
version NN N
of IN N
the DT N
World NNP N
Health NNP N
Organisation NNP N
Quality NNP N
of IN N
Life NNP N
Scale NNP N
WHOQoL NNP N
Results NNS N
indicated VBD N
that IN N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
both DT N
the DT N
C-STAI NNP N
score NN N
F NNP N
4.66 CD N
P NNP N
0.05 CD N
and CC N
the DT N
WHOQoL NNP N
score NN N
F NNP N
4.74 CD N
P NNP N
0.05 CD N
in IN N
the DT N
experimental JJ N
group NN N
Among IN N
the DT N
domains NNS N
of IN N
WHOQoL NNP N
a DT N
significant JJ N
difference NN N
was VBD N
shown VBN N
in IN N
physical JJ N
health/independence NN N
and CC N
general JJ N
perception NN N
of IN N
QoL NNP N
with IN N
the DT N
experimental JJ N
group NN N
demonstrating VBG N
better JJR N
functioning NN N
For IN N
the DT N
QoL-Colostomy NNP N
however RB N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
The DT N
results NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
PMRT NNP N
could MD N
enhance VB N
quality NN N
of IN N
life NN N
and CC N
decrease NN N
state NN N
anxiety NN N
in IN N
patients NNS 4_p
after IN 4_p
stoma NN 4_p
surgery NN 4_p
-DOCSTART- -X- O O

A DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
of IN N
fluvoxamine NN N
in IN N
adults NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
BACKGROUND NNP N
Autistic NNP N
disorder NN N
is VBZ N
characterized VBN N
by IN N
a DT N
fundamental JJ N
disturbance NN N
in IN N
social JJ N
interaction NN N
impairments NNS N
in IN N
communication NN N
and CC N
a DT N
markedly RB N
restricted JJ N
repertoire NN N
of IN N
activities NNS N
and CC N
interests NNS N
Abnormalities NNS N
in IN N
the DT N
serotonin NN N
neurotransmitter NN N
system NN N
have VBP N
been VBN N
identified VBN N
in IN N
some DT N
persons NNS N
with IN N
autism NN N
No DT N
consistently RB N
effective JJ N
and CC N
safe JJ N
drugs NNS N
have VBP N
been VBN N
developed VBN N
for IN N
treating VBG N
the DT N
symptoms NNS N
of IN N
autism NN N
METHODS NNP N
Thirty NNP 3_p
adults NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
completed VBD N
a DT N
12-week JJ N
double-blind NN N
placebo-controlled JJ N
trial NN N
of IN N
the DT N
potent NN N
and CC N
selective JJ N
serotonin NN N
uptake JJ N
inhibitor NN N
fluvoxamine NN N
maleate NN N
Behavioral JJ N
ratings NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
8 CD N
and CC N
12 CD N
weeks NNS N
of IN N
treatment NN N
RESULTS NNP N
Eight NNP N
53 CD N
of IN N
15 CD N
patients NNS N
in IN N
the DT N
fluvoxamine-treated JJ N
group NN N
were VBD N
categorized VBN N
as IN N
responders NNS N
compared VBN N
with IN N
none NN N
of IN N
15 CD N
in IN N
the DT N
placebo NN N
group NN N
P NNP N
.001 NNP N
Fluvoxamine NNP N
was VBD N
superior JJ N
to TO N
placebo VB N
in IN N
reducing VBG N
repetitive JJ N
thoughts NNS N
and CC N
behavior NN N
P NNP N
.001 NNP N
maladaptive JJ N
behavior NN N
P NNP N
.001 NNP N
and CC N
aggression NN N
P NNP N
.03 NNP N
and CC N
in IN N
improving VBG N
some DT N
aspects NNS N
of IN N
social JJ N
relatedness NN N
P NNP N
.04 NNP N
especially RB N
language NN N
usage NN N
P NNP N
.008 NNP N
Treatment JJ N
response NN N
was VBD N
not RB N
correlated VBN N
with IN N
age NN N
level NN N
of IN N
autistic JJ N
behavior NN N
or CC N
full-scale JJ N
IQ NNP N
Other JJ N
than IN N
mild JJ N
sedation NN N
and CC N
nausea NN N
in IN N
a DT N
few JJ N
patients NNS N
fluvoxamine NN N
was VBD N
well RB N
tolerated VBN N
No DT N
dyskinesias NN N
adverse JJ N
cardiovascular JJ N
events NNS N
or CC N
seizures NNS N
occurred VBD N
CONCLUSIONS NNP N
Fluvoxamine NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
the DT N
symptoms NNS N
of IN N
autistic JJ N
disorder NN N
in IN N
adults NNS N
Controlled JJ N
studies NNS N
of IN N
fluvoxamine NN N
and CC N
other JJ N
potent NN N
and CC N
selective JJ N
serotonin NN N
uptake JJ N
inhibitors NNS N
seem VBP N
warranted VBN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
four CD N
different JJ N
irrigation NN N
systems NNS N
in IN N
the DT N
removal NN N
of IN N
a DT N
root JJ N
canal JJ N
sealer NN N
OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficiency NN N
of IN N
sonic JJ N
ultrasonic JJ N
and CC N
hydrodynamic JJ N
devices NNS N
in IN N
the DT N
removal NN N
of IN N
a DT N
root JJ N
canal JJ N
sealer NN N
from IN N
the DT N
surface NN N
and CC N
from IN N
simulated JJ N
irregularities NNS N
of IN N
root NN N
canals NNS N
MATERIALS NNP N
AND CC N
METHODS NNP N
Fifty-three NNP 3_p
root NN 4_p
canals NNS 4_p
with IN 4_p
two CD 4_p
standardized JJ 4_p
grooves NNS 4_p
in IN 4_p
the DT 4_p
apical JJ 4_p
and CC 4_p
coronal JJ 4_p
parts NNS 4_p
of IN 4_p
longitudinally RB 4_p
split VBN 4_p
roots NNS 4_p
were VBD N
covered VBN N
with IN N
AH NNP N
Plus NNP N
root VBP N
canal JJ N
sealer NN N
Compared VBN N
were VBD N
the DT N
effects NNS N
of IN N
control NN N
syringe NN N
irrigation NN N
1 CD N
CanalBrush NN N
2 CD N
passive NN N
ultrasonic JJ N
irrigation NN N
3 CD N
EndoActivator NN N
and CC N
4 CD N
RinsEndo NN N
on IN N
the DT N
removal NN N
of IN N
the DT N
sealer NN N
The DT N
specimens NNS N
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
N NNP N
12 CD N
and CC N
one CD N
control NN N
group NN N
N NNP N
5 CD N
via IN N
randomization NN N
The DT N
amount NN N
of IN N
remaining VBG N
sealer NN N
in IN N
the DT N
root NN N
canal JJ N
irregularities NNS N
was VBD N
evaluated VBN N
under IN N
a DT N
microscope NN N
using VBG N
a DT N
4-grade JJ N
scoring NN N
system NN N
whereas IN N
the DT N
remaining VBG N
sealer NN N
on IN N
the DT N
root NN N
canal JJ N
surface NN N
was VBD N
evaluated VBN N
with IN N
a DT N
7-grade JJ N
scoring NN N
system NN N
RESULTS NNP N
Passive NNP N
ultrasonic JJ N
irrigation NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
other JJ N
tested JJ N
irrigation NN N
systems NNS N
or CC N
syringe JJ N
irrigation NN N
in IN N
removing VBG N
sealer NN N
from IN N
root JJ N
canal JJ N
walls NNS N
p JJ N
0.01 CD N
None NN N
of IN N
the DT N
techniques NNS N
had VBD N
a DT N
significant JJ N
effect NN N
on IN N
cleaning VBG N
the DT N
lateral JJ N
grooves NNS N
CONCLUSIONS NNP N
Within IN N
the DT N
limitations NNS N
of IN N
this DT N
study NN N
protocol VBZ N
ultrasonic JJ N
irrigation NN N
shows VBZ N
a DT N
superior JJ N
effect NN N
on IN N
sealer NN N
removal NN N
from IN N
the DT N
root NN N
canal JJ N
surface NN N
during IN N
endodontic JJ N
retreatment NN N
Cleaning NN N
of IN N
lateral JJ N
grooves NNS N
seems VBZ N
not RB N
to TO N
be VB N
possible JJ N
with IN N
one CD N
of IN N
the DT N
techniques NNS N
investigated VBN N
CLINICAL JJ N
RELEVANCE NNP N
Incomplete NNP N
removal NN N
of IN N
root JJ N
canal JJ N
sealer NN N
during IN N
re-treatment NN N
may MD N
cause VB N
treatment NN N
failure NN N
Passive NNP N
Ultrasonic NNP N
irrigation NN N
seems VBZ N
to TO N
be VB N
the DT N
most RBS N
effective JJ N
system NN N
to TO N
remove VB N
sealer NN N
from IN N
a DT N
root NN N
canal NN N
-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
weight NN N
training NN N
on IN N
bone JJ N
mineral JJ N
density NN N
and CC N
bone NN N
turnover NN N
in IN N
postmenopausal JJ 4_p
breast NN 4_p
cancer NN 4_p
survivors NNS 4_p
with IN 4_p
bone JJ 4_p
loss NN 4_p
a DT N
24-month JJ N
randomized NN N
controlled VBD N
trial NN N
SUMMARY VB N
This DT N
study NN N
examined VBD N
whether IN N
24 CD N
months NNS N
of IN N
weight JJ N
training NN N
exercises NNS N
enhanced VBD N
the DT N
effectiveness NN N
of IN N
risedronate NN N
calcium NN N
and CC N
vitamin NN N
D NNP N
in IN N
maintaining VBG N
or CC N
improving VBG N
bone JJ N
mineral JJ N
density NN N
BMD NNP N
in IN N
223 CD 3_p
postmenopausal NN 4_p
breast NN 4_p
cancer NN 4_p
survivors NNS 4_p
Subjects NNS N
who WP N
were VBD N
or CC N
=50 CD N
adherent NN N
to TO N
exercise VB N
had VBN N
no DT N
improvement NN N
in IN N
BMD NNP N
but CC N
were VBD N
less RBR N
likely JJ N
to TO N
lose VB N
BMD NNP N
INTRODUCTION NNP N
This DT N
study NN N
examined VBD N
whether IN N
1 CD N
postmenopausal NN 4_p
breast NN 4_p
cancer NN 4_p
survivors NNS 4_p
BCS NNP 4_p
with IN 4_p
bone NN 4_p
loss NN 4_p
taking VBG N
24 CD N
months NNS N
of IN N
risedronate NN N
calcium NN N
and CC N
vitamin NN N
D NNP N
had VBD N
increased VBN N
bone RB N
mineral JJ N
density NN N
BMD NNP N
at IN N
the DT N
total JJ N
hip NN N
femoral JJ N
neck NN N
L1-L4 NNP N
spine NN N
total JJ N
radius NN N
and CC N
33 CD N
radius NN N
and CC N
decreased VBD N
bone NN N
turnover NN N
2 CD N
subjects NNS N
who WP N
also RB N
participated VBD N
in IN N
strength/weight JJ N
training NN N
ST NNP N
exercises NNS N
had VBD N
greater JJR N
increases NNS N
in IN N
BMD NNP N
and CC N
greater JJR N
decreases NNS N
in IN N
bone NN N
turnover NN N
and CC N
3 CD N
subjects NNS N
who WP N
also RB N
exercised VBD N
were VBD N
more RBR N
likely JJ N
to TO N
preserve VB N
at IN N
least JJS N
maintain NN N
BMD NNP N
METHODS NNP N
Postmenopausal NNP 4_p
BCS NNP 4_p
223 CD 3_p
were VBD N
randomly RB N
assigned VBN N
to TO N
exercise VB N
plus JJ N
medication NN N
or CC N
medication NN N
only RB N
groups NNS N
Both DT N
groups NNS N
received VBD N
24 CD N
months NNS N
of IN N
1,200 CD N
mg NN N
of IN N
calcium NN N
and CC N
400 CD N
IU NNP N
of IN N
vitamin NNP N
D NNP N
daily RB N
and CC N
35 CD N
mg NN N
of IN N
risedronate JJ N
weekly JJ N
and CC N
the DT N
exercise NN N
group NN N
additionally RB N
had VBD N
ST NNP N
exercises NNS N
twice RB N
weekly RB N
RESULTS NNP N
After IN N
24 CD N
months NNS N
women NNS N
who WP N
took VBD N
medications NNS N
without IN N
exercising VBG N
had VBD N
significant JJ N
improvements NNS N
in IN N
BMD NNP N
at IN N
the DT N
total JJ N
hip NN N
+1.81 CD N
and CC N
spine NN N
+2.85 CD N
and CC N
significant JJ N
decreases NNS N
in IN N
Alkphase NNP N
B NNP N
-8.7 NNP N
and CC N
serum JJ N
NTx NNP N
-16.7 NNP N
Women NNS N
who WP N
also RB N
exercised VBD N
had VBD N
additional JJ N
increases NNS N
in IN N
BMD NNP N
at IN N
the DT N
femoral JJ N
neck NN N
+0.29 CD N
total JJ N
hip NN N
+0.34 CD N
spine NN N
+0.23 CD N
total JJ N
radius NN N
+0.30 CD N
and CC N
additional JJ N
decreases NNS N
in IN N
Alkphase NNP N
B NNP N
-2.4 NNP N
and CC N
Serum NNP N
NTx NNP N
-6.5 NNP N
Additional JJ N
changes NNS N
in IN N
BMD NNP N
and CC N
bone NN N
turnover NN N
with IN N
exercise NN N
were VBD N
not RB N
significant JJ N
Subjects NNS N
who WP N
were VBD N
or CC N
=50 CD N
adherent NN N
to TO N
exercise VB N
were VBD N
less RBR N
likely JJ N
to TO N
lose VB N
BMD NNP N
at IN N
the DT N
total JJ N
hip NN N
chi-square JJ N
1 CD N
4.66 CD N
p NN N
0.03 CD N
and CC N
femoral JJ N
neck NN N
chi-square JJ N
1 CD N
4.63 CD N
p NN N
0.03 CD N
CONCLUSION NNP N
Strength/weight NNP N
training NN N
exercises NNS N
may MD N
prevent VB N
loss NN N
of IN N
BMD NNP N
in IN N
postmenopausal NN N
BCS NNP N
at IN N
risk NN N
for IN N
bone NN N
loss NN N
-DOCSTART- -X- O O

Insulin NNP N
pump NN N
therapy NN N
started VBD N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
effects NNS N
on IN N
glycemic JJ N
control NN N
and CC N
pancreatic JJ N
β-cell NN N
function NN N
in IN N
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
BACKGROUND NNP N
In IN N
the DT N
interest NN N
of IN N
preserving VBG N
residual JJ N
insulin NN N
secretory NN N
capacity NN N
present NN N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
T1D NNP 4_p
we PRP N
compared VBN N
the DT N
efficacy NN N
of IN N
starting VBG N
insulin JJ N
pump NN N
therapy NN N
at IN N
diagnosis NN N
with IN N
standard JJ N
multiple JJ N
daily JJ N
insulin NN N
injections NNS N
MDIs NNP N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
pilot JJ N
trial NN N
comparing VBG N
MDI NNP N
therapy NN N
with IN N
continuous JJ N
subcutaneous JJ N
insulin NN N
therapy NN N
pump JJ N
therapy NN N
in IN N
24 CD 3_p
patients NNS N
8-18 CD 1_p
years NNS 1_p
old JJ 1_p
with IN N
newly RB 4_p
diagnosed VBN 4_p
T1D NNP 4_p
Subjects NNS N
were VBD N
evaluated VBN N
at IN N
enrollment NN N
and CC N
1 CD N
3 CD N
6 CD N
9 CD N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
diagnosis NN N
of IN N
T1D NNP N
Preservation NN N
of IN N
insulin NN N
secretion NN N
measured VBN N
by IN N
mixed-meal-stimulated JJ N
C-peptide JJ N
secretion NN N
was VBD N
compared VBN N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
treatment NN N
Between-group JJ N
differences NNS N
in IN N
glycosylated JJ N
hemoglobin NN N
HbA1c NNP N
continuous JJ N
glucose NN N
sensor NN N
data NNS N
insulin NN N
utilization NN N
anthropometric JJ N
measures NNS N
and CC N
patient JJ N
satisfaction NN N
with IN N
therapy NN N
were VBD N
also RB N
compared VBN N
at IN N
multiple JJ N
time NN N
points NNS N
RESULTS NNP N
Initiation NNP N
of IN N
pump NN N
therapy NN N
within IN N
1 CD N
month NN N
of IN N
diagnosis NN N
resulted VBD N
in IN N
consistently RB N
higher JJR N
mixed-meal JJ N
tolerance NN N
test-stimulated JJ N
C-peptide JJ N
values NNS N
at IN N
all DT N
time NN N
points NNS N
although IN N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
Nonetheless NNP N
improved JJ N
glycemic JJ N
control NN N
was VBD N
observed VBN N
in IN N
insulin JJ N
pump-treated JJ N
subjects NNS N
more JJR N
time NN N
spent VBN N
with IN N
normoglycemia NN N
better JJR N
mean JJ N
HbA1c NNP N
and CC N
pump-treated JJ N
subjects NNS N
reported VBN N
comparatively RB N
greater JJR N
satisfaction NN N
with IN N
route NN N
of IN N
treatment NN N
administration NN N
CONCLUSIONS NNP N
Initiation NNP N
of IN N
insulin NN N
pump NN N
therapy NN N
at IN N
diagnosis NN N
improved JJ N
glycemic JJ N
control NN N
was VBD N
well RB N
tolerated VBN N
and CC N
contributed VBD N
to TO N
improved VBN N
patient JJ N
satisfaction NN N
with IN N
treatment NN N
This DT N
study NN N
also RB N
suggests VBZ N
that IN N
earlier JJR N
use NN N
of IN N
pump NN N
therapy NN N
might MD N
help VB N
to TO N
preserve VB N
residual JJ N
β-cell NNP N
function NN N
although IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
would MD N
be VB N
required VBN N
to TO N
confirm VB N
this DT N
-DOCSTART- -X- O O

Effects NNS N
of IN N
individualized JJ N
breast NN N
cancer NN N
risk NN N
counseling NN N
a DT N
randomized JJ N
trial NN N
BACKGROUND NNP N
Studies NNPS N
have VBP N
shown VBN N
that IN N
a DT N
majority NN N
of IN N
women NNS N
with IN N
a DT N
family NN N
history NN N
of IN N
breast NN N
cancer NN N
have VBP N
exaggerated VBN N
perceptions NNS N
of IN N
their PRP$ N
own JJ N
risk NN N
of IN N
this DT N
disease NN N
and CC N
experience NN N
excessive JJ N
anxiety NN N
In IN N
response NN N
to TO N
the DT N
need NN N
to TO N
communicate VB N
more JJR N
accurate JJ N
risk NN N
information NN N
to TO N
these DT N
women NNS N
specialized JJ N
programs NNS N
for IN N
breast NN N
cancer NN N
risk NN N
counseling VBG N
have VBP N
been VBN N
initiated VBN N
in IN N
medical JJ N
centers NNS N
across IN N
the DT N
United NNP N
States NNPS N
PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
1 CD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
a DT N
standardized JJ N
protocol NN N
for IN N
individualized JJ N
breast NN N
cancer NN N
risk NN N
counseling VBG N
on IN N
comprehension NN N
of IN N
personal JJ N
risk NN N
among IN N
first-degree JJ 4_p
relatives NNS 4_p
of IN 4_p
index NN 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
and CC N
2 CD N
to TO N
identify VB N
women NNS N
most RBS N
and CC N
least JJS N
likely JJ N
to TO N
benefit VB N
from IN N
such JJ N
counseling NN N
METHODS NNP N
This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
individualized VBN N
breast NN N
cancer NN N
risk NN N
counseling VBG N
to TO N
general JJ N
health NN N
counseling NN N
control NN N
We PRP N
studied VBD N
200 CD 3_p
women NNS 2_p
aged VBN 1_p
35 CD 1_p
years NNS 1_p
and CC 1_p
older JJR 1_p
who WP N
had VBD N
a DT N
family NN 4_p
history NN 4_p
of IN 4_p
breast NN 4_p
cancer NN 4_p
in IN 4_p
a DT 4_p
first-degree JJ 4_p
relative NN 4_p
Women NNS 4_p
with IN N
a DT N
personal JJ 4_p
history NN 4_p
of IN 4_p
cancer NN 4_p
were VBD N
excluded VBN N
Risk NNP N
comprehension NN N
was VBD N
assessed VBN N
as IN N
the DT N
concordance NN N
between IN N
perceived VBN N
subjective JJ N
lifetime NN N
breast NN N
cancer NN N
risk NN N
and CC N
estimated VBN N
objective JJ N
lifetime NN N
risk NN N
RESULTS VB N
The DT N
results NNS N
of IN N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
women NNS N
who WP N
received VBD N
risk NN N
counseling NN N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
improve VB N
their PRP$ N
risk NN N
comprehension NN N
compared VBN N
with IN N
women NNS N
in IN N
the DT N
control NN N
condition NN N
odds NNS N
ratio VBP N
OR NNP N
3.5 CD N
95 CD N
confidence NN N
interval NN N
CI NNP N
1.3-9.5 CD N
P NNP N
.01 NNP N
However RB N
in IN N
both DT N
groups NNS N
about RB N
two CD N
thirds NNS N
of IN N
women NNS N
continued VBN N
to TO N
overestimate VB N
their PRP$ N
lifetime NN N
risks NNS N
substantially RB N
following VBG N
counseling VBG N
Examination NN N
of IN N
subjects NNS N
by IN N
treatment NN N
interaction NN N
effects NNS N
indicated VBD N
that IN N
risk NN N
counseling VBG N
did VBD N
not RB N
produce VB N
improved JJ N
comprehension NN N
among IN N
the DT N
large JJ N
proportion NN N
of IN N
women NNS N
who WP N
had VBD N
high JJ N
levels NNS N
of IN N
anxious JJ N
preoccupation NN N
with IN N
breast NN N
cancer NN N
at IN N
base NN N
line NN N
P NNP N
.02 NNP N
In IN N
addition NN N
white JJ N
women NNS N
were VBD N
less RBR N
likely JJ N
to TO N
benefit VB N
than IN N
African-American JJ N
women NNS N
OR NNP N
0.34 CD N
95 CD N
CI NNP N
0.11-0.99 NN N
P NNP N
.05 NNP N
CONCLUSION NNP N
Efforts NNPS N
to TO N
counsel NN N
women NNS N
about IN N
their PRP$ N
breast NN N
cancer NN N
risks NNS N
are VBP N
not RB N
likely JJ N
to TO N
be VB N
effective JJ N
unless IN N
their PRP$ N
breast NN N
cancer NN N
anxieties NNS N
are VBP N
also RB N
addressed VBN N
IMPLICATIONS NNP N
Attention NNP N
to TO N
the DT N
psychological JJ N
aspects NNS N
of IN N
breast NN N
cancer NN N
risk NN N
will MD N
be VB N
critical JJ N
in IN N
the DT N
development NN N
of IN N
risk-counseling JJ N
programs NNS N
that WDT N
incorporate VBP N
testing VBG N
for IN N
the DT N
recently RB N
cloned VBN N
breast NN N
cancer NN N
susceptibility NN N
gene NN N
BRCA1 NNP N
and CC N
BRCA2 NNP N
when WRB N
that DT N
gene NN N
has VBZ N
also RB N
been VBN N
cloned VBN N
-DOCSTART- -X- O O

Effectiveness NN N
of IN N
hygienic-dietary JJ N
recommendations NNS N
as IN N
enhancers NNS N
of IN N
antidepressant JJ N
treatment NN N
in IN N
patients NNS 4_p
with IN 4_p
depression NN 4_p
study NN N
protocol NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
BACKGROUND NNP N
In IN N
recent JJ N
years NNS N
some DT N
studies NNS N
have VBP N
been VBN N
published VBN N
supporting VBG N
the DT N
efficacy NN N
of IN N
light JJ N
exposure NN N
physical JJ N
activity NN N
sleep VB N
control NN N
and CC N
a DT N
Mediterranean NNP N
diet JJ N
pattern NN N
on IN N
the DT N
improvement NN N
or CC N
prevention NN N
of IN N
depression NN N
However RB N
to TO N
our PRP$ N
knowledge NN N
there EX N
have VBP N
been VBN N
no DT N
studies NNS N
using VBG N
all PDT N
these DT N
measures NNS N
together RB N
as IN N
an DT N
adjuvant JJ N
antidepressant NN N
strategy NN N
METHODS NNP N
Multicenter NNP N
randomized VBD N
controlled VBN N
two CD N
arm-parallel JJ N
clinical JJ N
trial NN N
Eighty NNP 3_p
depressed VBD 4_p
patients NNS 4_p
undergoing VBG 4_p
standard JJ 4_p
antidepressant JJ 4_p
treatment NN 4_p
will MD N
be VB N
advised VBN N
to TO N
follow VB N
four CD N
additional JJ N
hygienic-dietary JJ N
recommendations NNS N
about IN N
exercise NN N
diet JJ N
sunlight JJ N
exposure NN N
and CC N
sleep NN N
Outcome NNP N
measures NNS N
will MD N
be VB N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
6 CD N
month NN N
intervention NN N
period NN N
DISCUSSION NNP N
We PRP N
expect VBP N
the DT N
patients NNS N
in IN N
the DT N
active JJ N
recommendations NNS N
group NN N
to TO N
experience VB N
a DT N
greater JJR N
improvement NN N
in IN N
their PRP$ N
depressive NN N
symptoms NNS N
If IN N
so RB N
this DT N
would MD N
be VB N
a DT N
great JJ N
support NN N
for IN N
doctors NNS N
who WP N
might MD N
systematically RB N
recommend VB N
these DT N
simple JJ N
and CC N
costless JJ N
measures NNS N
especially RB N
in IN N
primary JJ N
care NN N
TRIAL NNP N
REGISTRATION NNP N
ISRCTN59506583 NNP N
-DOCSTART- -X- O O

Paternal NNP N
RHD NNP N
zygosity NN N
determination NN N
in IN N
Tunisians NNS 4_p
evaluation NN N
of IN N
three CD N
molecular JJ N
tests NNS N
BACKGROUND IN N
The DT N
choice NN N
of IN N
a DT N
molecular JJ N
test NN N
for IN N
first JJ N
intention NN N
determination NN N
of IN N
paternal JJ N
RHD NNP N
zygosity NN N
before IN N
entering VBG N
into IN N
invasive JJ N
diagnostics NNS N
is VBZ N
important JJ N
for IN N
the DT N
management NN N
of IN N
pregnancies NNS N
at IN N
risk NN N
of IN N
haemolytic JJ N
disease NN N
of IN N
the DT N
foetus NN N
and CC N
newborn RB N
related VBN N
to TO N
anti-RhD JJ N
MATERIALS NNP N
AND CC N
METHODS NNP N
RHD NNP N
zygosity NN N
was VBD N
evaluated VBN N
in IN N
370 CD 3_p
RH:1 NNP 4_p
Tunisian JJ 3_p
donors NNS 3_p
by IN N
polymerase NN N
chain NN N
reaction NN N
sequence-specific JJ N
polymorphism NN N
PCR-SSP NNP N
analysis NN N
and CC N
polymerase NN N
chain NN N
reaction NN N
restriction NN N
fragment NN N
length NN N
polymorphism NN N
PCR-RFLP NNP N
amplification NN N
of IN N
hybrid JJ N
Rhesus NNP N
box NN N
and CC N
by IN N
real JJ N
time NN N
quantitative JJ N
polymerase NN N
chain NN N
reaction NN N
RQ-PCR NNP N
specific NN N
for IN N
RHD NNP N
exon VBD N
5 CD N
To TO N
evaluate VB N
the DT N
accuracy NN N
of IN N
molecular JJ N
tests NNS N
in IN N
the DT N
cases NNS N
of IN N
discordant JJ N
results NNS N
the DT N
ten JJ N
exons NNS N
of IN N
RHD NNP N
and CC N
Rhesus NNP N
boxes NNS N
were VBD N
amplified VBN N
by IN N
PCR NNP N
and CC N
sequenced VBN N
RESULTS NNP N
Molecular JJ N
investigations NNS N
revealed VBD N
that IN N
our PRP$ N
370 CD 3_p
donors NNS 3_p
comprise VBP N
193 CD N
dizygous JJ N
and CC N
145 CD N
hemizygous JJ N
individuals NNS N
and CC N
32 CD N
subjects NNS N
whose WP$ N
zygosity NN N
remains VBZ N
unknown JJ N
Positive JJ N
predictive JJ N
values NNS N
were VBD N
higher JJR N
than IN N
99 CD N
for IN N
all PDT N
the DT N
methods NNS N
reaching VBG N
100 CD N
for IN N
RQ-PCR NNP N
Negative NNP N
predictive JJ N
values NNS N
were VBD N
83.24 CD N
87.27 CD N
and CC N
98 CD N
for IN N
PCR-SSP NNP N
PCR-RFLP NNP N
and CC N
RQ-PCR NNP N
respectively RB N
This DT N
study NN N
also RB N
revealed VBD N
19 CD N
novel JJ N
Rhesus NNP N
box NN N
polymorphisms NN N
and CC N
three CD N
novel NN N
RHD NNP N
alleles NNS N
RHD NNP N
Trp185Stop NNP N
RHD NNP N
Ala176Thr NNP N
and CC N
RHD NNP N
Ile342Ile NNP N
DISCUSSION NNP N
RQ-PCR NNP N
is VBZ N
the DT N
most RBS N
convenient JJ N
method NN N
for IN N
first JJ N
intention NN N
determination NN N
of IN N
paternal JJ N
RHD NNP N
zygosity NN N
in IN N
Tunisians NNPS N
However RB N
taking VBG N
into IN N
account NN N
positive JJ N
and CC N
negative JJ N
predictive NN N
values NNS N
PCR-RFLP NNP N
could MD N
be VB N
an DT N
alternative JJ N
despite IN N
the DT N
heterogeneity NN N
of IN N
Rhesus NNP N
boxes NNS N
and CC N
the DT N
complexity NN N
of IN N
RHD NNP N
-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
tunnelling VBG N
on IN N
epidural JJ N
catheter NN N
migration NN N
A DT N
prospective JJ N
randomised VBD N
study NN N
of IN N
82 CD 3_p
patients NNS 4_p
having VBG 4_p
postoperative JJ 4_p
epidural JJ 4_p
analgesia NN 4_p
was VBD N
performed VBN N
to TO N
determine VB N
whether IN N
the DT N
tunnelling NN N
of IN N
an DT N
epidural JJ N
catheter NN N
influences VBZ N
its PRP$ N
migration NN N
Tunnelling NN N
of IN N
the DT N
catheter NN N
subcutaneously RB N
for IN N
a DT N
distance NN N
of IN N
5 CD N
cm NN N
reduced VBD N
the DT N
incidence NN N
of IN N
inward JJ N
migration NN N
of IN N
1 CD N
cm NN N
or CC N
more JJR N
p JJ N
0.01 CD N
compared VBN N
to TO N
a DT N
standard JJ N
method NN N
of IN N
fixation NN N
with IN N
a DT N
transparent JJ N
adhesive JJ N
dressing NN N
This DT N
effect NN N
was VBD N
more RBR N
marked JJ N
if IN N
the DT N
epidural JJ N
catheter NN N
was VBD N
sited VBN N
in IN N
the DT N
thoracic NN N
rather RB N
than IN N
the DT N
lumbar JJ N
area NN N
Sixty CD N
two CD N
percent NN N
n JJ N
26 CD N
of IN N
tunnelled JJ N
catheters NNS N
remained VBD N
within IN N
0.5 CD N
cm NNS N
of IN N
their PRP$ N
original JJ N
position NN N
compared VBN N
to TO N
38 CD N
n JJ N
16 CD N
of IN N
non-tunnelled JJ N
catheters NNS N
although IN N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
Outward NNP N
catheter NN N
migration NN N
was VBD N
not RB N
reduced VBN N
by IN N
subcutaneous JJ N
tunnelling NN N
-DOCSTART- -X- O O

Limbal NNP N
epithelial NN N
autograft NN N
transplantation NN N
in IN N
treatment NN N
of IN N
pterygium NN 4_p
OBJECTIVE UH N
To TO N
observe VB N
the DT N
therapeutic JJ N
effects NNS N
of IN N
limbal JJ N
epithelial JJ N
autograft NN N
transplantation NN N
and CC N
pterygium NN N
excision NN N
in IN N
the DT N
treatment NN N
of IN N
pterygium NN 4_p
METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
paired-eye JJ N
trial NN N
was VBD N
studied VBN N
There EX N
were VBD N
208 CD 3_p
patients NNS 3_p
229 CD N
eyes NNS N
with IN N
initial JJ 4_p
pterygium NN 4_p
and CC N
they PRP N
were VBD N
allocated VBN N
to TO N
two CD N
groups NNS N
excision NN N
of IN N
pterygium NN N
with IN N
limbal JJ N
epithelial JJ N
autograft NN N
transplantation NN N
surgery NN N
A NNP N
group NN N
106 CD N
cases NNS N
and CC N
124 CD N
eyes NNS N
and CC N
simple JJ N
pterygium NN N
excision NN N
B NNP N
group NN N
102 CD N
cases NNS N
and CC N
105 CD N
eyes NNS N
The DT N
criteria NN N
for IN N
recovery NN N
were VBD N
corneal JJ N
transparency NN N
with IN N
stable JJ N
epithelial JJ N
healing NN N
and CC N
no DT N
abnormal JJ N
proliferation NN N
of IN N
pterygium-like JJ N
tissue NN N
The DT N
post-operative JJ N
follow-up JJ N
periods NNS N
ranged VBD N
from IN N
18 CD N
approximately RB N
28 CD N
22.4 CD N
+/- JJ N
4.9 CD N
months NNS N
RESULTS NNP N
Some DT N
of IN N
the DT N
patients NNS N
lost VBD N
follow-up JJ N
In IN N
the DT N
eyes NNS N
followed VBD N
up RB N
5 CD N
of IN N
11 CD N
2 CD N
eyes NNS N
4.5 CD N
in IN N
A NNP N
group NN N
and CC N
41 CD N
of IN N
96 CD N
eyes NNS N
42.7 CD N
in IN N
B NNP N
group NN N
were VBD N
recurred VBN N
the DT N
difference NN N
being VBG N
very RB N
significant JJ N
P NNP N
0.001 CD N
CONCLUSION NNP N
To TO N
provide VB N
a DT N
new JJ N
stem NN N
cell NN N
source NN N
limbal JJ N
epithelial JJ N
autograft NN N
transplantation NN N
for IN N
an DT N
injured JJ N
limb NN N
us PRP N
is VBZ N
a DT N
reasonable JJ N
therapeutic JJ N
method NN N
for IN N
the DT N
treatment NN N
of IN N
pterygium NN N
-DOCSTART- -X- O O

Compensation NN N
in IN N
intergroup JJ N
relations NNS N
an DT N
investigation NN N
of IN N
its PRP$ N
structural JJ N
and CC N
strategic JJ N
foundations NNS N
Recent JJ N
work NN N
in IN N
intergroup JJ N
relations NNS N
stresses VBZ N
the DT N
role NN N
of IN N
two CD N
fundamental JJ N
dimensions NNS N
competence NN N
and CC N
warmth NN N
which WDT N
organize VBP N
the DT N
perception NN N
of IN N
social JJ N
groups NNS N
A DT N
pattern NN N
often RB N
encountered VBN N
in IN N
people NNS N
's POS N
ratings NNS N
is VBZ N
one CD N
of IN N
compensation NN N
in IN N
that DT N
a DT N
group NN N
that WDT N
is VBZ N
evaluated VBN N
higher JJR N
than IN N
another DT N
group NN N
on IN N
one CD N
of IN N
the DT N
two CD N
fundamental JJ N
dimensions NNS N
is VBZ N
also RB N
judged VBN N
lower JJR N
on IN N
the DT N
other JJ N
fundamental JJ N
dimension NN N
Based VBN N
on IN N
Social NNP N
Identity NNP N
Theory NNP N
the DT N
present JJ N
work NN N
extends VBZ N
previous JJ N
research NN N
on IN N
compensation NN N
by IN N
examining VBG N
boundary JJ N
conditions NNS N
as RB N
well RB N
as IN N
underlying VBG N
psychological JJ N
processes NNS N
Two CD N
studies NNS N
involving VBG N
experimental JJ N
and CC N
correlational JJ N
evidence NN N
minimal JJ N
and CC N
real JJ N
groups NNS N
and CC N
different JJ N
kinds NNS N
of IN N
conflict NN N
reveal NN N
that IN N
compensation NN N
is VBZ N
more RBR N
likely JJ N
when WRB N
the DT N
groups NNS N
are VBP N
in IN N
asymmetrical JJ N
relation NN N
and CC N
share NN N
a DT N
cooperative JJ N
view NN N
of IN N
the DT N
intergroup NN N
setting NN N
Our PRP$ N
data NNS N
also RB N
suggest VBP N
that IN N
among IN N
members NNS N
of IN N
low JJ N
status NN N
groups NNS N
compensation NN N
is VBZ N
associated VBN N
with IN N
social JJ N
creativity NN N
In IN N
contrast NN N
and CC N
in IN N
line NN N
with IN N
the DT N
'noblesse NNP N
oblige NN N
effect NN N
members NNS N
of IN N
the DT N
high JJ N
status NN N
group NN N
would MD N
seem VB N
to TO N
rely VB N
on IN N
compensation NN N
as IN N
a DT N
means NN N
to TO N
appear VB N
non-discriminatory JJ N
-DOCSTART- -X- O O

Teacher DT N
and CC N
child JJ N
predictors NNS N
of IN N
achieving VBG N
IEP NNP N
goals NNS N
of IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
It PRP N
is VBZ N
encouraging VBG N
that IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
show VBP N
a DT N
strong JJ N
response NN N
to TO N
early JJ N
intervention NN N
yet RB N
more JJR N
research NN N
is VBZ N
needed VBN N
for IN N
understanding VBG N
the DT N
variability NN N
in IN N
responsiveness NN N
to TO N
specialized JJ N
programs NNS N
Treatment NNP N
predictor NN N
variables NNS N
from IN N
47 CD 3_p
teachers NNS 1_p
and CC 1_p
children NNS 1_p
who WP N
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
COMPASS NNP N
intervention NN N
Ruble JJ N
et NN N
al NN N
in IN N
The DT N
collaborative JJ N
model NN N
for IN N
promoting VBG N
competence NN N
and CC N
success NN N
for IN N
students NNS N
with IN N
ASD NNP N
Springer NNP N
New NNP N
York NNP N
2012a CD N
were VBD N
analyzed VBN N
Predictors NNS N
evaluated VBD N
against IN N
child NN N
IEP NNP N
goal NN N
attainment NN N
included VBD N
child NN N
teacher NN N
intervention NN N
practice NN N
and CC N
implementation NN N
practice NN N
variables NNS N
based VBN N
on IN N
an DT N
implementation NN N
science NN N
framework NN N
Dunst NNP N
and CC N
Trivette NNP N
in IN N
J NNP N
Soc NNP N
Sci NNP N
8:143-148 CD N
2012 CD N
Findings NNS N
revealed VBD N
one CD N
child NN N
engagement NN N
one CD N
teacher NN N
exhaustion NN N
two CD N
intervention NN N
quality NN N
IEP NNP N
quality NN N
for IN N
targeted VBN N
and CC N
not RB N
targeted JJ N
elements NNS N
and CC N
no DT N
implementation NN N
quality NN N
variables NNS N
accounted VBD N
for IN N
variance NN N
in IN N
child NN N
outcomes NNS N
when WRB N
analyzed VBN N
separately RB N
When WRB N
the DT N
four CD N
significant JJ N
variables NNS N
were VBD N
compared VBN N
against IN N
each DT N
other JJ N
in IN N
a DT N
single JJ N
regression NN N
analysis NN N
IEP NNP N
quality NN N
accounted VBD N
for IN N
one CD N
quarter NN N
of IN N
the DT N
variance NN N
in IN N
child NN N
outcomes NNS N
-DOCSTART- -X- O O

Social NNP N
skills NNS N
improvement NN N
in IN N
children NNS 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
High-functioning JJ N
autism NN N
HFA NNP N
is VBZ N
characterized VBN N
by IN N
persistent JJ N
impairment NN N
in IN N
social JJ N
interaction NN N
despite IN N
the DT N
absence NN N
of IN N
mental JJ N
retardation NN N
Although IN N
an DT N
increasing VBG N
number NN N
of IN N
group-based JJ N
programs NNS N
for IN N
the DT N
improvement NN N
of IN N
social JJ N
skills NNS N
have VBP N
been VBN N
described VBN N
randomized VBN N
controlled VBN N
trials NNS N
are VBP N
needed VBN N
to TO N
evaluate VB N
their PRP$ N
efficacy NN N
To TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
Social NNP N
Skills NNP N
Training NNP N
Group-based JJ N
Program NNP N
SST-GP NNP N
and CC N
a DT N
Leisure NN N
Activities VBZ N
Group-based JJ N
Program NNP N
LA-GP NNP N
on IN N
the DT N
perception NN N
of IN N
facial JJ N
emotions NNS N
and CC N
quality NN N
of IN N
life NN N
QoL NNP N
in IN N
young JJ N
people NNS N
with IN N
HFA NNP N
Eligible JJ N
patients NNS N
were VBD N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
HFA NNP 4_p
Participants NNS N
were VBD N
randomized VBN N
to TO N
the DT N
SST NNP N
or CC N
LA NNP N
group NN N
The DT N
primary JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
an DT N
improvement NN N
of IN N
2 CD N
points NNS N
in IN N
error NN N
rates NNS N
for IN N
facial JJ N
emotion NN N
labeling NN N
DANVA2 NNP N
from IN N
baseline NN N
After IN N
the DT N
6-month JJ N
training NN N
period NN N
the DT N
SST NNP N
Group NNP N
made VBD N
fewer JJR N
errors NNS N
in IN N
labeling VBG N
anger NN N
on IN N
adult NN N
faces VBZ N
whereas JJ N
error NN N
rates NNS N
in IN N
the DT N
LA NNP N
Group NNP N
remained VBD N
stable JJ N
Progress NN N
in IN N
the DT N
ability NN N
to TO N
recognize VB N
anger NN N
in IN N
the DT N
SST NNP N
Group NNP N
was VBD N
due JJ N
to TO N
better JJR N
recognition NN N
of IN N
low JJ N
intensity NN N
stimuli NN N
on IN N
adult NN N
faces VBZ N
QoL NNP N
increased VBD N
in IN N
the DT N
SST NNP N
Group NNP N
in IN N
the DT N
dimension NN N
of IN N
school NN N
environment NN N
as IN N
a DT N
marker NN N
of IN N
the DT N
transfer NN N
of IN N
skills NNS N
acquired VBN N
in IN N
the DT N
treatment NN N
setting VBG N
to TO N
their PRP$ N
use NN N
in IN N
the DT N
community NN N
The DT N
SST-GP NNP N
had VBD N
higher JJR N
efficacy NN N
than IN N
the DT N
LA-GP NNP N
Data NNP N
justify NN N
replication NN N
using VBG N
larger JJR N
samples NNS N
-DOCSTART- -X- O O

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
of IN N
the DT N
impact NN N
on IN N
quality NN N
of IN N
life NN N
of IN N
continuing VBG N
dexamethasone JJ N
beyond IN N
24 CD N
h NN N
following VBG N
adjuvant JJ N
chemotherapy NN N
for IN N
breast NN 4_p
cancer NN 4_p
Uncertainty NN N
remains VBZ N
about IN N
the DT N
optimal JJ N
anti-emetic JJ N
regimen NNS N
for IN N
control NN N
of IN N
delayed JJ N
nausea NN N
and CC N
vomiting NN N
after IN N
adjuvant JJ N
chemotherapy NN N
for IN N
breast NN N
cancer NN N
Many JJ N
patients NNS N
receive VBP N
dexamethasone NN N
but CC N
complain NN N
of IN N
insomnia NN N
anxiety/agitation NN N
and CC N
indigestion NN N
The DT N
aim NN N
was VBD N
to TO N
determine VB N
if IN N
patients NNS N
receiving VBG N
chemotherapy NN N
for IN N
breast NN 4_p
cancer NN 4_p
prefer VBP N
treatment NN N
with IN N
dexamethasone NN N
or CC N
placebo NN N
for IN N
prophylaxis NN N
against IN N
delayed VBN N
nausea NN N
and CC N
vomiting NN N
and CC N
to TO N
compare VB N
quality NN N
of IN N
life NN N
QOL NNP N
between IN N
the DT N
two CD N
treatments NNS N
In IN N
this DT N
randomized JJ N
double-blind JJ N
cross-over JJ N
trial NN N
we PRP N
compared VBN N
oral JJ N
dexamethasone NN N
4 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
days NNS N
versus VBP N
placebo NN N
for IN N
chemotherapy-naïve JJ 4_p
patients NNS 4_p
with IN 4_p
breast JJ 4_p
cancer NN 4_p
All DT N
patients NNS N
received VBD N
intravenous JJ N
granisetron NN N
and CC N
dexamethasone NN N
pre-chemotherapy NN N
and CC N
oral JJ N
granisetron NN N
on IN N
day NN N
2 CD N
Primary JJ N
endpoints NNS N
were VBD N
i NN N
patient NN N
preference NN N
ii NN N
difference NN N
between IN N
cycles NNS N
in IN N
change NN N
of IN N
QOL NNP N
from IN N
days NNS N
1 CD N
to TO N
8 CD N
Median JJ N
age NN N
of IN N
the DT N
94 CD 3_p
women NNS 2_p
was VBD N
51 CD 1_p
years NNS 1_p
range VB 1_p
27-76 JJ 1_p
79 CD N
received VBD N
fluorouracil/epirubicin/cyclophosphamide NN N
and CC N
15 CD N
received VBD N
doxorubicin/cyclophosphamide NN N
Thirteen JJ N
withdrew VBD N
pre-cycle JJ N
2 CD N
with IN N
no DT N
differences NNS N
between IN N
arms NNS N
Of IN N
80 CD N
patients NNS N
stating VBG N
a DT N
preference NN N
31 CD N
preferred JJ N
placebo NN N
39 CD N
95 CD N
CI NNP N
28-50 CD N
and CC N
37 CD N
46 CD N
95 CD N
CI NNP N
35-58 CD N
preferred VBD N
dexamethasone NN N
12 CD N
had VBD N
no DT N
preference NN N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
intensity NN N
of IN N
vomiting VBG N
nausea NN N
or CC N
time NN N
to TO N
onset VB N
of IN N
vomiting VBG N
There EX N
was VBD N
greater JJR N
decrease NN N
in IN N
global JJ N
QOL NNP N
p JJ N
0.06 CD N
when WRB N
patients NNS N
received VBD N
dexamethasone NN N
No DT N
other JJ N
symptom/QOL NN N
domains NNS N
differed VBD N
significantly RB N
In IN N
conclusion NN N
no DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
patient JJ N
preference NN N
QOL NNP N
or CC N
symptoms NNS N
regardless RB N
of IN N
whether IN N
dexamethasone NN N
or CC N
placebo NN N
was VBD N
used VBN N
after IN N
adjuvant JJ N
chemotherapy NN N
-DOCSTART- -X- O O

Salbutamol NNP N
or CC N
mist NN N
in IN N
acute JJ 4_p
bronchiolitis NN 4_p
BACKGROUND IN N
The DT N
role NN N
of IN N
bronchodilators NNS N
in IN N
the DT N
treatment NN N
of IN N
bronchiolitis NN N
remains VBZ N
controversial JJ N
METHODS VB N
A DT N
double-blind NN N
placebo NN N
controlled VBD N
trial NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
clinical JJ N
response NN N
to TO N
nebulized VBN N
salbutamol NN N
One CD 3_p
hundred CD 3_p
and CC 3_p
fifty-six JJ 3_p
infants NNS 1_p
aged VBN 1_p
between IN 1_p
7 CD 1_p
weeks NNS 1_p
and CC 1_p
24 CD 1_p
months NNS 1_p
who WP N
had VBD N
had VBN 4_p
an DT 4_p
episode NN 4_p
of IN 4_p
wheezing NN 4_p
and CC 4_p
other JJ 4_p
signs NNS 4_p
and CC 4_p
symptoms NNS 4_p
of IN 4_p
bronchiolitis NN 4_p
were VBD N
randomized VBN N
to TO N
three CD N
groups NNS N
as IN N
follows VBZ N
i NN N
nebulized VBD N
salbutamol NN N
was VBD N
administered VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
I PRP N
at IN N
a DT N
dose NN N
of IN N
0.15 CD N
mg/kg NNS N
in IN N
2 CD N
mL JJ N
saline NN N
ii NN N
saline NN N
was VBD N
nebulized VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
II NNP N
and CC N
iii NN N
in IN N
group NN N
III NNP N
52 CD N
patients NNS N
received JJ N
mist NN N
in IN N
a DT N
tent NN N
All DT N
three CD N
groups NNS N
were VBD N
administered VBN N
oxygen NN N
during IN N
the DT N
procedures NNS N
Treatment NNP N
was VBD N
repeated VBN N
with IN N
the DT N
same JJ N
agent NN N
after IN N
30 CD N
min NN N
if IN N
the DT N
respiratory NN N
score NN N
was VBD N
5 CD N
or CC N
more JJR N
Respiratory JJ N
rate NN N
heart NN N
rate NN N
oxygen NN N
saturation NN N
and CC N
presence NN N
of IN N
cyanosis NN N
wheezing VBG N
retractions NNS N
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
RESULTS VB N
The DT N
decrease NN N
in IN N
the DT N
respiratory NN N
score NN N
was VBD N
5.2 CD N
+/- JJ N
1.8 CD N
0.82 CD N
+/- JJ N
2.4 CD N
and CC N
1.7 CD N
+/- JJ N
1.3 CD N
in IN N
group NN N
I PRP N
II NNP N
and CC N
III NNP N
respectively RB N
The DT N
decrease NN N
in IN N
group NN N
I PRP N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
Heart NNP N
rate NN N
was VBD N
similar JJ N
between IN N
groups NNS N
Oxygen NNP N
saturation NN N
decreased VBD N
in IN N
group NN N
I PRP N
without IN N
reaching VBG N
statistical JJ N
significance NN N
CONCLUSIONS NNP N
Salbutamol NNP N
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
bronchiolitis NN N
-DOCSTART- -X- O O

Effects NNS N
of IN N
cuff NN N
inflation NN N
on IN N
self-recorded JJ N
blood NN N
pressure NN N
Changes NNS N
in IN N
continuously RB N
recorded VBN N
'Finapres NNS N
finger NN N
blood NN N
pressure NN N
in IN N
ten JJ 3_p
normotensive JJ 4_p
and CC N
seven CD 3_p
hypertensive JJ 4_p
subjects NNS N
induced VBN N
by IN N
self-inflation NN N
of IN N
the DT N
cuff NN N
or CC N
just RB N
wearing VBG N
the DT N
inflated JJ N
cuff NN N
were VBD N
studied VBN N
Inflating VBG N
the DT N
cuff NN N
caused VBD N
an DT N
instantaneous JJ N
rise NN N
in IN N
systolic JJ N
blood NN N
pressure NN N
of IN N
13 CD N
and CC N
12 CD N
mm NN N
Hg NNP N
hypertensive JJ N
and CC N
normotensive JJ N
subjects NNS N
respectively RB N
Wearing VBG N
the DT N
inflated JJ N
cuff NN N
did VBD N
not RB N
change VB N
blood NN N
pressure NN N
Thus VB N
the DT N
rise NN N
in IN N
pressure NN N
was VBD N
related VBN N
to TO N
the DT N
muscular JJ N
activity NN N
required VBN N
for IN N
cuff NN N
inflation NN N
Systolic NNP N
blood NN N
pressure NN N
took VBD N
on IN N
average JJ N
7 CD N
s NN N
and CC N
at IN N
most JJS N
21 CD N
s NN N
to TO N
return VB N
to TO N
baseline VB N
level NN N
after IN N
stopping VBG N
cuff NN N
inflation NN N
Since IN N
first JJ N
Korotkoff NNP N
sounds NNS N
may MD N
already RB N
be VB N
heard VBN N
after IN N
10-15 JJ N
s NN N
when WRB N
following VBG N
recommended VBD N
procedures NNS N
self-recorded JJ N
systolic JJ N
blood NN N
pressure NN N
may MD N
be VB N
recorded VBN N
as IN N
too RB N
high JJ N
when WRB N
subjects NNS N
inflate VBP N
their PRP$ N
cuff NN N
at IN N
too RB N
low JJ N
a DT N
pressure NN N
or CC N
deflate VB N
it PRP N
too RB N
fast RB N
-DOCSTART- -X- O O

A DT N
selective JJ N
angiotensin NN N
receptor NN N
antagonist NN N
Valsartan NNP N
produced VBD N
regression NN N
of IN N
left JJ 4_p
ventricular JJ 4_p
hypertrophy NN 4_p
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
arterial JJ N
stiffness NN N
We PRP N
investigated VBD N
whether IN N
a DT N
selective JJ N
angiotensin NN N
II NNP N
receptor NN N
blocker NN N
ARB NNP N
would MD N
have VB N
a DT N
regressive JJ N
effect NN N
on IN N
left NN N
ventricular JJ N
hypertrophy NN N
LVH NNP N
in IN N
patients NNS 4_p
on IN 4_p
continuous JJ 4_p
ambulatory JJ 4_p
peritoneal JJ 4_p
dialysis NN 4_p
CAPD NNP 4_p
In IN N
a DT N
double-blind NN N
study NN N
24 CD 3_p
CAPD NNP 4_p
patients NNS 4_p
with IN 4_p
LVH NNP 4_p
left VBD 4_p
ventricular JJ 4_p
mass NN 4_p
index NN 4_p
LVMi NNP 4_p
110 CD 4_p
g/m2 NN 4_p
for IN 4_p
women NNS 4_p
and CC N
LVMi NNP 4_p
137 CD 4_p
g/m2 NN 4_p
for IN 4_p
men NNS 4_p
were VBD N
randomized VBN N
to TO N
12 CD N
months NNS N
administration NN N
of IN N
either CC N
the DT N
ARB NNP N
valsartan NN N
n JJ N
14 CD N
or CC N
a DT N
placebo NN N
n JJ N
10 CD N
The DT N
target NN N
blood NN N
pressure NN N
BP NNP N
was VBD N
140/90 CD N
mmHg NN N
or CC N
lower JJR N
in IN N
both DT N
groups NNS N
The DT N
following JJ N
parameters NNS N
were VBD N
measured VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
aortic JJ N
and CC N
large-artery JJ N
compliance NN N
and CC N
arterial JJ N
wave NN N
reflections NNS N
pulse JJ N
wave VBP N
velocity NN N
PWV NNP N
and CC N
augmentation NN N
index NN N
AI NNP N
application NN N
tonometry NN N
and CC N
cardiac JJ N
echocardiography NN N
Periodically RB N
recorded VBN N
were VBD N
body JJ N
weight NN N
BP NNP N
mercury NN N
sphygmomanometer NN N
serum JJ N
creatinine NN N
electrolytes VBZ N
complete JJ N
blood NN N
cell NN N
counts NNS N
urine JJ N
volume NN N
drainage NN N
volume NN N
and CC N
weekly JJ N
creatinine NN N
clearance NN N
Two-way JJ N
analysis NN N
of IN N
variance NN N
for IN N
repeated JJ N
measurements NNS N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
Systolic NNP N
and CC N
diastolic JJ N
BP NNP N
were VBD N
both DT N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP N
The DT N
LVMi NNP N
was VBD N
significantly RB N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP N
to TO N
121 CD N
+/- JJ N
4 CD N
from IN N
145 CD N
+/- JJ N
5 CD N
but CC N
not RB N
in IN N
those DT N
receiving VBG N
placebo NN N
to TO N
137 CD N
+/- JJ N
3 CD N
from IN N
152 CD N
+/- JJ N
3 CD N
p NN N
0.05 CD N
The DT N
decrease NN N
in IN N
LVMi NNP N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
PWV NNP N
and CC N
AI NNP N
In IN N
CAPD NNP N
patients NNS N
with IN N
LVH NNP N
ARB NNP N
reduced VBD N
LVMi NNP N
in IN N
association NN N
with IN N
alterations NNS N
in IN N
arterial JJ N
hemodynamics NNS N
-DOCSTART- -X- O O

Parent-implemented JJ N
enhanced VBD N
milieu NNS N
teaching VBG N
with IN N
preschool JJ 1_p
children NNS 1_p
who WP 4_p
have VBP 4_p
intellectual JJ 4_p
disabilities NNS 4_p
PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
enhanced JJ N
milieu NN N
teaching NN N
EMT NNP N
implemented VBN N
by IN N
parents NNS N
and CC N
therapists NNS N
versus VBP N
therapists VBZ N
only RB N
on IN N
the DT N
language NN N
skills NNS N
of IN N
preschool NN 4_p
children NNS 4_p
with IN 4_p
intellectual JJ 4_p
disabilities NNS 4_p
IDs NNP 4_p
including VBG 4_p
children NNS 4_p
with IN 4_p
Down NNP 4_p
syndrome NN 4_p
and CC 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
METHOD NNP N
Seventy-seven JJ 3_p
children NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
2 CD N
treatments NNS N
parent NN N
therapist NN N
EMT NNP N
or CC N
therapist-only RB N
EMT NNP N
and CC N
received VBD N
36 CD N
intervention NN N
sessions NNS N
Children NNP N
were VBD N
assessed VBN N
before RB N
immediately RB N
after IN N
6 CD N
months NNS N
after IN N
and CC N
12 CD N
months NNS N
after IN N
intervention NN N
Separate JJ N
linear JJ N
regressions NNS N
were VBD N
conducted VBN N
for IN N
each DT N
standardized JJ N
and CC N
observational JJ N
measure NN N
at IN N
each DT N
time NN N
point NN N
RESULTS JJ N
Parents NNS N
in IN N
the DT N
parent NN N
therapist NN N
group NN N
demonstrated VBD N
greater JJR N
use NN N
of IN N
EMT NNP N
strategies NNS N
at IN N
home NN N
than IN N
untrained JJ N
parents NNS N
in IN N
the DT N
therapist-only JJ N
group NN N
and CC N
these DT N
effects NNS N
maintained VBD N
over IN N
time NN N
Effect JJ N
sizes NN N
for IN N
observational JJ N
measures NNS N
ranged VBD N
from IN N
d NN N
0.10 CD N
to TO N
d VB N
1.32 CD N
favoring VBG N
the DT N
parent NN N
therapist NN N
group NN N
with IN N
the DT N
largest JJS N
effect NN N
sizes VBZ N
found VBD N
12 CD N
months NNS N
after IN N
intervention NN N
CONCLUSION NNP N
Findings NNS N
from IN N
this DT N
study NN N
indicate VBP N
generally RB N
that IN N
there EX N
are VBP N
benefits NNS N
to TO N
training VBG N
parents NNS N
to TO N
implement VB N
naturalistic JJ N
language NN N
intervention NN N
strategies NNS N
with IN N
preschool JJ 4_p
children NNS 4_p
who WP 4_p
have VBP 4_p
ID NNP 4_p
and CC 4_p
significant JJ 4_p
language NN 4_p
impairments NNS 4_p
-DOCSTART- -X- O O

Interventions NNS N
in IN N
the DT N
initial JJ 4_p
prodromal JJ 4_p
states NNS 4_p
of IN 4_p
psychosis NN 4_p
in IN N
Germany NNP 4_p
concept NN N
and CC N
recruitment NN N
BACKGROUND VB N
The DT N
Early JJ N
Detection NN N
and CC N
Intervention NNP N
Programme NNP N
of IN N
the DT N
German JJ N
Research NNP N
Network NNP N
on IN N
Schizophrenia NNP N
GRNS NNP N
investigates VBZ N
the DT N
initial JJ N
prodromal JJ N
phase NN N
of IN N
psychosis NN N
in IN N
a DT N
multidimensional JJ N
approach NN N
Two CD N
intervention NN N
strategies NNS N
are VBP N
being VBG N
studied VBN N
by IN N
two CD N
large-scale JJ N
multicentre JJ N
projects NNS N
AIMS NNP N
To TO N
present VB N
the DT N
concept NN N
of IN N
the DT N
intervention NN N
studies NNS N
and CC N
to TO N
provide VB N
an DT N
interim JJ N
report NN N
of IN N
the DT N
recruitment JJ N
procedure NN N
METHOD NNP N
Comprehensive NNP N
cognitive-behavioural JJ N
therapy NN N
has VBZ N
been VBN N
developed VBN N
for IN N
patients NNS N
in IN N
the DT N
early JJ 4_p
initial JJ 4_p
prodromal JJ 4_p
state NN 4_p
For IN N
patients NNS N
in IN N
the DT N
late JJ 4_p
initial JJ 4_p
prodromal JJ 4_p
state NN 4_p
the DT N
atypical JJ N
neuroleptic JJ N
amisulpride NN N
is VBZ N
explored VBN N
Both DT N
interventions NNS N
are VBP N
evaluated VBN N
in IN N
randomised JJ N
controlled VBN N
trials NNS N
using VBG N
clinical JJ N
management NN N
as IN N
the DT N
control NN N
condition NN N
RESULTS NNP N
Between NNP N
January NNP N
2001 CD N
and CC N
March NNP N
2003 CD N
1212 CD 3_p
individuals NNS 4_p
seeking VBG 4_p
help NN 4_p
for IN 4_p
mental JJ 4_p
health NN 4_p
problems NNS 4_p
were VBD N
screened VBN N
for IN N
putative JJ N
prodromal NN N
symptoms NNS N
at IN N
four CD N
university NN N
centres NNS N
More JJR 3_p
than IN 3_p
388 CD 3_p
individuals NNS 3_p
fulfilled VBD 3_p
criteria NNS 3_p
for IN 3_p
both DT 3_p
interventions NNS 3_p
and CC 3_p
188 CD 3_p
48.5 CD 3_p
gave VBD 3_p
informed VBN 3_p
consent NN 3_p
to TO 3_p
participate VB 3_p
in IN 3_p
the DT 3_p
trials NNS 3_p
CONCLUSIONS VB N
The DT N
screening NN N
procedure NN N
appears VBZ N
to TO N
be VB N
feasible JJ N
and CC N
trial NN N
participation NN N
seems VBZ N
to TO N
be VB N
acceptable JJ N
to TO N
a DT N
relevant JJ N
proportion NN N
of IN N
people NNS N
at IN N
increased VBN N
risk NN N
of IN N
developing VBG N
psychosis NN N
-DOCSTART- -X- O O

Trial JJ N
design NN N
challenges NNS N
when WRB N
combining VBG N
medication NN N
and CC N
parent NN N
training NN N
in IN N
children NNS 1_p
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
This DT N
paper NN N
presents VBZ N
the DT N
rationale NN N
for IN N
a DT N
24-week JJ N
randomized JJ N
trial NN N
designed VBN N
to TO N
test VB N
whether IN N
risperidone NN N
plus CC N
structured JJ N
parent NN N
training NN N
would MD N
be VB N
superior JJ N
to TO N
risperidone VB N
only RB N
on IN N
measures NNS N
of IN N
noncompliance NN N
irritability NN N
and CC N
adaptive JJ N
functioning NN N
In IN N
this DT N
model NN N
medication NN N
reduces NNS N
tantrums NNS N
aggression NN N
and CC N
self-injury NN N
parent NN N
training NN N
promotes NNS N
improvement NN N
in IN N
noncompliance NN N
and CC N
adaptive JJ N
functioning NN N
Thus RB N
medication NN N
and CC N
parent NN N
training NN N
target NN N
related VBN N
but CC N
separate JJ N
outcomes RB N
At IN N
week NN N
24 CD N
the DT N
medication NN N
was VBD N
gradually RB N
withdrawn VBN N
to TO N
determine VB N
whether IN N
subjects NNS N
in IN N
the DT N
combined JJ N
treatment NN N
group NN N
could MD N
be VB N
managed VBN N
on IN N
a DT N
lower JJR N
dose NN N
or CC N
off IN N
medication NN N
without IN N
relapse NN N
Both DT N
symptom JJ N
reduction NN N
and CC N
functional JJ N
improvement NN N
are VBP N
important JJ N
clinical JJ N
treatment NN N
targets NNS N
Thus RB N
experimental JJ N
evidence NN N
on IN N
the DT N
beneficial JJ N
effects NNS N
of IN N
combining VBG N
pharmacotherapy NN N
and CC N
exportable JJ N
behavioral JJ N
interventions NNS N
is VBZ N
needed VBN N
to TO N
guide VB N
clinical JJ N
practice NN N
-DOCSTART- -X- O O

The DT N
immediate JJ N
efficacy NN N
of IN N
adjunctive JJ N
doxycycline NN N
in IN N
treatment NN N
of IN N
localized VBN 4_p
juvenile NN 4_p
periodontitis NN 4_p
A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
on IN N
the DT N
immediate JJ N
clinical JJ N
and CC N
microbiological JJ N
efficacy NN N
of IN N
doxycycline NN N
100 CD N
mg NN N
for IN N
14 CD N
days NNS N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
benefit NN N
of IN N
adjunctive JJ N
medication NN N
in IN N
16 CD 3_p
patients NNS 4_p
with IN 4_p
localized JJ 4_p
juvenile NN 4_p
periodontitis NN 4_p
Measurements NNS N
of IN N
gingival NN N
fluid NN N
flow NN N
probing VBG N
depths NNS N
bleeding VBG N
on IN N
probing VBG N
and CC N
suppuration NN N
were VBD N
determined VBN N
at IN N
2 CD N
periodontal JJ N
sites NNS N
with IN N
and CC N
2 CD N
without IN N
radiographic JJ N
attachment JJ N
loss NN N
at IN N
weeks NNS N
0 CD N
1 CD N
3 CD N
and CC N
8 CD N
Subgingival JJ N
bacterial JJ N
samples NNS N
were VBD N
taken VBN N
with IN N
curettes NNS N
from IN N
the DT N
same JJ N
sites NNS N
Spirochaetes NNS N
were VBD N
searched VBN N
for IN N
by IN N
dark-field JJ N
microscopy NN N
Actinobacillus CC N
actinomycetemcomitans NNS N
pigmented VBN N
and CC N
non-pigmented JJ N
Bacteroides NNP N
spp. NN N
Capnocytophaga NNP N
Fusobacterium NNP N
and CC N
Actinomyces NNP N
spp NN N
were VBD N
cultured VBN N
on IN N
various JJ N
selective JJ N
and CC N
non-selective JJ N
media NNS N
Bacterial JJ N
species NNS N
found VBN N
at IN N
least JJS N
in IN N
50 CD N
of IN N
the DT N
patients NNS N
and CC N
comprising VBG N
on IN N
average JJ N
5 CD N
or CC N
more JJR N
of IN N
the DT N
cultivable JJ N
flora NNS N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
Neither CC N
short-term JJ N
clinical JJ N
nor CC N
microbiological JJ N
efficacy NN N
beyond IN N
that DT N
of IN N
a DT N
course NN N
of IN N
mechanical JJ N
debridement NN N
alone RB N
was VBD N
found VBN N
by IN N
using VBG N
systemic JJ N
medication NN N
with IN N
doxycycline NN N
in IN N
patients NNS 4_p
with IN 4_p
localized JJ 4_p
juvenile NN 4_p
periodontitis NN 4_p
-DOCSTART- -X- O O

Protection NN N
of IN N
man NN N
from IN N
natural JJ N
infection NN N
with IN N
influenza JJ N
A2 NNP N
Hong NNP N
Kong NNP N
virus NN N
by IN N
amantadine NN N
a DT N
controlled JJ N
field NN N
trial NN N
Prophylactic JJ N
administration NN N
of IN N
amantadine NN N
in IN N
doses NNS N
of IN N
100 CD N
mg. NN N
twice RB N
a DT N
day NN N
offered VBN N
statistically RB N
significant JJ N
protection NN N
against IN N
influenza JJ N
A2 NNP N
infection NN N
in IN N
a DT N
double-blind JJ N
field NN N
trial NN N
involving VBG N
391 CD 3_p
medical JJ 4_p
student NN 4_p
volunteers NNS 4_p
during IN 4_p
the DT 4_p
influenza JJ 4_p
A2 NNP 4_p
Hong NNP 4_p
Kong NNP 4_p
epidemic VBP 4_p
in IN 4_p
Helsinki NNP 4_p
in IN 4_p
the DT 4_p
winter NN 4_p
of IN 4_p
1969 CD 4_p
Serologically RB N
verified JJ N
influenza NN N
as IN N
measured VBN N
by IN N
complement JJ N
fixation NN N
and/or NN N
haemagglutination NN N
inhibition NN N
occurred VBD N
in IN N
27 CD N
out IN N
of IN N
192 CD N
students NNS N
in IN N
the DT N
amantadine NN N
group NN N
against IN N
57 CD N
out IN N
of IN N
199 CD N
in IN N
the DT N
placebo NN N
group NN N
giving VBG N
a DT N
protection NN N
rate NN N
of IN N
52 CD N
-DOCSTART- -X- O O

Effect NN N
of IN N
rosuvastatin NN N
monotherapy NN N
or CC N
in IN N
combination NN N
with IN N
fenofibrate NN N
or CC N
ω-3 JJ N
fatty JJ N
acids NNS N
on IN N
lipoprotein JJ N
subfraction NN N
profile NN N
in IN N
patients NNS 4_p
with IN 4_p
mixed JJ 4_p
dyslipidaemia NN 4_p
and CC 4_p
metabolic JJ 4_p
syndrome NN 4_p
BACKGROUND NNP N
Raised VBD N
triglycerides NNS N
TG NNP N
decreased VBD N
high-density NN N
lipoprotein NN N
cholesterol NN N
HDL-C NNP N
levels NNS N
and CC N
a DT N
predominance NN N
of IN N
small JJ N
dense NN N
low JJ N
density NN N
lipoproteins NNS N
sdLDL NN N
are VBP N
characteristics NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
MetS NNP N
OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
high-dose JJ N
rosuvastatin NN N
monotherapy NN N
with IN N
moderate JJ N
dosing NN N
combined VBN N
with IN N
fenofibrate NN N
or CC N
ω-3 JJ N
fatty JJ N
acids NNS N
on IN N
the DT N
lipoprotein JJ N
subfraction NN N
profile NN N
in IN N
patients NNS 4_p
with IN 4_p
mixed JJ 4_p
dyslipidaemia NN 4_p
and CC 4_p
MetS NNP 4_p
METHODS NNP N
We PRP N
previously RB N
randomised VBD N
patients NNS 4_p
with IN 4_p
low-density JJ 4_p
lipoprotein NNS 4_p
cholesterol NN 4_p
LDL-C NNP 4_p
160 CD 4_p
and CC 4_p
TG NNP 4_p
200 CD 4_p
mg/dl NN 4_p
to TO N
rosuvastatin VB N
monotherapy NN N
40 CD N
mg/day NN N
R NNP N
group NN N
n RB N
30 CD N
or CC N
rosuvastatin $ N
10 CD N
mg/day NN N
combined VBN N
with IN N
fenofibrate JJ N
200 CD N
mg/day NN N
RF NNP N
group NN N
n RB N
30 CD N
or CC N
ω-3 JJ N
fatty JJ N
acids NNS N
2 CD N
g/day NN N
Rω NNP N
group NN N
n RB N
30 CD N
In IN N
the DT N
present JJ N
study NN N
only RB N
patients NNS 4_p
with IN 4_p
MetS NNP 4_p
were VBD N
included VBN N
24 CD N
23 CD N
and CC N
24 CD N
in IN N
the DT N
R NNP N
RF NNP N
and CC N
Rω NNP N
groups NNS N
respectively RB N
At IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
the DT N
lipoprotein JJ N
subfraction NN N
profile NN N
was VBD N
determined VBN N
by IN N
polyacrylamide JJ N
3 CD N
gel JJ N
electrophoresis NN N
RESULTS VB N
The DT N
mean JJ N
LDL NNP N
size NN N
was VBD N
significantly RB N
increased VBN N
in IN N
all DT N
groups NNS N
This DT N
change NN N
was VBD N
more RBR N
prominent JJ N
with IN N
RF NNP N
than IN N
with IN N
other JJ N
treatments NNS N
in IN N
parallel JJ N
with IN N
its PRP$ N
greater JJR N
hypotriglyceridemic JJ N
capacity NN N
p JJ N
0.05 CD N
compared VBN N
with IN N
R NNP N
and CC N
Rω NNP N
A DT N
decrease NN N
in IN N
insulin NN N
resistance NN N
by IN N
RF NNP N
was VBD N
also RB N
noted VBN N
Only RB N
RF NNP N
significantly RB N
raised VBD N
HDL-C NNP N
levels NNS N
by IN N
7.7 CD N
p NN N
0.05 CD N
by IN N
increasing VBG N
the DT N
cholesterol NN N
of IN N
small JJ N
HDL NNP N
particles NNS N
The DT N
cholesterol NN N
of IN N
larger JJR N
HDL NNP N
subclasses NNS N
was VBD N
significantly RB N
increased VBN N
by IN N
R NNP N
and CC N
Rω NNP N
CONCLUSIONS NNP N
All NNP N
regimens VBZ N
increased VBN N
mean JJ N
LDL NNP N
size NN N
RF NNP N
was VBD N
the DT N
most RBS N
effective JJ N
A DT N
differential JJ N
effect NN N
of IN N
treatments NNS N
was VBD N
noted VBN N
on IN N
the DT N
HDL NNP N
subfraction NN N
profile NN N
-DOCSTART- -X- O O

Inference-Based JJ N
Approach NNP N
versus NN N
Cognitive NNP N
Behavioral NNP N
Therapy NNP N
in IN N
the DT N
Treatment NNP N
of IN N
Obsessive-Compulsive NNP 4_p
Disorder NNP 4_p
with IN 4_p
Poor NNP 4_p
Insight NNP 4_p
A DT N
24-Session JJ N
Randomized NNP N
Controlled NNP N
Trial NNP N
OBJECTIVE NNP N
Obsessive-compulsive JJ N
disorder NN N
OCD NNP N
with IN N
poor JJ N
insight NN N
has VBZ N
severe JJ N
consequences NNS N
for IN N
patients NNS N
nonetheless RB N
no DT N
randomized VBN N
controlled VBN N
trial NN N
has VBZ N
ever RB N
been VBN N
performed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
any DT N
treatment NN N
specifically RB N
for IN N
poor-insight JJ N
OCD NNP N
A DT N
new JJ N
psychotherapy NN N
for IN N
OCD NNP N
the DT N
inference-based JJ N
approach NN N
IBA NNP N
targets NNS N
insight VBP N
in IN N
OCD NNP N
by IN N
strengthening VBG N
normal JJ N
sensory-driven JJ N
reality NN N
testing VBG N
The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
this DT N
new JJ N
treatment NN N
to TO N
the DT N
effectiveness NN N
of IN N
cognitive JJ N
behavior NN N
therapy NN N
CBT NNP N
for IN N
patients NNS 4_p
with IN 4_p
OCD NNP 4_p
with IN 4_p
poor JJ 4_p
insight NN 4_p
METHOD NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
in IN N
which WDT N
90 CD 3_p
patients NNS 4_p
with IN 4_p
OCD NNP 4_p
with IN 4_p
poor JJ 4_p
insight NN 4_p
received VBD N
either RB N
24 CD N
CBT NNP N
sessions NNS N
or CC N
24 CD N
IBA JJ N
sessions NNS N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Yale-Brown JJ N
Obsessive NNP N
Compulsive NNP N
Scale NNP N
YBOCS NNP N
Secondary JJ N
outcome NN N
measures NNS N
were VBD N
level NN N
of IN N
insight NN N
anxiety NN N
and CC N
depressive JJ N
symptoms NNS N
and CC N
quality NN N
of IN N
life NN N
Mixed-effects NNS N
models NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
treatment NN N
effect NN N
RESULTS NN N
In IN N
both DT N
conditions NNS N
a DT N
significant JJ N
OCD NNP N
symptom NN N
reduction NN N
was VBD N
reached VBN N
but CC N
no DT N
condition NN N
effects NNS N
were VBD N
established VBN N
Post NNP N
hoc NN N
in IN N
a DT N
small JJ N
subgroup NN N
of IN N
patients NNS N
with IN N
the DT N
worst JJS N
insight NN N
n JJ N
23 CD N
it PRP N
was VBD N
found VBN N
that IN N
the DT N
patients NNS N
treated VBN N
with IN N
the DT N
IBA NNP N
reached VBD N
a DT N
significantly RB N
higher JJR N
OCD NNP N
symptom VBZ N
reduction NN N
than IN N
the DT N
patients NNS N
treated VBN N
with IN N
CBT NNP N
estimated VBD N
marginal JJ N
mean NN N
-7.77 NNP N
t NN N
219.45 CD N
-2.4 NN N
p NN N
0.017 CD N
CONCLUSION NNP N
Patients NNPS 4_p
with IN 4_p
OCD NNP 4_p
with IN 4_p
poor JJ 4_p
insight JJ 4_p
improve VB N
significantly RB N
after IN N
psychological JJ N
treatment NN N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
both DT N
CBT NNP N
and CC N
the DT N
IBA NNP N
are VBP N
effective JJ N
treatments NNS N
for IN N
OCD NNP N
with IN N
poor JJ N
insight NN N
The DT N
IBA NNP N
might MD N
be VB N
more RBR N
promising JJ N
than IN N
CBT NNP N
for IN N
patients NNS N
with IN N
more RBR N
extreme JJ N
poor JJ N
insight NN N
-DOCSTART- -X- O O

The DT N
efficacy NN N
of IN N
prophylactic JJ N
ondansetron NN N
droperidol NN N
perphenazine NN N
and CC N
metoclopramide RB N
in IN N
the DT N
prevention NN N
of IN N
nausea NN N
and CC N
vomiting NN N
after IN N
major JJ N
gynecologic NN N
surgery NN N
The DT N
prophylactic JJ N
antiemetic JJ N
efficacy NN N
of IN N
intravenous JJ N
i.v JJ N
ondansetron NN N
droperidol NN N
perphenazine NN N
and CC N
metoclopramide NN N
was VBD N
evaluated VBN N
in IN N
a DT N
prospective JJ N
double-blind JJ N
study NN N
of IN N
360 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I-III NNP 4_p
patients NNS 4_p
undergoing VBG 4_p
total JJ 4_p
abdominal JJ 4_p
hysterectomy NN 4_p
TAH NNP 4_p
Subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
i.v. NN N
one CD N
of IN N
ondansetron NN N
4 CD N
mg NN N
droperidol VBZ N
1.25 CD N
mg NN N
perphenazine VBP N
5 CD N
mg NN N
metoclopramide RB N
10 CD N
mg NN N
or CC N
placebo RB N
prior JJ N
to TO N
induction NN N
of IN N
anesthesia NN N
Hypotension NNP N
immediately RB N
after IN N
administration NN N
of IN N
metoclopramide NN N
was VBD N
observed VBN N
in IN N
two CD N
patients NNS N
and CC N
four CD N
patients NNS N
given VBN N
ondansetron RP N
developed JJ N
profound NN N
systolic JJ N
hypotension NN N
at IN N
induction NN N
of IN N
anesthesia NN N
Twenty-two JJ N
percent NN N
of IN N
patients NNS N
receiving VBG N
droperidol NN N
became VBD N
sedated JJ N
Postoperatively RB N
patients NNS N
developing VBG N
severe JJ N
nausea NN N
retching NN N
or CC N
vomiting NN N
defined VBD N
as IN N
severe JJ N
emetic JJ N
sequelae NN N
SES NNP N
were VBD N
deemed VBN N
to TO N
have VB N
failed VBN N
antiemetic JJ N
prophylaxis NN N
and CC N
received VBN N
antiemetic JJ N
rescue NN N
A DT N
significantly RB N
larger JJR N
number NN N
of IN N
patients NNS N
who WP N
received VBD N
i.v NN N
ondansetron NN N
63 CD N
droperidol NN N
76 CD N
and CC N
perphenazine NN N
70 CD N
were VBD N
free JJ N
of IN N
SES NNP N
when WRB N
compared VBN N
to TO N
placebo VB N
43 CD N
P NNP N
0.05 CD N
Metoclopramide NNP N
was VBD N
ineffective JJ N
Although IN N
ondansetron NN N
droperidol NN N
and CC N
perphenazine NN N
were VBD N
effective JJ N
in IN N
providing VBG N
antiemetic JJ N
prophylaxis NN N
only RB N
i.v NN N
perphenazine NN N
was VBD N
free JJ N
of IN N
side JJ N
effects NNS N
Hence NNP N
we PRP N
conclude VBP N
that DT N
perphenazine NN N
is VBZ N
the DT N
best JJS N
choice NN N
for IN N
antiemetic JJ N
prophylaxis NN N
after IN N
TAH NNP N
-DOCSTART- -X- O O

Effects NNS N
of IN N
guided JJ N
imagery NN N
with IN N
relaxation NN N
training NN N
on IN N
anxiety NN N
and CC N
quality NN N
of IN N
life NN N
among IN N
patients NNS 4_p
with IN 4_p
inflammatory JJ 4_p
bowel NN 4_p
disease NN 4_p
BACKGROUND NNP N
Inflammatory NNP N
Bowel NNP N
Disease NNP N
IBD NNP N
impacts VBZ N
quality NN N
of IN N
life NN N
QoL NNP N
Psychological JJ N
factors NNS N
influence VBP N
the DT N
course NN N
of IN N
the DT N
disease NN N
and CC N
should MD N
be VB N
targeted VBN N
for IN N
intervention NN N
METHODS NNP N
Our PRP$ N
study NN N
was VBD N
a DT N
prospective JJ N
randomised VBD N
control NN N
trial NN N
Fifty-six JJ 3_p
outpatients NNS 3_p
were VBD N
randomly RB N
chosen VBN N
and CC N
allocated VBN N
to TO N
a DT N
treatment NN N
group NN N
or CC N
a DT N
waiting-list JJ N
control NN N
group NN N
Treatment NNP N
group NN N
patients NNS N
attended VBD N
three CD N
relaxation-training JJ N
sessions NNS N
and CC N
received VBD N
an DT N
audio JJ N
disc NN N
for IN N
home NN N
practice NN N
Evaluations NNS N
performed VBD N
pre JJ N
and CC N
post-treatment JJ N
state NN N
anxiety NN N
was VBD N
assessed VBN N
with IN N
the DT N
State-Trait NNP N
Anxiety NNP N
Inventory NNP N
QoL NNP N
with IN N
the DT N
IBD NNP N
Questionnaire NNP N
The DT N
Visual NNP N
Analogue NNP N
Scale NNP N
assessed VBD N
pain NN N
depression NN N
stress NN N
and CC N
mood NN N
Patients NNS N
completed VBD N
a DT N
symptom JJ N
monitoring NN N
diary NN N
The DT N
control NN N
group NN N
's POS N
symptoms NNS N
were VBD N
monitored VBN N
without IN N
study-related JJ N
treatment NN N
RESULTS NNP N
Thirty-nine JJ 3_p
subjects NNS 3_p
completed VBD 3_p
the DT 3_p
study NN 3_p
and CC N
were VBD N
included VBN N
in IN N
the DT N
data NN N
analysis NN N
Following VBG N
the DT N
relaxation-training JJ N
intervention NN N
the DT N
treatment NN N
group NN N
's POS N
n JJ N
18 CD N
measured VBN N
results NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
improvement NN N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
n JJ N
21 CD N
time NN N
by IN N
treatment NN N
interaction NN N
anxiety NN N
levels NNS N
decreased VBN N
p JJ N
0.01 CD N
QoL NNP N
and CC N
mood NN N
improved VBN N
p JJ N
0.05 CD N
while IN N
levels NNS N
of IN N
pain NN N
and CC N
stress NN N
decreased VBN N
p JJ N
0.01 CD N
CONCLUSIONS NNP N
Findings NNP N
indicate VBP N
IBD NNP N
patients NNS N
may MD N
benefit VB N
from IN N
relaxation NN N
training NN N
in IN N
their PRP$ N
holistic JJ N
care NN N
New NNP N
studies NNS N
as RB N
well RB N
as IN N
further JJ N
investigation NN N
of IN N
the DT N
subject NN N
are VBP N
warranted VBN N
-DOCSTART- -X- O O

The DT N
role NN N
of IN N
somatostatin NN N
octreotide JJ N
in IN N
the DT N
regulation NN N
of IN N
melatonin JJ N
secretion NN N
in IN N
healthy JJ 4_p
volunteers NNS 4_p
and CC 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
primary JJ 4_p
hypothyroidism NN 4_p
Somatostatin NNP N
has VBZ N
been VBN N
found VBN N
in IN N
the DT N
pineal JJ N
gland NN N
of IN N
several JJ N
animal JJ N
species NNS N
which WDT N
suggests VBZ N
that IN N
it PRP N
may MD N
be VB N
involved VBN N
in IN N
the DT N
regulation NN N
of IN N
melatonin JJ N
secretion NN N
Whether NNP N
somatostatin NN N
has VBZ N
regulatory JJ N
influence NN N
on IN N
melatonin NN N
secretion NN N
in IN N
man NN N
has VBZ N
never RB N
been VBN N
unequivocally RB N
shown VBN N
We PRP N
studied VBD N
the DT N
nocturnal JJ N
melatonin NN N
secretion NN N
in IN N
8 CD 3_p
healthy JJ 4_p
volunteers NNS 4_p
and CC N
6 CD 3_p
women NNS 2_p
with IN N
untreated JJ 4_p
primary JJ 4_p
hypothyroidism NN 4_p
a DT N
disease NN N
state NN N
that WDT N
is VBZ N
associated VBN N
with IN N
increased JJ N
nocturnal JJ N
secretion NN N
of IN N
melatonin NN N
The DT N
participants NNS N
were VBD N
given VBN N
subcutaneous JJ N
injections NNS N
at IN N
18:00 CD N
h NN N
and CC N
23:00 CD N
h NN N
of IN N
either DT N
saline NN N
or CC N
octreotide NN N
Sandostatin NNP N
each DT N
injection NN N
50 CD N
microg NN N
During IN N
the DT N
nights NNS N
when WRB N
the DT N
healthy JJ 4_p
volunteers NNS 4_p
were VBD N
given VBN N
octreotide RB N
melatonin JJ N
secretion NN N
was VBD N
similar JJ N
to TO N
that DT N
recorded VBN N
during IN N
administration NN N
of IN N
saline NN N
Also RB N
the DT N
urinary JJ N
excretion NN N
of IN N
melatonin NN N
was VBD N
of IN N
similar JJ N
magnitude NN N
at IN N
these DT N
two CD N
occasions NNS N
By IN N
contrast NN N
the DT N
GH NNP N
secretion NN N
was VBD N
significantly RB N
lower JJR N
the DT N
nights NNS N
the DT N
healthy JJ N
controls NNS N
were VBD N
given VBN N
octreotide RB N
GH NNP N
AUC NNP N
22.6+/-5.4 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
octreotide JJ N
and CC N
126.6+/-21.9 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
saline NN N
p CC N
0.01 CD N
The DT N
patients NNS 4_p
with IN 4_p
hypothyroidism NN 4_p
also RB N
showed VBD N
similar JJ N
nocturnal JJ N
melatonin NN N
secretion NN N
during IN N
octreotide NN N
and CC N
saline NN N
Urinary JJ N
excretion NN N
of IN N
melatonin NN N
also RB N
remained VBD N
unchanged JJ N
as IN N
did VBD N
GH NNP N
secretion NN N
The DT N
total JJ N
nocturnal JJ N
secretion NN N
of IN N
TSH NNP N
was VBD N
however RB N
significantly RB N
reduced VBN N
by IN N
octreotide NN N
TSH NNP N
AUC NNP N
562+/-136 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
octreotide JJ N
and CC N
851+/-185 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
saline NN N
p CC N
0.05 CD N
thus RB N
suggesting VBG N
that IN N
100 CD N
microg NN N
of IN N
octreotide NN N
should MD N
be VB N
sufficient JJ N
to TO N
inhibit VB N
also RB N
the DT N
pinealocytes NNS N
if IN N
their PRP$ N
function NN N
were VBD N
regulated VBN N
by IN N
somatostatin NN N
Since IN N
exogenous JJ N
somatostatin NN N
-- : N
in IN N
the DT N
form NN N
of IN N
octreotide NN N
-- : N
fails VBZ N
to TO N
influence VB N
nocturnal JJ N
secretion NN N
and CC N
urinary JJ N
excretion NN N
of IN N
melatonin NN N
in IN N
normal JJ 4_p
subjects NNS 4_p
and CC 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
primary JJ 4_p
hypothyroidism NN 4_p
it PRP N
is VBZ N
reasonable JJ N
to TO N
assume VB N
that DT N
endogenous JJ N
somatostatin NN N
may MD N
not RB N
be VB N
an DT N
important JJ N
regulator NN N
of IN N
melatonin JJ N
secretion NN N
in IN N
man NN N
-DOCSTART- -X- O O

Feasibility NN N
of IN N
two CD N
dose-dense JJ N
FEC NNP N
regimens VBZ N
with IN N
growth NN N
factor NN N
support NN N
for IN N
adjuvant JJ N
therapy NN N
in IN N
patients NNS 4_p
with IN 4_p
early JJ 4_p
breast NN 4_p
cancer NN 4_p
results NNS N
from IN N
a DT N
randomised JJ N
study NN N
of IN N
the DT N
Central NNP N
European NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
CECOG NNP N
Addition NN N
of IN N
epirubicin NN N
to TO N
adjuvant VB N
chemotherapy NN N
can MD N
provide VB N
important JJ N
benefits NNS N
for IN N
patients NNS 4_p
with IN 4_p
early JJ 4_p
breast NN 4_p
cancer NN 4_p
but CC N
the DT N
optimal JJ N
dose NN N
remains VBZ N
unclear JJ N
Further JJ N
improvements NNS N
can MD N
be VB N
achieved VBN N
with IN N
dose-dense JJ N
regimens NNS N
but CC N
densification NN N
of IN N
fluorouracil/epirubicin/cyclophosphamide NN N
FEC NNP N
has VBZ N
proved VBN N
difficult JJ N
with IN N
FEC NNP N
60 CD N
providing VBG N
little JJ N
benefit NN N
over IN N
standard JJ N
chemotherapy NN N
and CC N
FEC NNP N
100 CD N
associated VBN N
with IN N
toxicity NN N
We PRP N
investigated VBD N
the DT N
feasibility NN N
of IN N
two CD N
intermediate JJ N
dose-dense JJ N
FEC NNP N
regimens NNS N
Patients NNS N
were VBD N
randomised VBN N
to TO N
six CD N
cycles NNS N
of IN N
FEC NNP N
75 CD N
or CC N
FEC NNP N
90 CD N
with IN N
all DT N
three CD N
drugs NNS N
given VBN N
on IN N
day NN N
1 CD N
of IN N
each DT N
14-day JJ N
cycle NN N
Patients NNS N
also RB N
received VBD N
pegfilgrastim JJ N
6 CD N
mg NN N
as IN N
a DT N
single JJ N
subcutaneous JJ N
injection NN N
on IN N
day NN N
2 CD N
of IN N
each DT N
cycle NN N
The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
proportion NN N
of IN N
subjects NNS N
receiving VBG N
or CC N
=85 CD N
relative JJ N
dose JJ N
intensity NN N
and CC N
was VBD N
achieved VBN N
by IN N
96 CD N
and CC N
88 CD N
of IN N
patients NNS N
in IN N
the DT N
FEC NNP N
75 CD N
and CC N
FEC NNP N
90 CD N
arms NNS N
respectively RB N
Of IN N
147 CD N
FEC NNP N
75 CD N
infusions NNS N
4.1 CD N
were VBD N
delayed VBN N
while IN N
9.8 CD N
of IN N
143 CD N
FEC NNP N
90 CD N
infusions NNS N
were VBD N
delayed VBN N
The DT N
most RBS N
common JJ N
reasons NNS N
for IN N
delay NN N
were VBD N
adverse JJ N
events NNS N
and CC N
personal/logistical JJ N
reasons NNS N
One CD N
dose JJ N
reduction NN N
occurred VBD N
during IN N
the DT N
study NN N
FEC NNP N
90 CD N
related VBN N
to TO N
diarrhoea VB N
Grade VB N
3-4 JJ N
haematological JJ N
toxicities NNS N
were VBD N
reported VBN N
in IN N
two CD N
patients NNS N
in IN N
the DT N
FEC NNP N
90 CD N
arm NN N
There EX N
were VBD N
no DT N
incidences NNS N
of IN N
febrile JJ N
neutropenia NN N
during IN N
the DT N
study NN N
The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
increases NNS N
in IN N
liver NN N
enzymes NNS N
and CC N
gastrointestinal JJ N
events NNS N
no DT N
event NN N
resulted VBD N
in IN N
discontinuation NN N
Only RB N
one CD N
patient NN N
FEC NNP N
90 CD N
experienced VBD N
serious JJ N
adverse JJ N
events NNS N
vomiting VBG N
and CC N
throat VB N
oedema NN N
In IN N
conclusion NN N
dose-dense JJ N
FEC NNP N
75 CD N
and CC N
FEC NNP N
90 CD N
are VBP N
feasible JJ N
with IN N
pegfilgrastim JJ N
support NN N
These DT N
regimens NNS N
are VBP N
associated VBN N
with IN N
a DT N
very RB N
low JJ N
risk NN N
of IN N
Grade NNP N
3-4 JJ N
toxicity NN N
-DOCSTART- -X- O O

Additive JJ N
IOP-reducing JJ N
effect NN N
of IN N
latanoprost NN N
in IN N
patients NNS 4_p
insufficiently RB 4_p
controlled VBN 4_p
on IN 4_p
timolol NN 4_p
PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
on IN N
intraocular JJ N
pressure NN N
IOP NNP N
of IN N
switching VBG N
from IN N
timolol NN N
to TO N
latanoprost VB N
or CC N
adding VBG N
latanoprost NN N
to TO N
timolol VB N
in IN N
patients NNS 4_p
with IN 4_p
open JJ 4_p
angle NN 4_p
glaucoma NN 4_p
or CC 4_p
ocular JJ 4_p
hypertension NN 4_p
where WRB 4_p
IOP NNP 4_p
is VBZ 4_p
not RB 4_p
adequately RB 4_p
controlled VBN 4_p
with IN 4_p
timolol NN 4_p
METHODS NNP N
This DT N
was VBD N
a DT N
6-week JJ N
double-masked JJ N
randomised VBD N
multi-centre NN N
study NN N
53 CD 3_p
patients NNS 4_p
with IN 4_p
primary JJ 4_p
open JJ 4_p
angle NN 4_p
glaucoma NN 4_p
capsular JJ 4_p
glaucoma NN 4_p
or CC 4_p
ocular JJ 4_p
hypertension NN 4_p
with IN 4_p
an DT 4_p
IOP NNP 4_p
of IN 4_p
at IN 4_p
least JJS 4_p
21 CD 4_p
mmHg NN 4_p
on IN 4_p
current JJ 4_p
therapy NN 4_p
were VBD N
recruited VBN N
After IN N
a DT N
run-in JJ N
period NN N
of IN N
at IN N
least JJS N
2 CD N
weeks NNS N
on IN N
timolol NN N
5 CD N
mg/ml NN N
twice RB N
daily RB N
patients NNS N
were VBD N
randomised VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
One CD N
group NN N
continued VBD N
on IN N
timolol NN N
one CD N
switched VBN N
from IN N
timolol NN N
to TO N
latanoprost VB N
50 CD N
microg/ml NN N
once RB N
daily JJ N
and CC N
a DT N
third JJ N
group NN N
received VBD N
latanoprost RB N
in IN N
addition NN N
to TO N
timolol VB N
The DT N
efficacy NN N
was VBD N
evaluated VBN N
by IN N
comparing VBG N
IOP NNP N
at IN N
9 CD N
AM NNP N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
RESULTS NNP N
IOP NNP N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
mean JJ N
+/- NNP N
SEM NNP N
were VBD N
24.2 CD N
+/- JJ N
0.9 CD N
and CC N
23.8 CD N
+/- JJ N
1.0 CD N
mmHg NN N
n JJ N
16 CD N
for IN N
patients NNS N
continuing VBG N
on IN N
timolol NN N
26.3 CD N
+/- JJ N
1.2 CD N
and CC N
19.6 CD N
+/- JJ N
1.1 CD N
mmHg NN N
n JJ N
17 CD N
for IN N
patients NNS N
switching VBG N
to TO N
latanoprost VB N
and CC N
23.2 CD N
+/- JJ N
1.0 CD N
and CC N
17.5 CD N
+/- JJ N
0.8 CD N
mmHg NN N
n JJ N
17 CD N
for IN N
patients NNS N
with IN N
combined JJ N
treatment NN N
Adding VBG N
latanoprost NN N
to TO N
timolol VB N
reduced VBN N
IOP NNP N
with IN N
5.9 CD N
+/- JJ N
0.9 CD N
mmHg NN N
p JJ N
0.001 CD N
and CC N
switching VBG N
from IN N
timolol NN N
to TO N
latanoprost VB N
reduced VBN N
IOP NNP N
with IN N
5.0 CD N
+/- JJ N
0.9 CD N
mmHg NN N
p JJ N
0.001 CD N
which WDT N
caused VBD N
in IN N
each DT N
group NN N
a DT N
significant JJ N
IOP NNP N
reduction NN N
of IN N
about RB N
25 CD N
CONCLUSIONS VB N
The DT N
effect NN N
of IN N
latanoprost NN N
was VBD N
additive JJ N
to TO N
that DT N
of IN N
timolol NN N
and CC N
a DT N
good JJ N
effect NN N
on IN N
IOP NNP N
reduction NN N
was VBD N
also RB N
achieved VBN N
by IN N
switching VBG N
from IN N
timolol NN N
to TO N
latanoprost VB N
suggesting VBG N
that IN N
a DT N
switch NN N
in IN N
many JJ N
patients NNS N
is VBZ N
an DT N
effective JJ N
alternative NN N
to TO N
combination NN N
treatment NN N
-DOCSTART- -X- O O

Identifying VBG N
patients NNS N
at IN N
high JJ N
risk NN N
for IN N
neutropenic JJ N
complications NNS N
during IN N
chemotherapy NN N
for IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
with IN N
doxorubicin NN N
or CC N
pegylated VBN N
liposomal JJ N
doxorubicin NN N
the DT N
development NN N
of IN N
a DT N
prediction NN N
model NN N
OBJECTIVE UH N
To TO N
develop VB N
a DT N
cycle-based JJ N
risk NN N
prediction NN N
model NN N
for IN N
neutropenic JJ N
complications NNS N
NC NNP N
during IN N
chemotherapy NN N
with IN N
doxorubicin NN N
DOX NNP N
or CC N
a DT N
pegylated JJ N
liposomal JJ N
formulation NN N
PLD NNP N
for IN N
patients NNS 4_p
with IN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
MBC NNP 4_p
METHODS NNP N
Data NNP N
analyzed VBD N
was VBD N
from IN N
a DT N
phase NN N
III NNP N
randomized VBD N
clinical JJ N
trial NN N
of IN N
DOX NNP N
60 CD N
mg/m NN N
2 CD N
every DT N
3 CD N
weeks NNS N
or CC N
PLD NNP N
50 CD N
mg/m NN N
2 CD N
every DT N
4 CD N
weeks NNS N
for IN N
the DT N
first JJ N
line NN N
therapy NN N
for IN N
MBC NNP N
n JJ N
509 CD N
O'Brien NNP N
et RB N
al RB N
Ann NNP N
Oncol NNP N
2004 CD N
15:440-449 JJ N
NC NNP N
were VBD N
defined VBN N
as IN N
an DT N
absolute NN N
neutrophil NN N
count NN N
or CC N
=1.5 NNP N
x VBP N
10 CD N
9 CD N
cells/L NN N
ie JJ N
or CC N
=grade JJ N
II NNP N
before IN N
the DT N
next JJ N
cycle NN N
febrile JJ N
neutropenia NN N
or CC N
neutropenia NN N
with IN N
a DT N
documented JJ N
infection NN N
Patient NNP N
and CC N
hematologic JJ N
factors NNS N
potentially RB N
associated VBN N
with IN N
NC NNP N
were VBD N
evaluated VBN N
Factors NNS N
with IN N
a DT N
P NNP N
value NN N
of IN N
or CC N
=0.25 NNP N
within IN N
a DT N
cycle NN N
were VBD N
included VBN N
in IN N
a DT N
generalized JJ N
estimating NN N
equations NNS N
regression NN N
model NN N
Using VBG N
backward JJ N
elimination NN N
we PRP N
derived VBD N
a DT N
risk NN N
scoring VBG N
algorithm NN N
range VB N
0-63 NN N
from IN N
the DT N
final JJ N
reduced VBN N
model NN N
RESULTS NNP N
Risk NNP N
factors NNS N
retained VBD N
in IN N
the DT N
model NN N
included VBD N
poor JJ N
performance NN N
status NN N
absolute VB N
neutrophil JJ N
count NN N
or CC N
=2.0 VB N
x JJ N
10 CD N
9 CD N
cells/L NN N
in IN N
the DT N
previous JJ N
cycle NN N
the DT N
first JJ N
cycle NN N
of IN N
chemotherapy NN N
DOX NNP N
versus NN N
PLD NNP N
and CC N
advanced JJ N
age NN N
A DT N
precycle NN N
risk NN N
score NN N
from IN N
or CC N
=25 NN N
to TO N
40 CD N
for IN N
a DT N
given VBN N
patient NN N
was VBD N
identified VBN N
as IN N
being VBG N
the DT N
optimal JJ N
threshold NN N
for IN N
sensitivity NN N
58.0 CD N
and CC N
specificity NN N
78.7 CD N
Patients NNS N
with IN N
a DT N
score NN N
at IN N
or CC N
beyond IN N
this DT N
threshold NN N
would MD N
be VB N
considered VBN N
at IN N
high JJ N
risk NN N
for IN N
developing VBG N
NC NNP N
in IN N
later JJ N
cycles NNS N
CONCLUSION NNP N
The DT N
use NN N
of IN N
this DT N
model NN N
may MD N
enhance VB N
patient NN N
care NN N
by IN N
targeting VBG N
preventative JJ N
therapies NNS N
eg NN N
granulocyte NN N
colony NN N
stimulating VBG N
factor NN N
or CC N
PLD NNP N
to TO N
those DT N
MBC NNP N
patients NNS 4_p
most RBS N
likely JJ N
to TO N
experience VB N
NC NNP N
during IN N
anthracycline-based JJ N
chemotherapy NN N
-DOCSTART- -X- O O

Sedation NN N
during IN N
endoscopic NN N
retrograde NN 4_p
cholangiopancreatography NN 4_p
a DT N
randomized NN N
controlled VBN N
study NN N
of IN N
patient-controlled JJ N
propofol NN N
sedation NN N
and CC N
that IN N
given VBN N
by IN N
a DT N
nurse JJ N
anesthetist NN N
OBJECTIVE CC N
Different JJ N
regimens NNS N
are VBP N
used VBN N
for IN N
sedation NN N
during IN N
endoscopic NN N
retrograde NN N
cholangiopancreatography NN N
ERCP NNP N
Our PRP$ N
objectives NNS N
were VBD N
to TO N
compare VB N
safety NN N
ease NN N
of IN N
treatment NN N
recovery NN N
and CC N
patients NNS N
experiences NNS N
using VBG N
patient-controlled JJ N
sedation NN N
PCS NNP N
with IN N
propofol NN N
nurse JJ N
anesthetist-controlled JJ N
sedation NN N
ACS NNP N
or CC N
the DT N
department NN N
's POS N
standard NN N
of IN N
care NN N
midazolam VB N
given VBN N
by IN N
the DT N
procedure NN N
team NN N
control VB N
group NN N
MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
included VBD N
281 CD 3_p
adults NNS 1_p
in IN N
301 CD N
procedures NNS N
The DT N
PCS NNP N
group NN N
n JJ N
101 CD N
delivered VBN N
bolus JJ N
doses NNS N
of IN N
5 CD N
mg NN N
of IN N
propofol NN N
according VBG N
to TO N
their PRP$ N
need NN N
for IN N
sedation NN N
The DT N
ACS NNP N
group NN N
n JJ N
100 CD N
had VBD N
2-8 JJ N
mg/kg/h NN N
of IN N
propofol NN N
infused VBN N
with IN N
the DT N
target NN N
for IN N
sedation NN N
being VBG N
level JJ N
3 CD N
of IN N
the DT N
Observer NNP N
's POS N
Assessment NNP N
of IN N
Alertness/Sedation NNP N
OAA/S NNP N
scale NN N
The DT N
control NN N
group NN N
was VBD N
given VBN N
2-3 JJ N
mg NN N
of IN N
midazolam NN N
for IN N
induction NN N
and CC N
additional JJ N
1 CD N
mg NN N
if IN N
required VBN N
RESULTS NNP N
PCS NNP N
and CC N
ACS NNP N
increased VBD N
the DT N
ease NN N
of IN N
the DT N
procedure NN N
and CC N
reduced VBD N
the DT N
number NN N
of IN N
sedation NN N
failures NNS N
compared VBN N
to TO N
midazolam VB N
sedation NN N
ACS NNP N
n RB N
0 CD N
PCS NNP N
n VBD N
4 CD N
midazolam NN N
n IN N
20 CD N
The DT N
ACS NNP N
group NN N
had VBD N
more RBR N
deeply RB N
sedated JJ N
patients NNS N
OAA/S NNP N
level RB N
2 CD N
desaturation NN N
and CC N
obstructed VBD N
airways NNS N
than IN N
the DT N
PCS NNP N
and CC N
midazolam NN N
groups NNS N
Time NN N
to TO N
full JJ N
recovery NN N
Aldrete NNP N
score RB N
≥9 VBD N
was VBD N
shortest JJS N
following VBG N
PCS NNP N
PCS NNP N
resulted VBD N
in IN N
the DT N
least JJS N
fatigue NN N
and CC N
pain NN N
after IN N
the DT N
procedure NN N
Patients NNS N
preference NN N
for IN N
PCS NNP N
and CC N
ACS NNP N
was VBD N
the DT N
same JJ N
CONCLUSION NNP N
PCS NNP N
with IN N
propofol NN N
is VBZ N
superior JJ N
to TO N
midazolam VB N
and CC N
comparable VB N
to TO N
ACS NNP N
PCS NNP N
resulted VBD N
in IN N
a DT N
rapid JJ N
recovery NN N
fewer JJR N
respiratory NN N
events NNS N
and CC N
was VBD N
almost RB N
as RB N
effective JJ N
as IN N
ACS NNP N
in IN N
ensuring VBG N
a DT N
successful JJ N
examination NN N
-DOCSTART- -X- O O

Regional JJ N
ventricular JJ N
performance NN N
and CC N
exercise NN N
training NN N
in IN N
children NNS 1_p
and CC 1_p
young JJ 1_p
adults NNS 4_p
after IN 4_p
repair NN 4_p
of IN 4_p
tetralogy NN 4_p
of IN 4_p
Fallot NN 4_p
randomized VBN N
controlled VBD N
pilot NN N
study NN N
BACKGROUND NNP N
Public-health NNP N
guidelines NNS N
recommend VBP N
patients NNS N
with IN N
congenital JJ N
heart NN N
disease NN N
to TO N
exercise VB N
Studies NNS N
have VBP N
shown VBN N
that IN N
patients NNS N
with IN N
congenital JJ N
heart NN N
disease NN N
can MD N
improve VB N
physical JJ N
exercise NN N
capacity NN N
The DT N
effect NN N
of IN N
training VBG N
on IN N
regional JJ N
ventricular JJ N
performance NN N
has VBZ N
hardly RB N
been VBN N
studied VBN N
We PRP N
performed VBD N
a DT N
pilot NN N
study NN N
to TO N
assess VB N
whether IN N
an DT N
exercise NN N
training NN N
program NN N
would MD N
result VB N
in IN N
adverse JJ N
changes NNS N
of IN N
regional JJ N
ventricular JJ N
performance NN N
in IN N
patients NNS 4_p
with IN 4_p
corrected JJ 4_p
tetralogy NN 4_p
of IN 4_p
Fallot NNP 4_p
METHODS NNP N
AND CC N
RESULTS NNP N
Multicenter NNP N
prospective JJ N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
in IN N
patients NNS 4_p
with IN 4_p
tetralogy NN 4_p
of IN 4_p
Fallot NNP 4_p
aged VBD 1_p
10 CD 1_p
to TO 1_p
25 CD 1_p
years NNS 1_p
A DT N
12-week JJ N
standardized JJ N
aerobic JJ N
dynamic JJ N
exercise NN N
training NN N
program NN N
3 CD N
one-hour JJ N
sessions NNS N
per IN N
week NN N
was VBD N
used VBN N
Pre- JJ N
and CC N
post-training JJ N
cardiopulmonary JJ N
exercise NN N
tests NNS N
MRI NNP N
and CC N
echocardiography NN N
including VBG N
tissue-Doppler NN N
imaging NN N
were VBD N
performed VBN N
Patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
exercise NN N
group NN N
n=28 JJ N
or CC N
control VB N
group NN N
n=20 RB N
One CD N
patient NN N
in IN N
the DT N
exercise NN N
group NN N
dropped VBD N
out RP N
Change VB N
in IN N
tissue-Doppler NN N
imaging NN N
parameters NNS N
was VBD N
similar JJ N
in IN N
the DT N
exercise NN N
group NN N
and CC N
control NN N
group NN N
change NN N
in IN N
right JJ N
ventricle NN N
free JJ N
wall NN N
peak NN N
velocity NN N
E NNP N
exercise NN N
group NN N
0.8±2.6 CD N
cm/s NN N
control NN N
group NN N
0.9±4.1 CD N
peak JJ N
velocity NN N
A NNP N
exercise NN N
group NN N
0.4±2.4 CD N
m/s NN N
control NN N
group NN N
4.6±18.1 CD N
cm/s NN N
CONCLUSIONS VB N
This DT N
randomized VBN N
controlled VBD N
pilot NN N
study NN N
provides VBZ N
preliminary JJ N
data NNS N
suggesting VBG N
that IN N
regional JJ N
ventricular JJ N
performance NN N
is VBZ N
well RB N
maintained VBN N
during IN N
3-month JJ N
aerobic JJ N
dynamic JJ N
exercise NN N
training NN N
in IN N
children NNS N
and CC N
young JJ N
adults NNS N
with IN N
repaired JJ N
tetralogy NN N
of IN N
Fallot NNP N
This DT N
information NN N
might MD N
help VB N
patients NNS N
adhere VB N
to TO N
current JJ N
public-health NN N
guidelines NNS N
CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
http// NN N
www.trialregister.nl NN N
Unique NNP N
identifier NN N
NTR2731 NNP N
-DOCSTART- -X- O O

Atomoxetine NNP N
in IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
no DT N
effects NNS N
on IN N
social JJ N
functioning NN N
some DT N
beneficial JJ N
effects NNS N
on IN N
stereotyped JJ N
behaviors NNS N
inappropriate JJ N
speech NN N
and CC N
fear NN N
of IN N
change NN N
UNLABELLED NNP N
Abstract NNP N
Objective NNP N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
treatment NN N
effects NNS N
of IN N
atomoxetine NN N
on IN N
autism NN N
spectrum NN N
disorder NN N
ASD NNP N
symptoms NNS N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
both DT N
ASD NNP 4_p
and CC 4_p
attention-deficit/hyperactivity JJ 4_p
disorder NN 4_p
ADHD NNP 4_p
METHODS CC N
A DT N
total NN N
of IN N
97 CD 3_p
patients NNS N
6-17 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
ASD NNP 4_p
and CC 4_p
ADHD NNP 4_p
were VBD N
treated VBN N
with IN N
1.2 CD N
mg/kg/day NN N
of IN N
atomoxetine NN N
during IN N
an DT N
8 CD N
week NN N
double-blind JJ N
placebo-controlled JJ N
period NN N
Here RB N
we PRP N
investigated VBD N
effects NNS N
on IN N
two CD N
parent-based JJ N
secondary JJ N
outcome NN N
measures NNS N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
ABC NNP N
and CC N
the DT N
Children NNP N
's POS N
Social NNP N
Behavior NNP N
Questionnaire NNP N
CSBQ NNP N
RESULTS NNP N
After IN N
8 CD N
weeks NNS N
of IN N
double-blind JJ N
treatment NN N
atomoxetine JJ N
administration NN N
was VBD N
associated VBN N
with IN N
significant JJ N
treatment NN N
effects NNS N
on IN N
the DT N
ABC NNP N
subscales VBZ N
Hyperactivity NNP N
Inappropriate NNP N
Speech NNP N
and CC N
Stereotypic NNP N
Behavior NNP N
and CC N
on IN N
the DT N
CSBQ NNP N
subscale NN N
Fear NNP N
for IN N
Changes NNP N
CONCLUSIONS NNP N
Our PRP$ N
study NN N
results NNS N
indicate VBP N
no DT N
beneficial JJ N
effects NNS N
of IN N
atomoxetine NN N
on IN N
social JJ N
functioning NN N
However RB N
atomoxetine NN N
may MD N
ameliorate VB N
restricted VBN N
and CC N
stereotyped VBN N
behaviors NNS N
and CC N
communication NN N
This DT N
study NN N
has VBZ N
been VBN N
registered VBN N
in IN N
ClinicalTrials.gov NNP N
www.clinicaltrials.gov NN N
under IN N
registration NN N
number NN N
NCT00380692 NNP N
-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
cognitive-behavioral JJ N
therapy NN N
versus NN N
treatment NN N
as IN N
usual JJ N
for IN N
anxiety NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
a DT N
randomized NN N
controlled VBN N
trial NN N
OBJECTIVE UH N
To TO N
examine VB N
the DT N
efficacy NN N
of IN N
a DT N
modular JJ N
cognitive-behavioral JJ N
therapy NN N
CBT NNP N
protocol VBP N
relative JJ N
to TO N
treatment NN N
as IN N
usual JJ N
TAU NNP N
among IN N
children NNS 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
ASD NNP 4_p
and CC 4_p
clinically RB 4_p
significant JJ 4_p
anxiety NN 4_p
METHOD NNP N
A NNP N
total NN N
of IN N
45 CD 3_p
children NNS 1_p
7-11 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
high-functioning JJ 4_p
ASD NNP 4_p
and CC 4_p
clinically RB 4_p
significant JJ 4_p
anxiety NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
16 CD N
sessions NNS N
of IN N
weekly JJ N
CBT NNP N
or CC N
TAU NNP N
for IN N
an DT N
equivalent JJ N
duration NN N
After IN N
screening VBG N
assessments NNS N
were VBD N
conducted VBN N
at IN N
baseline NN N
post-treatment JJ N
and CC N
3-month JJ N
follow-up NN N
Raters NNPS N
were VBD N
blind RB N
to TO N
treatment NN N
condition NN N
RESULTS NNP N
Youth NNP N
receiving VBG N
CBT NNP N
showed VBD N
substantial JJ N
improvement NN N
relative NN N
to TO N
TAU VB N
on IN N
primary JJ N
anxiety NN N
outcomes NNS N
Of IN N
24 CD N
children NNS N
randomized VBN N
to TO N
the DT N
CBT NNP N
arm NN N
18 CD N
75 CD N
were VBD N
treatment NN N
responders NNS N
versus IN N
only RB N
3 CD N
of IN N
21 CD N
children NNS N
14 CD N
in IN N
the DT N
TAU NNP N
arm NN N
Gains NNS N
were VBD N
generally RB N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
for IN N
CBT NNP N
responders NNS N
CONCLUSIONS NNP N
Relative NNP N
to TO N
usual JJ N
care NN N
CBT NNP N
adapted VBD N
for IN N
anxious JJ N
youth NN N
with IN N
high-functioning JJ N
ASD NNP N
demonstrates VBZ N
large JJ N
effects NNS N
in IN N
reducing VBG N
anxiety NN N
symptoms NNS N
This DT N
study NN N
contributes VBZ N
to TO N
the DT N
growing VBG N
literature NN N
supporting VBG N
adapted VBN N
CBT NNP N
approaches NNS N
for IN N
treating VBG N
anxiety NN N
in IN N
youth NN N
with IN N
ASD NNP N
-DOCSTART- -X- O O

A DT N
physiotherapy NN N
service NN N
to TO N
an DT N
emergency NN N
extended VBD N
care NN N
unit NN N
does VBZ N
not RB N
decrease VB N
admission NN N
rates NNS N
to TO N
hospital VB N
a DT N
randomised JJ N
trial NN N
BACKGROUND NNP N
One CD N
of IN N
the DT N
reasons NNS N
physiotherapy NN N
services NNS N
are VBP N
provided VBN N
to TO N
emergency NN N
departments NNS N
EDs NNP N
and CC N
emergency NN N
extended VBN N
care NN N
units NNS N
EECUs NNP N
is VBZ N
to TO N
review VB N
patients NNS N
mobility NN N
to TO N
ensure VB N
they PRP N
are VBP N
safe JJ N
to TO N
be VB N
discharged VBN N
home NN N
AIM NNP N
To TO N
investigate VB N
whether IN N
a DT N
physiotherapy NN N
service NN N
to TO N
an DT N
EECU NNP N
altered VBD N
the DT N
rate NN N
of IN N
hospital NN N
admission NN N
rate NN N
of IN N
re-presentation NN N
to TO N
the DT N
ED NNP N
visits VBZ N
to TO N
community NN N
healthcare NN N
practitioners NNS N
return NN N
to TO N
usual JJ N
work/home/leisure NN N
activities NNS N
and CC N
patient JJ N
satisfaction NN N
METHODS NNP N
A DT N
randomised JJ N
trial NN N
with IN N
concealed JJ N
allocation NN N
assessor NN N
blinding NN N
and CC N
intention-to-treat JJ N
analysis NN N
was VBD N
undertaken VBN N
in IN N
an DT N
EECU NNP N
The DT N
sample NN N
comprised VBD N
186 CD 3_p
patients NNS N
mean JJ 1_p
age NN 1_p
70 CD 1_p
years NNS 1_p
123 CD 3_p
66 CD N
female NN 2_p
patients NNS N
130 CD 3_p
70 CD N
trauma NN 4_p
who WP N
were VBD N
referred VBN 4_p
for IN 4_p
physiotherapy NN 4_p
assessment/intervention NN 4_p
Referral JJ N
occurred VBD N
at IN N
any DT N
stage NN N
of IN N
the DT N
patients NNS N
EECU NNP N
admission NN N
All DT N
participants NNS N
received VBD N
medical/nursing VBG N
care NN N
as IN N
required VBN N
The DT N
physiotherapy NN N
group NN N
also RB N
received VBD N
physiotherapy JJ N
assessment/intervention NN N
RESULTS VB N
The DT N
physiotherapy NN N
group NN N
had VBD N
a DT N
4 CD N
95 CD N
CI NNP N
-18 CD N
to TO N
9 CD N
lower JJR N
rate NN N
of IN N
admission NN N
to TO N
hospital NN N
than IN N
the DT N
control NN N
group NN N
and CC N
a DT N
4 CD N
95 CD N
CI NNP N
-6 NNP N
to TO N
13 CD N
higher JJR N
rate NN N
of IN N
re-presentation NN N
to TO N
the DT N
ED NNP N
which WDT N
were VBD N
statistically RB N
non-significant JJ N
p≥0.45 NN N
Differences NNS N
between IN N
groups NNS N
for IN N
use NN N
of IN N
community NN N
healthcare NN N
resources NNS N
return NN N
to TO N
usual JJ N
work/home/leisure NN N
activities NNS N
and CC N
satisfaction NN N
with IN N
their PRP$ N
EECU NNP N
care NN N
were VBD N
small JJ N
and CC N
not RB N
significant JJ N
CONCLUSION VB N
A NNP N
physiotherapy NN N
service NN N
for IN N
EECU NNP N
patients NNS N
as IN N
provided VBN N
in IN N
this DT N
study NN N
did VBD N
not RB N
reduce VB N
the DT N
rate NN N
of IN N
hospital NN N
admission NN N
rate NN N
of IN N
re-presentation NN N
to TO N
the DT N
ED NNP N
use NN N
of IN N
community NN N
healthcare NN N
resources NNS N
or CC N
improve VB N
the DT N
rate NN N
of IN N
return NN N
to TO N
usual JJ N
work/home/leisure NN N
activities NNS N
or CC N
patient JJ N
satisfaction NN N
Trial JJ N
registration NN N
number NN N
ANZCTRN12609000106235 NNP N
-DOCSTART- -X- O O

Effect NN N
of IN N
treatment NN N
with IN N
paromomycin NN N
on IN N
endotoxemia NN N
in IN N
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
-- : N
a DT N
double-blind JJ N
placebo-controlled JJ N
trial NN N
The DT N
results NNS N
of IN N
experimental JJ N
and CC N
clinical JJ N
studies NNS N
support VBP N
the DT N
hypothesis NN N
that IN N
gut-derived JJ N
endotoxins NNS N
might MD N
be VB N
of IN N
relevance NN N
for IN N
the DT N
development NN N
and CC N
course NN N
of IN N
alcoholic JJ N
liver NN N
disease NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
nonabsorbable JJ N
broad-spectrum JJ N
antibiotic NN N
on IN N
endotoxemia NN N
in IN N
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
Fifty JJ 3_p
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
27 CD 3_p
with IN 4_p
cirrhosis NN 4_p
23 CD 3_p
without IN 4_p
cirrhosis NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
paromomycin NN N
sulfate NN N
3 CD N
x RB N
1 CD N
g/day NN N
or CC N
placebo NN N
in IN N
a DT N
double-blind JJ N
fashion NN N
for IN N
at IN N
least JJS N
3 CD N
weeks NNS N
and CC N
if IN N
possible JJ N
4 CD N
weeks NNS N
Endotoxin NNP N
concentration NN N
liver JJ N
function NN N
tests NNS N
and CC N
other JJ N
laboratory NN N
parameters NNS N
were VBD N
determined VBN N
in IN N
weekly JJ N
intervals NNS N
Endotoxin NNP N
concentration NN N
was VBD N
also RB N
determined VBN N
in IN N
15 CD 3_p
healthy JJ 4_p
controls NNS 4_p
Groups NNP N
receiving VBG N
paromomycin NN N
or CC N
placebo NN N
were VBD N
similar JJ N
for IN N
clinical JJ N
and CC N
biological JJ N
items NNS N
collected VBN N
initially RB N
Mean JJ N
initial JJ N
endotoxin NN N
concentrations NNS N
were VBD N
significantly RB N
elevated VBN N
in IN N
both DT N
groups NNS N
mean JJ N
+/- JJ N
SEM NNP N
paromomycin NN N
16.7 CD N
+/- JJ N
5.3 CD N
pg/ml NN N
placebo NN N
17.5 CD N
+/- JJ N
6.9 CD N
pg/ml NN N
healthy JJ N
controls NNS N
2.3 CD N
+/- JJ N
0.4 CD N
pg/ml NN N
Although IN N
the DT N
mean JJ N
endotoxin NN N
concentration NN N
was VBD N
lower JJR N
in IN N
the DT N
verum NN N
group NN N
after IN N
1 CD N
week NN N
paromomycin NN N
8.0 CD N
+/- JJ N
1.9 CD N
pg/ml NN N
placebo NN N
14.6 CD N
+/- JJ N
3.5 CD N
pg/ml NN N
p CC N
0.05 CD N
paromomycin JJ N
treatment NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
endotoxin NN N
concentration NN N
or CC N
liver JJ N
function NN N
tests NNS N
during IN N
the DT N
4-week JJ N
period NN N
The DT N
beneficial JJ N
effect NN N
of IN N
paromomycin NN N
treatment NN N
on IN N
endotoxemia NN N
in IN N
cirrhotics NNS N
reported VBN N
in IN N
earlier JJR N
studies NNS N
could MD N
not RB N
be VB N
reproduced VBN N
under IN N
the DT N
conditions NNS N
of IN N
this DT N
trial NN N
in IN N
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
-DOCSTART- -X- O O

Rapid JJ N
tightening NN N
of IN N
blood NN N
glucose NN N
control NN N
leads VBZ N
to TO N
transient VB N
deterioration NN N
of IN N
retinopathy NN N
in IN N
insulin NN 4_p
dependent NN 4_p
diabetes VBZ 4_p
mellitus NNS 4_p
the DT N
Oslo NNP N
study NN N
In IN N
a DT N
study NN N
of IN N
retinopathy NN N
during IN N
one CD N
year NN N
of IN N
tight JJ N
blood NN N
glucose VB N
control NN N
45 CD 3_p
type NN 4_p
I PRP 4_p
insulin JJ 4_p
dependent NN 4_p
diabetics NNS 4_p
without IN 4_p
proliferative JJ 4_p
retinopathy NN 4_p
were VBD N
randomised VBN N
to TO N
receive VB N
either RB N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
multiple JJ N
insulin NN N
injections NNS N
or CC N
conventional JJ N
insulin NN N
treatment NN N
controls NNS N
Near IN N
normoglycaemia NN N
was VBD N
achieved VBN N
with IN N
continuous JJ N
infusion NN N
and CC N
multiple JJ N
injections NNS N
but CC N
not RB N
with IN N
conventional JJ N
treatment NN N
Blind NNP N
evaluation NN N
of IN N
fluorescein JJ N
angiograms NNS N
performed VBD N
three CD N
monthly JJ N
showed VBD N
progression NN N
of IN N
retinopathy NN N
in IN N
the DT N
control NN N
group NN N
transient JJ N
deterioration NN N
in IN N
the DT N
continuous JJ N
infusion NN N
group NN N
and CC N
no DT N
change NN N
in IN N
the DT N
multiple JJ N
injection NN N
group NN N
Half PDT N
the DT N
patients NNS N
receiving VBG N
continuous JJ N
infusion NN N
and CC N
multiple JJ N
injections NNS N
developed VBD N
retinal JJ N
cotton NN N
wool NN N
spots NNS N
after IN N
three CD N
to TO N
six CD N
months NNS N
These DT N
changes NNS N
regressed VBD N
in IN N
all DT N
but CC N
four CD N
patients NNS N
after IN N
12 CD N
months NNS N
Control NNP N
patients NNS N
did VBD N
not RB N
develop VB N
cotton NN N
wool NN N
spots NNS N
Patients NNS N
who WP N
developed VBD N
cotton NN N
wool NN N
spots NNS N
are VBP N
characterised VBN N
by IN N
a DT N
larger JJR N
decrement NN N
in IN N
glycosylated JJ N
haemoglobin NN N
and CC N
blood NN N
glucose NN N
values NNS N
more RBR N
frequent JJ N
episodes NNS N
of IN N
hypoglycaemia NN N
a DT N
longer JJR N
duration NN N
of IN N
diabetes NNS N
and CC N
more RBR N
severe JJ N
retinopathy NN N
at IN N
onset NN N
A DT N
large JJ N
and CC N
rapid JJ N
fall NN N
in IN N
blood NN N
glucose JJ N
concentration NN N
may MD N
promote VB N
transient JJ N
deterioration NN N
of IN N
diabetic JJ N
retinopathy NN N
-DOCSTART- -X- O O

The DT N
course NN N
of IN N
depression NN N
in IN N
recent JJ 4_p
onset NN 4_p
rheumatoid NN 4_p
arthritis NN 4_p
the DT N
predictive JJ N
role NN N
of IN N
disability NN N
illness JJ N
perceptions NNS N
pain NN N
and CC N
coping NN N
BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
course NN N
of IN N
depression NN N
for IN N
patients NNS 4_p
with IN 4_p
recently RB 4_p
diagnosed VBN 4_p
rheumatoid NN 4_p
arthritis NN 4_p
RA NNP 4_p
and CC N
to TO N
investigate VB N
predictors NNS N
of IN N
depression NN N
METHODS NNP N
Twenty-two JJ 3_p
patients NNS 4_p
with IN 4_p
a DT 4_p
history NN 4_p
of IN 4_p
recently RB 4_p
diagnosed VBN 4_p
RA NNP 4_p
of IN 4_p
less JJR 4_p
than IN 4_p
2 CD 4_p
years NNS 4_p
were VBD N
assessed VBN N
on IN N
a DT N
variety NN N
of IN N
clinical JJ N
outcome NN N
and CC N
process NN N
measures NNS N
on IN N
six CD N
assessment JJ N
occasions NNS N
over IN N
a DT N
21-month JJ N
period NN N
These DT N
22 CD 3_p
patients NNS 3_p
constituted VBD N
the DT N
control NN N
group NN N
of IN N
a DT N
controlled VBN N
trial NN N
and CC N
received VBN N
standard JJ N
outpatient NN N
clinic JJ N
treatment NN N
during IN N
follow-up JJ N
RESULTS JJ N
Patients NNPS N
became VBD N
significantly RB N
more RBR N
depressed JJ N
over IN N
time NN N
A DT N
set NN N
of IN N
five CD N
factors NNS N
were VBD N
found VBN N
to TO N
consistently RB N
predict VB N
depression NN N
at IN N
the DT N
following JJ N
assessment NN N
These DT N
were VBD N
initial JJ N
level NN N
of IN N
depression NN N
disability NN N
pain NN N
beliefs VB N
about IN N
the DT N
consequences NNS N
of IN N
arthritis NN N
and CC N
coping VBG N
strategies NNS N
CONCLUSIONS VB N
The DT N
results NNS N
confirm VBP N
the DT N
importance NN N
of IN N
psychological JJ N
factors NNS N
in IN N
early JJ N
RA NNP N
and CC N
their PRP$ N
relative JJ N
independence NN N
from IN N
physical JJ N
findings NNS N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
document VB N
the DT N
importance NN N
of IN N
illness JJ N
perceptions NNS N
in IN N
recent JJ N
onset NN N
RA NNP N
-DOCSTART- -X- O O

Data NNP N
mining NN N
the DT N
ScanBrit NNP N
study NN N
of IN N
a DT N
gluten- JJ N
and CC N
casein-free JJ N
dietary JJ N
intervention NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
behavioural JJ N
and CC N
psychometric JJ N
measures NNS N
of IN N
dietary JJ N
response NN N
We PRP N
previously RB N
reported VBD N
results NNS N
based VBN N
on IN N
the DT N
examination NN N
of IN N
a DT N
gluten- JJ N
and CC N
casein-free JJ N
diet NN N
as IN N
an DT N
intervention NN N
for IN N
children NNS 4_p
diagnosed VBN 4_p
with IN 4_p
an DT 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
as IN N
part NN N
of IN N
the DT N
ScanBrit NNP N
collaboration NN N
Analysis NN N
based VBN N
on IN N
grouped JJ N
results NNS N
indicated VBD N
several JJ N
significant JJ N
differences NNS N
between IN N
dietary JJ N
and CC N
non-dietary JJ N
participants NNS N
across IN N
various JJ N
core NN N
and CC N
peripheral JJ N
areas NNS N
of IN N
functioning VBG N
Results NNP N
also RB N
indicated VBD N
some DT N
disparity NN N
in IN N
individual JJ N
responses NNS N
to TO N
dietary JJ N
modification NN N
potentially RB N
indicative JJ N
of IN N
responder NN N
and CC N
non-responder JJ N
differences NNS N
Further JJ N
examination NN N
of IN N
the DT N
behavioural JJ N
and CC N
psychometric JJ N
data NNS N
garnered VBN N
from IN N
participants NNS N
was VBD N
undertaken VBN N
with IN N
a DT N
view NN N
to TO N
determining VBG N
potential JJ N
factors NNS N
pertinent VBP N
to TO N
response NN N
to TO N
dietary JJ N
intervention NN N
Participants NNS N
with IN N
clinically RB N
significant JJ N
scores NNS N
indicative JJ N
of IN N
inattention NN N
and CC N
hyperactivity NN N
behaviours NNS N
and CC N
who WP N
had VBD N
a DT N
significant JJ N
positive JJ N
changes NNS N
to TO N
said VBD N
scores NNS N
were VBD N
defined VBN N
as IN N
responders NNS N
to TO N
the DT N
dietary JJ N
intervention NN N
Analyses NNS N
indicated VBD N
several JJ N
factors NNS N
to TO N
be VB N
potentially RB N
pertinent JJ N
to TO N
a DT N
positive JJ N
response NN N
to TO N
dietary JJ N
intervention NN N
in IN N
terms NNS N
of IN N
symptom NN N
presentation NN N
Chronological JJ N
age NN N
was VBD N
found VBN N
to TO N
be VB N
the DT N
strongest JJS N
predictor NN N
of IN N
response NN N
where WRB N
those DT N
participants NNS N
aged VBD N
between IN N
7 CD N
and CC N
9 CD N
years NNS N
seemed VBD N
to TO N
derive VB N
most JJS N
benefit NN N
from IN N
dietary JJ N
intervention NN N
Further CC N
analysis NN N
based VBN N
on IN N
the DT N
criteria NNS N
for IN N
original JJ N
study NN N
inclusion NN N
on IN N
the DT N
presence NN N
of IN N
the DT N
urine JJ N
compound NN N
trans-indolyl-3-acryloylglycine NN N
may MD N
also RB N
merit VB N
further JJ N
investigation NN N
These DT N
preliminary JJ N
observations NNS N
on IN N
potential JJ N
best JJS N
responder NN N
characteristics NNS N
to TO N
a DT N
gluten- JJ N
and CC N
casein-free JJ N
diet NN N
for IN N
children NNS N
with IN N
autism NN N
require VBP N
independent JJ N
replication NN N
-DOCSTART- -X- O O

Prevention NN N
of IN N
spinal JJ N
anesthesia-induced JJ N
hypotension NN N
in IN N
the DT 1_p
elderly JJ 1_p
comparison NN N
between IN N
preanesthetic JJ N
administration NN N
of IN N
crystalloids NNS N
colloids NNS N
and CC N
no DT N
prehydration NN N
The DT N
practice NN N
of IN N
routinely RB N
prehydrating VBG N
patients NNS N
by IN N
infusing VBG N
a DT N
crystalloid NN N
or CC N
colloid JJ N
solution NN N
up IN N
to TO N
1.0 CD N
L/70 NNP N
kg NN N
for IN N
prevention NN N
of IN N
spinal JJ N
anesthesia-induced JJ N
hypotension NN N
has VBZ N
been VBN N
challenged VBN N
recently RB N
after IN N
several JJ N
reports NNS N
of IN N
failure NN N
to TO N
demonstrate VB N
its PRP$ N
efficacy NN N
in IN N
young JJ N
women NNS N
We PRP N
compared VBN N
the DT N
incidence NN N
and CC N
frequency NN N
of IN N
hypotension NN N
and CC N
vasopressor NN N
therapy NN N
after IN N
spinal JJ N
anesthesia NN N
and CC N
no DT N
prehydration NN N
with IN N
crystalloid NN N
and CC N
colloid JJ N
prehydration NN N
in IN N
elderly JJ 1_p
patients NNS 1_p
Eighty-five JJ 3_p
ASA NNP 4_p
grade NN 4_p
I PRP 4_p
or CC 4_p
II NNP 4_p
patients NNS 4_p
aged VBN 4_p
60-89 CD 4_p
yr NN 4_p
for IN 4_p
elective JJ 4_p
total JJ 4_p
hip NN 4_p
replacement NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
500 CD N
mL NN N
crystalloid JJ N
solution NN N
Hartmanns NNP N
n JJ N
29 CD N
500 CD N
mL NN N
colloid NN N
Haemaccel NNP N
n JJ N
28 CD N
or CC N
no DT N
prehydration NN N
n JJ N
28 CD N
over IN N
10 CD N
min NNS N
prior RB N
to TO N
spinal JJ N
anesthesia NN N
Hypotension NNP N
was VBD N
defined VBN N
as IN N
a DT N
30 CD N
decrease NN N
from IN N
baseline JJ N
systolic JJ N
blood NN N
pressure NN N
BP NNP N
or CC N
systolic JJ N
90 CD N
mm NN N
Hg NNP N
and CC N
was VBD N
treated VBN N
with IN N
ephedrine JJ N
3-mg JJ N
boluses NNS N
Although IN N
absolute JJ N
systolic JJ N
BP NNP N
readings NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
colloid NN N
group NN N
between IN N
6 CD N
and CC N
30 CD N
min NN N
P NNP N
0.05 CD N
the DT N
incidence NN N
of IN N
hypotension NN N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
The DT N
incidence NN N
of IN N
ephedrine NN N
use NN N
incidence NN N
of IN N
nausea/vomiting NN N
and CC N
median JJ N
total NN N
dose NN N
of IN N
ephedrine NN N
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
We PRP N
conclude VBP N
that DT N
in IN N
elderly JJ 1_p
patients NNS 1_p
undergoing VBG 4_p
elective JJ 4_p
procedures NNS 4_p
withholding VBG N
prehydration NN N
is VBZ N
not RB N
associated VBN N
with IN N
any DT N
greater JJR N
degree NN N
of IN N
hypotension NN N
or CC N
need NN N
for IN N
vasopressor NN N
therapy NN N
compared VBN N
with IN N
crystalloid NN N
or CC N
colloid JJ N
prehydration NN N
-DOCSTART- -X- O O

Plasma NNP N
AGE-peptides NNP N
and CC N
C-peptide NNP N
in IN N
early-stage JJ 4_p
diabetic JJ 4_p
nephropathy JJ 4_p
patients NNS 4_p
on IN N
thiamine NN N
and CC N
pyridoxine NN N
therapy NN N
AIM IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
circulatory JJ N
AGE-peptide JJ N
levels NNS N
in IN N
diabetic JJ N
nephropathy NN N
and CC N
to TO N
observe VB N
the DT N
effects NNS N
of IN N
thiamine NN N
vitamin JJ N
B1 NNP N
and CC N
pyridoxine NN N
vitamin JJ N
B6 NNP N
therapy NN N
METHODS NNP N
Type NNP 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
N.=57 NNP 3_p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
as IN N
with IN N
nephropathy JJ N
N.=27 NNP N
and CC N
without IN N
nephropathy JJ N
N.=30 NNP N
Diabetic NNP 4_p
nephropathy JJ 4_p
patients NNS 4_p
were VBD N
treated VBN N
with IN N
either DT N
B6 NNP N
N.=12 NNP N
250 CD N
mg/day NN N
or CC N
B1+B6 NNP N
N.=15 NNP N
250 CD N
mg/day NN N
each DT N
for IN N
five CD N
months NNS N
At IN N
the DT N
beginning NN N
and CC N
the DT N
end NN N
of IN N
the DT N
experimentation NN N
period NN N
glucose NN N
HbA1c NNP N
triglyceride NN N
cholesterol NN N
insulin NN N
C-peptide NNP N
thiamine NN N
pyrophosphate NN N
pyridoxal JJ N
phosphate NN N
and CC N
AGE- NNP N
peptides NNS N
were VBD N
measured VBN N
RESULTS JJ N
AGE-peptides NNS N
were VBD N
higher JJR N
in IN N
the DT N
diabetic JJ N
group NN N
with IN N
nephropathy JJ N
than IN N
without IN N
nephropathy JJ N
P=0.005 NNP N
Within IN N
five CD N
months NNS N
AGE-peptides NNS N
increased VBD N
in IN N
the DT N
diabetic JJ N
group NN N
without IN N
nephropathy JJ N
P=0.042 NNP N
but CC N
not RB N
in IN N
the DT N
group NN N
with IN N
nephropathy JJ N
treated VBN N
either RB N
with IN N
B1+B6 NNP N
or CC N
B6 NNP N
In IN N
B6 NNP N
treated VBD N
group NN N
a DT N
substantial JJ N
decrease NN N
was VBD N
observed VBN N
in IN N
HbA1c NNP N
P=0.033 NNP N
B1+B6 NNP N
or CC N
B6 NNP N
treatment NN N
both DT N
caused VBD N
an DT N
increase NN N
in IN N
C-peptide NNP N
P=0.006 NNP N
P=0.004 NNP N
CONCLUSION NNP N
Among IN N
the DT N
parameters NNS N
measured VBD N
plasma JJ N
AGE-peptides NNP N
was VBD N
the DT N
only JJ N
parameter NN N
found VBD N
to TO N
be VB N
higher JJR N
in IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus JJ 4_p
patients NNS 4_p
with IN N
nephropathy JJ N
than IN N
without IN N
nephropathy JJ N
However RB N
patients NNS 4_p
with IN N
nephropathy JJ N
treated VBN N
with IN N
B1+B6 NNP N
or CC N
B6 NNP N
did VBD N
not RB N
display VB N
any DT N
further JJ N
increase NN N
in IN N
AGE-peptides NNP N
within IN N
five CD N
months NNS N
Both DT N
of IN N
the DT N
treatments NNS N
caused VBD N
an DT N
increase NN N
in IN N
C-peptide NNP N
-DOCSTART- -X- O O

Intravenous JJ N
treatment NN N
of IN N
postpartum NN 4_p
anemia NN N
with IN N
trivalent JJ N
ferrum NN N
preparation NN N
AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
assess VB N
the DT N
effectivity NN N
and CC N
safeness NN N
of IN N
intravenous JJ N
treatment NN N
of IN N
pospartal JJ N
anemia NN N
with IN N
trivalent JJ N
ferrum NN N
preparation NN N
TYPE NNP N
OF IN N
THE NNP N
STUDY NNP N
Prospective NNP N
randomized VBD N
study NN N
SETTING NNP N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
2nd CD N
Medical NNP N
Faculty NNP N
Charles NNP N
University NNP N
and CC N
Teaching NNP N
Hospital NNP N
Motol NNP N
Prague NNP 4_p
and CC N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
1st CD N
Medical NNP N
Faculty NNP N
and CC N
Teaching NNP N
Hospital NNP N
Bulovka NNP N
Prague NNP 4_p
METHODS NNP N
500 CD N
mg NN N
of IN N
sacharose JJ N
ferric JJ N
oxide NN N
Venofer NNP N
was VBD N
intravenously RB N
administered VBN N
in IN N
two CD N
days NNS N
regimen NNS N
to TO N
50 CD 3_p
women NNS 2_p
with IN N
clinical JJ 4_p
and CC 4_p
lab JJ 4_p
signs NNS 4_p
of IN 4_p
postpartal JJ 4_p
anemia NN 4_p
The DT N
effect NN N
of IN N
administered JJ N
drug NN N
was VBD N
determined VBN N
by IN N
comparsion NN N
of IN N
values NNS N
of IN N
red JJ N
blood NN N
count NN N
recovered VBD N
before IN N
the DT N
treatment NN N
2nd CD N
or CC N
3rd CD N
day NN N
post NN N
administration NN N
and CC N
two CD N
weeks NNS N
later RB N
The DT N
serum NN N
values NNS N
of IN N
soluble JJ N
transferrin NN N
receptors NNS N
and CC N
ferritin NNS N
were VBD N
observed VBN N
as IN N
markers NNS N
of IN N
iron NN N
cell NN N
saturation NN N
and CC N
body NN N
iron NN N
reserves NNS N
too RB N
Integral JJ N
part NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
monitoring NN N
of IN N
adverse JJ N
events NNS N
during IN N
the DT N
treatment NN N
RESULTS NNP N
Venofer NNP N
came VBD N
in IN N
sight NN N
as IN N
effective JJ N
drug NN N
in IN N
the DT N
treatment NN N
of IN N
pospartal JJ N
anemia NN N
and CC N
could MD N
become VB N
as IN N
the DT N
alternative NN N
to TO N
blood VB N
transfusion NN N
in IN N
mid-severe JJ N
cases NNS N
It PRP N
should MD N
be VB N
emphasized VBN N
that IN N
we PRP N
have VBP N
not RB N
encountered VBN N
any DT N
serious JJ N
adverse JJ N
event NN N
with IN N
intravenous JJ N
trivalent NN N
saccharose VBD N
ferric JJ N
oxide JJ N
treatment NN N
-DOCSTART- -X- O O

Salmeterol NNP N
plus CC N
fluticasone JJ N
propionate NN N
versus IN N
fluticasone NN N
propionate NN N
plus CC N
montelukast NN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
investigating VBG N
the DT N
effects NNS N
on IN N
airway JJ N
inflammation NN N
in IN N
asthma NN N
BACKGROUND NNP N
Few NNP N
studies NNS N
have VBP N
compared VBN N
treatment NN N
strategies NNS N
in IN N
patients NNS 4_p
with IN 4_p
asthma JJ 4_p
poorly RB N
controlled VBN N
on IN N
low JJ N
dose NN N
inhaled JJ N
corticosteroids NNS N
and CC N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
different JJ N
treatments NNS N
on IN N
airway JJ N
inflammation NN N
In IN N
this DT N
double-blind NN N
placebo-controlled JJ N
parallel JJ N
group NN N
study NN N
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
salmeterol NN N
plus CC N
fluticasone NN N
propionate NN N
FP NNP N
Seretide NNP N
SFC NNP N
and CC N
FP NNP N
plus CC N
montelukast NN N
FP/M NNP N
on IN N
sputum NN N
inflammatory NN N
markers NNS N
airway RB N
responsiveness NN N
lung NN N
function NN N
and CC N
symptoms NNS N
in IN N
adult NN 1_p
asthmatics NNS 4_p
METHODS NNP N
Sixty-six JJ 3_p
subjects NNS 3_p
were VBD N
randomised VBN N
to TO N
SFC NNP N
or CC N
FP/M NNP N
for IN N
12 CD N
weeks NNS N
The DT N
primary JJ N
outcome NN N
was VBD N
changes NNS N
in IN N
neutrophil NN N
eosinophil NN N
macrophage NN N
lymphocyte NN N
and CC N
epithelial JJ N
cell NN N
levels NNS N
in IN N
induced JJ N
sputum NN N
Additional NNP N
outcomes NNS N
included VBD N
the DT N
change NN N
in IN N
other JJ N
sputum JJ N
markers NNS N
of IN N
airway JJ N
inflammation NN N
airway RB N
responsiveness NN N
symptom NN N
control NN N
and CC N
lung NN N
function NN N
RESULTS NNP N
Both NNP N
treatments NNS N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
induced JJ N
sputum NN N
inflammatory NN N
cells NNS N
although IN N
there EX N
was VBD N
a DT N
trend NN N
for IN N
a DT N
reduction NN N
in IN N
sputum NN N
eosinophils NNS N
Both DT N
treatments NNS N
significantly RB N
improved VBN N
airway RB N
responsiveness NN N
whereas WP N
SFC NNP N
generally RB N
led VBD N
to TO N
greater JJR N
improvements NNS N
in IN N
symptom JJ N
control NN N
and CC N
lung NN N
function NN N
than IN N
FP/M NNP N
FP/M NNP N
led VBD N
to TO N
significantly RB N
greater JJR N
reductions NNS N
in IN N
sputum NN N
cysteinyl NN N
leukotrienes NNS N
than IN N
SFC NNP N
treatment NN N
ratio NN N
1.80 CD N
95 CD N
CI NNP N
1.09 CD N
2.94 CD N
CONCLUSION NNP N
Both DT N
treatments NNS N
led VBD N
to TO N
similar JJ N
control NN N
of IN N
eosinophilic JJ N
airway NN N
inflammation NN N
although IN N
PEF NNP N
and CC N
symptom VB N
control NN N
were VBD N
better JJR N
with IN N
SFC NNP N
STUDY NNP N
NUMBER NNP N
SAM40030 NNP N
SOLTA NNP N
-DOCSTART- -X- O O

Effects NNS N
of IN N
Saccharomyces NNP N
boulardii NN N
in IN N
children NNS 1_p
with IN N
acute JJ 4_p
diarrhoea NN 4_p
AIM NNP N
Certain NNP N
probiotic JJ N
agents NNS N
e.g NN N
Lactobacillus CC N
GG NNP N
have VBP N
shown VBN N
efficacy NN N
in IN N
clinical JJ N
trials NNS N
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
childhood NN N
diarrhoea NN N
but CC N
few JJ N
studies NNS N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
Saccharomyces NNP N
boulardii NN N
We PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
S. NNP N
boulardii NN N
in IN N
children NNS 4_p
with IN 4_p
acute JJ 4_p
diarrhoea NN 4_p
METHODS NNP N
Two CD 3_p
hundred VBD 3_p
children NNS 3_p
were VBD N
randomized VBN N
to TO N
receive VB N
S. NNP N
boulardii NN N
in IN N
a DT N
granulated JJ N
form NN N
in IN N
a DT N
daily JJ N
dose NN N
of IN N
250 CD N
mg NN N
S. NNP N
boulardii NNP N
group NN N
or CC N
placebo NN N
placebo JJ N
group NN N
for IN N
5 CD N
d. JJ N
Clinical NNP N
and CC N
demographic JJ N
characteristics NNS N
on IN N
admission NN N
were VBD N
similar JJ N
between IN N
the DT N
study NN N
groups NNS N
RESULTS VB N
The DT N
medians NNS N
of IN N
the DT N
average JJ N
stool NN N
frequency NN N
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
S. NNP N
boulardii NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
p JJ N
0.003 CD N
The DT N
duration NN N
of IN N
diarrhoea NN N
significantly RB N
reduced VBN N
in IN N
the DT N
S. NNP N
boulardii NN N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
4.7 CD N
vs RB N
5.5 CD N
d NN N
p JJ N
0.03 CD N
The DT N
effect NN N
of IN N
S. NNP N
boulardii NN N
on IN N
watery NN N
diarrhoea NN N
became VBD N
apparent JJ N
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
The DT N
duration NN N
of IN N
hospital NN N
stay NN N
was VBD N
shorter JJR N
in IN N
the DT N
S. NNP N
boulardii NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
2.9 CD N
vs RB N
3.9 CD N
d NN N
p JJ N
0.001 CD N
Four CD N
children NNS N
from IN N
the DT N
placebo NN N
group NN N
versus VBD N
only RB N
one CD N
child NN N
from IN N
the DT N
S. NNP N
boulardii NN N
group NN N
had VBD N
persisting VBG N
diarrhoea NN N
CONCLUSION VB N
The DT N
placebo-controlled JJ N
study NN N
suggested VBD N
that IN N
S. NNP N
boulardii VBP N
significantly RB N
reduced VBN N
the DT N
duration NN N
of IN N
acute JJ N
diarrhoea NN N
and CC N
the DT N
duration NN N
of IN N
hospital NN N
stay NN N
S. NNP N
boulardii NN N
seems VBZ N
to TO N
be VB N
a DT N
promising JJ N
agent NN N
for IN N
the DT N
amelioration NN N
of IN N
the DT N
course NN N
of IN N
acute JJ 4_p
diarrhoea NN 4_p
in IN 4_p
children NNS 4_p
when WRB N
used VBN N
therapeutically RB N
-DOCSTART- -X- O O

Conscious JJ N
analgesia/sedation NN N
with IN N
remifentanil NN N
and CC N
propofol NN N
versus NN N
total JJ N
intravenous JJ N
anesthesia NN N
with IN N
fentanyl NN N
midazolam NN N
and CC N
propofol NN N
for IN N
outpatient JJ 4_p
colonoscopy NN 4_p
BACKGROUND NNP N
This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
for IN N
colonoscopy NN N
analgesia/sedation NN N
with IN N
remifentanil NN N
and CC N
propofol NN N
might MD N
be VB N
more RBR N
effective JJ N
compared VBN N
with IN N
anesthesia NN N
by IN N
intravenous JJ N
administration NN N
of IN N
midazolam NN N
fentanyl NN N
and CC N
propofol NN N
METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized JJ N
trial NN N
100 CD 3_p
adult NN 1_p
patients NNS 1_p
received VBD N
either RB N
conscious JJ N
analgesia/sedation NN N
Sedation NNP N
group NN N
or CC N
total JJ N
intravenous JJ N
anesthesia NN N
TIVA NNP N
group NN N
Analgesia/sedation NN N
was VBD N
achieved VBN N
by IN N
infusion NN N
of IN N
remifentanil NN N
0.20 CD N
to TO N
0.25 CD N
microg/kg/min NN N
and CC N
propofol NN N
in IN N
titrated JJ N
doses NNS N
TIVA NNP N
was VBD N
induced VBN N
by IN N
intravenous JJ N
administration NN N
of IN N
fentanyl NN N
2 CD N
microg/kg NN N
midazolam FW N
0.05 CD N
mg/kg NN N
and CC N
propofol NN N
dosage NN N
titrated VBN N
Cardiorespiratory JJ N
parameters NNS N
and CC N
bispectral JJ N
index NN N
were VBD N
monitored VBN N
and CC N
recorded VBN N
The DT N
quality NN N
of IN N
the DT N
analgesia NN N
was VBD N
assessed VBN N
with IN N
a DT N
Numerical JJ N
Pain NN N
Rating NNP N
Scale NNP N
NRS NNP N
recovery NN N
level NN N
and CC N
return NN N
of IN N
psychomotor NN N
efficiency NN N
were VBD N
evaluated VBN N
with IN N
respectively RB N
the DT N
Aldrete NNP N
scale NN N
and CC N
a DT N
Modified NNP N
Post NNP N
Anesthesia NNP N
Discharge NNP N
Scoring NNP N
MPADS NNP N
system NN N
RESULTS VB N
Both DT N
groups NNS N
of IN N
50 CD N
patients NNS N
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
demographic VB N
data NNS N
initial JJ N
parameters NNS N
and CC N
duration NN N
of IN N
colonoscopy NN N
All DT N
patients NNS N
in IN N
the DT N
TIVA NNP N
group NN N
found VBD N
the DT N
colonoscopy NN N
painless NN N
NRS NNP N
score RB N
0 CD N
In IN N
the DT N
Sedation NNP N
group NN N
the DT N
average JJ N
pain NN N
intensity NN N
score NN N
was VBD N
0.4 CD N
0.8 CD N
There EX N
was VBD N
a DT N
marked JJ N
difference NN N
between IN N
the DT N
Sedation NNP N
and CC N
TIVA NNP N
groups NNS N
with IN N
respect NN N
to TO N
the DT N
time NN N
from IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
until IN N
the DT N
maximum JJ N
MPADS NNP N
score NN N
was VBD N
reached VBN N
respectively RB N
-6.9 NNP N
4.0 CD N
versus NN N
25.7 CD N
8.4 CD N
minutes NNS N
p JJ N
0.001 CD N
In IN N
the DT N
TIVA NNP N
group NN N
changes NNS N
in IN N
mean JJ N
arterial JJ N
pressure NN N
and CC N
heart NN N
rate NN N
and CC N
signs NNS N
of IN N
respiratory NN N
depression NN N
were VBD N
significant JJ N
p JJ N
0.05 CD N
CONCLUSIONS NNP N
Combined NNP N
administration NN N
of IN N
remifentanil NN N
and CC N
propofol NN N
for IN N
colonoscopy NN N
provides VBZ N
sufficient JJ N
analgesia NN N
satisfactory JJ N
hemodynamic JJ N
stability NN N
minor JJ N
respiratory NN N
depression NN N
and CC N
rapid JJ N
recovery NN N
and CC N
allows VBZ N
patients NNS N
to TO N
be VB N
discharged VBN N
approximately RB N
15 CD N
minutes NNS N
after IN N
the DT N
procedure NN N
-DOCSTART- -X- O O

Effect NNP N
of IN N
transcranial JJ N
electrostimulation NN N
on IN N
clinical JJ N
and CC N
laboratory JJ N
characteristics NNS N
in IN N
patients NNS 4_p
with IN 4_p
gastric JJ 4_p
ulcer JJ 4_p
The DT N
study NN N
included VBD N
100 CD 3_p
patients NNS 4_p
with IN 4_p
gastric JJ 4_p
ulcer NNS 4_p
aged VBN 1_p
from IN 1_p
16 CD 1_p
to TO 1_p
60 CD 1_p
years NNS 1_p
In IN N
58 CD N
patients NNS N
traditional JJ N
treatment NN N
was VBD N
supplemented VBN N
by IN N
transcranial JJ N
electrotherapy NN N
using VBG N
a DT N
TRANSAIR-02 JJ N
apparatus NN N
Laboratory NNP N
studies NNS N
included VBD N
measurements NNS N
of IN N
lactoferrin NN N
LF NNP N
and CC N
tumour JJ N
necrosis NN N
factor-alpha NN N
TNF-alpha NNP N
besides VBZ N
standard JJ N
analyses NNS N
Combined VBN N
treatment NN N
traditional JJ N
therapy NN N
plus CC N
electrostimulation NN N
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
duration NN N
of IN N
the DT N
main JJ N
symptoms NNS N
of IN N
the DT N
gastric JJ N
ulcer NN N
depending VBG N
on IN N
the DT N
severity NN N
of IN N
ulceration NN N
process NN N
patients NNS N
age NN N
and CC N
sex NN N
Moreover RB N
it PRP N
facilitated VBD N
ulcer JJ N
scarring NN N
and CC N
had VBD N
beneficial JJ N
effect NN N
on IN N
dynamics NNS N
of IN N
serum NN N
LF NNP N
and CC N
TNF-alpha NNP N
levels NNS N
-DOCSTART- -X- O O

Amonafide NN N
An DT N
active JJ N
agent NN N
in IN N
the DT N
treatment NN N
of IN N
previously RB 4_p
untreated VBN 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
-- : 4_p
a DT 4_p
cancer NN N
and CC N
leukemia NN N
group NN N
B NNP N
study NN N
CALGB NNP N
8642 CD N
Amonafide NNP N
is VBZ N
a DT N
new JJ N
imide JJ N
derivative NN N
of IN N
naphthalic JJ N
acid NN N
The DT N
drug NN N
had VBD N
demonstrated VBN N
significant JJ N
activity NN N
in IN N
preclinical JJ N
studies NNS N
and CC N
some DT N
activity NN N
in IN N
Phase NNP N
I PRP N
trials NNS N
The DT N
drug NN N
is VBZ N
extensively RB N
metabolized VBN N
and CC N
detected VBN N
in IN N
plasma NN N
and CC N
urine NN N
Its PRP$ N
toxicity NN N
has VBZ N
previously RB N
been VBN N
correlated VBN N
to TO N
the DT N
formation NN N
of IN N
an DT N
active JJ N
metabolite NN N
N-acetyl-amonafide NNP N
Amonafide NNP N
was VBD N
chosen VBN N
for IN N
inclusion NN N
in IN N
the DT N
Cancer NNP N
and CC N
Leukemia NNP N
Group NNP N
B NNP N
CALGB NNP N
master NN N
metastatic JJ N
breast NN N
cancer NN N
protocol NN N
CALGB NNP N
8642 CD N
randomizes VBZ N
previously RB 4_p
untreated VBN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
either CC N
to TO N
one CD N
of IN N
several JJ N
Phase NNP N
II NNP N
agents NNS N
given VBN N
for IN N
up IN N
to TO N
four CD N
cycles NNS N
and CC N
then RB N
followed VBN N
by IN N
standard JJ N
cyclophosphamide-doxorubicin-5-fluorouracil NN N
or CC N
to TO N
immediate VB N
treatment NN N
with IN N
standard JJ N
cyclophosphamide-doxorubicin-5-fluorouracil NN N
The DT N
end NN N
point NN N
of IN N
CALGB NNP N
8642 CD N
is VBZ N
to TO N
assess VB N
the DT N
difference NN N
in IN N
survival NN N
toxicity NN N
and CC N
overall JJ N
response NN N
when WRB N
limited JJ N
exposure NN N
to TO N
Phase NNP N
II NNP N
agents NNS N
precedes VBZ N
standard JJ N
chemotherapy NN N
This DT N
report NN N
deals VBZ N
only RB N
with IN N
amonafide RB N
as IN N
a DT N
Phase NNP N
II NNP N
agent NN N
Comparisons NNS N
with IN N
the DT N
cyclophosphamide-doxorubicin-5-fluorouracil JJ N
arm NN N
will MD N
not RB N
be VB N
addressed VBN N
Patients NNS 4_p
had VBD 4_p
to TO 4_p
have VB 4_p
histologically RB 4_p
documented VBN 4_p
measurable JJ 4_p
breast NN 4_p
cancer NN 4_p
and CC 4_p
a DT 4_p
performance NN 4_p
status NN 4_p
of IN 4_p
0-1 NNP 4_p
Patients NNS 4_p
could MD 4_p
not RB 4_p
have VB 4_p
had VBN 4_p
prior JJ 4_p
chemotherapy NN 4_p
for IN 4_p
metastatic JJ 4_p
disease NN 4_p
Prior NNP 4_p
adjuvant JJ 4_p
chemotherapy NN 4_p
was VBD 4_p
permitted VBN 4_p
Patients NNS 4_p
could MD 4_p
not RB 4_p
have VB 4_p
visceral JJ 4_p
crisis NN 4_p
Amonafide NNP N
was VBD N
given VBN N
at IN N
300 CD N
mg/m2/day JJ N
i.v NN N
for IN N
5 CD N
days NNS N
and CC N
repeated VBD N
at IN N
21-day JJ N
intervals NNS N
for IN N
a DT N
maximum NN N
of IN N
four CD N
cycles NNS N
Escalation NN N
and CC N
reduction NN N
in IN N
dose NN N
was VBD N
mandated VBN N
dependent NN N
on IN N
hematotoxicity NN N
or CC N
lack NN N
thereof NN N
Toxicity NN N
was VBD N
primarily RB N
hematological JJ N
and CC N
bimodal NN N
32 CD N
had VBD N
grade VBN N
3 CD N
or CC N
4 CD N
leukopenia NN N
and CC N
24 CD N
had VBD N
grade VBN N
3 CD N
or CC N
4 CD N
thrombocytopenia NN N
22 CD N
had VBD N
no DT N
leukopenia NN N
and CC N
44 CD N
had VBD N
no DT N
thrombocytopenia NN N
The DT N
response NN N
rate NN N
was VBD N
18 CD N
including VBG N
one CD N
complete JJ N
response NN N
When WRB N
response NN N
was VBD N
analyzed VBN N
by IN N
hematological JJ N
toxicity NN N
there EX N
was VBD N
a DT N
35.7 CD N
response NN N
if IN N
patients NNS N
had VBD N
leukopenia VBN N
grade NN N
3/4 CD N
versus IN N
8.3 CD N
P NNP N
0.08 CD N
There EX N
was VBD N
a DT N
50 CD N
response NN N
if IN N
patients NNS N
had VBD N
thrombocytopenia VBN N
grade NN N
3/4 CD N
versus IN N
7.1 CD N
P NNP N
0.01 CD N
We PRP N
conclude VBP N
that DT N
amonafide NN N
is VBZ N
somewhat RB N
active JJ N
in IN N
previously RB 4_p
untreated VBN 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
There EX N
may MD N
be VB N
a DT N
steep JJ N
dose-response NN N
curve NN N
based VBN N
on IN N
the DT N
significant JJ N
correlation NN N
between IN N
myelosuppression NN N
and CC N
response NN N
Rates NNS N
of IN N
responses NNS N
in IN N
patients NNS N
adequately RB N
dosed VBN N
i.e. FW N
with IN N
significant JJ N
hematotoxicity NN N
with IN N
amonafide NN N
ranged VBD N
from IN N
35 CD N
to TO N
50 CD N
Further JJ N
studies NNS N
will MD N
incorporate VB N
individualized JJ N
dosing NN N
based VBN N
on IN N
pretreatment NN N
acetylator NN N
phenotyping NN N
-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
intensive JJ N
early JJ N
intervention NN N
for IN N
children NNS 1_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
Young NNP 1_p
children NNS 1_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
intensive VB N
treatment NN N
or CC N
parent NN N
training NN N
The DT N
intensive JJ N
treatment NN N
group NN N
7 CD 3_p
with IN N
autism NN 4_p
8 CD 3_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
not RB 4_p
otherwise RB 4_p
specified VBN 4_p
-- : 4_p
NOS NNP 4_p
averaged VBD N
24.52 CD N
hours NNS N
per IN N
week NN N
of IN N
individual JJ N
treatment NN N
for IN N
one CD N
year NN N
gradually RB N
reducing VBG N
hours NNS N
over IN N
the DT N
next JJ N
1 CD N
to TO N
2 CD N
years NNS N
The DT N
parent NN N
training NN N
group NN N
7 CD 3_p
with IN 4_p
autism NN 4_p
6 CD 3_p
with IN 4_p
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
NOS NNP 4_p
received VBD N
3 CD N
to TO N
9 CD N
months NNS N
of IN N
parent NN N
training NN N
The DT N
groups NNS N
appeared VBD N
similar JJ N
at IN N
intake NN N
on IN N
all DT N
measures NNS N
however RB N
at IN N
follow-up JJ N
the DT N
intensive JJ N
treatment NN N
group NN N
outperformed VBD N
the DT N
parent NN N
training VBG N
group NN N
on IN N
measures NNS N
of IN N
intelligence NN N
visual-spatial JJ N
skills NNS N
language NN N
and CC N
academics NNS N
though IN N
not RB N
adaptive JJ N
functioning NN N
or CC N
behavior NN N
problems NNS N
Children NNP 1_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
NOS NNP N
may MD N
have VB N
gained VBN N
more JJR N
than IN N
those DT N
with IN N
autism NN N
-DOCSTART- -X- O O

The DT N
sympatho-adrenergic JJ N
stress NN N
reaction NN N
in IN N
ear JJ 4_p
surgery NN 4_p
using VBG N
various JJ N
anesthesia JJ N
technics NNS N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
various JJ N
anaesthetic JJ N
procedures NNS N
on IN N
the DT N
endocrine NN N
stress NN N
responses NNS N
during IN N
ear JJ 4_p
microsurgical JJ 4_p
operations NNS 4_p
Simple JJ 4_p
mastoidectomies NNS 4_p
radical JJ 4_p
mastoidectomies NNS 4_p
and CC 4_p
tympano NN 4_p
plastics NNS 4_p
were VBD N
carried VBN N
out IN N
in IN N
49 CD 3_p
patients NNS N
under IN N
the DT N
following VBG N
randomised VBD N
anaesthetic JJ N
procedures NNS N
Group NNP N
1 CD N
halothane NN N
anaesthesia NN N
and CC N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
lidocaine NN N
and CC N
ornipressin NN N
n JJ N
14 CD N
Group NNP N
2 CD N
fentanyl NN N
anaesthesia NN N
and CC N
retroauricular JJ N
anaesthesia NN N
with IN N
lidocaine NN N
and CC N
ornipressin NN N
n JJ N
10 CD N
Group NNP N
3 CD N
fentanyl NN N
anaesthesia NN N
and CC N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
lidocaine NN N
and CC N
epinephrine NN N
n JJ N
14 CD N
and CC N
Group NNP N
4 CD N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
prilocaine NN N
and CC N
epinephrine NN N
n JJ N
14 CD N
The DT N
plasma NN N
levels NNS N
of IN N
epinephrine NN N
norepinephrine NN N
glucose NN N
lactate NN N
and CC N
free JJ N
glycerol NN N
were VBD N
measured VBN N
in IN N
addition NN N
to TO N
mean VB N
arterial JJ N
pressure NN N
MAP NNP N
and CC N
heart NN N
rate NN N
HR NNP N
immediately RB N
before IN N
anaesthesia NN N
10 CD N
minutes NNS N
after IN N
skin JJ N
incision NN N
10 CD N
minutes NNS N
after IN N
having VBG N
started VBD N
bone CD N
drilling NN N
at IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
and CC N
3 CD N
hours NNS N
after IN N
operation NN N
All DT N
data NNS N
were VBD N
subjected VBN N
to TO N
covariance VB N
analysis NN N
including VBG N
the DT N
age NN N
factor NN N
Plasma NNP N
catecholamine JJ N
concentrations NNS N
remained VBD N
within IN N
the DT N
normal JJ N
range NN N
during IN N
the DT N
investigation NN N
in IN N
patients NNS N
subjected VBN N
to TO N
general JJ N
anaesthesia NN N
Groups NNP N
1-3 CD N
Plasma NNP N
catecholamines NNS N
epinephrine NN N
and CC N
norepinephrine NN N
increased VBD N
significantly RB N
in IN N
Group NNP N
4 CD N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
There EX N
were VBD N
no DT N
group NN N
variabilities VBZ N
with IN N
regard NN N
to TO N
MAP NNP N
and CC N
HR NNP N
The DT N
plasma NN N
levels NNS N
of IN N
epinephrine NN N
and CC N
norepinephrine JJ N
demonstrate NN N
a DT N
direct JJ N
response NN N
to TO N
stress NN N
followed VBN N
by IN N
a DT N
secondary JJ N
change NN N
in IN N
glucose NN N
lactate NN N
and CC N
free JJ N
glycerol NN N
The DT N
beneficial JJ N
effect NN N
of IN N
general JJ N
anaesthesia NN N
is VBZ N
documented VBN N
by IN N
normal JJ N
plasma NN N
levels NNS N
of IN N
epinephrine NN N
and CC N
norepinephrine NN N
throughout IN N
the DT N
operation NN N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
-DOCSTART- -X- O O

RESPECT-PTSD JJ N
re-engineering JJ N
systems NNS N
for IN N
the DT N
primary JJ N
care NN N
treatment NN N
of IN N
PTSD NNP 4_p
a DT N
randomized VBN N
controlled VBN N
trial NN N
BACKGROUND NNP N
Although IN N
collaborative JJ N
care NN N
is VBZ N
effective JJ N
for IN N
treating VBG N
depression NN N
and CC N
other JJ N
mental JJ N
disorders NNS N
in IN N
primary JJ N
care NN N
there EX N
have VBP N
been VBN N
no DT N
randomized JJ N
trials NNS N
of IN N
collaborative JJ N
care NN N
specifically RB N
for IN N
patients NNS 4_p
with IN 4_p
Posttraumatic NNP 4_p
stress NN 4_p
disorder NN 4_p
PTSD NNP 4_p
OBJECTIVE UH N
To TO N
compare VB N
a DT N
collaborative JJ N
approach NN N
the DT N
Three NNP N
Component NNP N
Model NNP N
3CM CD N
with IN N
usual JJ N
care NN N
for IN N
treating VBG N
PTSD NNP N
in IN N
primary JJ N
care NN N
DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
two-arm JJ N
parallel JJ N
randomized VBD N
clinical JJ N
trial NN N
PTSD JJ 4_p
patients NNS N
were VBD N
recruited VBN N
from IN N
five CD 4_p
primary JJ 4_p
care NN 4_p
clinics NNS 4_p
at IN 4_p
four CD 4_p
Veterans NNS 4_p
Affairs NNP 4_p
healthcare NN 4_p
facilities NNS 4_p
and CC N
randomized VBN N
to TO N
receive VB N
usual JJ N
care NN N
or CC N
usual JJ N
care NN N
plus CC N
3CM CD N
Blinded VBN N
assessors NNS N
collected VBD N
data NNS N
at IN N
baseline NN N
and CC N
3-month JJ N
and CC N
6-month JJ N
follow-up NN N
PARTICIPANTS JJ N
Participants NNS N
were VBD N
195 CD 3_p
Veterans NNPS 4_p
Their PRP$ N
average JJ 1_p
age NN 1_p
was VBD 1_p
45 CD 1_p
years NNS 1_p
91 CD 1_p
were VBD 1_p
male JJ 2_p
58 CD N
were VBD N
white JJ N
40 CD N
served VBN N
in IN N
Iraq NNP N
or CC N
Afghanistan NNP N
and CC N
42 CD N
served VBD N
in IN N
Vietnam NNP N
INTERVENTION NNP N
All NNP N
participants NNS N
received VBD N
usual JJ N
care NN N
Participants NNS N
assigned VBD N
to TO N
3CM CD N
also RB N
received VBD N
telephone NN N
care NN N
management NN N
Care NN N
managers NNS N
received VBD N
supervision NN N
from IN N
a DT N
psychiatrist NN N
MAIN NNP N
MEASURES NNP N
PTSD NNP N
symptom NN N
severity NN N
was VBD N
the DT N
primary JJ N
outcome NN N
Depression NNP N
functioning NN N
perceived VBD N
quality NN N
of IN N
care NN N
utilization NN N
and CC N
costs NNS N
were VBD N
secondary JJ N
outcomes NNS N
KEY JJ N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
3CM CD N
and CC N
usual JJ N
care NN N
in IN N
symptoms NNS N
or CC N
functioning VBG N
Participants NNS N
assigned VBD N
to TO N
3CM CD N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
mental JJ N
health NN N
visit NN N
fill VB N
an DT N
antidepressant JJ N
prescription NN N
and CC N
have VBP N
adequate VBN N
antidepressant JJ N
refills NNS N
3CM CD N
participants NNS N
also RB N
had VBD N
more RBR N
mental JJ N
health NN N
visits NNS N
and CC N
higher JJR N
outpatient NN N
pharmacy NN N
costs NNS N
CONCLUSIONS NNP N
Results NNP N
suggest VBP N
the DT N
need NN N
for IN N
careful JJ N
examination NN N
of IN N
the DT N
way NN N
that IN N
collaborative JJ N
care NN N
models NNS N
are VBP N
implemented VBN N
for IN N
treating VBG N
PTSD NNP N
and CC N
for IN N
additional JJ N
supports NNS N
to TO N
encourage VB N
primary JJ N
care NN N
providers NNS N
to TO N
manage VB N
PTSD NNP N
-DOCSTART- -X- O O

Effect NN N
of IN N
simvastatin NN N
on IN N
hemostasis NN N
in IN N
patients NNS 4_p
with IN 4_p
isolated JJ 4_p
hypertriglyceridemia NN 4_p
BACKGROUNDS/AIMS NNP N
Elevated NNP N
triglyceride NN N
levels NNS N
seem VBP N
to TO N
predispose VB N
to TO N
the DT N
earlier JJR N
development NN N
and CC N
accelerated JJ N
progression NN N
of IN N
coronary JJ N
artery NN N
disease NN N
In IN N
our PRP$ N
study NN N
we PRP N
assessed VBD N
for IN N
the DT N
first JJ N
time NN N
whether IN N
simvastatin JJ N
treatment NN N
affects NNS N
coagulation NN N
and CC N
fibrinolysis NN N
in IN N
patients NNS 4_p
with IN 4_p
isolated JJ 4_p
hypertriglyceridemia NN 4_p
METHODS NNP N
The DT N
study NN N
included VBD N
39 CD 3_p
patients NNS 4_p
with IN 4_p
elevated JJ 4_p
triglyceride NN 4_p
levels NNS 4_p
and CC 4_p
peripheral JJ 4_p
artery NN 4_p
sclerosis NN 4_p
treated VBD N
for IN N
90 CD N
days NNS N
with IN N
either DT N
simvastatin NN N
40 CD N
mg NNS N
daily RB N
or CC N
placebo NN N
Plasma NNP N
lipids NNS N
glucose JJ N
homeostasis NN N
markers NNS N
and CC N
hemostasic JJ N
variables NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
RESULTS NNP N
Simvastatin NNP N
but CC N
not RB N
placebo VB N
administered VBN N
to TO N
these DT N
patients NNS N
reduced VBD N
plasma JJ N
levels/activity NN N
of IN N
fibrinogen NN N
from IN N
3.5 CD N
± $ N
0.4 CD N
to TO N
2.8 CD N
± NNS N
0.3 CD N
g/l NN N
p NN N
0.01 CD N
factor NN N
VII NNP N
from IN N
144.2 CD N
± $ N
16.9 CD N
to TO N
112.5 CD N
± NNS N
14.0 CD N
p NN N
0.01 CD N
and CC N
plasminogen JJ N
activator NN N
inhibitor-1 NN N
from IN N
76.9 CD N
± $ N
13.5 CD N
to TO N
50.2 CD N
± NNS N
9.2 CD N
ng/ml NNS N
p VBP N
0.001 CD N
without IN N
a DT N
significant JJ N
reduction NN N
in IN N
von NN N
Willebrand NNP N
factor NN N
levels NNS N
and CC N
tended VBD N
to TO N
prolong VB N
the DT N
prothrombin NN N
and CC N
partial JJ N
thromboplastin NN N
times NNS N
CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
statin NN N
treatment NN N
produces VBZ N
a DT N
multidirectional JJ N
effect NN N
on IN N
coagulation NN N
and CC N
fibrinolysis NN N
in IN N
patients NNS N
with IN N
isolated JJ N
hypertriglyceridemia NN N
and CC N
that IN N
this DT N
treatment NN N
may MD N
bring VB N
some DT N
benefits NNS N
to TO N
patients NNS N
with IN N
elevated JJ N
triglyceride NN N
levels NNS N
-DOCSTART- -X- O O

Efficacy NNP N
of IN N
paliperidone NN N
extended-release JJ N
tablets NNS N
in IN N
the DT N
improvement NN N
of IN N
social JJ N
functions NNS N
in IN N
schizophrenics NNS 4_p
a DT N
randomized NN N
and CC N
controlled VBD N
study NN N
OBJECTIVE UH N
To TO N
explore VB N
the DT N
efficacy NN N
of IN N
paliperidone NN N
extended-release JJ N
tablets NNS N
in IN N
the DT N
improvement NN N
of IN N
social JJ N
functions NNS N
in IN N
schizophrenics NNS 4_p
METHODS NNP N
A NNP N
total NN N
of IN N
81 CD 3_p
schizophrenics NNS 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
study NN N
group NN N
with IN N
paliperidone NN N
extended-release JJ N
tablets NNS N
and CC N
control NN N
group NN N
with IN N
risperidone NN N
for IN N
a DT N
12-week JJ N
treatment NN N
They PRP N
were VBD N
assessed VBN N
and CC N
analyzed VBN N
by IN N
positive JJ N
and CC N
negative JJ N
symptoms NNS N
scales NNS N
PANSS NNP N
social JJ N
disability NN N
screening VBG N
schedule NN N
SDSS NNP N
and CC N
treatment NN N
emergent NN N
symptom NN N
scale NN N
TESS NNP N
at IN N
baseline NN N
6 CD N
th NN N
weekend NN N
and CC N
12 CD N
th NN N
weekend NN N
RESULTS NNP N
In IN N
study NN N
group NN N
the DT N
factors NNS N
and CC N
total JJ N
scores NNS N
of IN N
PANSS NNP N
in IN N
the DT N
12 CD N
th NN N
weekend NN N
of IN N
treatment NN N
12.0 CD N
± RB N
2.8 CD N
12.1 CD N
± RB N
3.6 CD N
26.2 CD N
± RB N
5.0 CD N
50.2 CD N
± RB N
8.7 CD N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
at IN N
baseline JJ N
24.7 CD N
± RB N
5.3 CD N
23.8 CD N
± RB N
3.6 CD N
45.0 CD N
± RB N
2.9 CD N
93.5 CD N
± RB N
6.8 CD N
t JJ N
9.60-16.78 CD N
P NNP N
0.05 CD N
In IN N
study NN N
group NN N
the DT N
positive JJ N
factor NN N
negative JJ N
factor NN N
and CC N
total JJ N
scores NNS N
of IN N
PANSS NNP N
in IN N
the DT N
12 CD N
th NN N
weekend NN N
of IN N
treatment NN N
12.0 CD N
± RB N
2.8 CD N
12.1 CD N
± RB N
3.6 CD N
50.2 CD N
± RB N
8.7 CD N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
6 CD N
th NN N
weekend NN N
of IN N
treatment NN N
14.2 CD N
± RB N
1.8 CD N
14.6 CD N
± RB N
2.4 CD N
56.5 CD N
± RB N
6.4 CD N
t JJ N
2.58-4.26 CD N
P NNP N
0.05 CD N
In IN N
the DT N
12 CD N
th NN N
weekend NN N
of IN N
treatment NN N
the DT N
factors NNS N
and CC N
total JJ N
scores NNS N
of IN N
PANSS NNP N
in IN N
study NN N
group NN N
12.0 CD N
± RB N
2.8 CD N
12.1 CD N
± RB N
3.6 CD N
26.2 CD N
± RB N
5.0 CD N
50.2 CD N
± RB N
8.7 CD N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
control NN N
group NN N
16.9 CD N
± RB N
4.9 CD N
18.7 CD N
± RB N
5.3 CD N
32.5 CD N
± RB N
5.1 CD N
68.1 CD N
± RB N
13.0 CD N
t JJ N
-4.28 NNP N
-- : N
5.67 CD N
P NNP N
0.05 CD N
In IN N
study NN N
group NN N
the DT N
total JJ N
scores NNS N
of IN N
SDSS NNP N
in IN N
the DT N
12 CD N
th NN N
weekend NN N
of IN N
treatment NN N
5.93 CD N
± RB N
2.78 CD N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
at IN N
baseline NN N
13.9 CD N
± RB N
3.4 CD N
t JJ N
10.83 CD N
P NNP N
0.05 CD N
In IN N
study NN N
group NN N
the DT N
total JJ N
scores NNS N
of IN N
SDSS NNP N
in IN N
the DT N
12 CD N
th NN N
weekend NN N
of IN N
treatment NN N
5.9 CD N
± RB N
2.8 CD N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
6 CD N
th NN N
weekend NN N
of IN N
treatment NN N
7.6 CD N
± RB N
2.9 CD N
t JJ N
5.21 CD N
P NNP N
0.05 CD N
But CC N
there EX N
was VBD N
no DT N
significant JJ N
improvement NN N
in IN N
control NN N
group NN N
t JJ N
1.88 CD N
P NNP N
0.05 CD N
In IN N
the DT N
12 CD N
th NN N
weekend NN N
of IN N
treatment NN N
the DT N
total JJ N
scores NNS N
of IN N
SDSS NNP N
in IN N
study NN N
group NN N
5.9 CD N
± RB N
2.8 CD N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
control NN N
group NN N
8.8 CD N
± RB N
2.9 CD N
t JJ N
-4.49 NNP N
P NNP N
0.05 CD N
No UH N
severe JJ N
adverse JJ N
effect NN N
was VBD N
reported VBN N
in IN N
either DT N
group NN N
CONCLUSION NNP N
Paliperidone NNP N
extended-release JJ N
tablets NNS N
are VBP N
effective JJ N
to TO N
improve VB N
social JJ N
functions NNS N
and CC N
psychiatric JJ N
symptoms NNS N
of IN N
schizophrenics NNS N
-DOCSTART- -X- O O

Phase NNP N
III NNP N
study NN N
of IN N
two CD N
different JJ N
dosing VBG N
schedules NNS N
of IN N
erythropoietin NN N
in IN N
anemic JJ 4_p
patients NNS 4_p
with IN 4_p
cancer NN 4_p
PURPOSE NNP N
To TO N
compare VB N
maintenance NN N
epoetin NN N
alfa NN N
administered VBD N
once RB N
every DT N
3 CD N
weeks NNS N
with IN N
continued JJ N
weekly JJ N
epoetin NN N
alfa NN N
for IN N
patients NNS 4_p
with IN 4_p
cancer-associated JJ 4_p
anemia NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
Eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
at IN N
enrollment NN N
to TO N
receive VB N
three CD N
weekly JJ N
doses NNS N
of IN N
epoetin NN N
alfa NN N
40,000 CD N
U NNP N
subcutaneously RB N
SC NNP N
followed VBN N
by IN N
either DT N
standard JJ N
weekly JJ N
epoetin NN N
alfa NN N
40K CD N
arm NN N
or CC N
120,000 CD N
U NNP N
of IN N
epoetin NN N
alfa NN N
120K CD N
arm NN N
SC NNP N
every DT N
3 CD N
weeks NNS N
for IN N
18 CD N
additional JJ N
weeks NNS N
RESULTS NNP N
Three CD 3_p
hundred VBD 3_p
sixty-five JJ 3_p
patients NNS 3_p
were VBD N
enrolled VBN N
One CD N
hundred VBD N
eighty-three JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
the DT N
40K CD N
arm NN N
and CC N
182 CD N
were VBD N
assigned VBN N
to TO N
the DT N
120K CD N
arm NN N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
proportion NN N
of IN N
patients NNS N
requiring VBG N
transfusions NNS N
during IN N
the DT N
study NN N
23 CD N
in IN N
40K CD N
arm NN N
and CC N
18 CD N
in IN N
120K CD N
arm NN N
P NNP N
.22 NNP N
or CC N
specifically RB N
during IN N
the DT N
maintenance NN N
phase NN N
13 CD N
in IN N
40K CD N
arm NN N
v NN N
15 CD N
in IN N
120K CD N
arm NN N
P NNP N
.58 NNP N
Patients NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
40K CD N
arm NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
or CC N
2 CD N
or CC N
or CC N
3 CD N
g/dL NN N
hemoglobin NN N
Hb NNP N
increment NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
drug NN N
dose RB N
held VBD N
because IN N
of IN N
high JJ N
Hb NNP N
and CC N
had VBD N
higher JJR N
mean JJ N
end-of-study JJ N
Hb NNP N
levels NNS N
Toxicities NNS N
including VBG N
thromboembolism NN N
and CC N
overall JJ N
survival NN N
were VBD N
similar JJ N
Patients NNS N
in IN N
the DT N
40K CD N
arm NN N
had VBD N
a DT N
higher JJR N
global JJ N
quality NN N
of IN N
life NN N
QOL NNP N
at IN N
baseline NN N
for IN N
unclear JJ N
reasons NNS N
whereas JJ N
patients NNS N
in IN N
the DT N
120K CD N
arm NN N
had VBD N
a DT N
greater JJR N
global JJ N
QOL NNP N
improvement NN N
during IN N
the DT N
study NN N
so IN N
end-of-study JJ N
QOL NNP N
was VBD N
equivalent JJ N
CONCLUSION NN N
After IN N
three CD N
weekly JJ N
doses NNS N
of IN N
epoetin NN N
alfa NN N
40,000 CD N
U NNP N
a DT N
dose NN N
of IN N
120,000 CD N
U NNS N
can MD N
be VB N
administered VBN N
safely RB N
once RB N
every DT N
3 CD N
weeks NNS N
without IN N
increasing VBG N
transfusion NN N
needs NNS N
or CC N
sacrificing VBG N
QOL NNP N
The DT N
Hb NNP N
increment NN N
is VBZ N
somewhat RB N
greater JJR N
with IN N
continued JJ N
weekly JJ N
epoetin NN N
alfa NN N
Lack NNP N
of IN N
blinding VBG N
as IN N
a DT N
result NN N
of IN N
different JJ N
treatment NN N
schedules NNS N
may MD N
have VB N
confounded VBN N
results NNS N
-DOCSTART- -X- O O

Virtual JJ N
reality NN N
hypnosis NN N
for IN N
pain NN N
associated VBN N
with IN N
recovery NN N
from IN N
physical JJ 4_p
trauma NN 4_p
Pain VB N
following VBG N
traumatic JJ N
injuries NNS N
is VBZ N
common JJ N
can MD N
impair VB N
injury JJ N
recovery NN N
and CC N
is VBZ N
often RB N
inadequately RB N
treated VBN N
In IN N
particular JJ N
the DT N
role NN N
of IN N
adjunctive JJ N
nonpharmacologic JJ N
analgesic JJ N
techniques NNS N
is VBZ N
unclear JJ N
The DT N
authors NNS N
report VBP N
a DT N
randomized VBN N
controlled VBD N
study NN N
of IN N
21 CD 3_p
hospitalized JJ 4_p
trauma NN 4_p
patients NNS 4_p
to TO N
assess VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
virtual JJ N
reality NN N
hypnosis NN N
VRH NNP N
-hypnotic JJ N
induction NN N
and CC N
analgesic JJ N
suggestion NN N
delivered VBN N
by IN N
customized JJ N
virtual JJ N
reality NN N
VR NNP N
hardware/software NN N
Subjective JJ N
pain NN N
ratings NNS N
were VBD N
obtained VBN N
immediately RB N
and CC N
8 CD N
hours NNS N
after IN N
VRH NNP N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
standard VB N
analgesic JJ N
care NN N
and CC N
compared VBN N
to TO N
both DT N
adjunctive JJ N
VR NNP N
without IN N
hypnosis NN N
and CC N
standard JJ N
care NN N
alone RB N
VRH JJ N
patients NNS N
reported VBD N
less RBR N
pain JJ N
intensity NN N
and CC N
less JJR N
pain NN N
unpleasantness JJ N
compared VBN N
to TO N
control VB N
groups NNS N
These DT N
preliminary JJ N
findings NNS N
suggest VBP N
that IN N
VRH NNP N
analgesia NN N
is VBZ N
a DT N
novel JJ N
technology NN N
worthy NN N
of IN N
further JJ N
study NN N
both DT N
to TO N
improve VB N
pain NN N
management NN N
and CC N
to TO N
increase VB N
availability NN N
of IN N
hypnotic JJ N
analgesia NN N
to TO N
populations NNS N
without IN N
access NN N
to TO N
therapist-provided JJ N
hypnosis NN N
and CC N
suggestion NN N
-DOCSTART- -X- O O

Why WRB N
were VBD N
the DT N
results NNS N
of IN N
the DT N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
HOPE NNP N
trial NN N
so IN N
astounding VBG N
The DT N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
HOPE NNP N
study NN N
was VBD N
important JJ N
because IN N
it PRP N
showed VBD N
the DT N
benefits NNS N
of IN N
ramipril NN N
an DT N
angiotensin-converting JJ N
enzyme NN N
ACE NNP N
inhibitor NN N
in IN N
patients NNS 4_p
at IN 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
cardiovascular JJ 4_p
events NNS 4_p
Treatment NN N
with IN N
ramipril NN N
significantly RB N
reduced VBD N
the DT N
rates NNS N
of IN N
death NN N
myocardial JJ N
infarction NN N
stroke NN N
coronary JJ N
revascularization NN N
cardiac JJ N
arrest NN N
and CC N
heart NN N
failure NN N
as RB N
well RB N
as IN N
the DT N
risk NN N
of IN N
diabetes-related JJ N
complications NNS N
and CC N
of IN N
diabetes NNS N
itself PRP N
The DT N
effects NNS N
of IN N
therapy NN N
with IN N
vitamin JJ N
E NN N
were VBD N
also RB N
evaluated VBN N
but CC N
no DT N
statistical JJ N
benefits NNS N
were VBD N
shown VBN N
The DT N
benefits NNS N
of IN N
ACE NNP N
inhibitor NN N
therapy NN N
that WDT N
were VBD N
observed VBN N
were VBD N
likely JJ N
due JJ N
to TO N
a DT N
variety NN N
of IN N
mechanisms NNS N
not RB N
just RB N
a DT N
reduction NN N
in IN N
blood NN N
pressure NN N
-DOCSTART- -X- O O

Anti-emetic JJ N
efficacy NN N
of IN N
prophylactic JJ N
granisetron NNS N
compared VBN N
with IN N
perphenazine NN N
for IN N
the DT N
prevention NN N
of IN N
post-operative JJ N
vomiting NN N
in IN N
children NNS 1_p
We PRP N
have VBP N
compared VBN N
the DT N
efficacy NN N
of IN N
granisetron NN N
with IN N
perphenazine NN N
in IN N
the DT N
prevention NN N
of IN N
vomiting VBG N
after IN N
tonsillectomy NN 4_p
with IN 4_p
or CC 4_p
without IN 4_p
adenoidectomy NN 4_p
in IN N
children NNS 1_p
In IN N
a DT N
prospective JJ N
randomized VBN N
double-blind JJ N
study NN N
90 CD 3_p
paediatric JJ 1_p
patients NNS 1_p
ASA NNP 1_p
I PRP 1_p
aged VBN 1_p
4-10 CD 1_p
years NNS 1_p
received VBD N
granisetron NN N
40 CD N
mg JJ N
kg-1 NN N
or CC N
perphenazine VB N
70 CD N
mg JJ N
kg-1 NN N
n JJ N
45 CD N
each DT N
intravenously RB N
immediately RB N
after IN N
an DT N
inhalation NN N
induction NN N
of IN N
anaesthesia NN N
A DT N
standard JJ N
general JJ N
anaesthetic JJ N
technique NN N
was VBD N
employed VBN N
throughout IN N
A DT N
complete JJ N
response NN N
defined VBD N
as IN N
no DT N
emesis NN N
with IN N
no DT N
need NN N
for IN N
another DT N
rescue NN N
antiemetic JJ N
during IN N
the DT N
first JJ N
3 CD N
h NN N
0-3 JJ N
h NN N
after IN N
anesthesia NN N
was VBD N
87 CD N
with IN N
granisetron NN N
and CC N
78 CD N
with IN N
perphenazine NN N
P NNP N
0.204 CD N
The DT N
corresponding JJ N
incidence NN N
during IN N
the DT N
next JJ N
21 CD N
h NN N
3-24 JJ N
h NN N
after IN N
anaesthesia NN N
was VBD N
87 CD N
and CC N
62 CD N
P NNP N
0.007 CD N
No UH N
clinically RB N
serious JJ N
adverse JJ N
events NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
We PRP N
conclude VBP N
that DT N
granisetron NN N
is VBZ N
a DT N
better JJR N
anti-emetic JJ N
than IN N
perphenazine NN N
for IN N
the DT N
long-term JJ N
prevention NN N
of IN N
post-operative JJ N
vomiting NN N
in IN N
children NNS 1_p
undergoing VBG 1_p
general JJ 1_p
anaesthesia NN 1_p
for IN 4_p
tonsillectomy NN 4_p
-DOCSTART- -X- O O

A DT N
New NNP N
Interactive NNP N
Screening NNP N
Test NNP N
for IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
in IN N
Toddlers NNP 1_p
OBJECTIVE NNP N
To TO N
develop VB N
a DT N
clinically RB N
valid JJ N
interactive JJ N
level NN N
2 CD N
screening NN N
assessment NN N
for IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
ASD NNP 4_p
in IN N
toddlers NNS 1_p
that WDT N
is VBZ N
brief JJ N
easily RB N
administered VBN N
and CC N
scored VBN N
by IN N
clinicians NNS N
STUDY NNP N
DESIGN NNP N
We PRP N
describe VBP N
the DT N
development NN N
training NN N
standardization NN N
and CC N
validation NN N
of IN N
the DT N
Rapid NNP N
Interactive NNP N
Screening NNP N
Test NNP N
for IN N
Autism NNP N
in IN N
Toddlers NNP N
RITA-T NNP N
with IN N
ASD-specific NNP N
diagnostic JJ N
instruments NNS N
The DT N
RITA-T JJ N
can MD N
be VB N
administered VBN N
and CC N
scored VBN N
in IN N
10 CD N
minutes NNS N
We PRP N
studied VBD N
the DT N
validity NN N
of IN N
the DT N
RITA-T NNP N
to TO N
distinguish VB N
between IN N
toddlers NNS 4_p
with IN 4_p
ASD NNP 4_p
from IN 4_p
toddlers NNS 4_p
with IN 4_p
developmental JJ 4_p
delay NN 4_p
DD NNP 4_p
/non-ASD NN 4_p
in IN 4_p
an DT 4_p
early JJ 4_p
childhood NN 4_p
clinic NN 4_p
We PRP N
also RB N
evaluated VBD N
the DT N
test NN N
's POS N
performance NN N
in IN N
toddlers NNS 1_p
with IN 4_p
no DT 4_p
developmental JJ 4_p
concerns NNS 4_p
We PRP N
identified VBD N
a DT N
cutoff NN N
score NN N
based VBN N
on IN N
sensitivity NN N
specificity NN N
and CC N
positive JJ N
predictive JJ N
value NN N
of IN N
the DT N
RITA-T NNP N
that WDT N
best JJS N
differentiates NNS N
between IN N
ASD NNP N
and CC N
DD/non-ASD NNP N
RESULTS VB N
A DT 3_p
total NN 3_p
of IN 3_p
61 CD 3_p
toddlers NNS 3_p
were VBD N
enrolled VBN N
RITA-T JJ N
scores NNS N
were VBD N
correlated VBN N
with IN N
ASD-specific NNP N
diagnostic JJ N
tools NNS N
r VB N
0.79 CD N
P NNP N
.01 NNP N
and CC N
ASD NNP N
clinical JJ N
diagnoses NNS N
r VB N
0.77 CD N
P NNP N
.01 NNP N
Mean JJ N
scores NNS N
were VBD N
significantly RB N
different JJ N
in IN N
subjects NNS N
with IN N
ASD NNP N
those DT N
with IN N
DD/non-ASD NNP N
and CC N
those DT N
with IN N
no DT N
developmental JJ N
concerns NNS N
20.8 CD N
vs RB N
13 CD N
vs NN N
10.6 CD N
respectively RB N
P NNP N
.0001 NNP N
At IN N
a DT N
cutoff NN N
score NN N
of IN N
14 CD N
the DT N
RITA-T NNP N
had VBD N
a DT N
sensitivity NN N
of IN N
1.00 CD N
specificity NN N
of IN N
0.84 CD N
and CC N
positive JJ N
predictive JJ N
value NN N
of IN N
0.88 CD N
for IN N
identifying VBG N
ASD NNP N
risk NN N
in IN N
a DT N
high-risk JJ N
group NN N
CONCLUSION VB N
The DT N
RITA-T NNP N
is VBZ N
a DT N
promising JJ N
new JJ N
level NN N
2 CD N
interactive JJ N
screening VBG N
tool NN N
for IN N
improving VBG N
the DT N
early JJ N
identification NN N
of IN N
ASD NNP 4_p
in IN 4_p
toddlers NNS 4_p
in IN N
general JJ N
pediatric NN N
and CC N
early JJ N
intervention NN N
settings NNS N
and CC N
allowing VBG N
access NN N
to TO N
treatment NN N
-DOCSTART- -X- O O

Fluoroscopic NNP N
functional JJ N
evaluation NN N
of IN N
bileaflet NN N
prostheses NNS N
effect NN N
of IN N
different JJ N
intraoperative JJ N
valve NN N
orientation NN N
Fluoroscopy NNP N
is VBZ N
a DT N
reliable JJ N
easy JJ N
and CC N
readily RB N
available JJ N
technique NN N
to TO N
follow-up JJ N
prosthesis NN N
functioning NN N
after IN N
heart NN N
valve NN N
surgery NN N
The DT N
different JJ N
orientation NN N
given VBN N
to TO N
the DT N
prosthesis NN N
may MD N
represent VB N
a DT N
limitation NN N
of IN N
the DT N
technique NN N
accounting NN N
for IN N
unsatisfactory JJ N
results NNS N
in IN N
10 CD N
to TO N
40 CD N
of IN N
the DT N
cases NNS N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
and CC N
to TO N
what WP N
extent VB N
different JJ N
intraoperative JJ N
valve NN N
orientation NN N
influence NN N
feasibility NN N
and CC N
accuracy NN N
of IN N
postoperative JJ N
fluoroscopic JJ N
evaluation NN N
of IN N
bileaflet NN N
prostheses NNS N
We PRP N
prospectively RB N
evaluated VBD N
90 CD 3_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
aortic JJ 4_p
mitral JJ 4_p
and/or JJ 4_p
tricuspid JJ 4_p
valve FW 4_p
replacement NN 4_p
with IN 4_p
Sorin NNP 4_p
Bicarbon NNP 4_p
or CC 4_p
CarboMedics NNPS 4_p
bileaflet NN 4_p
prostheses NNS 4_p
Fifty NNP N
percent NN N
of IN N
the DT N
patients NNS N
in IN N
each DT N
group NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
prostheses NNS N
oriented VBN N
in IN N
a DT N
perpendicular NN N
or CC N
a DT N
parallel JJ N
position NN N
with IN N
respect NN N
to TO N
the DT N
ventricular JJ N
septum NN N
Fluoroscopic NNP N
evaluation NN N
was VBD N
considered VBN N
appropriate JJ N
when WRB N
the DT N
prosthesis NN N
tilting VBG N
disk NN N
projection NN N
was VBD N
obtained VBN N
The DT N
valve NN N
's POS N
hemodynamic JJ N
performance NN N
was VBD N
investigated VBN N
through IN N
Doppler NNP N
study NN N
A DT N
proper JJ N
fluoroscopic NN N
evaluation NN N
was VBD N
rapidly RB N
15 CD N
+/- JJ N
5 CD N
seconds NNS N
achieved VBN N
in IN N
all DT N
patients NNS N
with IN N
the DT N
former JJ N
orientation NN N
whereas IN N
it PRP N
was VBD N
impossible JJ N
to TO N
obtain VB N
it PRP N
in IN N
8 CD N
of IN N
20 CD N
40 CD N
19 CD N
of IN N
20 CD N
95 CD N
and CC N
4 CD N
of IN N
5 CD N
80 CD N
of IN N
patients NNS N
with IN N
the DT N
latter JJ N
orientation NN N
In IN N
the DT N
remaining VBG N
patients NNS N
extremely RB N
angulated VBN N
uneasy JJ N
projection NN N
was VBD N
often RB N
required VBN N
to TO N
get VB N
a DT N
correct JJ N
fluoroscopic NN N
image NN N
The DT N
Doppler NNP N
study NN N
showed VBD N
a DT N
similarly RB N
favorable JJ N
hemodynamic JJ N
performance NN N
regardless NN N
of IN N
valve JJ N
orientation NN N
Prosthesis NNP N
orientation NN N
crucially RB N
affects VBZ N
the DT N
rate NN N
of IN N
success NN N
of IN N
the DT N
fluoroscopic JJ N
evaluation NN N
The DT N
orientation NN N
perpendicular NN N
to TO N
the DT N
ventricular JJ N
septum NN N
greatly RB N
facilitates VBZ N
the DT N
postoperative JJ N
feasibility NN N
and CC N
accuracy NN N
of IN N
fluoroscopy NN N
and CC N
it PRP N
is VBZ N
not RB N
detrimental JJ N
to TO N
the DT N
valve NN N
's POS N
hemodynamic JJ N
performance NN N
This DT N
valve JJ N
orientation NN N
may MD N
provide VB N
a DT N
better JJR N
fluoroscopic NN N
window NN N
whenever WRB N
a DT N
valve NN N
dysfunction NN N
is VBZ N
suspected VBN N
-DOCSTART- -X- O O

Prediction NN N
of IN N
creatinine JJ N
clearance NN N
from IN N
serum JJ N
creatinine NN N
in IN N
patients NNS 4_p
with IN 4_p
rheumatoid JJ 4_p
arthritis NN 4_p
comparison NN N
of IN N
six CD N
formulae NNS N
and CC N
one CD N
nomogram NN N
The DT N
estimation NN N
of IN N
glomerular JJ N
filtration NN N
rate NN N
is VBZ N
important JJ N
for IN N
the DT N
medical JJ N
treatment NN N
of IN N
patients NNS 4_p
with IN 4_p
rheumatoid JJ 4_p
arthritis NN 4_p
RA NNP 4_p
However RB N
the DT N
determination NN N
of IN N
endogenous JJ N
creatinine JJ N
clearance NN N
Clcr NNP N
from IN N
a DT N
24-h JJ N
urine JJ N
collection NN N
is VBZ N
an DT N
unreliable JJ N
and CC N
time-consuming JJ N
procedure NN N
We PRP N
therefore RB N
tested VBD N
the DT N
accuracy NN N
of IN N
six CD N
equations NNS N
and CC N
one CD N
nomogram NN N
for IN N
the DT N
prediction NN N
of IN N
Clcr NNP N
from IN N
serum JJ N
creatinine NN N
Scr NNP N
in IN N
38 CD 3_p
patients NNS 3_p
with IN 3_p
RA NNP 3_p
and CC N
20 CD 3_p
controls NNS 3_p
A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
for IN N
all DT N
methods NNS N
in IN N
the DT N
controls NNS N
r VB N
0.83-0.94 NN N
and CC N
RA NNP N
patients NNS N
r JJ N
0.51-0.69 NN N
The DT N
methods NNS N
did VBD N
not RB N
overestimate VB N
Clcr NNP N
in IN N
RA NNP N
In IN N
the DT N
RA NNP N
group NN N
the DT N
simple JJ N
formula NN N
published VBN N
by IN N
Cockcroft NNP N
Clcr NNP N
140 CD N
age NN N
x VBZ N
body NN N
weight NN N
72 CD N
x NNP N
Scr NNP N
x $ N
0.85 CD N
for IN N
females NNS N
showed VBD N
the DT N
best JJS N
correlation NN N
with IN N
the DT N
measured VBN N
Clcr NNP N
In IN N
RA NNP N
the DT N
Cockroft NNP N
formula NN N
can MD N
reliably RB N
be VB N
used VBN N
to TO N
predict VB N
Clcr NNP N
from IN N
Scr NNP N
-DOCSTART- -X- O O

Oral JJ N
ciprofloxacin NN N
vs. FW N
intramuscular JJ N
ceftriaxone NN N
as IN N
empiric JJ N
treatment NN N
of IN N
acute JJ 4_p
invasive JJ 4_p
diarrhea NN 4_p
in IN N
children NNS 1_p
BACKGROUND NNP N
Acute NNP N
invasive JJ N
diarrhea NN N
is VBZ N
a DT N
potentially RB N
serious JJ N
condition NN N
in IN N
children NNS 1_p
Because IN N
of IN N
the DT N
increasing VBG N
resistance NN N
of IN N
enteric JJ N
pathogens NNS N
to TO N
commonly RB N
used JJ N
oral JJ N
antibiotics NNS N
intramuscular JJ N
ceftriaxone NN N
has VBZ N
become VBN N
the DT N
routine JJ N
drug NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
invasive JJ N
diarrhea NN N
requiring VBG N
an DT N
emergency NN N
visit NN N
in IN N
southern JJ N
Israel NNP N
The DT N
inconvenience NN N
of IN N
this DT N
parenteral JJ N
regimen NNS N
created VBD N
an DT N
increased VBN N
need NN N
for IN N
oral JJ N
pediatric JJ N
formulations NNS N
for IN N
the DT N
treatment NN N
of IN N
invasive JJ N
diarrhea NN N
OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
a DT N
suspension NN N
formulation NN N
of IN N
ciprofloxacin NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ 4_p
invasive JJ 4_p
diarrhea NN 4_p
in IN N
infants NNS 1_p
and CC 1_p
children NNS 1_p
PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP N
July NNP N
1996 CD N
through IN N
December NNP N
1997 CD N
201 CD 3_p
evaluable JJ N
children NNS 1_p
ages VBZ 1_p
6 CD 1_p
months NNS 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
35 CD 1_p
1 CD 1_p
year NN 1_p
70 CD 1_p
3 CD 1_p
years NNS 1_p
presenting VBG 4_p
with IN 4_p
acute JJ 4_p
invasive JJ 4_p
diarrhea NN 4_p
at IN 4_p
the DT 4_p
Pediatric NNP 4_p
Emergency NNP 4_p
Room NNP 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ciprofloxacin NN N
suspension NN N
10 CD N
mg/kg NN N
twice RB N
a DT N
day NN N
im NN N
placebo NN N
n CC N
95 CD N
or CC N
im VB N
ceftriaxone NN N
50 CD N
mg/kg/day NN N
placebo NN N
suspension NN N
n CC N
106 CD N
for IN N
3 CD N
days NNS N
in IN N
a DT N
double JJ N
blind NN N
manner NN N
Stool NNP N
cultures NNS N
for IN N
Shigella NNP N
Salmonella NNP N
Campylobacter NNP N
spp NN N
and CC N
diarrheagenic JJ N
Escherichia NNP N
coli NNS N
were VBD N
obtained VBN N
on IN N
Days NNP N
1 CD N
3 CD N
4 CD N
to TO N
5 CD N
and CC N
21 CD N
+/- JJ N
5 CD N
Clinical JJ N
response NN N
and CC N
safety NN N
were VBD N
assessed VBN N
on IN N
Days NNP N
1 CD N
2 CD N
3 CD N
4 CD N
to TO N
5 CD N
and CC N
21 CD N
+/- JJ N
5 CD N
RESULTS NNP N
We PRP N
isolated VBD N
127 CD N
pathogens NNS N
from IN N
121 CD N
60 CD N
patients NNS N
73 CD N
57 CD N
Shigella NNP N
23 CD N
18 CD N
Salmonella NNP N
18 CD N
14 CD N
E. NNP N
coli NNS N
and CC N
13 CD N
10 CD N
Campylobacter NNP N
Overall NNP N
bacteriologic JJ N
eradication NN N
on IN N
Day NNP N
4 CD N
to TO N
5 CD N
was VBD N
99 CD N
for IN N
Shigella NNP N
77 CD N
for IN N
Salmonella NNP N
and CC N
77 CD N
for IN N
Campylobacter NNP N
with IN N
no DT N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
Clinical JJ N
cure NN N
or CC N
improvement NN N
was VBD N
observed VBN N
in IN N
100 CD N
and CC N
99 CD N
of IN N
the DT N
ciprofloxacin NN N
and CC N
ceftriaxone NN N
groups NNS N
respectively RB N
Serum NNP N
ciprofloxacin NN N
values NNS N
determined VBN N
on IN N
Day NNP N
3 CD N
of IN N
the DT N
treatment NN N
were VBD N
higher JJR N
in IN N
the DT N
majority NN N
of IN N
patients NNS N
than IN N
were VBD N
the DT N
MIC50 NNP N
and CC N
MIC90 NNP N
values NNS N
for IN N
the DT N
Shigella NNP N
and CC N
Salmonella NNP N
spp NN N
isolated VBN N
Possible JJ N
drug-related JJ N
adverse JJ N
events NNS N
occurred VBD N
in IN N
13 CD N
patients NNS N
ciprofloxacin NN N
8 CD N
8 CD N
ceftriaxone NN N
5 CD N
4.7 CD N
and CC N
were VBD N
mild NNS N
and CC N
transient NN N
Joint JJ N
examination NN N
was VBD N
normal JJ N
during IN N
and CC N
after IN N
completion NN N
of IN N
therapy NN N
in IN N
all DT N
patients NNS N
CONCLUSION NNP N
Oral NNP N
ciprofloxacin NN N
was VBD N
as IN N
safe JJ N
and CC N
effective JJ N
as IN N
intramuscular JJ N
ceftriaxone NN N
for IN N
the DT N
empiric JJ N
treatment NN N
of IN N
acute JJ N
invasive JJ N
diarrhea NN N
in IN N
ambulatory JJ 4_p
pediatric JJ 4_p
patients NNS 4_p
requiring VBG 4_p
an DT 4_p
emergency NN 4_p
room NN 4_p
visit NN 4_p
-DOCSTART- -X- O O

Prospective JJ N
study NN N
of IN N
short JJ N
and CC N
ultrashort JJ N
regimens NNS N
of IN N
gonadotropin-releasing JJ N
hormone NN N
agonist NN N
in IN N
an DT N
in IN N
vitro JJ N
fertilization NN N
program NN N
OBJECTIVE NNP N
To TO N
assess VB N
the DT N
usefulness NN N
of IN N
the DT N
ultrashort JJ N
regimen NNS N
of IN N
gonadotropin-releasing JJ N
hormone NN N
agonist NN N
GnRH-a NNP N
in IN N
ovulation NN N
induction NN N
in IN N
an DT N
in IN 4_p
vitro JJ 4_p
fertilization NN 4_p
IVF NNP 4_p
program NN N
DESIGN VB N
A DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
short JJ N
and CC N
ultrashort JJ N
regimens NNS N
of IN N
GnRH-a NNP N
SETTING NN N
Aberdeen NNP N
Assisted NNP N
Reproduction NNP N
Unit NNP N
PATIENTS NNP N
Forty-eight JJ 3_p
patients NNS 4_p
having VBG 4_p
IVF NNP 4_p
for IN 4_p
the DT 4_p
first JJ 4_p
time NN 4_p
were VBD N
randomized VBN N
between IN N
the DT N
two CD N
protocols NNS N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Response NNP N
to TO N
ovarian JJ N
stimulation NN N
and CC N
occurrence NN N
of IN N
spontaneous JJ N
luteinizing VBG N
hormone NN N
LH NNP N
surges VBZ N
RESULTS NNP N
In IN N
ovulation NN N
induction NN N
fertilization NN N
and CC N
pregnancy NN N
rates NNS N
the DT N
ultrashort JJ N
regimen NNS N
produces VBZ N
results NNS N
that WDT N
were VBD N
no DT N
different JJ N
to TO N
the DT N
short JJ N
regimen NNS N
but CC N
it PRP N
did VBD N
not RB N
always RB N
prevent VB N
an DT N
LH NNP N
surge NN N
CONCLUSION VB N
The DT N
ultrashort JJ N
regimen NNS N
can MD N
be VB N
a DT N
useful JJ N
alternative NN N
for IN N
ovarian JJ N
stimulation NN N
of IN N
patients NNS N
undergoing VBG 4_p
IVF NNP 4_p
-DOCSTART- -X- O O

Combined VBN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
improves VBZ N
peers NNS 4_p
perceptions NNS N
of IN N
autism NN N
Authors NNS N
examined VBD N
the DT N
combined JJ N
effects NNS N
of IN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
on IN N
peers NNS 4_p
perceptions NNS N
and CC N
behavioral JJ N
intentions NNS N
toward IN N
an DT N
unfamiliar JJ N
child NN 4_p
with IN 4_p
autism NN 4_p
Children NNP 1_p
N NNP N
576 CD 3_p
M NNP 1_p
age NN 1_p
10.06 CD 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB N
two CD N
videotapes NNS N
of IN N
a DT N
boy NN N
engaging VBG N
in IN N
typical JJ N
and CC N
autistic JJ N
behaviors NNS N
receiving VBG N
either RB N
descriptive JJ N
AUT-D NNP N
or CC N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
AUT-D NNP N
E NNP N
Children NNP N
responded VBD N
to TO N
measures NNS N
of IN N
attitudes NNS N
Adjective NNP N
Checklist NNP N
and CC N
behavioral JJ N
intentions NNS N
Shared NNP N
Activities NNP N
Questionnaire NNP N
Children NNP N
rated VBD N
the DT N
typical JJ N
boy NN N
more RBR N
favorably RB N
than IN N
the DT N
boy NN N
showing VBG N
autistic JJ N
symptoms NNS N
When WRB N
compared VBN N
to TO N
descriptive VB N
information NN N
alone RB N
the DT N
combination NN N
of IN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
resulted VBD N
in IN N
improved JJ N
third- JJ N
and CC N
fourth-graders NNS N
but CC N
not RB N
fifth-graders NNS N
attitudes NNS N
toward IN N
the DT N
child NN N
with IN N
autism NN N
Combined VBN N
information NN N
improved VBN N
behavioral JJ N
intentions NNS N
across IN N
grades NNS N
however RB N
girls NNS N
vs. FW N
boys NNS N
were VBD N
more RBR N
responsive JJ N
to TO N
information NN N
as IN N
evidenced VBN N
by IN N
differences NNS N
in IN N
academic JJ N
intentions NNS N
The DT N
combination NN N
of IN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
about IN N
autism NN N
appears VBZ N
to TO N
have VB N
a DT N
positive JJ N
effect NN N
on IN N
children NNS 1_p
's POS 1_p
attitudes NNS N
and CC N
behavioral JJ N
intentions NNS N
Implications NNS N
of IN N
the DT N
findings NNS N
are VBP N
briefly RB N
discussed VBN N
as RB N
well RB N
as IN N
study NN N
limitations NNS N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
-DOCSTART- -X- O O

Double-blind NNP N
placebo-controlled JJ N
study NN N
of IN N
the DT N
effectiveness NN N
and CC N
tolerability NN N
of IN N
10 CD N
and CC N
30 CD N
mg NN N
ketorolac NN N
tromethamine NN N
suppositories NNS N
in IN N
post-cholecystectomy JJ N
pain NN N
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
ketorolac NN N
tromethamine NN N
10 CD N
mg NN N
and CC N
30 CD N
mg NN N
suppositories NNS N
in IN N
comparison NN N
to TO N
placebo VB N
after IN N
single JJ N
dose JJ N
administration NN N
in IN N
patients NNS 4_p
suffering VBG 4_p
from IN 4_p
post-operative JJ 4_p
pain NN 4_p
after IN 4_p
cholecystectomy NN 4_p
DESIGN NNP N
Double-blind NNP N
randomized VBD N
controlled VBD N
study NN N
SETTING NNP N
Anaesthesia NNP N
Service NNP N
PATIENTS NNP N
99 CD 3_p
patients NNS 4_p
with IN 4_p
severe JJ 4_p
pain NN 4_p
following VBG 4_p
surgery NN 4_p
INTERVENTIONS NNP N
Cholecystectomy NNP N
MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
analgesia JJ N
activity NN N
of IN N
ketorolac NN N
tromethamine NN N
10 CD N
mg NN N
and CC N
30 CD N
mg NN N
suppositories NNS N
were VBD N
evaluated VBN N
after IN N
single JJ N
dose JJ N
administration NN N
by IN N
assessing VBG N
pain NN N
intensity NN N
and CC N
pain NN N
relief NN N
using VBG N
a DT N
4 CD N
point NN N
scale NN N
VRS NNP N
At IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
overall JJ N
assessment NN N
of IN N
safety NN N
and CC N
efficacy NN N
were VBD N
recorded VBN N
by IN N
physician JJ N
and CC N
patient JJ N
The DT N
results NNS N
show VBP N
that IN N
in IN N
both DT N
active JJ N
groups NNS N
after IN N
30 CD N
and CC N
until IN N
4 CD N
hours NNS N
pain VBP N
intensity NN N
decreased VBN N
significantly RB N
with IN N
respect NN N
to TO N
the DT N
baseline NN N
However RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
groups NNS N
of IN N
p NN N
0.02 CD N
p NN N
0.01 CD N
and CC N
p VB N
0.05 CD N
was VBD N
found VBN N
in IN N
favour NN N
of IN N
the DT N
30 CD N
mg NN N
dose NN N
respectively RB N
at IN N
30 CD N
6 CD N
and CC N
8 CD N
hours NNS N
after IN N
administration NN N
All PDT N
the DT N
patients NNS N
treated VBN N
with IN N
placebo JJ N
suppositories NNS N
required VBN N
another DT N
rescue NN N
analgesic JJ N
drug NN N
and CC N
withdrew NN N
from IN N
the DT N
trial NN N
Three CD N
patients NNS N
complained VBD N
adverse JJ N
events NNS N
not RB N
related VBN N
to TO N
treatment NN N
two CD N
on IN N
placebo NN N
and CC N
one CD N
on IN N
ketorolac NN N
10 CD N
mg NN N
The DT N
systemic JJ N
and CC N
local JJ N
tolerability NN N
of IN N
the DT N
drug NN N
was VBD N
good JJ N
CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
ketorolac $ N
30 CD N
mg NN N
suppositories NNS N
are VBP N
effective JJ N
in IN N
clinical JJ N
conditions NNS N
such JJ N
as IN N
after IN N
surgery NN N
in IN N
which WDT N
pain NN N
control NN N
must MD N
be VB N
achieved VBN N
within IN N
the DT N
shortest JJ N
time NN N
interval NN N
and CC N
maintained VBD N
or CC N
improved VBN N
by IN N
means NNS N
of IN N
a DT N
single JJ N
route NN N
of IN N
administration NN N
-DOCSTART- -X- O O

Clinical JJ N
performance NN N
of IN N
the DT N
Reichert NNP N
AT550 NNP N
a DT N
new JJ N
non-contact JJ N
tonometer NN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
level NN N
of IN N
accuracy NN N
for IN N
measurements NNS N
of IN N
intra-ocular JJ N
pressure NN N
IOP NNP N
obtained VBD N
with IN N
a DT N
new JJ N
non-contact JJ N
tonometer NN N
NCT NNP N
the DT N
Reichert NNP N
AT550 NNP N
Measurements NNS N
were VBD N
compared VBN N
against IN N
those DT N
obtained VBN N
with IN N
the DT N
Reichert NNP N
Xpert NNP N
Plus NNP N
Goldmann NNP N
applanation NN N
tonometer NN N
and CC N
Perkins NNP N
tonometer NN N
Thirty-five JJ 3_p
university NN 4_p
students NNS 4_p
were VBD 4_p
assessed VBN 4_p
with IN N
the DT N
four CD N
tonometers NNS N
in IN N
a DT N
randomised JJ N
order NN N
with IN N
non-contact JJ N
tonometry NN N
performed VBD N
first RB N
Each DT N
of IN N
the DT N
four CD N
measurement NN N
devices NNS N
had VBD N
its PRP$ N
own JJ N
trained JJ N
clinical JJ N
observer NN N
Plots NNP N
of IN N
differences NNS N
of IN N
IOP NNP N
as IN N
a DT N
function NN N
of IN N
the DT N
mean NN N
for IN N
each DT N
pair NN N
of IN N
instruments NNS N
were VBD N
obtained VBN N
No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
when WRB N
comparing VBG N
the DT N
AT550 NNP N
NCT NNP N
with IN N
contact JJ N
applanation NN N
tonometry NN N
AT NNP N
p JJ N
0.05 CD N
displaying VBG N
the DT N
closest JJS N
level NN N
of IN N
agreement NN N
as IN N
represented VBN N
by IN N
the DT N
lowest JJS N
mean JJ N
difference NN N
and CC N
the DT N
narrowest JJS N
confidence NN N
interval NN N
with IN N
the DT N
Goldmann NNP N
tonometer NN N
limits NNS N
of IN N
agreement NN N
0.12+/-2.17 NN N
In IN N
conclusion NN N
readings NNS N
of IN N
IOP NNP N
with IN N
the DT N
AT550 NNP N
NCT NNP N
are VBP N
clinically RB N
comparable JJ N
with IN N
those DT N
obtained VBN N
with IN N
Goldmann NNP N
tonometry NN N
in IN N
a DT N
population NN N
with IN N
IOP NNP N
within IN N
the DT N
normal JJ N
range NN N
-DOCSTART- -X- O O

Clinical NNP N
study NN N
on IN N
treatment NN N
of IN N
endometriosis-related JJ 4_p
infertility NN 4_p
patients NNS 4_p
by IN N
laparoscopic NN N
surgery NN N
in IN N
combination NN N
of IN N
quyu JJ N
jiedu NN N
recipe NN N
OBJECTIVE NNP N
To TO N
study VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
the DT N
laparoscopic NN N
surgery NN N
in IN N
combination NN N
of IN N
Quyu NNP N
Jiedu NNP N
Recipe NNP N
QYJDR NNP N
on IN N
endometriosis NN 4_p
EMs NNP 4_p
-related VBD 4_p
infertility NN 4_p
patients NNS 4_p
METHODS NNP N
130 CD 3_p
EMs-related JJ 4_p
infertility NN 4_p
patients NNS 4_p
of IN N
blood NN 4_p
stasis NN 4_p
and CC 4_p
toxin NN 4_p
accumulation NN 4_p
syndrome NN 4_p
diagnosed VBD 4_p
and CC 4_p
treated VBN 4_p
by IN 4_p
laparoscopic NN 4_p
surgery NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
i.e. FW N
the DT N
test NN N
group NN N
75 CD N
cases NNS N
and CC N
the DT N
control NN N
group NN N
55 CD N
cases NNS N
All DT N
patients NNS N
received VBD N
routine JJ N
progesterone NN N
treatment NN N
after IN N
laparoscopic NN N
surgery NN N
QYJDR NNP N
was VBD N
given VBN N
to TO N
patients NNS N
in IN N
the DT N
test NN N
group NN N
after IN N
laparoscopic NN N
surgery NN N
lasting VBG N
for IN N
twelve JJ N
months NNS N
The DT N
pregnancy NN N
rate NN N
within IN N
one CD N
year NN N
after IN N
laparoscopic NN N
surgery NN N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
The DT N
Chinese JJ N
medicine NN N
syndrome NN N
integrals NNS N
serum JJ N
endometrium NN N
antibody NN N
EMAb NNP N
and CC N
cancer NN N
antigen NN N
125 CD N
CA125 NNP N
levels NNS N
were VBD N
compared VBN N
between IN N
before RB N
drug NN N
therapy NN N
and CC N
three CD N
months NNS N
after IN N
drug NN N
therapy NN N
RESULTS VB N
The DT N
pregnancy NN N
rate NN N
within IN N
one CD N
year NN N
after IN N
laparoscopic NN N
surgery NN N
was VBD N
higher RBR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
61.33 CD N
46/75 CD N
vs FW N
45.45 CD N
25/55 CD N
showing VBG N
significant JJ N
difference NN N
P NNP N
0.05 CD N
The DT N
Chinese JJ N
medicine NN N
syndrome JJ N
integral NN N
was VBD N
16.07 CD N
+/- JJ N
6.77 CD N
score NN N
and CC N
7.25 CD N
+/- JJ N
3.27 CD N
score NN N
before IN N
and CC N
3 CD N
months NNS N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
test NN N
group NN N
while IN N
it PRP N
was VBD N
15.92 CD N
+/- JJ N
7.51 CD N
score NN N
and CC N
12.73 CD N
+/- JJ N
6.12 CD N
score NN N
in IN N
the DT N
control NN N
group NN N
The DT N
Chinese JJ N
medicine NN N
syndrome JJ N
integral JJ N
after IN N
drug NN N
therapy NN N
was VBD N
lower JJR N
than IN N
that DT N
before IN N
drug NN N
therapy NN N
in IN N
the DT N
same JJ N
group NN N
Besides IN N
the DT N
integral JJ N
difference NN N
between IN N
before IN N
and CC N
after IN N
drug NN N
therapy NN N
was VBD N
higher RBR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
9.12 CD N
+/- JJ N
6.16 CD N
score NN N
vs NN N
3.48 CD N
+/- JJ N
2.06 CD N
score NN N
showing VBG N
statistical JJ N
difference NN N
P NNP N
0.05 CD N
After IN N
three-month JJ N
drug NN N
therapy NN N
the DT N
serum NN N
EMAb NNP N
negative JJ N
conversion NN N
rate NN N
was VBD N
obviously RB N
higher JJR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
44.44 CD N
vs JJ N
15.62 CD N
showing VBG N
statistical JJ N
difference NN N
P NNP N
0.05 CD N
The DT N
serum NN N
CA125 NNP N
level NN N
was VBD N
31.88 CD N
+/- JJ N
15.78 CD N
U/mL NNP N
before IN N
drug NN N
therapy NN N
and CC N
18.82 CD N
+/- JJ N
10.08 CD N
U/mL NNP N
three CD N
months NNS N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
test NN N
group NN N
while IN N
it PRP N
was VBD N
30.63 CD N
+/- JJ N
19.28 CD N
U/mL NN N
and CC N
18.05 CD N
+/- JJ N
11.20 CD N
U/mL NNP N
respectively RB N
in IN N
the DT N
control NN N
group NN N
It PRP N
was VBD N
lowered VBN N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
two CD N
groups NNS N
with IN N
statistical JJ N
difference NN N
P NNP N
0.05 CD N
There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
after IN N
drug NN N
therapy NN N
P NNP N
0.05 CD N
CONCLUSIONS VB N
The DT N
laparoscopic NN N
surgery NN N
in IN N
combination NN N
of IN N
QYJDR NNP N
could MD N
effectively RB N
improve VB N
clinical JJ N
symptoms NNS N
of IN N
EMs NNP N
patients NNS N
of IN N
blood NN N
stasis NN N
and CC N
toxin NN N
accumulation NN N
syndrome NN N
promote VBP N
negative JJ N
conversion NN N
of IN N
EMAb NNP N
lower JJR N
serum NN N
CA125 NNP N
levels NNS N
and CC N
elevate VB N
the DT N
clinical JJ N
pregnancy NN N
rate NN N
QYJDR NNP N
is VBZ N
an DT N
effective JJ N
formula NN N
in IN N
treatment NN N
of IN N
EMs-related JJ N
infertility NN N
-DOCSTART- -X- O O

The DT N
safety NN N
of IN N
whey JJ N
protein NN N
concentrate NN N
derived VBN N
from IN N
the DT N
milk NN N
of IN N
cows NNS N
immunized VBN N
against IN N
Clostridium NNP N
difficile NN N
A DT N
whey JJ N
protein NN N
concentrate NN N
prepared VBN N
from IN N
the DT N
milk NN N
of IN N
cows NNS N
that WDT N
have VBP N
been VBN N
immunized VBN N
against IN N
Clostridium NNP N
difficile NN N
C. NNP N
difficile NN N
and CC N
its PRP$ N
toxins NNS N
toxin NN N
A NNP N
and CC N
toxin NN N
B NNP N
is VBZ N
produced VBN N
for IN N
use NN N
as IN N
a DT N
medical JJ N
food NN N
for IN N
the DT N
dietary JJ N
management NN N
of IN N
patients NNS 4_p
with IN 4_p
C. NNP 4_p
difficile-associated JJ 4_p
diarrhea NN 4_p
CDAD NNP 4_p
to TO N
prevent VB N
a DT N
relapse NN N
of IN N
the DT N
infection NN N
The DT N
safety NN N
of IN N
anti-C. JJ N
difficile NN N
whey NN N
protein VBP N
concentrate NN N
anti-CD JJ N
WPC NNP N
is VBZ N
supported VBN N
by IN N
analytical JJ N
data NNS N
comparing VBG N
the DT N
composition NN N
of IN N
raw JJ N
milk NN N
from IN N
immunized JJ N
cows NNS N
versus VBP N
that IN N
from IN N
non-immunized JJ N
cows NNS N
and CC N
the DT N
composition NN N
of IN N
anti-CD JJ N
WPC NNP N
versus NN N
that IN N
of IN N
regular JJ N
whey NN N
protein NN N
concentrate NN N
Additionally RB N
a DT N
prospective JJ N
clinical JJ N
study NN N
was VBD N
conducted VBN N
in IN N
77 CD 3_p
patients NNS 4_p
with IN 4_p
CDAD NNP 4_p
to TO N
demonstrate VB N
the DT N
safety NN N
of IN N
consuming VBG N
anti-CD JJ N
WPC NNP N
to TO N
prevent VB N
relapse NN N
of IN N
the DT N
infection NN N
This DT N
study NN N
which WDT N
included VBD N
adverse JJ N
event NN N
monitoring NN N
physical JJ N
examinations NNS N
and CC N
extensive JJ N
hematological NN N
and CC N
biochemical JJ N
assessments NNS N
showed VBD N
that IN N
anti-CD JJ N
WPC NNP N
is VBZ N
safe JJ N
to TO N
consume VB N
by IN N
patients NNS 4_p
with IN 4_p
CDAD NNP 4_p
The DT N
available JJ N
analytical JJ N
and CC N
clinical JJ N
evidence NN N
demonstrate NN N
that IN N
anti-CD JJ N
WPC NNP N
is VBZ N
safe JJ N
for IN N
use NN N
by IN N
individuals NNS 4_p
with IN 4_p
CDAD NNP 4_p
under IN N
the DT N
described JJ N
conditions NNS N
of IN N
use NN N
-DOCSTART- -X- O O

Psychological JJ N
mediators NNS N
of IN N
bupropion NN N
sustained-release NN N
treatment NN N
for IN N
smoking VBG N
cessation NN N
AIM IN N
The DT N
study NN N
aimed VBN N
to TO N
test VB N
simultaneously RB N
our PRP$ N
understanding NN N
of IN N
the DT N
effects NNS N
of IN N
bupropion NN N
sustained-release NN N
SR NNP N
treatment NN N
on IN N
putative JJ N
mediators NNS N
and CC N
our PRP$ N
understanding NN N
of IN N
determinants NNS N
of IN N
post-quit NN N
abstinence NN N
including VBG N
withdrawal NN N
distress NN N
cigarette NN N
craving NN N
positive JJ N
affect NN N
and CC N
subjective JJ N
reactions NNS N
to TO N
cigarettes NNS N
smoked VBN N
during IN N
a DT N
lapse NN N
The DT N
specificity NN N
of IN N
bupropion NN N
SR NNP N
effects NNS N
was VBD N
also RB N
tested VBN N
in IN N
exploratory JJ N
analyses NNS N
DESIGN NNP N
Data NNP N
from IN N
a DT N
randomized VBN N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
bupropion NN N
SR NNP N
were VBD N
submitted VBN N
to TO N
mediation NN N
analyses NNS N
SETTING NN N
Center NNP N
for IN N
Tobacco NNP N
Research NNP N
and CC N
Intervention NNP N
Madison NNP 4_p
WI NNP 4_p
USA NNP 4_p
PARTICIPANTS VB N
A DT N
total NN N
of IN N
403 CD 3_p
adult NN 4_p
daily JJ 4_p
smokers NNS 4_p
without IN 4_p
contraindications NNS 4_p
to TO 4_p
bupropion VB 4_p
SR NNP 4_p
use NN 4_p
INTERVENTION NN N
Participants NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
a DT N
9-week JJ N
course NN N
of IN N
bupropion NN N
SR NNP N
or CC N
placebo NN N
pill NN N
and CC N
to TO N
receive VB N
eight CD N
brief JJ N
individual JJ N
counseling NN N
sessions NNS N
or CC N
no DT N
counseling NN N
MEASUREMENTS NNP N
Ecological NNP N
momentary JJ N
assessment NN N
ratings NNS N
of IN N
smoking VBG N
behavior NN N
and CC N
putative JJ N
mediators NNS N
were VBD N
collected VBN N
pre- JJ N
and CC N
post-quit NN N
FINDINGS NNP N
Results NNP N
of IN N
structural JJ N
equation NN N
and CC N
hierarchical JJ N
linear JJ N
models NNS N
did VBD N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
bupropion NN N
SR NNP N
treatment NN N
improves VBZ N
short-term JJ N
abstinence NN N
by IN N
reducing VBG N
withdrawal NN N
distress NN N
or CC N
affecting VBG N
the DT N
subjective JJ N
effects NNS N
of IN N
a DT N
lapse NN N
cigarette NN N
but CC N
provided VBD N
partial JJ N
support NN N
for IN N
mediation NN N
by IN N
cigarette NN N
craving VBG N
reduction NN N
and CC N
enhanced VBD N
positive JJ N
affect NN N
Bupropion NNP N
SR NNP N
effects NNS N
on IN N
point-prevalence NN N
abstinence NN N
at IN N
1 CD N
month NN N
post-quit NN N
were VBD N
also RB N
mediated VBN N
partially RB N
by IN N
enhanced JJ N
motivation NN N
to TO N
quit VB N
and CC N
self-efficacy NN N
CONCLUSIONS NNP N
Results NNP N
provided VBD N
some DT N
support NN N
for IN N
models NNS N
of IN N
bupropion NN N
SR NNP N
treatment NN N
and CC N
relapse NN N
and CC N
suggested VBD N
that IN N
motivational JJ N
processes NNS N
may MD N
partially RB N
account VB N
for IN N
bupropion NN N
SR NNP N
efficacy NN N
-DOCSTART- -X- O O

Development NNP N
of IN N
renal JJ N
disease NN N
in IN N
people NNS 4_p
at IN 4_p
high JJ 4_p
cardiovascular JJ 4_p
risk NN 4_p
results NNS N
of IN N
the DT N
HOPE NNP N
randomized VBD N
study NN N
In IN N
people NNS 4_p
with IN 4_p
diabetes NNS 4_p
renal JJ N
disease NN N
tends VBZ N
to TO N
progress VB N
from IN N
microalbuminuria NN N
to TO N
clinical JJ N
proteinuria NN N
to TO N
renal JJ N
insufficiency NN N
Little JJ N
evidence NN N
has VBZ N
been VBN N
published VBN N
for IN N
the DT N
nondiabetic JJ N
population NN N
This DT N
study NN N
retrospectively RB N
analyzed VBD N
changes NNS N
of IN N
proteinuria NN N
over IN N
4.5 CD N
yr NNS N
in IN N
the DT N
HOPE NNP N
Heart NNP N
Outcomes NNP N
and CC N
Prevention NNP N
Evaluation NNP N
study NN N
which WDT N
compared VBN N
ramipril NN N
's POS N
effects NNS N
to TO N
placebo VB N
in IN N
9297 CD N
participants NNS N
including VBG N
3577 CD N
with IN N
diabetes NNS N
and CC N
1956 CD N
with IN N
microalbuminuria NN N
This DT N
report NN N
is VBZ N
restricted VBN N
to TO N
7674 CD 3_p
participants NNS 4_p
with IN 4_p
albuminuria NNS 4_p
data NNS 4_p
at IN 4_p
baseline NN 4_p
and CC 4_p
at IN 4_p
follow-up JJ 4_p
Inclusion NN N
criteria NNS N
were VBD N
known VBN N
vascular JJ N
disease NN N
or CC N
diabetes VBZ N
plus CC N
one CD N
other JJ N
cardiovascular JJ N
risk NN N
factor NN N
exclusion NN N
criteria NNS N
included VBD N
heart NN N
failure NN N
or CC N
known VBN N
impaired JJ N
left VBD N
ventricular JJ N
function NN N
dipstick-positive JJ N
proteinuria NN N
1+ CD N
and CC N
serum JJ N
creatinine NN N
2.3 CD N
mg/dl NN N
200 CD N
microM NN N
Baseline NNP N
microalbuminuria NN N
predicted VBD N
subsequent JJ N
clinical JJ N
proteinuria NN N
for IN N
the DT N
study NN N
participants NNS N
overall JJ N
adjusted VBN N
odds NNS N
ratio VBP N
OR NNP N
17.5 CD N
95 CD N
confidence NN N
interval NN N
CI NNP N
12.6 CD N
to TO N
24.4 CD N
in IN N
participants NNS N
without IN N
diabetes NNS N
OR NNP N
16.7 CD N
95 CD N
CI NNP N
8.6 CD N
to TO N
32.4 CD N
and CC N
in IN N
participants NNS N
with IN N
diabetes NNS N
OR NNP N
18.2 CD N
95 CD N
CI NNP N
12.4 CD N
to TO N
26.7 CD N
Any DT N
progression NN N
of IN N
albuminuria NNS N
defined VBN N
as IN N
new JJ N
microalbuminuria NNS N
or CC N
new JJ N
clinical JJ N
proteinuria NN N
occurred VBD N
in IN N
1859 CD N
participants NNS N
1542 CD N
developed VBD N
new JJ N
microalbuminuria NNS N
and CC N
317 CD N
participants NNS N
developed VBD N
clinical JJ N
proteinuria NN N
Ramipril NNP N
reduced VBD N
the DT N
risk NN N
for IN N
any DT N
progression NN N
OR NNP N
0.87 CD N
95 CD N
CI NNP N
0.78 CD N
to TO N
0.97 CD N
P NNP N
0.0146 CD N
People NNS N
without IN N
and CC N
with IN N
diabetes NNS N
who WP N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
cardiovascular JJ N
disease NN N
are VBP N
also RB N
at IN N
risk NN N
for IN N
a DT N
progressive JJ N
rise NN N
in IN N
albuminuria NN N
Microalbuminuria NNP N
itself PRP N
predicts VBZ N
clinical JJ N
proteinuria NNS N
in IN N
nondiabetic JJ 4_p
and CC 4_p
in IN 4_p
diabetic JJ 4_p
people NNS 4_p
Ramipril JJ N
prevents NNS N
or CC N
delays VBZ N
the DT N
progression NN N
of IN N
albuminuria NN N
-DOCSTART- -X- O O

Antazoline/tetryzoline NNP N
eyedrops NNS N
in IN N
comparison NN N
with IN N
levocabastine JJ N
eyedrops NNS N
in IN N
acute JJ 4_p
allergic JJ 4_p
conjunctivitis NN 4_p
BACKGROUND NNP N
Allergic NNP N
conjunctivitis NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
frequent JJ N
allergic JJ N
diseases NNS N
of IN N
the DT N
anterior JJ N
eye NN N
segment NN N
METHODS NNP N
This DT N
multicentre NN N
clinical JJ N
trial NN N
was VBD N
an DT N
investigation NN N
to TO N
compare VB N
the DT N
antiallergic JJ N
efficacy NN N
local JJ N
tolerance NN N
and CC N
safety NN N
of IN N
Antazolin/Tetryzolin NNP N
eye NN N
drops NNS N
and CC N
Levocabastine NNP N
eye NN N
drops NNS N
69 CD 3_p
patients NNS 3_p
were VBD N
treated VBN N
over IN N
a DT N
2 CD N
weeks NNS N
course NN N
of IN N
therapy NN N
The DT N
subjective JJ N
and CC N
objective JJ N
ocular NN N
symptoms NNS N
were VBD N
documented VBN N
over IN N
the DT N
treatment NN N
period NN N
RESULTS NNP N
Both NNP N
eye NN N
drops NNS N
reduced VBD N
subjective JJ N
and CC N
objective JJ N
ocular NN N
symptoms NNS N
effective JJ N
The DT N
difference NN N
between IN N
the DT N
treatments NNS N
p JJ N
0.0395 CD N
was VBD N
the DT N
faster JJ N
onset NN N
of IN N
action NN N
of IN N
Antazolin/Tetryzolin NNP N
30 CD N
minutes NNS N
after IN N
administration NN N
of IN N
the DT N
first JJ N
drop NN N
of IN N
trial NN N
medication NN N
CONCLUSION VB N
A DT N
fast JJ N
and CC N
effective JJ N
onset NN N
of IN N
action NN N
is VBZ N
of IN N
high JJ N
clinical JJ N
relevance NN N
Therefore IN N
the DT N
benefits NNS N
of IN N
using VBG N
Antazolin/Tetryzolin NNP N
eye NN N
drops NN N
was VBD N
clearly RB N
outweigh JJ N
-DOCSTART- -X- O O

Subjective JJ N
and CC N
objective JJ N
levels NNS N
of IN N
physical JJ N
activity NN N
and CC N
their PRP$ N
association NN N
with IN N
cardiorespiratory NN N
fitness NN N
in IN N
rheumatoid JJ 4_p
arthritis NN 4_p
patients NNS 4_p
INTRODUCTION NNP N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were VBD N
a DT N
to TO N
examine VB N
the DT N
agreement NN N
between IN N
subjective JJ N
assessed JJ N
via IN N
the DT N
International NNP N
Physical NNP N
Activity NNP N
Questionnaire NNP N
IPAQ NNP N
and CC N
objective JJ N
accelerometry NN N
GT3X NNP N
physical JJ N
activity NN N
PA NNP N
levels NNS N
in IN N
patients NNS 4_p
with IN 4_p
rheumatoid JJ 4_p
arthritis NN 4_p
RA NNP 4_p
and CC N
b NN N
to TO N
evaluate VB N
the DT N
associations NNS N
of IN N
RA NNP N
patients NNS N
subjective JJ N
and CC N
objective JJ N
PA NNP N
to TO N
their PRP$ N
scores NNS N
on IN N
the DT N
maximal JJ N
oxygen NN N
uptake JJ N
test NN N
VO2max NNP N
METHODS PDT N
The DT N
participants NNS N
wore VBD N
the DT N
GT3X NNP N
for IN N
seven CD N
days NNS N
before IN N
completing VBG N
the DT N
IPAQ NNP N
and CC N
VO2max NNP N
test NN N
The DT N
Bland-Altman NNP N
plot NN N
was VBD N
used VBN N
to TO N
illustrate VB N
the DT N
agreement NN N
between IN N
the DT N
objective NN N
and CC N
subjective JJ N
PA NNP N
data NN N
and CC N
the DT N
Wilcoxon NNP N
test NN N
was VBD N
employed VBN N
to TO N
examine VB N
the DT N
differences NNS N
The DT N
association NN N
between IN N
the DT N
PA NNP N
measurement NN N
and CC N
VO2max NNP N
test NN N
was VBD N
examined VBN N
via IN N
the DT N
correlations NNS N
and CC N
the DT N
magnitude NN N
was VBD N
presented VBN N
by IN N
the DT N
Steiger NNP N
's POS N
Z NNP N
value NN N
RESULTS NNP N
Sixty-eight JJ 3_p
RA NNP 4_p
patients NNS N
age=55±13 JJ 1_p
years NNS 1_p
body NN N
mass NN N
index NN N
27.8±5.4 CD N
kg/m2 NN N
median NN N
of IN N
disease NN N
duration=5 NN N
2-8 JJ N
yrs NN N
were VBD N
recruited VBN N
Smaller NNP N
differences NNS N
between IN N
the DT N
subjective JJ N
and CC N
objective JJ N
measures NNS N
were VBD N
found VBN N
when WRB N
PA NNP N
was VBD N
assessed VBN N
at IN N
the DT N
moderate JJ N
level NN N
Wilcoxon NNP N
tests NNS N
revealed VBD N
that IN N
patients NNS N
reported VBD N
less JJR N
time NN N
spent VBN N
engaged VBN N
in IN N
sedentary JJ N
behaviours NNS N
Z=-6.80 NNP N
P NNP N
0.01 CD N
and CC N
light JJ N
PA NNP N
Z=-6.89 NNP N
P NNP N
0.01 CD N
and CC N
more JJR N
moderate JJ N
PA NNP N
Z=-6.26 NNP N
P NNP N
0.01 CD N
than IN N
was VBD N
objectively RB N
indicated VBN N
Significant NNP N
positive JJ N
correlations NNS N
were VBD N
revealed VBN N
between IN N
VO2max NNP N
with IN N
all DT N
PA NNP N
levels NNS N
derived VBN N
from IN N
accelerometry NN N
light JJ N
PA NNP N
rho=.35 NN N
P NNP N
.01 NNP N
moderate JJ N
PA NNP N
rho=.34 NN N
P=.01 NNP N
moderate JJ N
and CC N
vigorous JJ N
PA NNP N
MVPA NNP N
rho=.33 NN N
P=.01 NNP N
and CC N
a DT N
negative JJ N
association NN N
to TO N
sedentary JJ N
time NN N
ST NNP N
emerged VBD N
rho=-.27 JJ N
P=.04 NNP N
IPAQ-reported JJ N
moderate JJ N
PA NNP N
and CC N
MVPA NNP N
positively RB N
correlated VBD N
with IN N
maxV02 NN N
rho=.25 NN N
P=.01 NNP N
rho=.27 NN N
P=.01 NNP N
respectively RB N
Differences NNS N
between IN N
the DT N
magnitude NN N
of IN N
correlations NNS N
between IN N
the DT N
IPAQ-VO2 NNP N
max NN N
and CC N
GT3X-VO2 NNP N
max NN N
were VBD N
only RB N
significant JJ N
for IN N
ST NNP N
Z=3.43 NNP N
P NNP N
.01 NNP N
CONCLUSIONS NNP N
Via NNP N
responses VBZ N
to TO N
the DT N
IPAQ NNP N
RA NNP N
patients NNS N
reported VBD N
that IN N
they PRP N
were VBD N
less JJR N
sedentary JJ N
and CC N
engaged VBN N
in IN N
more RBR N
higher JJR N
intensity NN N
PA NNP N
than IN N
what WP N
was VBD N
objectively RB N
assessed VBN N
Accelerometry NNP N
data NNS N
correlated VBD N
with IN N
VO2max NNP N
at IN N
all DT N
PA NNP N
levels NNS N
Only RB N
subjective JJ N
moderate NN N
and CC N
MPVA NNP N
correlated VBD N
with IN N
VO2max NNP N
Findings NNS N
suggest VBP N
that IN N
self-reported JJ N
PA NNP N
and CC N
ST NNP N
should MD N
be VB N
interpreted VBN N
with IN N
caution NN N
in IN N
people NNS N
with IN N
RA NNP N
and CC N
complemented VBN N
with IN N
accelerometry NN N
when WRB N
possible JJ N
TRIAL NNP N
REGISTRATION NNP N
Trial NNP N
registration NN N
ClinicalTrials.gov NNP N
ISRCTN04121489 NNP N
Registered VBD N
5 CD N
September NNP N
2012 CD N
-DOCSTART- -X- O O

Chronic NNP N
vasodilator NN N
therapy NN N
with IN N
flosequinan NN N
in IN N
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
long-term JJ N
effect NN N
of IN N
flosequinan NN N
a DT N
new JJ N
orally RB N
administered VBN N
arterial JJ N
and CC N
venous JJ N
dilator NN N
on IN N
the DT N
clinical JJ N
course NN N
of IN N
patients NNS 4_p
with IN 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
Seventeen JJ 3_p
patients NNS 4_p
on IN 4_p
chronic JJ 4_p
digitalis NN 4_p
and CC 4_p
diuretic JJ 4_p
therapy NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
flosequinan NN N
n JJ N
9 CD N
or CC N
placebo NN N
n JJ N
8 CD N
in IN N
a DT N
double-blind JJ N
fashion NN N
Changes NNS N
in IN N
symptomatology NN N
exercise NN N
performance NN N
and CC N
left VBD N
ventricular JJ N
function NN N
were VBD N
assessed VBN N
serially RB N
during IN N
the DT N
two-month JJ N
treatment NN N
period NN N
During IN N
the DT N
course NN N
of IN N
therapy NN N
a DT N
modest JJ N
improvement NN N
in IN N
the DT N
symptom NN N
scores NNS N
and CC N
functional JJ N
classification NN N
of IN N
the DT N
flosequinan-treated JJ N
patients NNS N
was VBD N
observed VBN N
Flosequinan NNP N
evoked VBD N
a DT N
significant JJ N
increase NN N
in IN N
maximal JJ N
exercise NN N
capacity NN N
While IN N
long-term JJ N
flosequinan JJ N
administration NN N
also RB N
effected VBD N
a DT N
progressive JJ N
increase NN N
in IN N
resting VBG N
heart NN N
rate NN N
it PRP N
did VBD N
not RB N
consistently RB N
improve VB N
indices NNS N
of IN N
left JJ N
ventricular JJ N
systolic JJ N
function NN N
The DT N
addition NN N
of IN N
chronic JJ N
vasodilator NN N
therapy NN N
with IN N
flosequinan NN N
to TO N
standard VB N
digitalis-diuretic JJ N
regimens NNS N
is VBZ N
capable JJ N
of IN N
inducing VBG N
clinical JJ N
improvement NN N
in IN N
patients NNS 4_p
with IN 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
Trials NNS N
involving VBG N
larger JJR N
patient JJ N
populations NNS N
will MD N
be VB N
necessary JJ N
to TO N
confirm VB N
the DT N
results NNS N
of IN N
this DT N
preliminary JJ N
study NN N
and CC N
to TO N
determine VB N
the DT N
extent NN N
of IN N
clinical JJ N
improvement NN N
subpopulations NNS N
benefited VBD N
role NN N
in IN N
heart NN N
failure NN N
therapeutics NNS N
and CC N
so RB N
forth JJ N
-DOCSTART- -X- O O

Long-term JJ N
survival NN N
in IN N
a DT N
phase NN N
III NNP N
randomised VBD N
study NN N
of IN N
topotecan JJ N
versus NN N
paclitaxel NN N
in IN N
advanced JJ 4_p
epithelial JJ 4_p
ovarian JJ 4_p
carcinoma NN 4_p
BACKGROUND IN N
We PRP N
have VBP N
continued VBN N
to TO N
monitor VB N
the DT N
survival NN N
of IN N
patients NNS N
randomised VBN N
in IN N
a DT N
previously RB N
reported VBN N
multicentre JJ N
phase NN N
III NNP N
study NN N
of IN N
topotecan JJ N
versus NN N
paclitaxel NN N
in IN N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
epithelial JJ 4_p
ovarian JJ 4_p
cancer NN 4_p
who WP 4_p
had VBD 4_p
failed VBN 4_p
one CD 4_p
prior JJ 4_p
platinum-based JJ 4_p
regimen NNS 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS 4_p
with IN 4_p
bidimensionally RB 4_p
measurable JJ 4_p
disease NN 4_p
were VBD N
randomised VBN N
to TO N
topotecan VB N
1.5 CD N
mg/m NN N
2 CD N
/day NN N
for IN N
5 CD N
days NNS N
or CC N
paclitaxel NN N
175 CD N
mg/m NN N
2 CD N
/day NN N
as IN N
a DT N
3-h JJ N
infusion NN N
every DT N
21 CD N
days NNS N
Patients NNS N
were VBD N
eligible JJ N
for IN N
treatment NN N
with IN N
the DT N
alternate NN N
therapy NN N
at IN N
third JJ N
line NN N
The DT N
European JJ N
Organisation NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
Quality NNP N
of IN N
Life NNP N
EORTC NNP N
QOL NNP N
-C30 VBP N
questionnaire NN N
was VBD N
also RB N
used VBN N
to TO N
measure VB N
eight CD N
symptoms NNS N
at IN N
baseline NN N
and CC N
during IN N
each DT N
course NN N
pain NN N
anorexia NN N
diarrhoea NN N
fatigue NN N
nausea NN N
and CC N
vomiting NN N
dyspnea NN N
constipation NN N
and CC N
insomnia NN N
RESULTS VB N
A DT N
total NN N
of IN N
226 CD 3_p
patients NNS N
were VBD N
evaluable JJ N
for IN N
response NN N
Demographic JJ N
characteristics NNS N
were VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
as IN N
were VBD N
results NNS N
of IN N
the DT N
EORTC NNP N
QOL-30 NNP N
questionnaire NN N
For IN N
the DT N
topotecan JJ N
group NN N
median JJ N
time NN N
to TO N
progression NN N
was VBD N
18.9 CD N
weeks NNS N
range NN N
1 CD N
to TO N
92.6+ CD N
weeks NNS N
25 CD N
censored VBN N
and CC N
for IN N
paclitaxel NN N
14.7 CD N
weeks NNS N
range NN N
1 CD N
to TO N
137.3+ CD N
weeks NNS N
12.3 CD N
censored VBN N
P NNP N
0.076 CD N
At IN N
4 CD N
years NNS N
post-randomisation NN N
median JJ N
survival NN N
in IN N
the DT N
topotecan JJ N
group NN N
was VBD N
63.0 CD N
weeks NNS N
range NN N
1 CD N
to TO N
238.4+ CD N
weeks NNS N
20.5 CD N
censored VBN N
and CC N
for IN N
paclitaxel NN N
53.0 CD N
weeks NNS N
range NN N
1 CD N
to TO N
226.3+ CD N
weeks NNS N
12.3 CD N
censored VBN N
P NNP N
0.44 CD N
CONCLUSION NNP N
Topotecan NNP N
continues VBZ N
to TO N
demonstrate VB N
comparable JJ N
efficacy NN N
and CC N
survival NN N
to TO N
paclitaxel VB N
with IN N
manageable JJ N
and CC N
non-cumulative JJ N
haematological JJ N
toxicity NN N
Non-haematological JJ N
toxicity NN N
was VBD N
generally RB N
mild VBN N
for IN N
both DT N
groups NNS N
The DT N
long-term JJ N
survival NN N
rate NN N
indicates VBZ N
substantial JJ N
therapeutic JJ N
benefit NN N
for IN N
this DT N
group NN N
of IN N
patients NNS N
receiving VBG N
topotecan JJ N
at IN N
relapse NN N
of IN N
ovarian JJ 4_p
cancer NN 4_p
-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
continuous JJ N
femoral JJ N
nerve NN N
block NN N
CFNB NNP N
and CC N
continuous JJ N
epidural JJ N
infusion NN N
CEI NNP N
in IN N
postoperative JJ N
analgesia NN N
and CC N
knee NN N
rehabilitation NN N
after IN N
total JJ 4_p
knee NN 4_p
arthroplasty NN 4_p
TKA NNP 4_p
BACKGROUND NNP N
Postoperative NNP N
epidural JJ N
analgesia NN N
EA NNP N
and CC N
femoral JJ N
nerve NN N
block NN N
FNB NNP N
provided VBD N
effective JJ N
pain NN N
relief NN N
However RB N
EA NNP N
has VBZ N
common JJ N
side NN N
effects NNS N
such JJ N
as IN N
nausea NN N
vomiting VBG N
pruritus NN N
dizziness NN N
and CC N
hypotension NN N
Some DT N
investigations NNS N
found VBD N
that IN N
those DT N
side JJ N
effects NNS N
were VBD N
less RBR N
in IN N
FNB NNP N
than IN N
in IN N
EA NNP N
However RB N
the DT N
analgesic JJ N
equivalent NN N
of IN N
both DT N
techniques NNS N
have VBP N
not RB N
been VBN N
confirmed VBN N
OBJECTIVE IN N
The DT N
authors NNS N
compared VBN N
continuous JJ N
epidural JJ N
infusion NN N
CEI NNP N
with IN N
continuous JJ N
femoral JJ N
nerve NN N
block NN N
CFNB NNP N
regarding VBG N
the DT N
postoperative JJ N
analgesic JJ N
efficacy NN N
side NN N
effects NNS N
postoperative JJ N
knee NN N
rehabilitation NN N
and CC N
hospital JJ N
length NN N
of IN N
stay NN N
LOS NNP N
MATERIAL NNP N
AND NNP N
METHOD NNP N
In IN N
this DT N
prospective JJ N
randomized VBN N
controlled VBD N
study NN N
61 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I-III NNP 4_p
patients NNS 4_p
scheduled VBN 4_p
for IN 4_p
elective JJ 4_p
unilateral JJ 4_p
total NN 4_p
knee NN 4_p
arthroplasty NN 4_p
TKA NNP 4_p
under IN 4_p
spinal JJ 4_p
anesthesia NN 4_p
SA NNP 4_p
participated VBD N
The DT N
patients NNS N
were VBD N
allocated VBN N
into IN N
two CD N
groups NNS N
In IN N
the DT N
ward NN N
patients NNS N
in IN N
Group NNP N
I PRP N
CEI NNP N
were VBD N
maintained VBN N
by IN N
continuous JJ N
infusion NN N
of IN N
0.125 CD N
levobupivacaine NN N
with IN N
morphine JJ N
0.0125 CD N
mg/ml NN N
4 CD N
ml/hr NN N
Group NNP N
II NNP N
CFNB NNP N
were VBD N
maintained VBN N
by IN N
0.125 CD N
levobupivacaine NN N
8 CD N
ml/hr NN N
RESULTS JJ N
Patients NNPS N
in IN N
the DT N
CFNB NNP N
group NN N
the DT N
VAS NNP N
scores NNS N
at IN N
PO6-12 NNP N
hr NN N
and CC N
tramadol NN N
IV NNP N
requirement NN N
were VBD N
significantly RB N
greater JJR N
than IN N
the DT N
CEI NNP N
group NN N
VAS NNP N
PO6 NNP N
hr VBD N
p-value JJ N
0.001 CD N
PO12 NNP N
hr VBD N
p-value JJ N
0.004 CD N
Patients NNS N
in IN N
the DT N
CEI NNP N
group NN N
experienced VBD N
dizziness NN N
pruritus NN N
and CC N
PONV NNP N
more JJR N
than IN N
the DT N
CFNB NNP N
group NN N
significantly RB N
Patient JJ N
satisfaction NN N
was VBD N
greater JJR N
with IN N
the DT N
CFNB NNP N
group NN N
although IN N
postoperative JJ N
knee NN N
rehabilitation NN N
and CC N
the DT N
hospital NN N
LOS NNP N
were VBD N
not RB N
different JJ N
CONCLUSION NNP N
CFNB NNP N
represents VBZ N
the DT N
optimal JJ N
analgesia NN N
with IN N
fewer JJR N
side NN N
effects NNS N
and CC N
greater JJR N
patient NN N
satisfaction NN N
The DT N
rehabilitation NN N
indices NNS N
and CC N
duration NN N
of IN N
hospital NN N
stay NN N
are VBP N
comparable JJ N
in IN N
both DT N
groups NNS N
-DOCSTART- -X- O O

Clinical JJ N
effects NNS N
of IN N
root NN N
instrumentation NN N
using VBG N
conventional JJ N
steel NN N
or CC N
non-tooth JJ N
substance NN N
removing VBG N
plastic NN N
curettes NNS N
during IN N
supportive JJ N
periodontal JJ N
therapy NN N
SPT NNP N
Although IN N
root NN N
instrumentation NN N
has VBZ N
been VBN N
accepted VBN N
as IN N
the DT N
most RBS N
important JJ N
cause-related JJ N
treatment NN N
of IN N
periodontal JJ N
diseases NNS N
repeated VBD N
scaling NN N
and CC N
root NN N
planing NN N
may MD N
over VB N
time NN N
result NN N
in IN N
substantive JJ N
loss NN N
of IN N
tooth JJ N
substance NN N
and CC N
increased JJ N
sensitivity NN N
of IN N
the DT N
teeth NN N
In IN N
an DT N
effort NN N
to TO N
minimize VB N
these DT N
side JJ N
effects NNS N
of IN N
therapy NN N
non-root JJ N
substance NN N
removing VBG N
curettes NNS N
have VBP N
been VBN N
developed VBN N
However RB N
the DT N
clinical JJ N
effects NNS N
of IN N
such JJ N
plastic NN N
curettes NNS N
with IN N
regard NN N
to TO N
the DT N
control NN N
of IN N
the DT N
periodontal JJ N
infection NN N
has VBZ N
not RB N
yet RB N
been VBN N
established VBN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
therefore RB N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
root NN N
instrumentation NN N
using VBG N
plastic NN N
curettes NNS N
Universal NNP N
Perio NNP N
Soft NNP N
Scaler NNP N
Hawe-Neos NNP N
Dental NNP N
Bioggio NNP N
TI NNP N
Switzerland NNP N
versus VBP N
conventional JJ N
steel NN N
curettes NNS N
on IN N
the DT N
periodontal JJ N
conditions NNS N
during IN N
supportive JJ N
periodontal JJ N
therapy NN N
40 CD 3_p
subjects NNS 3_p
participated VBN N
in IN N
this DT N
parallel NN N
randomized VBN N
double JJ N
blind NN N
prospective JJ N
longitudinal JJ N
clinical JJ N
study NN N
following VBG N
active JJ N
peridontal JJ N
therapy NN N
20 CD 3_p
subjects NNS N
served VBD N
as IN N
a DT N
control NN N
group NN N
and CC N
were VBD N
treated VBN N
with IN N
conventional JJ N
steel NN N
curettes NNS N
during IN N
a DT N
supportive JJ N
periodontal NN N
care NN N
visit NN N
SPT NNP N
The DT N
other JJ N
20 CD 3_p
subjects NNS N
the DT N
experimental JJ N
group NN N
were VBD N
treated VBN N
using VBG N
plastic NN N
curettes NNS N
during IN N
a DT N
similar JJ N
SPT NNP N
visit NN N
Clinical JJ N
parameters NNS N
such JJ N
as IN N
bleeding VBG N
on IN N
probing VBG N
BOP NNP N
and CC N
probing VBG N
pocket NN N
depth NN N
PPD NNP N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
3-6 JJ N
months NNS N
later RB N
at IN N
the DT N
next JJ N
regular JJ N
SPT NNP N
visit NN N
In IN N
addition NN N
the DT N
BOP NNP N
percentage NN N
was VBD N
determined VBN N
10 CD N
days NNS N
following VBG N
baseline NN N
The DT N
results NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
treatment NN N
modalities NNS N
regarding VBG N
BOP NNP N
and CC N
PPD NNP N
at IN N
any DT N
observation NN N
time NN N
Both DT N
treatments NNS N
were VBD N
effective JJ N
in IN N
reducing VBG N
the DT N
BOP NNP N
percentage NN N
which WDT N
ranged VBD N
from IN N
17-42 CD N
at IN N
baseline NN N
by IN N
about IN N
40 CD N
after IN N
10 CD N
days NNS N
mean JJ N
BOP NNP N
baseline NN N
26 CD N
mean JJ N
BOP NNP N
after IN N
10 CD N
days NNS N
16 CD N
This DT N
clinical JJ N
study NN N
suggests VBZ N
that IN N
non-root JJ N
substance NN N
removing VBG N
curettes NNS N
may MD N
be VB N
valuable JJ N
instruments NNS N
for IN N
periodontally RB N
treated JJ N
patients NNS N
during IN N
maintenance NN N
care NN N
thus RB N
minimizing VBG N
trauma NN N
on IN N
the DT N
hard JJ N
structures NNS N
of IN N
the DT N
teeth NN N
-DOCSTART- -X- O O

Quality NN N
of IN N
individual JJ N
INR NNP N
control NN N
and CC N
the DT N
risk NN N
of IN N
stroke NN N
and CC N
bleeding VBG N
events NNS N
in IN N
atrial JJ 4_p
fibrillation NN 4_p
patients NNS 4_p
a DT N
nested JJ N
case NN N
control NN N
analysis NN N
of IN N
the DT N
ACTIVE NNP N
W NNP N
study NN N
INTRODUCTION NNP N
Time NNP N
in IN N
therapeutic JJ N
range NN N
TTR NNP N
for IN N
international JJ N
normalized JJ N
ratio NN N
INR NNP N
is VBZ N
an DT N
accepted JJ N
quality NN N
measure NN N
of IN N
anticoagulation NN N
control NN N
in IN N
patient JJ N
populations NNS N
but CC N
its PRP$ N
usefulness NN N
for IN N
predicting VBG N
stroke NN N
and CC N
bleeding NN N
in IN N
individuals NNS N
is VBZ N
not RB N
well RB N
understood RB N
MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
nested JJ N
case NN N
control NN N
analysis NN N
among IN N
ACTIVE NNP 4_p
W NNP 4_p
study NN 4_p
patients NNS 4_p
cases NNS 4_p
with IN 4_p
stroke NN 4_p
and CC 4_p
cases NNS 4_p
with IN 4_p
bleeding NN 4_p
were VBD 4_p
separately RB 4_p
matched VBN 4_p
with IN 4_p
controls NNS 4_p
Several JJ N
anticoagulation NN N
quality NN N
measures NNS N
were VBD N
compared VBN N
overall JJ N
and CC N
in IN N
a DT N
time-dependent JJ N
manner NN N
RESULTS CC N
32 CD 3_p
cases NNS 4_p
with IN 4_p
ischemic JJ 4_p
stroke NN 4_p
and CC N
234 CD 3_p
cases NNS 4_p
with IN 4_p
bleeding NN 4_p
in IN N
the DT N
analysis NN N
were VBD N
matched VBN N
in IN N
a DT N
4:1 CD N
ratio NN N
to TO N
122 CD N
and CC N
865 CD N
controls NNS N
respectively RB N
Follow-up JJ N
duration NN N
was VBD N
257±154days CD N
for IN N
the DT N
stroke NN N
analysis NN N
and CC N
222±146days CD N
for IN N
the DT N
bleeding NN N
analysis NN N
Compared VBN N
with IN N
their PRP$ N
respective NN N
controls NNS N
the DT N
study NN N
mean JJ N
TTR NNP N
of IN N
both DT N
stroke NN N
cases NNS N
53.9 CD N
±25.1 NNP N
vs VBZ N
63.4 CD N
±24.8 NN N
p=0.055 CC N
and CC N
bleeding VBG N
cases NNS N
56.2 CD N
±25.4 NNP N
vs VBZ N
63.4 CD N
±26.8 NN N
p CC N
0.001 CD N
was VBD N
lower JJR N
Time NNP N
below IN N
range NN N
for IN N
stroke NN N
and CC N
time NN N
above IN N
range NN N
for IN N
bleeding VBG N
were VBD N
only RB N
greater JJR N
in IN N
the DT N
last JJ N
month NN N
leading VBG N
up RP N
to TO N
the DT N
event NN N
not RB N
over IN N
the DT N
entire JJ N
study NN N
period NN N
Rather CC N
over IN N
the DT N
entire JJ N
study NN N
period NN N
bleeding VBG N
cases NNS N
spent VBD N
more JJR N
time NN N
below IN N
range NN N
than IN N
controls NNS N
26.8 CD N
±25.9 NNP N
vs VBZ N
20.8 CD N
±24.0 NN N
p=0.001 NN N
CONCLUSIONS NNP N
TTR NNP N
was VBD N
lower JJR N
in IN N
individual JJ N
AF NNP N
patients NNS N
with IN N
stroke NN N
or CC N
bleeding NN N
compared VBN N
with IN N
matched JJ N
controls NNS N
in IN N
ACTIVE NNP N
W. NNP N
Maintaining VBG N
a DT N
high JJ N
TTR NNP N
with IN N
equal JJ N
importance NN N
to TO N
avoid VB N
low JJ N
and CC N
high JJ N
INRs NNP N
is VBZ N
a DT N
relevant JJ N
goal NN N
of IN N
individual JJ N
patient NN N
treatment NN N
to TO N
prevent VB N
stroke NN N
and CC N
bleeding NN N
-DOCSTART- -X- O O

The DT N
prophylactic JJ N
effect NN N
of IN N
itraconazole JJ N
capsules NNS N
and CC N
fluconazole JJ N
capsules NNS N
for IN N
systemic JJ N
fungal JJ N
infections NNS N
in IN N
patients NNS 4_p
with IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
and CC 4_p
myelodysplastic JJ 4_p
syndromes NNS 4_p
a DT N
Japanese JJ 4_p
multicenter NN N
randomized VBN N
controlled VBN N
study NN N
We PRP N
performed VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
comparing VBG N
the DT N
prophylactic JJ N
effects NNS N
of IN N
capsule NN N
forms NNS N
of IN N
fluconazole NN N
n JJ N
110 CD N
and CC N
itraconazole JJ N
n JJ N
108 CD N
in IN N
patients NNS 4_p
with IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
AML NNP 4_p
or CC 4_p
myelodysplastic JJ 4_p
syndromes NNS 4_p
MDS NNP 4_p
during IN 4_p
and CC 4_p
after IN 4_p
chemotherapy NN 4_p
There EX N
were VBD N
4 CD N
cases NNS N
with IN N
possible JJ N
systemic JJ N
fungal JJ N
infection NN N
in IN N
the DT N
itraconazole NN N
group NN N
and CC N
there EX N
were VBD N
8 CD N
possible JJ N
and CC N
3 CD N
probable JJ N
cases NNS N
in IN N
the DT N
fluconazole JJ N
group NN N
Adverse JJ N
events NNS N
did VBD N
not RB N
significantly RB N
differ VB N
in IN N
the DT N
2 CD N
groups NNS N
In IN N
patients NNS N
with IN N
MDS NNP N
or CC N
in IN N
the DT N
remission-induction JJ N
phase NN N
of IN N
chemotherapy NN N
the DT N
numbers NNS N
of IN N
cases NNS N
with IN N
probable JJ N
or CC N
possible JJ N
infections NNS N
were VBD N
lower JJR N
in IN N
the DT N
itraconazole NN N
group NN N
than IN N
in IN N
the DT N
fluconazole NN N
group NN N
whereas IN N
no DT N
difference NN N
was VBD N
seen VBN N
in IN N
patients NNS N
with IN N
AML NNP N
or CC N
in IN N
the DT N
consolidation NN N
phase NN N
of IN N
therapy NN N
In IN N
patients NNS N
with IN N
neutrophil JJ N
counts NNS N
of IN N
0.1 CD N
x $ N
10 CD N
9 CD N
/L NN N
lasting VBG N
for IN N
more JJR N
than IN N
4 CD N
weeks NNS N
the DT N
frequency NN N
of IN N
infection NN N
in IN N
the DT N
fluconazole JJ N
group NN N
5 CD N
of IN N
9 CD N
patients NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
itraconazole JJ N
group NN N
0 CD N
of IN N
7 CD N
patients NNS N
P NNP N
.03 NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN N
in IN N
patients NNS 4_p
with IN 4_p
AML NNP 4_p
or CC 4_p
MDS NNP 4_p
who WP 4_p
received VBD 4_p
chemotherapy NN 4_p
and CC N
that IN N
the DT N
efficacy NN N
of IN N
itraconazole NN N
for IN N
prophylaxis NN N
against IN N
systemic JJ N
fungal JJ N
disease NN N
is VBZ N
not RB N
inferior JJ N
to TO N
that DT N
of IN N
fluconazole NN N
-DOCSTART- -X- O O

Comparison NNP N
of IN N
weakness NN N
progression NN N
in IN N
inclusion NN 4_p
body NN 4_p
myositis NN 4_p
during IN N
treatment NN N
with IN N
methotrexate NN N
or CC N
placebo NN N
We PRP N
investigated VBD N
whether IN N
5 CD N
to TO N
20mg CD N
per IN N
week NN N
oral JJ N
methotrexate NN N
could MD N
slow VB N
down RP N
disease NN N
progression NN N
in IN N
44 CD 3_p
patients NNS 4_p
with IN 4_p
inclusion NN 4_p
body NN 4_p
myositis NN 4_p
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
over IN N
48 CD N
weeks NNS N
Mean NNP N
change NN N
of IN N
quantitative JJ N
muscle NN N
strength NN N
testing VBG N
sum NN N
scores NNS N
was VBD N
the DT N
primary JJ N
study NN N
outcome JJ N
measure NN N
Quantitative JJ N
muscle NN N
strength NN N
testing VBG N
sum NN N
scores NNS N
declined VBD N
in IN N
both DT N
treatment NN N
groups NNS N
-0.2 CD N
for IN N
methotrexate NN N
and CC N
-3.4 CD N
for IN N
placebo NN N
95 CD N
confidence NN N
interval NN N
-2.5 NNP N
to TO N
+9.1 CD N
for IN N
difference NN N
There EX N
were VBD N
also RB N
no DT N
differences NNS N
in IN N
manual JJ N
muscle NN N
testing VBG N
sum JJ N
scores NNS N
activity NN N
scale NN N
scores NNS N
and CC N
patients NNS N
own JJ N
assessments NNS N
after IN N
48 CD N
weeks NNS N
of IN N
treatment NN N
Serum NNP N
creatine JJ N
kinase NN N
activity NN N
decreased VBN N
significantly RB N
in IN N
the DT N
methotrexate NN N
group NN N
We PRP N
conclude VBP N
that IN N
oral JJ N
methotrexate NN N
did VBD N
not RB N
slow VB N
down RP N
progression NN N
of IN N
muscle NN N
weakness NN N
but CC N
decreased VBD N
serum JJ N
creatine JJ N
kinase NN N
activity NN N
-DOCSTART- -X- O O

Distinct NNP N
fast RB N
and CC N
slow VB N
processes NNS N
contribute VBP N
to TO N
the DT N
selection NN N
of IN N
preferred JJ N
step NN N
frequency NN N
during IN N
human JJ 4_p
walking VBG N
Humans NNPS N
spontaneously RB N
select VB N
a DT N
step NN N
frequency NN N
that WDT N
minimizes VBZ N
the DT N
energy NN N
expenditure NN N
of IN N
walking VBG N
This DT N
selection NN N
might MD N
be VB N
embedded VBN N
within IN N
the DT N
neural JJ N
circuits NNS N
that WDT N
generate VBP N
gait NNS N
so RB N
that IN N
the DT N
optimum NN N
is VBZ N
pre-programmed JJ N
for IN N
a DT N
given VBN N
walking VBG N
speed NN N
Or CC N
perhaps RB N
step JJ N
frequency NN N
is VBZ N
directly RB N
optimized VBN N
based VBN N
on IN N
sensed JJ N
feedback NN N
of IN N
energy NN N
expenditure NN N
Direct JJ N
optimization NN N
is VBZ N
expected VBN N
to TO N
be VB N
slow JJ N
due JJ N
to TO N
the DT N
compounded JJ N
effect NN N
of IN N
delays NNS N
and CC N
iteration NN N
whereas IN N
a DT N
pre-programmed JJ N
mechanism NN N
presumably RB N
allows VBZ N
for IN N
faster JJR N
step NN N
frequency NN N
selection NN N
albeit JJ N
dependent NN N
on IN N
prior JJ N
experience NN N
To TO N
test VB N
for IN N
both DT N
pre-programmed JJ N
selection NN N
and CC N
direct JJ N
optimization NN N
we PRP N
applied VBD N
perturbations NNS N
to TO N
treadmill VB N
walking VBG N
to TO N
elicit VB N
transient JJ N
changes NNS N
in IN N
step NN N
frequency NN N
We PRP N
found VBD N
that IN N
human JJ N
step NN N
frequency NN N
adjustments NNS N
n JJ N
7 CD N
occurred VBD N
with IN N
two CD N
components NNS N
the DT N
first JJ N
dominating VBG N
the DT N
response NN N
66 CD N
± RB N
10 CD N
of IN N
total JJ N
amplitude JJ N
change NN N
mean JJ N
± NNP N
SD NNP N
and CC N
occurring VBG N
quite RB N
quickly RB N
1.44 CD N
± RB N
1.14 CD N
s NNS N
to TO N
complete VB N
95 CD N
of IN N
total JJ N
change NN N
The DT N
other JJ N
component NN N
was VBD N
of IN N
smaller JJR N
amplitude NN N
35 CD N
± RB N
10 CD N
of IN N
total JJ N
change NN N
and CC N
took VBD N
tens NNS N
of IN N
seconds NNS N
27.56 CD N
± RB N
16.18 CD N
s NN N
for IN N
95 CD N
completion NN N
The DT N
fast JJ N
process NN N
appeared VBD N
to TO N
be VB N
too RB N
fast JJ N
for IN N
direct JJ N
optimization NN N
and CC N
more RBR N
indicative JJ N
of IN N
a DT N
pre-programmed JJ N
response NN N
It PRP N
also RB N
persisted VBD N
even RB N
with IN N
unusual JJ N
closed-loop JJ N
perturbations NNS N
that WDT N
conflicted VBD N
with IN N
prior JJ N
experience NN N
and CC N
rendered VBD N
the DT N
response NN N
energetically RB N
suboptimal JJ N
The DT N
slow JJ N
process NN N
was VBD N
more RBR N
consistent JJ N
with IN N
the DT N
timing NN N
expected VBN N
for IN N
direct JJ N
optimization NN N
Our PRP$ N
interpretation NN N
of IN N
these DT N
results NNS N
is VBZ N
that IN N
humans NNS N
may MD N
rely VB N
heavily RB N
on IN N
pre-programmed JJ N
gaits NNS N
to TO N
rapidly RB N
select VB N
their PRP$ N
preferred JJ N
step NN N
frequency NN N
and CC N
then RB N
gradually RB N
fine-tune JJ N
that IN N
selection NN N
with IN N
direct JJ N
optimization NN N
-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
preoperative JJ N
oral JJ N
pregabalin NN N
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN N
infusion NN N
on IN N
postoperative JJ N
morphine NN N
requirement NN N
in IN N
patients NNS 4_p
undergoing VBG 4_p
laparatomy NN 4_p
OBJECTIVES NNP N
To TO N
evaluate VB N
and CC N
compare VB N
the DT N
effects NNS N
of IN N
preoperative JJ N
oral JJ N
pregabalin NN N
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN N
infusion NN N
on IN N
postoperative JJ N
morphine NN N
requirement NN N
adverse JJ N
effects NNS N
patients NNS N
satisfaction NN N
mobilization NN N
time NN N
to TO N
first JJ N
defecation NN N
and CC N
time NN N
to TO N
discharge VB N
in IN N
patients NNS N
undergoing VBG N
laparotomy NN N
METHODS NNP N
Eighty NNP 3_p
patients NNS N
18 CD 1_p
to TO 1_p
65 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
undergoing VBG 4_p
elective JJ 4_p
laparotomy NN 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
n=20 JJ N
in IN N
each DT N
group NN N
group NN N
C NNP N
placebo NN N
capsules NNS N
and CC N
normal JJ N
saline JJ N
infusion NN N
perioperatively RB N
control NN N
group NN N
L NNP N
placebo NN N
capsules NNS N
and CC N
lidocaine JJ N
1 CD N
mg⁄kg RB N
intravenous JJ N
bolus NN N
dose NN N
followed VBN N
by IN N
2 CD N
mg⁄kg⁄h JJ N
infusion NN N
until IN N
skin JJ N
closure NN N
group NN N
P NNP N
150 CD N
mg JJ N
oral JJ N
pregabalin NN N
and CC N
normal JJ N
saline JJ N
infusion NN N
perioperatively RB N
and CC N
group NN N
PL NNP N
150 CD N
nbsp NN N
mg CC N
oral JJ N
pregabalin NN N
and CC N
lidocaine NN N
2 CD N
mg⁄kg⁄h NN N
infusion NN N
until IN N
skin JJ N
closure NN N
Hemodynamic NNP N
parameters NNS N
visual JJ N
analogue NN N
scale NN N
VAS NNP N
scores VBZ N
analgesic JJ N
consumption NN N
side NN N
effects NNS N
time NN N
to TO N
mobilization VB N
time NN N
to TO N
first JJ N
defecation NN N
time NN N
to TO N
discharge VB N
and CC N
patients NNS N
satisfaction NN N
were VBD N
recorded VBN N
RESULTS NNP N
VAS NNP N
scores NNS N
of IN N
group NN N
L NNP N
group NN N
P NNP N
and CC N
group NN N
PL NNP N
were VBD N
lower JJR N
than IN N
group NN N
C NNP N
P NNP N
0.05 CD N
Morphine NNP N
consumption NN N
of IN N
group NN N
P NNP N
and CC N
group NN N
PL NNP N
was VBD N
lower JJR N
than IN N
group NN N
C NNP N
P NNP N
0.05 CD N
Incidence NN N
of IN N
nausea NN N
in IN N
group NN N
C NNP N
was VBD N
higher JJR N
than IN N
group NN N
L NNP N
and CC N
group NN N
PL NNP N
Time NNP N
to TO N
first VB N
defecation NN N
and CC N
mobilization NN N
were VBD N
shorter JJR N
in IN N
group NN N
L NNP N
and CC N
group NN N
PL NNP N
compared VBN N
with IN N
group NN N
C NNP N
P NNP N
0.05 CD N
CONCLUSION NNP N
Preoperative NNP N
oral JJ N
pregabalin NN N
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN N
infusion NN N
decreased VBD N
postoperative JJ N
VAS NNP N
scores NNS N
Preoperative JJ N
oral JJ N
pregabalin NN N
decreased VBD N
morphine JJ N
requirement NN N
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN N
infusion NN N
hastened VBD N
gastrointestinal JJ N
motility NN N
and CC N
mobilization NN N
and CC N
decreased VBD N
the DT N
incidence NN N
of IN N
nausea NN N
in IN N
patients NNS N
undergoing VBG N
laparotomy NN N
Therefore RB N
preoperative JJ N
pregabalin NN N
with IN N
or CC N
without IN N
lidocaine JJ N
provides VBZ N
superior JJ N
pain NN N
relief NN N
in IN N
patients NNS N
undergoing VBG N
laparatomy NN N
-DOCSTART- -X- O O

Gastric NNP N
dysrhythmia NN N
in IN N
infants NNS 1_p
with IN N
gastrointestinal JJ 4_p
diseases NNS 4_p
measured VBN N
by IN N
epigastric JJ N
impedance NN N
BACKGROUND NNP N
Gastrointestinal NNP N
symptoms NNS N
have VBP N
been VBN N
reported VBN N
in IN N
association NN N
with IN N
myoelectrical JJ N
dysrhythmia NN N
where WRB N
different JJ N
types NNS N
of IN N
gastric JJ N
electrical JJ N
activity NN N
have VBP N
been VBN N
described VBN N
These DT N
types NNS N
of IN N
gastric JJ N
myoelectrical JJ N
activity NN N
and CC N
dysrhythmia NN N
can MD N
be VB N
measured VBN N
by IN N
electrogastrography NN N
using VBG N
cutaneous JJ N
electrodes NNS N
Epigastric JJ N
impedance NN N
is VBZ N
a DT N
non-invasive JJ N
method NN N
used VBN N
to TO N
study VB N
gastric JJ N
emptying VBG N
time NN N
and CC N
gastric JJ N
phasic JJ N
activity NN N
At IN N
present JJ N
no DT N
study NN N
of IN N
gastric JJ N
dysrhythmia NN N
measured VBN N
with IN N
epigastric JJ N
impedance NN N
has VBZ N
been VBN N
presented VBN N
and CC N
the DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
gastric JJ N
rhythms NN N
by IN N
means NNS N
of IN N
impedance NN N
gastrography NN N
in IN N
control NN N
infants NNS N
compared VBN N
to TO N
infants NNS 4_p
with IN 4_p
different JJ 4_p
gastrointestinal JJ 4_p
diseases NNS 4_p
before IN N
and CC N
after IN N
treatment NN N
of IN N
their PRP$ N
disease NN N
METHOD NNP N
21 CD 3_p
patients NNS 4_p
age NN 1_p
0-2 CD 1_p
months NNS 1_p
and CC N
40 CD 3_p
healthy JJ 4_p
infants NNS 1_p
age NN 1_p
0-2 CD 1_p
months NNS 1_p
were VBD N
investigated VBN N
The DT N
patients NNS 4_p
suffered VBD 4_p
from IN 4_p
partial JJ 4_p
or CC 4_p
total JJ 4_p
intestinal JJ 4_p
obstruction NN 4_p
necrotizing VBG 4_p
enterocolitis NN 4_p
or CC 4_p
pyloric JJ 4_p
stenosis.All NN 4_p
infants NNS 4_p
were VBD 4_p
fasting VBG 4_p
and CC N
studied VBN N
during IN N
periods NNS N
of IN N
at IN N
least JJS N
one CD N
hour NN N
The DT N
patients NNS N
were VBD N
examined VBN N
in IN N
the DT N
acute NN N
state NN N
and CC N
after IN N
treatment NN N
when WRB N
possible JJ N
RESULTS VB N
A DT N
pathologic JJ N
result NN N
was VBD N
found VBN N
in IN N
90 CD N
of IN N
the DT N
patients NNS N
A DT N
persistent JJ N
phasic JJ N
activity NN N
pattern NN N
was VBD N
found VBN N
in IN N
19 CD N
of IN N
the DT N
21 CD N
patients NNS N
high JJ N
frequency NN N
phasic JJ N
activity NN N
in IN N
11 CD N
of IN N
the DT N
21 CD N
patients NNS N
Short-term JJ N
phasic JJ N
activity NN N
was VBD N
only RB N
found VBN N
in IN N
13 CD N
out IN N
of IN N
40 CD N
of IN N
the DT N
normal JJ N
infants NNS N
32.5 CD N
CONCLUSION NNP N
Using NNP N
epigastric JJ N
impedance NN N
we PRP N
found VBD N
that IN N
infants NNS N
with IN N
partial JJ N
or CC N
total JJ N
intestinal JJ N
obstruction NN N
had VBD N
gastric JJ N
phasic JJ N
activity NN N
which WDT N
was VBD N
not RB N
found VBN N
in IN N
the DT N
control NN N
infants NNS N
The DT N
origin NN N
of IN N
the DT N
gastric JJ N
phasic JJ N
activity NN N
patterns NNS N
is VBZ N
unknown JJ N
but CC N
they PRP N
may MD N
be VB N
related VBN N
to TO N
electrical JJ N
control NN N
activity NN N
-DOCSTART- -X- O O

Sleep-anticipating JJ N
effects NNS N
of IN N
melatonin NN N
in IN N
the DT N
human JJ 4_p
brain NN N
Melatonin NNP N
the DT N
hormone NN N
produced VBN N
nocturnally RB N
by IN N
the DT N
pineal NN N
gland NN N
is VBZ N
an DT N
endogenous JJ N
regulator NN N
of IN N
the DT N
sleep-wake JJ N
cycle NN N
The DT N
effects NNS N
of IN N
melatonin NN N
on IN N
brain NN N
activities NNS N
and CC N
their PRP$ N
relation NN N
to TO N
induction NN N
of IN N
sleepiness NN N
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo NN N
controlled VBD N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
fMRI NN N
study NN N
Melatonin NNP N
but CC N
not RB N
placebo VB N
reduced VBN N
task-related JJ N
activity NN N
in IN N
the DT N
rostro-medial JJ N
aspect NN N
of IN N
the DT N
occipital JJ N
cortex NN N
during IN N
a DT N
visual-search JJ N
task NN N
and CC N
in IN N
the DT N
auditory JJ N
cortex NN N
during IN N
a DT N
music NN N
task NN N
These DT N
effects NNS N
correlated VBD N
with IN N
subjective JJ N
measurements NNS N
of IN N
fatigue NN N
In IN N
addition NN N
melatonin NN N
enhanced VBD N
the DT N
activation NN N
in IN N
the DT N
left NN N
parahippocampus NN N
in IN N
an DT N
autobiographic JJ N
memory NN N
task NN N
Results VB N
demonstrate NN N
that IN N
melatonin NN N
modulates NNS N
brain NN N
activity NN N
in IN N
a DT N
manner NN N
resembling VBG N
actual JJ N
sleep NN N
although IN N
subjects NNS N
are VBP N
fully RB N
awake RB N
Furthermore RB N
the DT N
fatigue NN N
inducing VBG N
effect NN N
of IN N
melatonin NN N
on IN N
brain NN N
activity NN N
is VBZ N
essentially RB N
different JJ N
from IN N
that DT N
of IN N
sleep JJ N
deprivation NN N
thus RB N
revealing VBG N
differences NNS N
between IN N
fatigues NNS N
related VBN N
to TO N
the DT N
circadian JJ N
sleep NN N
regulation NN N
as IN N
opposed VBN N
to TO N
increased VBN N
homeostatic JJ N
sleep NN N
need NN N
Our PRP$ N
findings NNS N
highlight VBD N
the DT N
role NN N
of IN N
melatonin NN N
in IN N
priming VBG N
sleep-associated JJ N
brain NN N
activation NN N
patterns NNS N
in IN N
anticipation NN N
of IN N
sleep NN N
-DOCSTART- -X- O O

Custom-fit NNP N
minimally RB N
invasive JJ N
total JJ N
knee NN N
arthroplasty NN N
effect NN N
on IN N
blood NN N
loss NN N
and CC N
early JJ N
clinical JJ N
outcomes NNS N
PURPOSE NNP N
Recently NNP N
new JJ N
custom-fit JJ N
pin NN N
guides NNS N
in IN N
total JJ N
knee NN N
arthroplasty NN N
TKA NNP N
have VBP N
been VBN N
introduced VBN N
Use NN N
of IN N
these DT N
guides NNS N
may MD N
reduce VB N
operating NN N
time NN N
Use NN N
of IN N
the DT N
guides NNS N
combined VBN N
with IN N
the DT N
absence NN N
of IN N
intramedullary JJ N
alignment NN N
jigs NNS N
may MD N
lead VB N
to TO N
reduced VB N
blood NN N
loss NN N
and CC N
improved VBN N
early JJ N
outcomes NNS N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
blood NN N
loss NN N
and CC N
early JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS 4_p
undergoing VBG 4_p
minimally RB 4_p
invasive JJ 4_p
TKA NNP 4_p
using VBG N
custom-fit JJ N
magnetic JJ N
resonance NN N
imaging NN N
MRI NNP N
-based VBD N
pin NN N
guides NNS N
METHODS NNP N
A NNP N
prospective JJ N
study NN N
in IN N
80 CD 3_p
patients NNS 3_p
was VBD N
carried VBN N
out RP N
Patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
equal JJ N
groups NNS N
In IN N
one CD N
group NN N
intramedullary JJ N
alignment NN N
jigs NNS N
were VBD N
used VBN N
In IN N
the DT N
second JJ N
group NN N
custom-fit JJ N
MRI-based JJ N
pin NN N
guides NNS N
were VBD N
used VBN N
All DT N
patients NNS N
received VBD N
the DT N
same JJ N
cemented VBD N
posterior-stabilized JJ N
implant NN N
through IN N
a DT N
mini-midvastus JJ N
approach NN N
The DT N
volume NN N
in IN N
the DT N
drain NN N
bottles NNS N
was VBD N
recorded VBN N
after IN N
48 CD N
h. JJ N
Hb NNP N
loss NN N
was VBD N
estimated VBN N
by IN N
subtracting VBG N
the DT N
postoperative NN N
from IN N
the DT N
preoperative JJ N
Hb NNP N
level NN N
Transfusion NN N
requirements NNS N
and CC N
surgical JJ N
time NN N
were VBD N
recorded VBN N
Outcome JJ N
measures NNS N
were VBD N
Knee NNP N
Society NNP N
Scores NNP N
KSS NNP N
knee JJ N
flexion NN N
knee VB N
swelling VBG N
and CC N
pain NN N
RESULTS NNP N
There EX N
was VBD N
lower JJR N
mean JJ N
drainage NN N
of IN N
blood NN N
in IN N
the DT N
custom-fit JJ N
group NN N
391 CD N
ml NN N
vs. FW N
603 CD N
ml NN N
p CC N
0.0001 CD N
There EX N
was VBD N
no DT N
difference NN N
in IN N
estimated VBN N
loss NN N
of IN N
Hb NNP N
3.6 CD N
g/dl NN N
vs. FW N
4.1 CD N
g/dl NN N
n.s CC N
and CC N
in IN N
transfusion NN N
requirements NNS N
7.5 CD N
vs. FW N
10 CD N
n.s. CC N
Surgical JJ N
time NN N
was VBD N
reduced VBN N
in IN N
the DT N
custom-fit JJ N
group NN N
12 CD N
min NN N
less JJR N
p NN N
0.001 CD N
KSS NNP N
measured VBD N
at IN N
week NN N
2 CD N
6 CD N
and CC N
12 CD N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
Knee NNP N
flexion NN N
measured VBN N
on IN N
days NNS N
7 CD N
10 CD N
and CC N
at IN N
week NN N
6 CD N
12 CD N
and CC N
knee VB N
swelling VBG N
and CC N
pain NN N
measured VBN N
on IN N
days NNS N
1 CD N
3 CD N
10 CD N
and CC N
at IN N
week NN N
6 CD N
12 CD N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
CONCLUSIONS NNP N
Using VBG N
custom-fit JJ N
pin NN N
guides NNS N
reduces NNS N
blood NN N
drainage NN N
but CC N
not RB N
the DT N
estimated VBN N
Hb NNP N
loss NN N
in IN N
minimally RB N
invasive JJ N
TKA NNP N
and CC N
does VBZ N
not RB N
affect VB N
transfusion NN N
rate NN N
Surgical JJ N
time NN N
is VBZ N
reduced VBN N
There EX N
is VBZ N
no DT N
effect NN N
on IN N
the DT N
early JJ N
clinical JJ N
outcomes NNS N
LEVEL NN N
OF IN N
EVIDENCE NNP N
Therapeutic NNP N
study NN N
Level NNP N
I PRP N
-DOCSTART- -X- O O

Effects NNS N
of IN N
auditory JJ N
integrative JJ N
training NN N
on IN N
autistic JJ 4_p
children NNS 1_p
OBJECTIVE NNP N
To TO N
explore VB N
the DT N
short-term JJ N
treatment NN N
effect NN N
of IN N
the DT N
auditory JJ N
integrative JJ N
training NN N
on IN N
autistic JJ 4_p
children NNS 1_p
and CC N
provide VB N
them PRP N
with IN N
clinical JJ N
support NN N
for IN N
rehabilitative JJ N
treatment NN N
METHODS NNP N
A NNP N
total NN N
of IN N
81 CD 3_p
cases NNS 4_p
of IN 4_p
autistic JJ 4_p
children NNS 4_p
were VBD N
selected VBN N
through IN N
the DT N
standard NN N
of IN N
DSM-4 NNP N
and CC N
clinical JJ N
case NN N
study NN N
was VBD N
used VBN N
They PRP N
were VBD N
divided VBN N
randomly RB N
into IN N
experimental JJ N
group NN N
and CC N
control VB N
one CD N
and CC N
respectively RB N
received VBD N
auditory JJ N
integrative JJ N
training NN N
and CC N
no DT N
training NN N
based VBN N
on IN N
the DT N
multiple JJ N
therapies NNS N
The DT N
patients NNS N
were VBD N
investigated VBN N
using VBG N
clinical JJ N
manifestation NN N
and CC N
Autism NNP N
Behavior NNP N
Checklist NNP N
ABC NNP N
and CC N
intelligence NN N
quotient NN N
IQ NNP N
before IN N
and CC N
after IN N
six CD N
months NNS N
of IN N
treatment NN N
The DT N
effect NN N
was VBD N
evaluated VBN N
through IN N
the DT N
changes NNS N
of IN N
clinical JJ N
manifestations NNS N
and CC N
scores NNS N
of IN N
ABC NNP N
and CC N
IQ NNP N
The DT N
changes NNS N
of IN N
scores NNS N
of IN N
IQ NNP N
were VBD N
determined VBN N
with IN N
Gesell NNP N
and CC N
WPPSI NNP N
or CC N
WISC-R NNP N
RESULTS NNP N
Compared VBD N
with IN N
40 CD N
patients NNS N
of IN N
the DT N
control NN N
group NN N
after IN N
the DT N
six CD N
months NNS N
of IN N
the DT N
auditory JJ N
integrative JJ N
training NN N
41 CD N
of IN N
the DT N
experimental JJ N
group NN N
had VBD N
greatly RB N
improved VBN N
in IN N
many JJ N
aspects NNS N
such JJ N
as IN N
the DT N
disorders NNS N
of IN N
their PRP$ N
language NN N
social JJ N
interactions NNS N
and CC N
typical JJ N
behavior NN N
symptoms NNS N
while IN N
they PRP N
had VBD N
not RB N
changed VBN N
in IN N
their PRP$ N
abnormal JJ N
behaviors NNS N
The DT N
scores NNS N
of IN N
IQ NNP N
or CC N
DQ NNP N
had VBD N
increased VBN N
and CC N
scores NNS N
of IN N
ABC NNP N
had VBD N
dropped VBN N
The DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
greatly RB N
significant JJ N
in IN N
statistics NNS N
P NNP N
0.01 CD N
The DT N
decreasing VBG N
level NN N
of IN N
both DT N
ABC NNP N
scores NNS N
and CC N
the DT N
increasing VBG N
level NN N
of IN N
the DT N
IQ NNP N
scores NNS N
were VBD N
negatively RB N
correlated VBN N
with IN N
age NN N
and CC N
the DT N
decreasing VBG N
level NN N
of IN N
ABC NNP N
scores NNS N
was VBD N
in IN N
line NN N
regression NN N
positive JJ N
correlation NN N
with IN N
base NN N
IQ NNP N
CONCLUSION NNP N
The DT N
treatment NN N
of IN N
auditory JJ N
integrative JJ N
training NN N
AIT NNP N
could MD N
greatly RB N
improve VB N
on IN N
language NN N
disorders NNS N
the DT N
difficulties NNS N
of IN N
social JJ N
interactions NNS N
typical JJ N
behavior NN N
symptoms NNS N
and CC N
developmental JJ N
levels NNS N
therefore IN N
it PRP N
is VBZ N
positive JJ N
to TO N
the DT N
autistic JJ 4_p
children NNS 4_p
in IN N
its PRP$ N
short-term JJ N
treatment NN N
effect NN N
-DOCSTART- -X- O O

Randomized VBN N
phase NN N
II NNP N
study NN N
of IN N
two CD N
different JJ N
schedules NNS N
of IN N
gemcitabine NN N
and CC N
oral JJ N
S-1 NNP N
in IN N
chemo-naïve JJ 4_p
patients NNS N
with IN N
advanced JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
INTRODUCTION NNP N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
and CC N
to TO N
compare VB N
dosing VBG N
schedules NNS N
of IN N
gemcitabine NN N
combined VBN N
with IN N
S-1 NNP N
in IN N
chemo-naïve JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
patients NNS 4_p
METHODS NNP N
Patients NNPS N
with IN N
chemo-naïve JJ 4_p
stage NN 4_p
IIIB/IV NNP 4_p
non-small NN 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
were VBD N
randomized VBN N
into IN N
two CD N
treatment NN N
arms NNS N
Patients NNS N
were VBD N
given VBN N
oral JJ N
S-1 NNP N
60 CD N
mg/m/d NN N
twice RB N
a DT N
day NN N
from IN N
days NNS N
1 CD N
to TO N
14 CD N
with IN N
gemcitabine NN N
1000 CD N
mg/m/d NN N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
arm VB N
A NNP N
or CC N
on IN N
days NNS N
8 CD N
and CC N
15 CD N
arm NN N
B NNP N
This DT N
cycle NN N
was VBD N
repeated VBN N
every DT N
21 CD N
days NNS N
RESULTS VB N
A DT N
total NN N
of IN N
80 CD 3_p
patients NNS N
were VBD N
entered VBN N
in IN N
this DT N
trial NN N
The DT N
primary JJ N
end NN N
point NN N
of IN N
this DT N
study NN N
was VBD N
response NN N
rate NN N
The DT N
response NN N
rates NNS N
of IN N
arm NN N
A NNP N
and CC N
arm NN N
B NNP N
were VBD N
22.0 CD N
and CC N
28.9 CD N
respectively RB N
p JJ N
0.606 CD N
Median JJ N
time NN N
to TO N
treatment NN N
failure NN N
in IN N
arm NN N
A NN N
was VBD N
3.6 CD N
months NNS N
and CC N
4.8 CD N
months NNS N
in IN N
arm NN N
B NNP N
Median JJ N
time NN N
to TO N
progression NN N
in IN N
arm NN N
A NN N
was VBD N
4.1 CD N
months NNS N
and CC N
5.5 CD N
months NNS N
in IN N
arm NN N
B NNP N
Median JJ N
survival JJ N
time NN N
in IN N
arm NN N
A NN N
and CC N
arm NN N
B NNP N
was VBD N
15.5 CD N
months NNS N
and CC N
18.8 CD N
months NNS N
respectively RB N
The DT N
toxicity NN N
profile NN N
was VBD N
relatively RB N
mild JJ N
and CC N
did VBD N
not RB N
differ VB N
very RB N
much RB N
between IN N
two CD N
arms NNS N
CONCLUSION VB N
The DT N
combination NN N
of IN N
gemcitabine NN N
and CC N
S-1 NNP N
was VBD N
determined VBN N
to TO N
be VB N
feasible JJ N
and CC N
effective JJ N
for IN N
advanced JJ N
non-small JJ N
cell NN N
lung NN N
cancer NN N
We PRP N
selected VBD N
arm NN N
B NNP N
for IN N
further JJ N
studies NNS N
because IN N
of IN N
its PRP$ N
higher JJR N
response NN N
rate NN N
and CC N
survival NN N
data NNS N
-DOCSTART- -X- O O

Cophenylcaine NNP N
spray NN N
vs. FW N
placebo NN N
in IN N
flexible JJ 4_p
nasendoscopy NN 4_p
a DT N
prospective JJ N
double-blind NN N
randomised VBD N
controlled VBN N
trial NN N
Practices NNS N
vary VBP N
across IN N
the DT N
UK NNP N
on IN N
the DT N
use NN N
of IN N
topical JJ N
preparation NN N
prior RB N
to TO N
flexible JJ N
fibreoptic JJ N
nasendoscopy NN N
In IN N
this DT N
double-blind NN N
study NN N
we PRP N
randomised VBD N
98 CD 3_p
patients NNS 3_p
to TO N
receive VB N
cophenylcaine NN N
or CC N
placebo NN N
nasal JJ N
spray NN N
before IN N
flexible JJ 4_p
nasendoscopy NN 4_p
A DT N
visual JJ N
analogue NN N
scale NN N
1-100 JJ N
was VBD N
used VBN N
to TO N
record VB N
pain NN N
unpleasantness NN N
of IN N
taste NN N
and CC N
overall JJ N
discomfort NN N
experienced VBD N
Overall JJ N
the DT N
procedure NN N
was VBD N
associated VBN N
with IN N
minimal JJ N
pain NN N
and CC N
discomfort NN N
in IN N
both DT N
groups NNS N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN N
or CC N
overall JJ N
discomfort NN N
experienced VBD N
between IN N
the DT N
two CD N
groups NNS N
however RB N
the DT N
sensation NN N
of IN N
bad JJ N
taste NN N
was VBD N
significantly RB N
worse JJR N
in IN N
the DT N
cophenylcaine NN N
group NN N
In IN N
linear JJ N
regression NN N
factors NNS N
that WDT N
predicted VBD N
the DT N
overall JJ N
unpleasantness NN N
of IN N
the DT N
experience NN N
were VBD N
primarily RB N
pain VBN N
experienced JJ N
and CC N
secondarily JJ N
unpleasantness NN N
of IN N
taste NN N
We PRP N
conclude VBP N
that IN N
the DT N
routine JJ N
use NN N
of IN N
cophenylcaine NN N
for IN N
nasal JJ N
preparation NN N
is VBZ N
not RB N
justified VBN N
before IN N
flexible JJ 4_p
nasendoscopy NN 4_p
-DOCSTART- -X- O O

EORTC NNP N
protocols NNS N
in IN N
prostatic JJ 4_p
cancer NN 4_p
An DT N
interim JJ N
report NN N
Two CD N
parallel JJ N
prospective JJ N
randomized VBN N
studies NNS N
have VBP N
been VBN N
undertaken VBN N
by IN N
the DT N
EORTC NNP N
Urological NNP N
Group NNP N
in IN N
previously RB 4_p
untreated JJ 4_p
patients NNS 4_p
with IN 4_p
prostatic JJ 4_p
cancer NN 4_p
in IN N
order NN N
to TO N
compare VB N
low JJ N
dose JJ N
Stilboestrol NNP N
versus NN N
Cyproterone NNP N
acetate NN N
versus NN N
Medroxyprogesterone NNP N
acetate NN N
in IN N
the DT N
first JJ N
trial NN N
and CC N
Stilboestrol NNP N
versus VBP N
Estracyt NNP N
in IN N
the DT N
second JJ N
trial NN N
Although IN N
the DT N
follow JJ N
up NN N
is VBZ N
still RB N
short JJ N
no DT N
superiority NN N
of IN N
the DT N
other JJ N
drugs NNS N
over IN N
Stilboestrol NNP N
had VBD N
appeared VBN N
so RB N
far RB N
with IN N
regard NN N
to TO N
either DT N
objective JJ N
response NN N
or CC N
significant JJ N
side NN N
effects NNS N
apart RB N
from IN N
gynaecomastia NN N
In IN N
the DT N
third JJ N
trial NN N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
disease NN 4_p
no RB 4_p
longer RBR 4_p
responsive VB 4_p
to TO 4_p
hormonal JJ 4_p
treatment NN 4_p
were VBD N
randomized VBN N
to TO N
either DT N
Adriamycin NNP N
or CC N
Procarbazine NNP N
Toxicity NN N
and CC N
early JJ N
death NN N
were VBD N
particularly RB N
frequent JJ N
in IN N
Procarbazine NNP N
treated VBD N
patients NNS N
whereas NNS N
most JJS N
patients NNS N
progressed VBN N
in IN N
both DT N
treatment NN N
groups NNS N
-DOCSTART- -X- O O

A DT N
double-blind NN N
randomized VBN N
controlled VBN N
multicenter NN N
safety NN N
and CC N
immunogenicity NN N
study NN N
of IN N
a DT N
refrigerator-stable JJ N
formulation NN N
of IN N
Zostavax NNP N
The DT N
vaccine NN N
Zostavax NNP N
has VBZ N
been VBN N
shown VBN N
to TO N
prevent VB N
herpes NNS N
zoster NNP N
HZ NNP N
and CC N
postherpetic JJ N
neuralgia NN N
and CC N
is VBZ N
recommended VBN N
for IN N
individuals NNS N
or CC N
=60 CD N
years NNS N
of IN N
age NN N
This DT N
study NN N
compared VBN N
the DT N
safety NN N
and CC N
the DT N
immunogenicity NN N
of IN N
a DT N
refrigerator-stable JJ N
formulation NN N
Zostavax NNP N
refrigerated VBD N
with IN N
those DT N
of IN N
the DT N
current JJ N
formulation NN N
Zostavax NNP N
frozen RB N
in IN N
subjects NNS 1_p
or CC 1_p
=50 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
Subjects VBZ 4_p
with IN 4_p
a DT 4_p
negative JJ 4_p
history NN 4_p
for IN 4_p
HZ NNP 4_p
were VBD N
randomized VBN N
1:1 CD N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
formulation NN N
Enrollment NN 1_p
was VBD 1_p
stratified VBN 1_p
1:2 CD 1_p
by IN 1_p
age NN 1_p
50 CD 1_p
to TO 1_p
59 CD 1_p
years NNS 1_p
and CC 1_p
or CC 1_p
=60 CD 1_p
years NNS 1_p
Safety NN N
was VBD N
evaluated VBN N
for IN N
28 CD N
days NNS N
postvaccination NN N
Varicella-zoster JJ N
virus NN N
VZV NNP N
antibody NN N
responses NNS N
were VBD N
measured VBN N
by IN N
a DT N
glycoprotein JJ N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
gpELISA NN N
The DT N
primary JJ N
endpoints NNS N
were VBD N
the DT N
VZV NNP N
antibody NN N
geometric JJ N
mean NN N
titer NN N
GMT NNP N
day NN N
28 CD N
the DT N
VZV NNP N
antibody NN N
geometric JJ N
mean NN N
rise NN N
GMR NNP N
days NNS N
1 CD N
to TO N
28 CD N
and CC N
the DT N
incidence NN N
of IN N
vaccine-related JJ N
serious JJ N
adverse JJ N
experiences NNS N
AEs NNP N
over IN N
28 CD N
days NNS N
The DT N
refrigerated JJ N
n JJ N
182 CD N
and CC N
frozen JJ N
n JJ N
185 CD N
formulations NNS N
induced VBD N
similar JJ N
GMTs NNP N
727.4 CD N
and CC N
834.4 CD N
gpELISA NN N
units/ml NN N
respectively RB N
the DT N
estimated VBN N
GMT NNP N
ratio NN N
refrigerated VBN N
formulation/frozen RB N
formulation NN N
was VBD N
0.87 CD N
95 CD N
confidence NN N
interval NN N
0.71 CD N
to TO N
1.07 CD N
The DT N
GMRs NNPS N
were VBD N
2.6- JJ N
and CC N
2.9-fold JJ N
respectively RB N
No DT N
vaccine-related JJ N
serious JJ N
AEs NNP N
were VBD N
reported VBN N
in IN N
either DT N
group NN N
and CC N
the DT N
safety NN N
profiles NNS N
of IN N
the DT N
formulations NNS N
were VBD N
generally RB N
similar JJ N
The DT N
frequencies NNS N
of IN N
injection-site JJ N
AEs NNP N
during IN N
follow-up JJ N
were VBD N
35.6 CD N
and CC N
46.4 CD N
in IN N
the DT N
refrigerated JJ N
and CC N
the DT N
frozen JJ N
formulation NN N
groups NNS N
respectively RB N
and CC N
were VBD N
generally RB N
mild VBN N
The DT N
frequencies NNS N
of IN N
systemic JJ N
AEs NNP N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
and CC N
those DT N
of IN N
vaccine-related JJ N
AEs NNP N
were VBD N
approximately RB N
6 CD N
in IN N
both DT N
groups NNS N
The DT N
refrigerator-stable JJ N
formulation NN N
of IN N
Zostavax NNP N
has VBZ N
an DT N
acceptable JJ N
safety NN N
profile NN N
and CC N
is VBZ N
as RB N
immunogenic JJ N
as IN N
the DT N
frozen JJ N
formulation NN N
thus RB N
the DT N
vaccine NN N
may MD N
be VB N
used VBN N
in IN N
clinical JJ N
settings NNS N
where WRB N
freezer NN N
availability NN N
is VBZ N
limited VBN N
-DOCSTART- -X- O O

Local JJ N
immunotherapy NN N
by IN N
inhalation NN N
of IN N
a DT N
powder NN N
extract NN N
in IN N
asthma NN N
due JJ N
to TO N
house NN N
dust NN N
mite NN N
Dermatophagoides NNP N
pteronyssinus NN N
a DT N
double-blind JJ N
comparison NN N
with IN N
parenteral JJ N
immunotherapy NN N
To TO N
verify VB N
the DT N
efficacy NN N
and CC N
the DT N
tolerability NN N
of IN N
local JJ N
immunotherapy NN N
LI NNP N
by IN N
inhalation NN N
of IN N
a DT N
powder NN N
extract NN N
of IN N
house NN N
dust NN N
mite NN N
HDM NNP N
in IN N
comparison NN N
with IN N
parenteral JJ N
immunotherapy NN N
PI NNP N
by IN N
injection NN N
10 CD 3_p
patients NNS 4_p
with IN 4_p
asthma NNS 4_p
due JJ 4_p
to TO 4_p
HDM NNP 4_p
were VBD N
studied VBN N
in IN N
a DT N
blind JJ N
fashion NN N
5 CD N
patients NNS N
Group NNP N
A NNP N
underwent NN N
LI NNP N
and CC N
subcutaneous JJ N
injections NNS N
of IN N
placebo NN N
5 CD N
patients NNS N
Group NNP N
B NNP N
underwent NN N
PI NNP N
and CC N
inhalation NN N
of IN N
lactose NN N
for IN N
6 CD N
months NNS N
In IN N
both DT N
groups NNS N
each DT N
inhalation NN N
was VBD N
preceded VBN N
by IN N
premedication NN N
with IN N
disodium NN N
cromoglycate NN N
DSCG NNP N
40 CD N
mg NN N
In IN N
Group NNP N
A NNP N
a DT N
significant JJ N
decrease NN N
in IN N
symptoms NNS N
score NN N
and CC N
in IN N
peak JJ N
expiratory NN N
flow NN N
PEF NNP N
-derived VBD N
parameters NNS N
was VBD N
observed VBN N
already RB N
after IN N
3 CD N
months NNS N
of IN N
treatment NN N
and CC N
2 CD N
patients NNS N
lost VBD N
the DT N
late JJ N
component NN N
of IN N
the DT N
bronchial JJ N
response NN N
to TO N
the DT N
challenge NN N
with IN N
HDM NNP N
No NNP N
significant JJ N
variation NN N
was VBD N
found VBN N
in IN N
bronchial JJ N
responsiveness NN N
to TO N
methacholine VB N
and CC N
ultrasonically RB N
nebulized VBN N
distilled JJ N
water NN N
UNDW NNP N
and CC N
in IN N
immunologic JJ N
humoral JJ N
and CC N
cellular JJ N
parameters NNS N
in IN N
peripheral JJ N
blood NN N
after IN N
treatment NN N
in IN N
either DT N
group NN N
No DT N
local JJ N
important JJ N
adverse JJ N
reactions NNS N
were VBD N
observed VBN N
in IN N
Group NNP N
A NNP N
and CC N
no DT N
systemic JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
in IN N
either DT N
group NN N
We PRP N
conclude VBP N
that DT N
LI NNP N
is VBZ N
as RB N
effective JJ N
as IN N
PI NNP N
but CC N
more RBR N
rapid JJ N
in IN N
its PRP$ N
action NN N
in IN N
the DT N
treatment NN N
of IN N
asthma NNS N
due JJ N
to TO N
HDM NNP N
Moreover RB N
LI NNP N
is VBZ N
locally RB N
well RB N
tolerated VBN N
providing VBG N
DSCG NNP N
is VBZ N
inhaled VBN N
before IN N
each DT N
therapeutic JJ N
inhalation NN N
and CC N
does VBZ N
not RB N
induce VB N
systemic JJ N
side NN N
effects NNS N
-DOCSTART- -X- O O

Antioxidant JJ N
supplementation NN N
and CC N
exercise-induced JJ N
oxidative JJ N
stress NN N
in IN N
the DT 1_p
60-year-old JJ 1_p
as IN N
measured VBN N
by IN N
antipyrine NN N
hydroxylates NNS N
The DT N
effects NNS N
of IN N
12 CD N
weeks NNS N
of IN N
antioxidant JJ N
supplementation NN N
on IN N
exercise-induced JJ N
oxidative JJ N
stress NN N
were VBD N
investigated VBN N
in IN N
older JJR 1_p
adults NNS 1_p
60 CD 1_p
SE NNP 1_p
1 CD 1_p
years NNS 1_p
BMI NNP 1_p
26 CD 1_p
SE NNP 1_p
1 CD 1_p
kg/m NN 1_p
2 CD 1_p
Subjects NNS N
were VBD N
randomly RB N
divided VBN N
in IN N
two CD N
groups NNS N
supplementation NN N
n JJ N
11 CD N
with IN N
100 CD N
mg NNS N
dl-alpha-tocopheryl JJ N
acetate NN N
200 CD N
mg NN N
ascorbic JJ N
acid NN N
and CC N
2 CD N
mg NN N
beta-carotene NN N
and CC N
placebo NN N
n JJ N
9 CD N
Before IN N
and CC N
after IN N
the DT N
12 CD N
week NN N
supplementation NN N
period NN N
subjects NNS N
cycled VBD N
for IN N
45 CD N
min NN N
at IN N
submaximal JJ N
intensity NN N
50 CD N
maximal JJ N
workload NN N
capacity NN N
Antipyrine NNP N
was VBD N
used VBN N
as IN N
marker NN N
for IN N
oxidative JJ N
stress NN N
Antipyrine NNP N
reacts VBZ N
quickly RB N
with IN N
hydroxyl JJ N
radicals NNS N
to TO N
form VB N
para- JJ N
and CC N
ortho-hydroxyantipyrine JJ N
The DT N
latter JJ N
metabolite NN N
is VBZ N
not RB N
formed VBN N
in IN N
man NN N
through IN N
the DT N
mono-oxygenase JJ N
pathway NN N
of IN N
cytochrome JJ N
P450 NNP N
Daily NNP N
supplementation NN N
significantly RB N
increased VBD N
plasma JJ N
concentrations NNS N
of IN N
alpha-tocopherol NN N
and CC N
beta-carotene NN N
in IN N
the DT N
supplemented VBN N
group NN N
Delta NNP N
14.4 CD N
SE NNP N
3.2 CD N
and CC N
0.4 CD N
se VB N
0.1 CD N
micromol/l NN N
P NNP N
0.001 CD N
and CC N
P NNP N
0.01 CD N
No DT N
significant JJ N
differences NNS N
within IN N
and CC N
between IN N
groups NNS N
were VBD N
observed VBN N
in IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
the DT N
ratios NNS N
para- JJ N
and CC N
ortho-hydroxyantipyrine JJ N
to TO N
antipyrine VB N
In IN N
addition NN N
supplementation NN N
did VBD N
not RB N
affect VB N
the DT N
exercise-induced JJ N
increase NN N
in IN N
thiobarbituric JJ N
acid NN N
reactive JJ N
substances NNS N
in IN N
plasma NN N
In IN N
conclusion NN N
in IN N
60-year-old JJ 1_p
subjects NNS 1_p
antioxidant JJ N
supplementation NN N
had VBD N
no DT N
effect NN N
on IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
oxidative JJ N
stress NN N
as IN N
measured VBN N
by IN N
free JJ N
radical JJ N
products NNS N
of IN N
antipyrine NN N
-DOCSTART- -X- O O

Review NN N
of IN N
the DT N
Multicenter NNP N
Trial NNP N
Committee NNP N
report NN N
a DT N
prospective JJ N
randomized VBN N
study NN N
on IN N
the DT N
prophylaxis NN N
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
The DT N
etiology NN N
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
DVT NNP N
is VBZ N
thought VBN N
to TO N
be VB N
due JJ N
to TO N
a DT N
combination NN N
of IN N
factors NNS N
including VBG N
stasis NN N
a DT N
hypercoagulable JJ N
state NN N
and CC N
venous JJ N
endothelial JJ N
damage NN N
Methods NNS N
of IN N
prophylaxis NN N
are VBP N
directed VBN N
toward IN N
correcting VBG N
one CD N
or CC N
more JJR N
of IN N
these DT N
pathologic JJ N
events NNS N
Methods NNS N
counteracting VBG N
more JJR N
than IN N
one CD N
of IN N
these DT N
factors NNS N
can MD N
be VB N
expected VBN N
to TO N
be VB N
even RB N
more RBR N
effective JJ N
The DT N
combination NN N
of IN N
dihydroergotamine NN N
DHE NNP N
and CC N
heparin NN N
was VBD N
anticipated VBN N
to TO N
minimize VB N
stasis NN N
and CC N
the DT N
hypercoagulable JJ N
state NN N
respectively RB N
Based VBN N
upon IN N
current JJ N
experimental JJ N
evidence NN N
and CC N
current JJ N
theory NN N
an DT N
additional JJ N
benefit NN N
might MD N
include VB N
minimizing VBG N
venous JJ N
endothelial JJ N
injury NN N
by IN N
controlling VBG N
venomotor NN N
tone NN N
A DT N
prospective JJ N
randomized VBN N
double-blind JJ N
multicenter JJ N
trial NN N
was VBD N
designed VBN N
and CC N
performed VBN N
in IN N
the DT N
United NNP 4_p
States NNPS 4_p
evaluating VBG N
the DT N
prophylactic JJ N
efficacy NN N
of IN N
DHE NNP N
0.5 CD N
mg NN N
plus CC N
heparin JJ N
5000 CD N
U NNP N
DHE NNP N
0.5 CD N
mg NN N
plus CC N
heparin JJ N
2500 CD N
U NNP N
heparin NN N
5000 CD N
U NNP N
and CC N
DHE NNP N
0.5 CD N
mg NN N
versus NN N
placebo NN N
General NNP 4_p
surgical JJ 4_p
patients NNS 4_p
including VBG 4_p
those DT 4_p
undergoing JJ 4_p
noncardiac JJ 4_p
thoracic NN 4_p
and CC 4_p
pelvic JJ 4_p
operations NNS 4_p
who WP 4_p
were VBD 4_p
identified VBN 4_p
at IN 4_p
moderate JJ 4_p
to TO 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
postop JJ 4_p
DVT NNP 4_p
were VBD 4_p
included VBN 4_p
Study NNP N
medications NNS N
were VBD N
injected VBN N
subcutaneously RB N
two CD N
hours NNS N
preoperatively RB N
and CC N
every DT N
12 CD N
hours NNS N
postoperatively RB N
for IN N
5-7 JJ N
days NNS N
or CC N
until IN N
the DT N
125I-fibrinogen-uptake JJ N
test NN N
RFUT NNP N
became VBD N
positive JJ N
Eight NNP 3_p
hundred VBD 3_p
and CC 3_p
eighty JJ 3_p
eight CD 3_p
patients NNS N
were VBD N
entered VBN N
into IN N
this DT N
trial NN N
and CC N
744 CD 3_p
85 CD N
completed VBD N
the DT N
study NN N
Results NNP N
showed VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
DHE/Hep NNP N
5000 CD N
compared VBN N
to TO N
placebo VB N
p NN N
less JJR N
than IN N
0.01 CD N
and CC N
compared VBN N
to TO N
other JJ N
active JJ N
agents NNS N
p NN N
less JJR N
than IN N
0.05 CD N
None NN N
of IN N
the DT N
other JJ N
active JJ N
agents NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
prophylactic JJ N
benefit NN N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
-DOCSTART- -X- O O

Improving VBG N
wound IN N
healing VBG N
after IN 4_p
nose JJ 4_p
surgery NN 4_p
by IN N
combined JJ N
administration NN N
of IN N
xylometazoline NNP N
and CC N
dexpanthenol JJ N
BACKGROUND NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
examination NN N
of IN N
efficacy NN N
and CC N
tolerability NN N
of IN N
an DT N
application-form NN N
of IN N
the DT N
new JJ N
combination NN N
of IN N
Xylometazoline NN N
with IN N
Dexpanthenol NNP N
Nasic NNP N
versus FW N
Xylometazoline NNP N
alone RB N
PATIENTS NNP N
AND CC N
METHODS NNP N
Randomized NNP N
verum NN N
controlled VBD N
parallel-group-comparison NN N
of IN N
two CD N
weeks NNS N
treatment NN N
of IN N
a DT N
nasal-spray JJ N
61 CD 3_p
inpatients NNS 4_p
with IN 4_p
the DT 4_p
diagnosis NN 4_p
Rhinitis NNP 4_p
following VBG 4_p
nasal JJ 4_p
operation NN 4_p
were VBD N
included VBN N
in IN N
this DT N
study NN N
and CC N
30 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
verum NN N
and CC N
placebo NN N
each DT N
The DT N
assessment NN N
of IN N
nasal-breathing-resistance NN N
according VBG N
to TO N
scores NNS N
was VBD N
defined VBN N
as IN N
target-parameter NN N
Confirmatory NNP N
statistical JJ N
analysis NN N
was VBD N
carried VBN N
out RP N
according VBG N
to TO N
Wilcoxon-Mann-Whitney-U JJ N
two-sided JJ N
at IN N
alpha JJ N
or CC N
0.05 CD N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
superiority NN N
of IN N
the DT N
combination NN N
of IN N
Xylometazoline-Dexpanthenol JJ N
nasal-spray JJ N
versus NN N
Xylometazoline NNP N
nasal NN N
spray NN N
could MD N
be VB N
proven VBN N
for IN N
the DT N
target-parameter NN N
as IN N
clinically RB N
relevant JJ N
and CC N
statistically RB N
significant JJ N
The DT N
clinically RB N
proven JJ N
efficacy NN N
is VBZ N
emphasized VBN N
by IN N
good JJ N
tolerability NN N
of IN N
both DT N
treatments NNS N
Due NNP N
to TO N
easy VB N
handling NN N
of IN N
the DT N
nasal-spray JJ N
a DT N
good JJ N
compliance NN N
was VBD N
confirmed VBN N
CONCLUSION NNP N
Distinct NNP N
improvement NN N
of IN N
symptoms NNS N
in IN N
patients NNS 4_p
following VBG 4_p
nasal JJ 4_p
operations NNS 4_p
underlines VBP N
the DT N
efficacy NN N
of IN N
both DT N
medications NNS N
With IN N
respect NN N
to TO N
the DT N
tolerability NN N
therapy NN N
with IN N
the DT N
combination NN N
is VBZ N
more RBR N
beneficial JJ N
in IN N
comparison NN N
to TO N
the DT N
alternative JJ N
therapy NN N
The DT N
result NN N
of IN N
this DT N
controlled VBN N
clinical JJ N
study NN N
confirms VBZ N
that IN N
the DT N
combination NN N
Xylometazoline-Dexpanthenol NNP N
is VBZ N
an DT N
enlargement NN N
and CC N
improvement NN N
of IN N
effective JJ N
medicinal JJ N
treatment NN N
of IN N
rhinitis NN 4_p
following VBG 4_p
nasal JJ 4_p
operation NN 4_p
in IN N
comparison NN N
to TO N
therapy VB N
with IN N
Xylometazoline NNP N
alone RB N
-DOCSTART- -X- O O

Changes NNS N
in IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
the DT N
plasma NN N
lipid JJ N
esters NNS N
during IN N
lipid-lowering JJ N
treatment NN N
with IN N
diet JJ N
clofibrate NN N
and CC N
niceritrol NN N
Reduction NN N
of IN N
the DT N
proportion NN N
of IN N
linoleate NN N
by IN N
clofibrate NN N
but CC N
not RB N
by IN N
niceritrol NN N
The DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
the DT N
plasma NN N
lipid JJ N
esters NNS N
has VBZ N
been VBN N
studied VBN N
during IN N
lipid-lowering JJ N
treatment NN N
of IN N
95 CD 3_p
patients NNS 3_p
with IN 3_p
atherosclerotic JJ 3_p
disease NN 3_p
During IN N
the DT N
first JJ N
two CD N
months NNS N
of IN N
the DT N
trial NN N
only RB N
a DT N
diet NN N
was VBD N
prescribed VBN N
During IN N
the DT N
ensuing VBG N
two CD N
months NNS N
either CC N
clofibrate NN N
or CC N
niceritrol NN N
a DT N
nicotinic JJ N
acid NN N
ester NN N
was VBD N
added VBN N
in IN N
a DT N
randomized JJ N
order NN N
During IN N
the DT N
last JJ N
two CD N
months NNS N
the DT N
second JJ N
drug NN N
was VBD N
added VBN N
The DT N
combined JJ N
treatment NN N
with IN N
diet JJ N
clofibrate NN N
and CC N
niceritrol NN N
caused VBN N
highly RB N
significant JJ N
serum NN N
lipid JJ N
reductions NNS N
The DT N
fatty JJ N
acid JJ N
composition NN N
in IN N
the DT N
plasma NN N
lipid JJ N
esters NNS N
was VBD N
determined VBN N
in IN N
samples NNS N
from IN N
each DT N
trial NN N
period NN N
to TO N
measure VB N
the DT N
degree NN N
of IN N
dietary JJ N
adherence NN N
During IN N
dietary JJ N
treatment NN N
the DT N
relative JJ N
content NN N
of IN N
saturated JJ N
and CC N
monounsaturated VBD N
fatty JJ N
acids NNS N
secreased VBD N
and CC N
the DT N
polyunsaturated JJ N
fatty JJ N
acids NNS N
increased VBD N
with IN N
an DT N
increasing VBG N
ratio NN N
between IN N
pulyunsaturated VBN N
and CC N
saturated VBN N
fatty JJ N
acids NNS N
P/S NNP N
ratio NN N
in IN N
the DT N
cholesterol NN N
esters NNS N
and CC N
triglycerides NNS N
Only RB N
minor JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
the DT N
phospholipids NNS N
The DT N
changes NNS N
caused VBN N
by IN N
the DT N
diet NN N
were VBD N
partly RB N
reversed VBN N
by IN N
clofibrate NN N
while IN N
niceritrol NN N
did VBD N
not RB N
cause VB N
any DT N
major JJ N
changes NNS N
of IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
Clofibrate NNP N
treatment NN N
coincided VBD N
with IN N
increasing VBG N
amounts NNS N
of IN N
monounsaturated JJ N
fatty JJ N
acids NNS N
especially RB N
oleate JJ N
18 CD N
1 CD N
in IN N
the DT N
cholesterol NN N
esters NNS N
triglycerides NNS N
and CC N
phospholipids NNS N
while IN N
there EX N
were VBD N
significant JJ N
reductions NNS N
of IN N
the DT N
content NN N
of IN N
linoleic NN N
18 CD N
2 CD N
acid NN N
in IN N
both CC N
the DT N
cholesterol NN N
esters NNS N
and CC N
triglycerides NNS N
The DT N
18 CD N
2/18 CD N
1 CD N
ratio NN N
decreased VBN N
significantly RB N
in IN N
all PDT N
the DT N
lipid JJ N
esters NNS N
analyzed VBD N
However RB N
the DT N
P/S NNP N
ratio NN N
was VBD N
not RB N
significantly RB N
affected VBN N
partly RB N
because IN N
the DT N
relative JJ N
content NN N
of IN N
saturated JJ N
fatty JJ N
acids NNS N
also RB N
tended VBD N
to TO N
decrease VB N
during IN N
clofibrate JJ N
treatment NN N
It PRP N
is VBZ N
concluded VBN N
that IN N
addition NN N
of IN N
clofibrate NN N
treatment NN N
to TO N
patients NNS N
who WP N
are VBP N
on IN N
a DT N
diet JJ N
enriched VBN N
with IN N
polyunsaturated JJ N
fats NNS N
is VBZ N
associated VBN N
with IN N
a DT N
change NN N
from IN N
polyunsaturated VBN N
to TO N
monounsaturated VBN N
fatty JJ N
acids NNS N
in IN N
the DT N
plasma NN N
lipid JJ N
esters NNS N
but CC N
does VBZ N
not RB N
significantly RB N
effect NN N
the DT N
ratio NN N
between IN N
polyunsaturated VBN N
and CC N
saturated VBN N
fatty JJ N
acids NNS N
The DT N
fatty JJ N
acid NN N
changes NNS N
caused VBN N
by IN N
clofibrate NN N
treatment NN N
and CC N
counteracted VBN N
by IN N
an DT N
increased JJ N
amount NN N
of IN N
polyunsaturated JJ N
fat NN N
in IN N
the DT N
diet NN N
-DOCSTART- -X- O O

Phase NNP N
III NNP N
study NN N
of IN N
concurrent JJ N
chemoradiotherapy NN N
versus NN N
radiotherapy NN N
alone RB N
for IN N
advanced JJ 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
positive JJ N
effect NN N
on IN N
overall JJ N
and CC N
progression-free JJ N
survival NN N
PURPOSE NNP N
Nasopharyngeal NNP N
carcinoma NN N
NPC NNP N
is VBZ N
a DT N
radiosensitive JJ N
and CC N
chemosensitive JJ N
tumor NN N
This DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
compared VBN N
concurrent JJ N
chemoradiotherapy NN N
CCRT NNP N
versus NN N
radiotherapy NN N
RT NNP N
alone RB N
in IN N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
NPC NNP 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP 4_p
December NNP 4_p
1993 CD 4_p
to TO 4_p
April NNP 4_p
1999 CD 4_p
284 CD 3_p
patients NNS 4_p
with IN 4_p
1992 CD 4_p
American NNP 4_p
Joint NNP 4_p
Committee NNP 4_p
on IN 4_p
Cancer NNP 4_p
stage NN 4_p
III NNP 4_p
to TO 4_p
IV NNP 4_p
M0 NNP 4_p
NPC NNP 4_p
were VBD N
randomly RB N
allocated VBN N
into IN N
two CD N
arms NNS N
Similar JJ N
dosage NN N
and CC N
fractionation NN N
of IN N
RT NNP N
was VBD N
administered VBN N
in IN N
both DT N
arms NNS N
The DT N
investigational JJ N
arm NN N
received VBD N
two CD N
cycles NNS N
of IN N
concurrent JJ N
chemotherapy NN N
with IN N
cisplatin NN N
20 CD N
mg/m NN N
2 CD N
/d NN N
plus CC N
fluorouracil JJ N
400 CD N
mg/m NN N
2 CD N
/d NN N
by IN N
96-hour CD N
continuous JJ N
infusion NN N
during IN N
the DT N
weeks NNS N
1 CD N
and CC N
5 CD N
of IN N
RT NNP N
Survival NNP N
analysis NN N
was VBD N
estimated VBN N
by IN N
the DT N
Kaplan-Meier NNP N
method NN N
and CC N
compared VBN N
by IN N
the DT N
log-rank JJ N
test NN N
RESULTS NNP N
Baseline NNP N
patient JJ N
characteristics NNS N
were VBD N
comparable JJ N
in IN N
both DT N
arms NNS N
After IN N
a DT N
median JJ N
follow-up NN N
of IN N
65 CD N
months NNS N
26.2 CD N
37 CD N
of IN N
141 CD N
and CC N
46.2 CD N
66 CD N
of IN N
143 CD N
of IN N
patients NNS N
developed JJ N
tumor NN N
relapse NN N
in IN N
the DT N
CCRT NNP N
and CC N
RT-alone NNP N
groups NNS N
respectively RB N
The DT N
5-year JJ N
overall JJ N
survival NN N
rates NNS N
were VBD N
72.3 CD N
for IN N
the DT N
CCRT NNP N
arm NN N
and CC N
54.2 CD N
for IN N
the DT N
RT-only JJ N
arm NN N
P NNP N
=.0022 NNP N
The DT N
5-year JJ N
progression-free JJ N
survival NN N
rates NNS N
were VBD N
71.6 CD N
for IN N
the DT N
CCRT NNP N
group NN N
compared VBN N
with IN N
53.0 CD N
for IN N
the DT N
RT-only JJ N
group NN N
P NNP N
=.0012 NNP N
Although IN N
significantly RB N
more JJR N
toxicity NN N
was VBD N
noted VBN N
in IN N
the DT N
CCRT NNP N
arm NN N
including VBG N
leukopenia NN N
and CC N
emesis NN N
compliance NN N
with IN N
the DT N
combined JJ N
treatment NN N
was VBD N
good JJ N
The DT N
second JJ N
cycle NN N
of IN N
concurrent JJ N
chemotherapy NN N
was VBD N
refused VBN N
by IN N
nine CD N
patients NNS N
and CC N
was VBD N
delayed VBN N
for IN N
or CC N
1 CD N
week NN N
for IN N
another DT N
nine CD N
patients NNS N
There EX N
were VBD N
no DT N
treatment-related JJ N
deaths NNS N
in IN N
either DT N
arm NN N
CONCLUSION NN N
We PRP N
conclude VBP N
that DT N
CCRT NNP N
is VBZ N
superior JJ N
to TO N
RT VB N
alone RB N
for IN N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
NPC NNP 4_p
in IN N
endemic JJ N
areas NNS N
-DOCSTART- -X- O O

Effects NNS N
of IN N
low-dose JJ N
aspirin NN N
on IN N
clinic NN N
and CC N
ambulatory JJ N
blood NN N
pressure NN N
in IN N
treated JJ 4_p
hypertensive JJ 4_p
patients NNS 4_p
Collaborative NNP N
Group NNP N
of IN N
the DT N
Primary NNP N
Prevention NNP N
Project NNP N
PPP NNP N
-- : N
Hypertension NNP N
study NN N
Nonsteroidal NNP N
antiinflammatory JJ N
drugs NNS N
may MD N
affect VB N
blood NN N
pressure NN N
BP NNP N
control NN N
in IN N
hypertensive JJ 4_p
patients NNS 4_p
receiving VBG 4_p
drug NN 4_p
treatment NN 4_p
but CC N
data NNS N
on IN N
the DT N
effects NNS N
of IN N
low-dose JJ N
aspirin NNS N
are VBP N
scanty RB N
This DT N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
chronic JJ N
treatment NN N
with IN N
low JJ N
doses NNS N
of IN N
aspirin NN N
100 CD N
mg/day NN N
on IN N
clinic NN N
and CC N
ambulatory JJ N
systolic NN N
SBP NNP N
and CC N
diastolic JJ N
DBP NNP N
BP NNP N
in IN N
hypertensives NNS N
on IN N
chronic NN N
stable JJ N
antihypertensive JJ N
therapy NN N
The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
framework NN N
of IN N
the DT N
Primary NNP N
Prevention NNP N
Project NNP N
PPP NNP N
a DT N
randomized VBN N
controlled VBN N
factorial JJ N
trial NN N
on IN N
the DT N
preventive JJ N
effect NN N
of IN N
aspirin NN N
or CC N
vitamin NN N
E NN N
in IN N
people NNS 4_p
with IN 4_p
one CD 4_p
or CC 4_p
more JJR 4_p
cardiovascular JJ 4_p
risk NN 4_p
factors NNS 4_p
Fifteen NNP N
Italian JJ N
hypertension NN 4_p
units NNS N
studied VBD N
142 CD 3_p
hypertensive JJ 4_p
patients NNS N
76 CD 3_p
men NNS 3_p
66 CD 3_p
women NNS 3_p
mean JJ 1_p
age NN 1_p
59 CD 1_p
+/- JJ 1_p
5.9 CD 1_p
years NNS 1_p
treated VBD 4_p
with IN 4_p
different JJ 4_p
antihypertensive JJ 4_p
drugs NNS 4_p
71 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
aspirin VB N
and CC N
71 CD N
served VBD N
as IN N
controls NNS N
All DT N
patients NNS N
underwent VBD N
a DT N
clinic JJ N
BP NNP N
evaluation NN N
with IN N
an DT N
automatic JJ N
sphygmomanometer NN N
and CC N
a DT N
24-h JJ N
ambulatory NN N
BP NNP N
monitoring NN N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
months NNS N
of IN N
aspirin JJ N
treatment NN N
At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
the DT N
changes NNS N
in IN N
clinic JJ N
SBP NNP N
and CC N
DBP NNP N
were VBD N
not RB N
statistically RB N
different JJ N
in IN N
treated JJ N
and CC N
untreated JJ N
subjects NNS N
Ambulatory NNP N
SBP NNP N
and CC N
DBP NNP N
after IN N
3 CD N
months NNS N
of IN N
aspirin JJ N
treatment NN N
were VBD N
similar JJ N
to TO N
baseline VB N
deltaSBP NN N
-0.5 NN N
mmHg NN N
95 CD N
confidence NN N
intervals NNS N
CI NNP N
from IN N
-1.9 NN N
to TO N
+2.9 VB N
mm JJ N
Hg NNP N
and CC N
deltaDBP JJ N
-1.1 NNP N
mm NN N
Hg NNP N
95 CD N
CI NNP N
from IN N
-2.5 NNP N
to TO N
+0.3 VB N
mm JJ N
Hg NNP N
The DT N
pattern NN N
was VBD N
similar JJ N
in IN N
the DT N
control NN N
group NN N
No DT N
interaction NN N
was VBD N
found VBN N
between IN N
aspirin NN N
and CC N
the DT N
most RBS N
used JJ N
antihypertensive JJ N
drug NN N
classes NNS N
angiotensin IN N
converting VBG N
enzyme JJ N
inhibitors NNS N
and CC N
calcium NN N
antagonists NNS N
Despite IN N
the DT N
relatively RB N
small JJ N
sample NN N
size NN N
our PRP$ N
results NNS N
seem VBP N
to TO N
exclude VB N
any DT N
significant JJ N
influence NN N
of IN N
low-dose JJ N
aspirin NN N
on IN N
BP NNP N
control NN N
in IN N
hypertensives NNS N
under IN N
treatment NN N
-DOCSTART- -X- O O

Randomized VBN N
controlled VBD N
study NN N
of IN N
chemoimmunotherapy NN N
with IN N
bestatin NN N
of IN N
acute JJ 4_p
nonlymphocytic JJ 4_p
leukemia NN 4_p
in IN N
adults NNS 1_p
A DT N
new JJ N
immunomodulating NN N
agent NN N
bestatin NN N
INN NNP N
Ubenimex NNP N
has VBZ N
low JJ N
toxicity NN N
even RB N
after IN N
long-term JJ N
oral JJ N
administration NN N
and CC N
has VBZ N
significant JJ N
modifications NNS N
in IN N
immunological JJ N
response NN N
A DT N
cooperative JJ N
randomized NN N
controlled VBD N
study NN N
of IN N
bestatin NN N
immunotherapy NN N
in IN N
combination NN N
with IN N
remission NN N
maintenance NN N
chemotherapy NN N
for IN N
adult NN 1_p
acute JJ 4_p
nonlymphocytic JJ 4_p
leukemia NN 4_p
ANLL NNP 4_p
was VBD N
performed VBN N
After IN N
induction NN N
of IN N
complete JJ N
remission NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
bestatin NN N
group NN N
30 CD N
mg/bw NN N
per IN N
os NN N
po NN N
daily RB N
and CC N
the DT N
control NN N
group NN N
The DT N
101 CD 3_p
eligible JJ N
cases NNS N
bestatin NN N
48 CD 3_p
control NN N
53 CD 3_p
were VBD N
analyzed VBN N
the DT N
bestatin NN N
group NN N
achieved VBD N
longer JJR N
remission NN N
than IN N
the DT N
control NN N
group NN N
and CC N
a DT N
statistically RB N
significant JJ N
longer JJR N
survival NN N
Though IN N
this DT N
prolongation NN N
of IN N
remission NN N
was VBD N
not RB N
significant JJ N
in IN N
the DT N
bestatin NN N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
in IN N
the DT N
15-49 JJ N
yr NN N
age NN N
group NN N
in IN N
the DT N
50-65 JJ N
yr NN N
age NN N
group NN N
it PRP N
was VBD N
significantly RB N
longer JJR N
Bestatin NNP N
is VBZ N
shown VBN N
to TO N
be VB N
a DT N
clinically RB N
useful JJ N
drug NN N
for IN N
immunotherapy NN N
of IN N
adult NN N
ANLL NNP N
since IN N
it PRP N
has VBZ N
prolonged VBN N
survival NN N
and CC N
remission NN N
especially RB N
in IN N
elderly JJ N
patients NNS N
with IN N
few JJ N
side-effects NNS N
-DOCSTART- -X- O O

Remote NNP N
ischaemic JJ N
conditioning NN N
before IN N
hospital JJ N
admission NN N
as IN N
a DT N
complement NN N
to TO N
angioplasty VB N
and CC N
effect NN N
on IN N
myocardial JJ N
salvage NN N
in IN N
patients NNS 4_p
with IN 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
a DT N
randomised JJ N
trial NN N
BACKGROUND NNP N
Remote NNP N
ischaemic JJ N
preconditioning NN N
attenuates NNS N
cardiac JJ N
injury NN N
at IN N
elective JJ N
surgery NN N
and CC N
angioplasty NN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
remote VBP N
ischaemic JJ N
conditioning NN N
during IN N
evolving VBG N
ST-elevation NNP N
myocardial JJ N
infarction NN N
and CC N
done VBN N
before IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
increases VBZ N
myocardial JJ N
salvage NN N
METHODS NNP N
333 CD 3_p
consecutive JJ 4_p
adult NN 4_p
patients NNS 4_p
with IN 4_p
a DT 4_p
suspected VBN 4_p
first JJ 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
by IN N
computerised JJ N
block NN N
randomisation NN N
to TO N
receive VB N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
with IN N
n=166 JJ N
patients NNS N
versus NN N
without IN N
n=167 NN N
remote VBP N
conditioning VBG N
intermittent JJ N
arm NN N
ischaemia NN N
through IN N
four CD N
cycles NNS N
of IN N
5-min JJ N
inflation NN N
and CC N
5-min JJ N
deflation NN N
of IN N
a DT N
blood-pressure JJ N
cuff NN N
Allocation NN N
was VBD N
concealed VBN N
with IN N
opaque NN N
sealed VBN N
envelopes NNS N
Patients NNS N
received VBD N
remote JJ N
conditioning NN N
during IN N
transport NN N
to TO N
hospital NN N
and CC N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
hospital NN N
The DT N
primary JJ N
endpoint NN N
was VBD N
myocardial JJ N
salvage NN N
index NN N
at IN N
30 CD N
days NNS N
after IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
measured VBN N
by IN N
myocardial JJ N
perfusion NN N
imaging NN N
as IN N
the DT N
proportion NN N
of IN N
the DT N
area NN N
at IN N
risk NN N
salvaged VBN N
by IN N
treatment NN N
analysis NN N
was VBD N
per IN N
protocol NN N
This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
number NN N
NCT00435266 NNP N
FINDINGS NNP N
82 CD 3_p
patients NNS 4_p
were VBD 4_p
excluded VBN 4_p
on IN 4_p
arrival NN 4_p
at IN 4_p
hospital NN 4_p
because IN 4_p
they PRP 4_p
did VBD 4_p
not RB 4_p
meet VB 4_p
inclusion NN 4_p
criteria NNS 4_p
32 CD 3_p
were VBD 4_p
lost VBN 4_p
to TO 4_p
follow-up NN 4_p
and CC 4_p
77 CD 3_p
did VBD 4_p
not RB 4_p
complete VB 4_p
the DT 4_p
follow-up JJ 4_p
with IN N
data NNS N
for IN N
salvage NN N
index NN N
Median JJ N
salvage NN N
index NN N
was VBD N
0.75 CD N
IQR NNP N
0.50-0.93 CD N
n=73 NN N
in IN N
the DT N
remote JJ N
conditioning NN N
group NN N
versus VBD N
0.55 CD N
0.35-0.88 CD N
n=69 NN N
in IN N
the DT N
control NN N
group NN N
with IN N
median JJ N
difference NN N
of IN N
0.10 CD N
95 CD N
CI NNP N
0.01-0.22 CD N
p=0.0333 NN N
mean JJ N
salvage NN N
index NN N
was VBD N
0.69 CD N
SD NNP N
0.27 CD N
versus NN N
0.57 CD N
0.26 CD N
with IN N
mean JJ N
difference NN N
of IN N
0.12 CD N
95 CD N
CI NNP N
0.01-0.21 CD N
p=0.0333 NN N
Major JJ N
adverse JJ N
coronary JJ N
events NNS N
were VBD N
death NN N
n=3 JJ N
per IN N
group NN N
reinfarction NN N
n=1 JJ N
per IN N
group NN N
and CC N
heart NN N
failure NN N
n=3 JJ N
per IN N
group NN N
INTERPRETATION NNP N
Remote NNP N
ischaemic JJ N
conditioning NN N
before IN N
hospital JJ N
admission NN N
increases VBZ N
myocardial JJ N
salvage NN N
and CC N
has VBZ N
a DT N
favourable JJ N
safety NN N
profile NN N
Our PRP$ N
findings NNS N
merit VBP N
a DT N
larger JJR N
trial NN N
to TO N
establish VB N
the DT N
effect NN N
of IN N
remote JJ N
conditioning NN N
on IN N
clinical JJ N
outcomes NNS N
FUNDING NN N
Fondation NNP N
Leducq NNP N
-DOCSTART- -X- O O

Assessment NN N
of IN N
acute JJ N
bronchodilator NN N
effects NNS N
from IN N
specific JJ N
airway NN N
resistance NN N
changes NNS N
in IN N
stable JJ 4_p
COPD NNP 4_p
patients NNS 4_p
BACKGROUND NNP N
In IN N
COPD NNP 4_p
patients NNS 4_p
reversibility NN N
is VBZ N
currently RB N
evaluated VBN N
from IN N
the DT N
changes NNS N
of IN N
forced JJ N
expiratory NN N
volume NN N
at IN N
1s CD N
ΔFEV1 NN N
and CC N
forced VBN N
vital JJ N
capacity NN N
ΔFVC NNP N
By IN N
lowering VBG N
peripheral JJ N
airway RB N
smooth JJ N
muscle NN N
tone NN N
bronchodilators NNS N
should MD N
decrease VB N
dynamic JJ N
hyperinflation NN N
gas NN N
trapping NN N
and CC N
possibly RB N
dyspnea VB N
at IN N
rest NN N
Hence NNP N
we PRP N
hypothesize VBP N
that IN N
specific JJ N
airway NN N
resistance NN N
changes NNS N
ΔsRAW NN N
should MD N
better RBR N
characterize VB N
the DT N
acute JJ N
response NN N
to TO N
bronchodilators NNS N
METHODS NNP N
On IN N
two CD N
days NNS N
60 CD 3_p
COPD NNP 4_p
patients NNS N
underwent JJ N
dyspnea JJ N
evaluation NN N
VAS NNP N
score NN N
and CC N
pulmonary JJ N
function NN N
testing VBG N
at IN N
baseline NN N
and CC N
one CD N
hour NN N
after IN N
placebo NN N
or CC N
300μg CD N
indacaterol JJ N
administration NN N
RESULTS NNP N
Spirographic NNP N
and CC N
ΔsRAW-based JJ N
criteria NNS N
identified VBN N
as IN N
responders NNS N
24 CD N
and CC N
45 CD N
patients NNS N
respectively RB N
ΔsRAW NN N
correlated VBD N
with IN N
changes NNS N
of IN N
intrathoracic NN N
gas NN N
volume NN N
ΔITGV NN N
r=0.61 NN N
p CC N
0.001 CD N
residual JJ N
volume NN N
ΔRV NN N
r=0.60 NN N
p CC N
0.001 CD N
ΔFVC NNP N
r=0.44 NN N
p=0.001 NN N
and CC N
ΔVAS NNP N
r=0.73 NN N
p CC N
0.001 CD N
while IN N
ΔFEV1 NN N
correlated VBD N
only RB N
with IN N
ΔFVC NNP N
r=0.34 NN N
p=0.008 NN N
Significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
ΔITGV NN N
p=0.002 NN N
ΔRV NNP N
p=0.023 NN N
and CC N
ΔVAS NNP N
p JJ N
0.001 CD N
occurred VBD N
only RB N
if IN N
patients NNS N
were VBD N
stratified VBN N
according VBG N
to TO N
ΔsRAW NNP N
CONCLUSIONS NNP N
In IN N
assessing VBG N
the DT N
acute JJ N
functional JJ N
effect NN N
of IN N
bronchodilators NNS N
ΔsRAW-based JJ N
criterion NN N
is VBZ N
preferable JJ N
to TO N
FEV1-FVC-based JJ N
criteria NNS N
being VBG N
more RBR N
closely RB N
related VBN N
to TO N
bronchodilator-induced JJ N
improvements NNS N
of IN N
lung NN N
mechanics NNS N
and CC N
dyspnea NN N
at IN N
rest NN N
-DOCSTART- -X- O O

Inverse JJ N
Effect NNP N
of IN N
Fluoxetine NNP N
on IN N
Medial NNP N
Prefrontal NNP N
Cortex NNP N
Activation NNP N
During IN N
Reward NNP N
Reversal NNP N
in IN N
ADHD NNP 4_p
and CC 4_p
Autism NNP 4_p
Attention NNP 4_p
deficit NN 4_p
hyperactivity NN 4_p
disorder NN 4_p
ADHD NNP 4_p
and CC 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
ASD NNP 4_p
share NN N
brain NN N
function NN N
abnormalities NNS N
during IN N
cognitive JJ N
flexibility NN N
Serotonin NNP N
is VBZ N
involved VBN N
in IN N
both DT N
disorders NNS N
and CC N
selective JJ N
serotonin NN N
reuptake NN N
inhibitors NNS N
SSRIs NNP N
can MD N
modulate VB N
cognitive JJ N
flexibility NN N
and CC N
improve VB N
behavior NN N
in IN N
both DT N
disorders NNS N
Thus RB N
this DT N
study NN N
investigates VBZ N
shared VBN N
and CC N
disorder-specific JJ N
brain NN N
dysfunctions NNS N
in IN N
these DT N
2 CD N
disorders NNS N
during IN N
reward NN N
reversal NN N
and CC N
the DT N
acute JJ N
effects NNS N
of IN N
an DT N
SSRI NNP N
on IN N
these DT N
Age-matched JJ N
boys NNS N
with IN N
ADHD NNP N
15 CD 3_p
ASD NNP N
18 CD 3_p
and CC N
controls NNS N
21 CD 3_p
were VBD N
compared VBN N
with IN N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
fMRI JJ N
during IN N
a DT N
reversal NN N
task NN N
Patients NNS N
were VBD N
scanned VBN N
twice RB N
under IN N
either DT N
an DT N
acute NN N
dose NN N
of IN N
Fluoxetine NNP N
or CC N
placebo NN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
randomized JJ N
design NN N
Repeated-measures JJ N
analyses NNS N
within IN N
patients NNS N
assessed JJ N
drug NN N
effects NNS N
Patients NNS N
under IN N
each DT N
drug NN N
condition NN N
were VBD N
compared VBN N
with IN N
controls NNS N
to TO N
assess VB N
normalization NN N
effects NNS N
fMRI NN N
data NNS N
showed VBD N
that IN N
under IN N
placebo NN N
ASD NNP N
boys VBZ N
underactivated JJ N
medial JJ N
prefrontal NN N
cortex NN N
mPFC NN N
compared VBN N
with IN N
control NN N
and CC N
ADHD NNP N
boys NNS N
Both DT N
patient JJ N
groups NNS N
shared VBD N
decreased JJ N
precuneus NN N
activation NN N
Under IN N
Fluoxetine NNP N
mPFC JJ N
activation NN N
was VBD N
up-regulated JJ N
and CC N
normalized VBN N
in IN N
ASD NNP N
boys NNS N
relative VBP N
to TO N
controls NNS N
but CC N
down-regulated JJ N
in IN N
ADHD NNP N
boys NNS N
relative VBP N
to TO N
placebo VB N
which WDT N
was VBD N
concomitant NN N
with IN N
worse JJR N
task NN N
performance NN N
in IN N
ADHD NNP N
Fluoxetine NNP N
therefore NN N
has VBZ N
inverse JJ N
effects NNS N
on IN N
mPFC JJ N
activation NN N
in IN N
ASD NNP N
and CC N
ADHD NNP N
during IN N
reversal NN N
learning NN N
suggesting VBG N
dissociated VBN N
underlying JJ N
serotonin NN N
abnormalities NNS N
-DOCSTART- -X- O O

Intervention NN N
pilot NN N
for IN N
parents NNS 1_p
of IN 1_p
children NNS 1_p
with IN N
autistic JJ 4_p
spectrum NN 4_p
disorder NN 4_p
Parents NNS 1_p
of IN 1_p
children NNS 1_p
who WP N
receive VBP N
the DT N
diagnosis NN 4_p
of IN 4_p
autistic JJ 4_p
spectrum NN 4_p
disorder NN 4_p
ASD NNP 4_p
experience NN N
a DT N
situational JJ N
crisis NN N
related VBN N
to TO N
receiving VBG N
the DT N
diagnosis NN N
which WDT N
causes VBZ N
feelings NNS N
of IN N
distress NN N
and CC N
urgency NN N
to TO N
access NN N
services NNS N
for IN N
the DT N
affected JJ N
child NN N
This DT N
paper NN N
describes VBZ N
a DT N
randomized JJ N
trial NN N
n JJ N
31 CD N
that WDT N
was VBD N
conducted VBN N
at IN N
a DT N
regional JJ N
diagnostic JJ N
center NN N
of IN N
a DT N
large JJ N
metropolitan JJ N
children NNS N
's POS N
hospital NN N
to TO N
a DT N
refine NN N
a DT N
nursing NN N
intervention NN N
designed VBN N
for IN N
parents NNS 4_p
of IN 4_p
children NNS 4_p
with IN 4_p
ASD NNP 4_p
and CC N
b NN N
to TO N
identify VB N
methodological JJ N
revisions NNS N
for IN N
a DT N
larger JJR N
study NN N
A DT N
secondary JJ N
purpose NN N
was VBD N
to TO N
test VB N
the DT N
effects NNS N
of IN N
a DT N
post-diagnosis JJ N
nursing NN N
intervention NN N
on IN N
parents NNS N
reports NNS N
of IN N
stress NN N
impact NN N
of IN N
event NN N
diagnosis NN N
and CC N
use NN N
of IN N
services NNS N
after IN N
a DT N
child NN N
is VBZ N
newly RB N
diagnosed VBN N
with IN N
ASD NNP N
The DT N
intervention NN N
consisted VBD N
of IN N
usual JJ N
care NN N
plus CC N
3 CD N
hours NNS N
contact NN N
with IN N
a DT N
pediatric JJ N
nurse NN N
practitioner NN N
PNP NNP N
for IN N
counseling NN N
instruction NN N
and CC N
assistance NN N
with IN N
implementation NN N
of IN N
the DT N
recommended VBN N
treatment NN N
plan NN N
The DT N
control NN N
group NN N
received VBD N
only RB N
the DT N
usual JJ N
care NN N
post-diagnosis NN N
which WDT N
consisted VBD N
of IN N
a DT N
1-hour JJ N
consultation NN N
session NN N
to TO N
receive VB N
the DT N
results NNS N
of IN N
diagnostic JJ N
tests NNS N
and CC N
a DT N
written VBN N
copy NN N
of IN N
the DT N
recommended VBN N
treatment NN N
plan NN N
provided VBN N
by IN N
a DT N
developmental JJ N
pediatrician JJ N
and/or NN N
PNP NNP N
Between NNP N
group NN N
differences NNS N
in IN N
measures NNS N
of IN N
impact NN N
of IN N
event NN N
and CC N
perceived VBD N
stress JJ N
were VBD N
not RB N
statistically RB N
significant JJ N
This DT N
was VBD N
attributed VBN N
to TO N
a DT N
small JJ N
sample NN N
size NN N
A NNP N
larger JJR N
study NN N
is VBZ N
feasible JJ N
and CC N
recommended VBD N
with IN N
an DT N
expanded JJ N
nursing NN N
intervention NN N
and CC N
a DT N
significantly RB N
larger JJR N
sample NN N
recruited VBD N
from IN N
an DT N
additional JJ N
recruitment NN N
site NN N
Nurses NNS N
working VBG N
with IN N
this DT N
special JJ N
population NN N
must MD N
recognize VB N
that IN N
parents NNS N
have VBP N
information NN N
and CC N
counseling NN N
needs NNS N
that WDT N
begin VBP N
after IN N
they PRP N
receive VBP N
the DT N
diagnosis NN N
of IN N
ASD NNP N
for IN N
their PRP$ N
child NN N
and CC N
can MD N
address VB N
these DT N
needs NNS N
with IN N
a DT N
standardized JJ N
nursing NN N
intervention NN N
-DOCSTART- -X- O O

Effect NNP N
of IN N
branch NN N
chain NN N
amino NN N
acid NN N
enriched VBD N
formula NN N
on IN N
postoperative JJ N
fatigue NN N
and CC N
nutritional JJ N
status NN N
after IN 4_p
digestive JJ 4_p
surgery NN 4_p
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
branch NN N
chain NN N
amino NN N
acid NN N
BCAA NNP N
enriched VBD N
formula NN N
on IN N
nutritional JJ N
status NN N
and CC N
postoperative JJ N
fatigue NN N
for IN N
digestive JJ 4_p
surgery NN 4_p
patients NNS 4_p
METHODS NNP N
Forty NNP 3_p
patients NNS 4_p
who WP 4_p
underwent VBP 4_p
digestive JJ 4_p
surgery NN 4_p
were VBD N
randomly RB N
received VBN N
parenteral JJ N
nutrition NN N
with IN N
either DT N
BCAA NNP N
enriched VBD N
study NN N
group NN N
n=20 RB N
or CC N
routine JJ N
amino NN N
acid NN N
control NN N
group NN N
n=20 RB N
for IN N
seven CD N
consecutive JJ N
days NNS N
Nitrogen NNP N
balance NN N
serum JJ N
total NN N
protein NN N
albumin NN N
prealbumin NN N
transferrin NN N
retinol NN N
binding NN N
protein NN N
and CC N
postoperative JJ N
fatigue NN N
score NN N
were VBD N
monitored VBN N
during IN N
the DT N
postoperative JJ N
period NN N
RESULTS VB N
The DT N
cumulative JJ N
postoperative JJ N
fatigue NN N
scores NNS N
were VBD N
lower JJR N
in IN N
BCAA NNP N
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
at IN N
the DT N
4th CD N
5th CD N
and CC N
7th CD N
day NN N
after IN N
operation NN N
P NNP N
0.05 CD N
Patients NNS N
achieved VBD N
positive JJ N
nitrogen NN N
balance NN N
2 CD N
days NNS N
earlier RBR N
in IN N
the DT N
study NN N
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
cumulative JJ N
nitrogen NN N
balance NN N
between IN N
the DT N
two CD N
groups NNS N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
elevation NN N
of IN N
serum JJ N
total JJ N
protein NN N
albumin NN N
prealbumin NN N
transferrin NN N
at IN N
the DT N
7th CD N
day NN N
after IN N
operation NN N
between IN N
the DT N
two CD N
groups NNS N
P NNP N
0.05 CD N
compared VBN N
with IN N
those DT N
at IN N
the DT N
first JJ N
day NN N
after IN N
operation NN N
The DT N
serum JJ N
level NN N
of IN N
retinol NN N
binding VBG N
protein NN N
was VBD N
higher JJR N
in IN N
BCAA-enriched NNP N
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
P=0.004 NNP N
CONCLUSION NNP N
TPN NNP N
with IN N
BCAA NNP N
enriched VBD N
formula NN N
can MD N
reduce VB N
postoperative JJ N
fatigue NN N
score NN N
and CC N
improve VB N
the DT N
nutritional JJ N
status NN N
for IN N
digestive JJ 4_p
surgery NN 4_p
patients NNS 4_p
-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
two CD N
types NNS N
of IN N
teacher NN N
training NN N
on IN N
implementation NN N
of IN N
Smart NNP N
Choices NNPS N
a DT N
tobacco NN N
prevention NN N
curriculum NN N
This DT N
study NN N
examined VBD N
the DT N
implementation NN N
phase NN N
of IN N
a DT N
four-year JJ N
research NN N
project NN N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
strategies NNS N
to TO N
increase VB N
diffusion NN N
of IN N
Smart NNP N
Choices NNP N
a DT N
school-based JJ N
tobacco NN N
prevention NN N
program NN N
The DT N
impact NN N
on IN N
curriculum JJ N
implementation NN N
of IN N
two CD N
approaches NNS N
to TO N
teacher VB N
training NN N
are VBP N
compared VBN N
School JJ 4_p
districts NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
live JJ N
workshop NN N
training NN N
or CC N
video NN N
training NN N
condition NN N
The DT N
outcome NN N
of IN N
the DT N
evaluation NN N
was VBD N
teachers NNS N
implementation NN N
of IN N
Smart NNP N
Choices NNP N
Results NNP N
show VBP N
a DT N
lower JJR N
proportion NN N
of IN N
video-trained JJ N
teachers NNS N
implemented VBD N
the DT N
curriculum NN N
but CC N
overall JJ N
completeness NN N
and CC N
fidelity NN N
of IN N
implementation NN N
for IN N
those DT N
teachers NNS N
who WP N
did VBD N
teach VB N
the DT N
curriculum NN N
were VBD N
comparable JJ N
for IN N
the DT N
two CD N
groups NNS N
Video-trained JJ N
teachers NNS N
however RB N
were VBD N
less RBR N
likely JJ N
to TO N
use VB N
brainstorming NN N
and CC N
student NN N
presentations/role NN N
plays NNS N
two CD N
of IN N
the DT N
methods NNS N
prescribed VBN N
by IN N
the DT N
curriculum NN N
Implications NNS N
of IN N
the DT N
results NNS N
for IN N
teacher JJ N
training NN N
are VBP N
discussed VBN N
-DOCSTART- -X- O O

Postural NNP N
biofeedback NN N
and CC N
locomotion NN N
reeducation NN N
in IN N
stroke NN 4_p
patients NNS 4_p
AIMS NNP N
To TO N
compare VB N
in IN N
post-acute JJ 4_p
hemiparetic JJ 4_p
patients NNS 4_p
gait NN N
improvement NN N
after IN N
conventional JJ N
physical JJ N
therapy NN N
alone RB N
or CC N
with IN N
a DT N
specialised JJ N
balance NN N
retraining VBG N
program NN N
PATIENTS VB N
Twenty-six JJ 3_p
patients NNS 4_p
within IN 4_p
3 CD 4_p
months NNS 4_p
of IN 4_p
onset NN 4_p
of IN 4_p
stroke NN 4_p
were VBD N
randomised VBN N
to TO N
receive VB N
physical JJ N
therapy NN N
control VB N
group NN N
or CC N
therapy NN N
and CC N
retraining NN N
experimental JJ N
group NN N
most JJS N
of IN N
the DT N
patients NNS N
in IN N
both DT N
groups NNS N
with IN N
left JJ N
hemiplegia NN N
The DT N
experimental JJ N
group NN N
was VBD N
significantly RB N
older JJR N
than IN N
the DT N
control NN N
group NN N
METHOD NNP N
Thirteen NNP N
patients NNS N
received VBD N
early JJ N
conventional JJ N
therapy NN N
and CC N
13 CD N
received VBD N
therapy NN N
combined VBN N
with IN N
standing VBG N
balance NN N
training NN N
by IN N
biofeedback NN N
BPM NNP N
Monitor NNP N
Clinical JJ N
measures NNS N
were VBD N
collected VBN N
at IN N
entry NN N
J0 NNP N
once RB N
when WRB N
subjects NNS N
began VBD N
to TO N
walk VB N
JM NNP N
and CC N
30 CD N
days NNS N
later RB N
JM NNP N
30 CD N
Gait NNP N
spatiotemporal JJ N
parameters NNS N
were VBD N
collected VBN N
by IN N
use NN N
of IN N
the DT N
Vicon NNP N
system NN N
at IN N
JM NNP N
and CC N
JM NNP N
30 CD N
RESULTS VB N
Whatever IN N
the DT N
method NN N
of IN N
rehabilitation NN N
the DT N
clinical JJ N
scores NNS N
improved VBN N
significantly RB N
between IN N
J0 NNP N
and CC N
JM NNP N
30 CD N
except IN N
for IN N
spasticity NN N
The DT N
time NN N
between IN N
stroke NN N
and CC N
the DT N
beginning NN N
of IN N
walking NN N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
both DT N
groups NNS N
Gait NNP N
velocity NN N
increased VBD N
significantly RB N
between IN N
JM NNP N
and CC N
JM NNP N
30 CD N
in IN N
both DT N
groups NNS N
with IN N
no DT N
difference NN N
between IN N
groups NNS N
The DT N
walking NN N
pattern NN N
was VBD N
improved VBN N
for IN N
both DT N
groups NNS N
with IN N
a DT N
significant JJ N
increase NN N
of IN N
the DT N
duration NN N
of IN N
the DT N
paretic JJ N
limb NN N
single JJ N
stance NN N
The DT N
experimental JJ N
group NN N
significantly RB N
improved VBD N
the DT N
duration NN N
of IN N
the DT N
reception NN N
double JJ N
stance NN N
on IN N
the DT N
paretic JJ N
limb NN N
between IN N
JM NNP N
and CC N
JM NNP N
30 CD N
compared VBN N
with IN N
the DT N
control NN N
group NN N
P NNP N
0.03 CD N
CONCLUSION NNP N
Both NNP N
groups NNS N
demonstrated VBD N
improvement NN N
in IN N
the DT N
rehabilitation NN N
unit NN N
The DT N
benefits NNS N
of IN N
visual JJ N
biofeedback NN N
by IN N
forceplate NN N
system NN N
training VBG N
suggest JJ N
particular JJ N
improvement NN N
of IN N
anticipation NN N
equilibrium NN N
with IN N
conventional JJ N
therapy NN N
-DOCSTART- -X- O O

Youth NN 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
comprehend NN N
lexicalized VBN N
and CC N
novel JJ N
primary JJ N
conceptual JJ N
metaphors NNS N
Individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
ASD NNP 4_p
have VBP N
difficulty NN N
comprehending VBG N
metaphors NNS N
However RB N
no DT N
study NN N
to TO N
date NN N
has VBZ N
examined VBN N
whether IN N
or CC N
not RB N
they PRP N
understand VBP N
conceptual JJ N
metaphors NNS N
i.e NN N
mappings NNS N
between IN N
conceptual JJ N
structures NNS N
which WDT N
could MD N
be VB N
the DT N
building NN N
blocks NNS N
of IN N
metaphoric JJ N
thinking NN N
and CC N
understanding NN N
We PRP N
investigated VBD N
whether IN N
13 CD 3_p
participants NNS 4_p
with IN 4_p
ASD NNP 4_p
age NN 1_p
7 CD 1_p
03-22 CD 1_p
03 CD 1_p
and CC N
13 CD 3_p
age-matched JJ 4_p
typically RB 4_p
developing VBG 4_p
TD NNP 4_p
controls NNS 4_p
could MD N
comprehend VB N
lexicalized JJ N
conceptual JJ N
metaphors NNS N
e.g. NN N
Susan NNP N
is VBZ N
a DT N
warm JJ N
person NN N
and CC N
novel JJ N
ones NNS N
e.g. NN N
Susan NNP N
is VBZ N
a DT N
toasty JJ N
person NN N
Individuals NNS 4_p
with IN 4_p
ASD NNP 4_p
performed VBD N
at IN N
greater JJR N
than IN N
chance NN N
levels NNS N
on IN N
both DT N
metaphor NN N
types NNS N
although IN N
their PRP$ N
performance NN N
was VBD N
lower JJR N
than IN N
TD CD N
participants NNS N
We PRP N
discuss VBP N
the DT N
theoretical JJ N
relevance NN N
of IN N
these DT N
findings NNS N
and CC N
educational JJ N
implications NNS N
-DOCSTART- -X- O O

Comparison NNP N
of IN N
propofol NN N
droperidol NN N
and CC N
metoclopramide NN N
for IN N
prophylaxis NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
after IN N
breast NN 4_p
cancer NN 4_p
surgery NN 4_p
a DT N
prospective JJ N
randomized VBN N
double-blind JJ N
placebo-controlled JJ N
study NN N
in IN N
Japanese JJ 4_p
patients NNS 4_p
BACKGROUND NNP N
Breast NNP N
cancer NN N
surgery NN N
performed VBN N
with IN N
the DT N
patient NN N
under IN N
general JJ N
anesthesia NN N
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
relatively RB N
high JJ N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
PONV NNP N
Between $ N
60 CD N
and CC N
80 CD N
of IN N
patients NNS N
who WP N
undergo VBP N
mastectomy NNS N
with IN N
axillary JJ N
dissection NN N
experience NN N
PONV NNP N
We PRP N
previously RB N
reported VBD N
that IN N
propofol NN N
at IN N
a DT N
subhypnotic JJ N
dose NN N
of IN N
0.5 CD N
mg/kg NN N
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
preventing VBG N
PONV NNP N
in IN N
women NNS N
who WP N
undergo VBP N
mastectomy NN N
OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
a DT N
subhypnotic JJ N
dose NN N
of IN N
propofol NN N
with IN N
the DT N
conventional JJ N
antiemetics NNS N
droperidol NN N
and CC N
metoclopramide NN N
for IN N
the DT N
prophylaxis NN N
of IN N
PONV NNP N
after IN N
breast NN 4_p
cancer NN 4_p
surgery NN 4_p
in IN 4_p
Japanese JJ 4_p
patients NNS 4_p
METHODS NNP N
In IN N
this DT N
prospective JJ N
randomized VBN N
double-blind JJ N
placebo-controlled JJ N
study NN N
Japanese JJ 4_p
women NNS 4_p
were VBD N
randomized VBN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
to TO N
receive VB N
IV NNP N
administration NN N
of IN N
propofol JJ N
0.5 CD N
mg/kg NN N
droperidol VBZ N
20 CD N
microg/kg NN N
metoclopramide RB N
0.2 CD N
mg/kg NN N
or CC N
placebo NN N
isotonic JJ N
saline NN N
immediately RB N
after IN N
skin JJ N
suture NN N
A DT N
standard JJ N
general JJ N
anesthetic JJ N
technique NN N
including VBG N
sevoflurane NN N
and CC N
air NN N
in IN N
oxygen NN N
was VBD N
used VBN N
All DT N
episodes NNS N
of IN N
PONV NNP N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
anesthesia JJ N
administration NN N
were VBD N
recorded VBN N
by IN N
an DT N
investigator NN N
who WP N
was VBD N
blinded VBN N
to TO N
treatment NN N
assignment NN N
The DT N
investigator NN N
questioned VBD N
the DT N
patients NNS N
as IN N
to TO N
whether IN N
they PRP N
experienced VBD N
extrapyramidal NN N
symptoms NNS N
To TO N
maintain VB N
the DT N
integrity NN N
of IN N
the DT N
study NN N
results NNS N
none NN N
of IN N
the DT N
patients NNS N
received VBD N
preanesthetic JJ N
medication NN N
RESULTS VB N
A DT N
total NN N
of IN N
100 CD 3_p
women NNS N
mean JJ 1_p
SD NNP 1_p
age NN 1_p
52 CD 1_p
7 CD 1_p
years NNS 1_p
height VBD 4_p
154 CD 4_p
6 CD 4_p
cm NN 4_p
weight NN 4_p
54 CD 4_p
7 CD 4_p
kg NN 4_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
Each DT N
study NN N
group NN N
comprised VBD N
25 CD N
patients NNS N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
patient VB N
demographics NNS N
surgery NN N
type NN N
or CC N
awakening VBG N
time NN N
The DT N
prevalences NNS N
of IN N
PONV NNP N
0 CD N
to TO N
24 CD N
hours NNS N
after IN N
anesthesia NN N
were VBD N
28 CD N
with IN N
propofol NN N
P NNP N
0.005 CD N
32 CD N
with IN N
droperidol NN N
P NNP N
0.011 CD N
and CC N
60 CD N
with IN N
metoclopramide NN N
P NNP N
NS NNP N
compared VBN N
with IN N
placebo NN N
68 CD N
No DT N
significant JJ N
difference NN N
in IN N
the DT N
prevalence NN N
of IN N
PONV NNP N
was VBD N
found VBN N
between IN N
patients NNS N
receiving VBG N
propofol NN N
and CC N
those DT N
receiving VBG N
droperidol NN N
and CC N
propofol NN N
and CC N
droperidol NN N
were VBD N
associated VBN N
with IN N
significantly RB N
lower JJR N
prevalences NNS N
of IN N
PONV NNP N
compared VBN N
with IN N
metoclopramide NN N
P NNP N
0.022 CD N
and CC N
P NNP N
0.043 CD N
respectively RB N
Extrapyramidal NNP N
symptoms NNS N
were VBD N
not RB N
reported VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
CONCLUSIONS VB N
The DT N
prevalences NNS N
of IN N
PONV NNP N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
propofol NN N
0.5 CD N
mg/kg NN N
and CC N
droperidol NN N
20 CD N
microg/kg NN N
0 CD N
to TO N
24 CD N
hours NNS N
after IN N
anesthesia NN N
in IN N
this DT N
small JJ N
select JJ N
group NN N
of IN N
Japanese JJ N
women NNS N
who WP N
underwent VBP N
breast NN N
cancer NN N
surgery NN N
The DT N
prevalences NNS N
of IN N
PONV NNP N
were VBD N
significantly RB N
lower JJR N
with IN N
propofol NN N
and CC N
droperidol NN N
compared VBN N
with IN N
metoclopramide JJ N
0.2 CD N
mg/kg NN N
and CC N
placebo NN N
-DOCSTART- -X- O O

Oral NNP N
contraceptive NN N
use NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
cardiovascular JJ N
reactivity NN N
in IN N
nonsmokers NNS N
Women NNS N
who WP N
smoke VBD N
and CC N
take VB N
oral JJ N
contraceptives NNS N
OCs NNP N
have VBP N
significantly RB N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
but CC N
the DT N
exact JJ N
mechanismsfor VBZ N
the DT N
increased VBN N
risk NN N
are VBP N
not RB N
known VBN N
Cardiovascular JJ N
reactivity NN N
to TO N
psychological JJ N
stress NN N
may MD N
be VB N
one CD N
mechanism NN N
for IN N
the DT N
enhanced JJ N
risk NN N
but CC N
the DT N
small JJ N
number NN N
of IN N
studies NNS N
examining VBG N
whether IN N
OC NNP N
users NNS N
who WP N
smoke VBP N
have VBP N
greater JJR N
reactivity NN N
have VBP N
produced VBN N
mixed JJ N
results NNS N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
chronic JJ N
cigarette NN N
smoking NN N
acute JJ N
nicotine JJ N
administration NN N
and CC N
OC NNP N
use VBP N
on IN N
cardiovascular NN N
and CC N
lipid JJ N
reactivity NN N
Sixty NNP 3_p
healthy JJ 4_p
women NNS 4_p
half NN 4_p
of IN 4_p
whom WP 4_p
had VBD 4_p
been VBN 4_p
using VBG 4_p
OCs NNP 4_p
for IN 4_p
at IN 4_p
least JJS 4_p
the DT 4_p
previous JJ 4_p
6 CD 4_p
months NNS 4_p
participated VBN N
in IN N
the DT N
study NN N
Approximately RB N
two CD 4_p
thirds NNS 4_p
were VBD 4_p
smokers NNS 4_p
and CC N
were VBD N
randomized VBN N
to TO N
be VB N
tested VBN N
after IN N
either DT N
a DT N
12-hr JJ N
nicotine JJ N
deprivation NN N
or CC N
administration NN N
of IN N
nicotine JJ N
gum NN N
One CD 4_p
third WDT 4_p
were VBD 4_p
nonsmokers NNS 4_p
Heart NNP N
rate NN N
blood NN N
pressure NN N
and CC N
lipid JJ N
measures NNS N
were VBD N
taken VBN N
at IN N
rest NN N
during IN N
a DT N
videotaped JJ N
speech NN N
task NN N
and CC N
during IN N
recovery NN N
from IN N
the DT N
task NN N
Results NNS N
indicated VBD N
that IN N
among IN N
OC NNP N
nonusers NNS N
there EX N
was VBD N
no DT N
effect NN N
of IN N
smoking VBG N
status NN N
or CC N
nicotine JJ N
administration NN N
on IN N
cardiovascular JJ N
reactivity NN N
However RB N
among IN N
OC NNP N
users NNS N
nonsmokers NNS N
had VBD N
significantly RB N
greater JJR N
heart NN N
rate NN N
and CC N
diastolic JJ N
blood NN N
pressure NN N
reactivity NN N
to TO N
stress VB N
These DT N
data NNS N
show VBP N
that IN N
acute JJ N
nicotine JJ N
administration NN N
in IN N
the DT N
form NN N
of IN N
nicotine JJ N
gum NN N
has VBZ N
no DT N
effect NN N
on IN N
cardiovascular NN N
or CC N
lipid JJ N
stress NN N
reactivity NN N
in IN N
women NNS N
However RB N
OC NNP N
use NN N
among IN N
nonsmoking JJ N
women NNS N
is VBZ N
associated VBN N
with IN N
greater JJR N
cardiovascular JJ N
reactivity NN N
to TO N
stress VB N
-DOCSTART- -X- O O

Analysis NN N
of IN N
prevention NN 4_p
program NN 4_p
effectiveness NN N
with IN N
clustered VBN N
data NNS N
using VBG N
generalized JJ N
estimating NN N
equations NNS N
Experimental JJ N
studies NNS N
of IN N
prevention NN N
programs NNS N
often RB N
randomize VBP N
clusters NNS N
of IN N
individuals NNS N
rather RB N
than IN N
individuals NNS N
to TO N
treatment NN N
conditions NNS N
When WRB N
the DT N
correlation NN N
among IN N
individuals NNS N
within IN N
clusters NNS N
is VBZ N
not RB N
accounted VBN N
for IN N
in IN N
statistical JJ N
analysis NN N
the DT N
standard JJ N
errors NNS N
are VBP N
biased VBN N
potentially RB N
resulting VBG N
in IN N
misleading VBG N
conclusions NNS N
about IN N
the DT N
significance NN N
of IN N
treatment NN N
effects NNS N
This DT N
study NN N
demonstrates VBZ N
the DT N
generalized JJ N
estimating NN N
equations NNS N
GEE NNP N
method NN N
focusing VBG N
specifically RB N
on IN N
the DT N
GEE-independent NNP N
method NN N
to TO N
control VB N
for IN N
within-cluster JJ N
correlation NN N
in IN N
regression NN N
models NNS N
with IN N
either DT N
continuous JJ N
or CC N
binary JJ N
outcomes NNS N
The DT N
GEE-independent JJ N
method NN N
yields NNS N
consistent JJ N
and CC N
robust JJ N
variance NN N
estimates NNS N
Data NNS N
from IN N
project NN N
DARE NNP N
a DT N
youth NN 1_p
substance NN 4_p
abuse NN 4_p
prevention NN 4_p
program NN 4_p
are VBP N
used VBN N
for IN N
illustration NN N
-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
selamectin NN N
against IN N
fleas NNS N
and CC N
heartworms NNS N
in IN N
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
presented VBD 4_p
as IN 4_p
veterinary JJ 4_p
patients NNS 4_p
in IN 4_p
North NNP 4_p
America NNP 4_p
A NNP N
series NN N
of IN N
randomized VBN N
controlled VBN N
masked VBD N
field NN N
studies NNS N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
selamectin NN N
in IN N
the DT N
treatment NN N
of IN N
flea NN N
infestations NNS N
on IN N
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
and CC N
in IN N
the DT N
prevention NN N
of IN N
heartworm NN N
infection NN N
in IN N
dogs NNS N
In IN N
addition NN N
observations NNS N
were VBD N
made VBN N
on IN N
the DT N
beneficial JJ N
effect NN N
of IN N
selamectin NN N
treatment NN N
on IN N
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
showing VBG 4_p
signs NNS 4_p
of IN 4_p
flea NN 4_p
allergy NN 4_p
dermatitis NN 4_p
FAD NNP 4_p
In IN N
all DT N
studies NNS N
selamectin VBP N
was VBD N
applied VBN N
topically RB N
once RB N
per IN N
month NN N
in IN N
unit NN N
doses NNS N
providing VBG N
a DT N
minimum JJ N
dosage NN N
of IN N
6mgkg CD N
-1 NN N
Dogs NNS 4_p
and CC 4_p
cats NNS 4_p
with IN 4_p
naturally RB 4_p
occurring VBG 4_p
flea NN 4_p
infestations NNS 4_p
some DT 4_p
of IN 4_p
which WDT 4_p
also RB 4_p
had VBD 4_p
signs NNS 4_p
associated VBN 4_p
with IN 4_p
FAD NNP 4_p
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
three CD N
months NNS N
of IN N
topical JJ N
treatment NN N
with IN N
selamectin NN N
220 CD 3_p
dogs NNS 3_p
189 CD 3_p
cats NNS 3_p
or CC N
a DT N
positive-control JJ N
product NN N
dogs NNS N
fenthion NN N
n=81 RB N
cats NNS N
pyrethrins NNS N
n=66 NN N
Selamectin NNP N
was VBD N
administered VBN N
on IN N
days NNS N
0 CD N
30 CD N
and CC N
60 CD N
Day NNP N
0 CD N
was VBD N
defined VBN N
as IN N
the DT N
day NN N
that IN N
the DT N
animal NN N
first RB N
received VBD N
treatment NN N
Flea NN N
burdens NNS N
were VBD N
assessed VBN N
by IN N
flea NN N
comb NN N
counts NNS N
and CC N
clinical JJ N
evaluations NNS N
of IN N
FAD NNP N
were VBD N
performed VBN N
before IN N
treatment NN N
and CC N
on IN N
days NNS N
14 CD N
30 CD N
60 CD N
and CC N
90 CD N
On IN N
days NNS N
30 CD N
60 CD N
and CC N
90 CD N
mean JJ N
flea NN N
counts NNS N
in IN N
selamectin-treated JJ N
dogs NNS N
were VBD N
reduced VBN N
by IN N
92.1 CD N
99.0 CD N
and CC N
99.8 CD N
and CC N
mean JJ N
flea NN N
counts NNS N
in IN N
fenthion-treated JJ N
dogs NNS N
were VBD N
reduced VBN N
by IN N
81.5 CD N
86.8 CD N
and CC N
86.1 CD N
respectively RB N
compared VBN N
with IN N
day NN N
0 CD N
counts NNS N
Also RB N
on IN N
days NNS N
30 CD N
60 CD N
and CC N
90 CD N
mean JJ N
flea NN N
counts NNS N
in IN N
selamectin-treated JJ N
cats NNS N
were VBD N
reduced VBN N
by IN N
92.5 CD N
98.3 CD N
and CC N
99.3 CD N
and CC N
mean JJ N
flea NN N
counts NNS N
in IN N
pyrethrin-treated JJ N
cats NNS N
were VBD N
reduced VBN N
by IN N
66.4 CD N
73.9 CD N
and CC N
81.3 CD N
respectively RB N
compared VBN N
with IN N
day NN N
0 CD N
counts NNS N
Selamectin NNP N
also RB N
was VBD N
beneficial JJ N
in IN N
alleviating VBG N
signs NNS N
in IN N
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
diagnosed VBD 4_p
clinically RB 4_p
with IN 4_p
FAD NNP 4_p
A NNP N
total NN N
of IN N
397 CD 3_p
dogs NNS 4_p
free JJ 4_p
of IN 4_p
adult NN 4_p
heartworm NN 4_p
infection NN 4_p
from IN 4_p
four CD 4_p
heartworm-endemic JJ 4_p
areas NNS 4_p
of IN 4_p
the DT 4_p
USA NNP 4_p
were VBD N
allocated VBN N
randomly RB N
to TO N
six CD N
months NNS N
of IN N
treatment NN N
with IN N
selamectin NN N
n=298 JJ N
or CC N
ivermectin NN N
n=99 JJ N
Selamectin NNP N
achieved VBD N
a DT N
heartworm JJ N
prevention NN N
rate NN N
of IN N
100 CD N
with IN N
all DT N
dogs NNS N
testing VBG N
negative JJ N
for IN N
microfilariae NN N
and CC N
adult NN N
heartworm NN N
antigen NN N
on IN N
days NNS N
180 CD N
and CC N
300 CD N
Selamectin NNP N
was VBD N
administered VBN N
to TO N
a DT N
total NN N
of IN N
673 CD 3_p
dogs NNS 3_p
and CC 3_p
347 CD 3_p
cats NNS 3_p
having VBG N
an DT N
age NN N
range NN N
of IN N
6 CD N
weeks NNS N
to TO N
19 CD N
years NNS N
3954 CD N
doses NNS N
The DT N
animals NNS N
included VBD N
19 CD 3_p
purebred VBD 4_p
or CC 4_p
crossbred JJ 4_p
Collies NNS 4_p
Bearded NNP 4_p
Border NNP 4_p
and CC 4_p
unspecified JJ 4_p
There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
events NNS N
Results NNS N
of IN N
these DT N
studies NNS N
indicated VBD N
that IN N
selamectin NN N
was VBD N
highly RB N
effective JJ N
in IN N
the DT N
control NN N
of IN N
flea NN N
infestations NNS N
in IN N
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
without IN N
the DT N
need NN N
for IN N
simultaneous JJ N
treatment NN N
of IN N
the DT N
environment NN N
or CC N
of IN N
in-contact JJ N
animals NNS N
and CC N
also RB N
was VBD N
beneficial JJ N
in IN N
alleviating VBG N
signs NNS N
associated VBN N
with IN N
FAD NNP N
Selamectin NNP N
also RB N
was VBD N
100 CD N
effective JJ N
in IN N
preventing VBG N
the DT N
development NN N
of IN N
canine NN N
heartworms NNS N
and CC N
was VBD N
safe JJ N
for IN N
topical JJ N
use NN N
in IN N
dogs NNS 4_p
and CC 4_p
cats NNS 4_p
-DOCSTART- -X- O O

Methodology NNP N
of IN N
serial JJ N
ECG NNP N
classification NN N
using VBG N
an DT N
adaptation NN N
of IN N
the DT N
NOVACODE NNP N
for IN N
Q NNP N
wave VBP N
myocardial JJ N
infarction NN N
in IN N
the DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
BARI NNP N
Serial JJ N
electrocardiographic JJ N
ECG NNP N
changes NNS N
are VBP N
a DT N
critical JJ N
component NN N
of IN N
the DT N
diagnostic JJ N
algorithm NN N
for IN N
classification NN N
of IN N
myocardial JJ N
ischemic JJ N
events NNS N
in IN N
large-scale JJ N
clinical JJ N
trials NNS N
This DT N
study NN N
describes VBZ N
a DT N
computerized JJ N
serial JJ N
ECG NNP N
classification NN N
program NN N
developed VBN N
at IN N
the DT N
St. NNP N
Louis NNP N
University NNP N
Core NNP N
ECG NNP N
Laboratory NNP N
for IN N
use NN N
in IN N
the DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
BARI NNP N
trial NN N
in IN N
which WDT N
patients NNS 4_p
with IN 4_p
multivessel JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
or CC N
percutaneous JJ N
transluminal JJ N
coronary JJ N
angioplasty NN N
The DT N
St. NNP N
Louis NNP N
University NNP N
program NN N
detects NNS N
and CC N
codes VBZ N
serial JJ N
changes NNS N
in IN N
Q NNP N
ST NNP N
and CC N
T NNP N
wave VBP N
items NNS N
according VBG N
to TO N
Minnesota NNP N
code NN N
MC NNP N
criteria VBP N
using VBG N
a DT N
modified JJ N
NOVACODE NNP N
hierarchical JJ N
classification NN N
system NN N
Measurements NNS N
using VBG N
a DT N
seven-power NN N
calibrated VBN N
coding NN N
loupe NN N
are VBP N
used VBN N
to TO N
generate VB N
the DT N
MC NNP N
from IN N
a DT N
customized JJ N
software NN N
program NN N
Significant NNP N
minor VBD N
or CC N
major JJ N
changes NNS N
are VBP N
detected VBN N
by IN N
the DT N
serial JJ N
comparison NN N
program NN N
and CC N
referred VBD N
to TO N
a DT N
physician JJ N
coder NN N
for IN N
verification NN N
Serial JJ N
comparison NN N
coding NN N
rules NNS N
are VBP N
used VBN N
to TO N
adjust VB N
for IN N
weaknesses NNS N
in IN N
the DT N
standard JJ N
MC NNP N
classification NN N
system NN N
resulting VBG N
from IN N
instability NN N
at IN N
decision NN N
boundaries NNS N
Of IN N
4,244 CD 3_p
BARI NNP N
randomized VBN N
and CC N
registry NN 4_p
study NN 4_p
participants NNS 4_p
with IN 4_p
follow-up JJ 4_p
ECGs NNP 4_p
received VBD 4_p
at IN 4_p
the DT 4_p
Core NNP 4_p
ECG NNP 4_p
Laboratory NNP 4_p
as IN 4_p
of IN 4_p
March NNP 4_p
1995 CD 4_p
a DT N
grade NN N
2 CD N
MC NNP N
Q NNP N
wave VBP N
progression NN N
was VBD N
noted VBN N
in IN N
568 CD N
participants NNS N
13.4 CD N
using VBG N
MC NNP N
criteria NNS N
alone RB N
as IN N
compared VBN N
with IN N
367 CD N
8.6 CD N
after IN N
the DT N
St. NNP N
Louis NNP N
University NNP N
coding NN N
rules NNS N
were VBD N
applied VBN N
The DT N
incidence NN N
of IN N
grade NN N
1 CD N
MC NNP N
Q NNP N
wave VBP N
progressions NNS N
was VBD N
16.4 CD N
697/4,244 CD N
versus NN N
6.1 CD N
259/4,244 CD N
when WRB N
the DT N
St. NNP N
Louis NNP N
University NNP N
program NN N
was VBD N
applied VBN N
Intraobserver NNP N
variability NN N
for IN N
grade NN N
2 CD N
Q NNP N
wave VBP N
progression NN N
codes NNS N
determined VBD N
from IN N
a DT N
sample NN N
of IN N
812 CD N
serial NN N
-DOCSTART- -X- O O

Safety NN N
tolerability NN N
and CC N
immunogenicity NN N
after IN N
1 CD N
and CC N
2 CD N
doses NNS N
of IN N
zoster NN N
vaccine NN N
in IN N
healthy JJ 4_p
adults NNS 1_p
≥60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
BACKGROUND NNP N
Incidence NNP N
and CC N
severity NN N
of IN N
herpes NNS N
zoster NNP N
HZ NNP N
and CC N
postherpetic JJ N
neuralgia JJ N
increase NN N
with IN N
age NN N
associated VBN N
with IN N
age-related JJ N
decrease NN N
in IN N
immunity NN N
to TO N
varicella-zoster JJ N
virus NN N
VZV NNP N
One CD N
dose NN N
of IN N
zoster NN N
vaccine NN N
ZV NNP N
has VBZ N
demonstrated VBN N
substantial JJ N
protection NN N
against IN N
HZ NNP N
this DT N
study NN N
examined VBD N
impact NN N
of IN N
a DT N
second JJ N
dose NN N
of IN N
ZV NNP N
METHODS NNP N
Randomized NNP N
double-blind NN N
multicenter NN N
study NN N
with IN N
210 CD 3_p
subjects NNS N
≥60 CD 1_p
years NNS 1_p
old JJ N
compared VBN N
immunity NN N
and CC N
safety NN N
profiles NNS N
after IN N
one CD N
and CC N
two CD N
doses NNS N
of IN N
ZV NNP N
separated VBN N
by IN N
6 CD N
weeks NNS N
vs. FW N
placebo NN N
Immunogenicity NNP N
was VBD N
evaluated VBN N
using VBG N
VZV NNP N
interferon-gamma JJ N
IFN-γ NNP N
enzyme-linked JJ N
immunospot NN N
ELISPOT NNP N
assay NN N
and CC N
VZV NNP N
glycoprotein VBD N
enzyme-linked JJ N
immunosorbent NN N
antibody NN N
gpELISA NN N
assay NN N
Adverse JJ N
experiences NNS N
AEs NNP N
were VBD N
recorded VBN N
on IN N
a DT N
standardized JJ N
Vaccination NNP N
Report NNP N
Card NNP N
RESULTS NNP N
No NNP N
serious JJ N
vaccine-related JJ N
AEs NNP N
occurred VBD N
VZV NNP N
IFN-γ NNP N
ELISPOT NNP N
geometric JJ N
mean NN N
count NN N
GMC NNP N
of IN N
spot-forming JJ N
cells NNS N
per IN N
10 CD N
6 CD N
peripheral JJ N
blood NN N
mononuclear JJ N
cells NNS N
increased VBN N
in IN N
the DT N
ZV NNP N
group NN N
from IN N
16.9 CD N
prevaccination NN N
to TO N
49.5 CD N
and CC N
32.8 CD N
at IN N
2 CD N
and CC N
6 CD N
weeks NNS N
postdose RB N
1 CD N
respectively RB N
Two CD N
weeks NNS N
6 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
postdose RB N
2 CD N
GMC NNP N
was VBD N
44.3 CD N
42.9 CD N
and CC N
36.5 CD N
respectively RB N
GMC NNP N
in IN N
the DT N
placebo NN N
group NN N
did VBD N
not RB N
change NN N
during IN N
the DT N
study NN N
The DT N
peak JJ N
ELISPOT NNP N
response NN N
occurred VBD N
∼2 NNP N
weeks NNS N
after IN N
each DT N
ZV NNP N
dose NN N
The DT N
gpELISA NN N
geometric JJ N
mean NN N
titers NNS N
GMTs NNP N
in IN N
the DT N
ZV NNP N
group NN N
were VBD N
higher JJR N
than IN N
in IN N
the DT N
placebo NN N
group NN N
at IN N
6 CD N
weeks NNS N
after IN N
each DT N
dose NN N
Correlation NN N
between IN N
the DT N
IFN-γ NNP N
ELISPOT NNP N
and CC N
gpELISA NN N
assays NNS N
was VBD N
poor JJ N
CONCLUSIONS NNP N
ZV NNP N
was VBD N
generally RB N
well-tolerated JJ N
and CC N
immunogenic JJ N
in IN N
adults NNS N
≥60 CD N
years NNS N
old JJ N
A DT N
second JJ N
dose NN N
of IN N
ZV NNP N
was VBD N
generally RB N
safe JJ N
but CC N
did VBD N
not RB N
boost VB N
VZV-specific NNP N
immunity NN N
beyond IN N
levels NNS N
achieved VBN N
postdose RB N
1 CD N
-DOCSTART- -X- O O

A DT N
controlled VBN N
study NN N
of IN N
psychiatric JJ N
hospital NN N
versus NN N
community NN N
treatment NN N
the DT N
effect NN N
on IN N
relatives NNS N
One CD 3_p
hundred CD 3_p
and CC 3_p
twenty JJ 3_p
patients NNS 4_p
presenting VBG 4_p
at IN 4_p
Macquarie NNP 4_p
Hospital NNP 4_p
for IN 4_p
admission NN 4_p
were VBD N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
The DT N
control NN N
group NN N
patients NNS N
received VBD N
standard JJ N
hospital NN N
care NN N
and CC N
follow-up NN N
The DT N
project NN N
group NN N
patients NNS N
were VBD N
not RB N
admitted VBN N
if IN N
this DT N
could MD N
be VB N
avoided VBN N
instead RB N
they PRP N
were VBD N
taken VBN N
back RB N
to TO N
the DT N
community NN N
by IN N
the DT N
project NN N
team NN N
who WP N
provided VBD N
them PRP N
and CC N
their PRP$ N
relatives NNS N
with IN N
comprehensive JJ N
assertive JJ N
and CC N
prolonged JJ N
follow-up JJ N
treatment NN N
backed VBN N
by IN N
a DT N
24-hour JJ N
crisis NN N
service NN N
The DT N
majority NN N
63 CD N
of IN N
the DT N
project NN N
group NN N
had VBD N
no DT N
admission NN N
during IN N
the DT N
10 CD N
month NN N
study NN N
period NN N
Initially RB N
the DT N
burden NN N
on IN N
the DT N
relatives NNS N
of IN N
the DT N
project NN N
group NN N
was VBD N
higher JJR N
but CC N
by IN N
one CD N
month NN N
it PRP N
was VBD N
somewhat RB N
lower JJR N
and CC N
by IN N
four CD N
months NNS N
it PRP N
was VBD N
significantly RB N
lower JJR N
than IN N
the DT N
burden NN N
on IN N
the DT N
control NN N
group NN N
relatives VBZ N
Relatives NNS N
of IN N
the DT N
project NN N
group NN N
patients NNS N
were VBD N
significantly RB N
more RBR N
satisfied JJ N
with IN N
the DT N
treatment NN N
than IN N
control NN N
group NN N
relatives VBZ N
It PRP N
is VBZ N
clearly RB N
feasible JJ N
to TO N
treat VB N
most JJS N
psychiatric JJ 4_p
patients NNS 4_p
in IN N
the DT N
community NN N
without IN N
increasing VBG N
the DT N
burden NN N
on IN N
their PRP$ N
relatives NNS N
-DOCSTART- -X- O O

Effect NNP N
of IN N
liu NN N
wei NN N
di NN N
huang NN N
or CC N
jin NN N
gui NN N
shen NN N
qi JJ N
decoction NN N
as IN N
on IN N
adjuvant JJ N
treatment NN N
in IN N
small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
Eighty-three JJ 3_p
patients NNS 4_p
with IN 4_p
small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
were VBD N
randomized VBN N
with IN N
or CC N
without IN N
using VBG N
a DT N
traditional JJ N
Chinese JJ N
Kidney-tonifying NNP N
decoction NN N
Liu NNP N
Wei NNP N
Di NNP N
Huang NNP N
or CC N
Jin NNP N
Gui NNP N
Shen NNP N
Qi NNP N
medicinal JJ N
decoction NN N
in IN N
chemotherapy NN N
or CC N
radiotherapy NN N
courses NNS N
74 CD 3_p
patients NNS 3_p
were VBD N
availble JJ N
to TO N
be VB N
analysis NN N
The DT N
two CD N
treatment NN N
groups NNS N
were VBD N
well-matched JJ N
in IN N
age NN N
sex NN N
stage NN N
and CC N
performance NN N
status NN N
There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
response NN N
rate NN N
and CC N
the DT N
median JJ N
survival NN N
between IN N
two CD N
groups NNS N
The DT N
overall JJ N
response NN N
rate NN N
CR+PR NNP N
was VBD N
91.5 CD N
for IN N
Chinese JJ N
herb NN N
group NN N
and CC N
46.9 CD N
for IN N
control NN N
group NN N
P NNP N
less JJR N
than IN N
0.001 CD N
The DT N
median JJ N
survival NN N
was VBD N
16 CD N
months NNS N
for IN N
the DT N
traditional JJ N
Chinese JJ N
Kidney-tonifying NNP N
decoction NN N
group NN N
and CC N
10 CD N
months NNS N
for IN N
the DT N
control NN N
group NN N
P NNP N
less JJR N
than IN N
0.05 CD N
Survival JJ N
curve NN N
Kaplan-meire NNP N
's POS N
of IN N
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
better JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
10 CD N
patients NNS N
of IN N
Chinese JJ N
herb NN N
group NN N
was VBD N
alive JJ N
beyond IN N
more JJR N
than IN N
2 CD N
years NNS N
Until IN N
now RB N
4 CD N
patients NNS N
in IN N
the DT N
Chinese JJ N
herb NN N
group NN N
one CD N
in IN N
the DT N
control NN N
group NN N
are VBP N
still RB N
enjoying VBG N
their PRP$ N
disease-free JJ N
life NN N
for IN N
more JJR N
than IN N
7 CD N
years NNS N
Hematologic NNP N
toxicities NNS N
were VBD N
observed VBN N
much RB N
frequently RB N
in IN N
the DT N
patients NNS N
of IN N
the DT N
control NN N
group NN N
P NNP N
less JJR N
than IN N
0.005 CD N
and CC N
0.01/WBC CD N
and CC N
BPC NNP N
Results NNS N
of IN N
animal JJ N
experiments NNS N
with IN N
the DT N
same JJ N
traditional JJ N
medicinal JJ N
decoctions NNS N
as IN N
used VBN N
in IN N
clinic NN N
have VBP N
showed VBN N
immuno-enhancement JJ N
activities NNS N
These DT N
results NNS N
have VBP N
showed VBN N
that IN N
the DT N
traditional JJ N
Chinese JJ N
Kidney-tonifying NNP N
decoction NN N
may MD N
enhance VB N
non-specific JJ N
immunology NN N
activities NNS N
and CC N
may MD N
be VB N
much JJ N
useful JJ N
for IN N
solid JJ 4_p
cancer NN 4_p
patients NNS 4_p
as IN N
an DT N
adjuvant JJ N
treatment NN N
-DOCSTART- -X- O O

Comparison NNP N
of IN N
budesonide JJ N
Turbuhaler NNP N
with IN N
budesonide JJ N
aqua NN N
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
Rhinocort NNP N
Study NNP N
Group NNP N
OBJECTIVE NNP N
To TO N
compare VB N
the DT N
effect NN N
of IN N
budesonide NN N
Turbuhaler NNP N
400 CD N
microg/day NN N
with IN N
budesonide JJ N
aqua NN N
256 CD N
microg/day NN N
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
SAR NNP N
Secondarily RB N
to TO N
ascertain VB N
patients NNS N
preferences NNS N
for IN N
the DT N
two CD N
nasal JJ N
devices NNS N
and CC N
to TO N
assess VB N
quality NN N
of IN N
life NN N
DESIGN NNP N
Randomized NNP N
multicentre NN N
double-blind JJ N
double- JJ N
dummy NN N
parallel JJ N
groups NNS N
study NN N
SETTING NNP N
Private NNP N
practices NNS N
and CC N
hospital NN N
clinics NNS N
in IN N
Ontario NNP N
Quebec NNP N
and CC N
Manitoba NNP N
POPULATION NNP N
Two CD 3_p
hundred VBD 3_p
and CC 3_p
eighty-four JJ 3_p
out-patients NNS 4_p
with IN N
SAR NNP 4_p
who WP N
were VBD N
symptomatic JJ 4_p
during IN 4_p
the DT 4_p
ragweed NN 4_p
season NN 4_p
volunteered VBD N
for IN N
enrolment NN N
243 CD 3_p
randomized VBN N
RESULTS JJ N
Mean JJ N
daily JJ N
nasal NN N
symptom NN N
scores NNS N
were VBD N
significantly RB N
reduced VBN N
with IN N
treatment NN N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
from IN N
baseline NN N
for IN N
eye NN N
symptoms NNS N
Most JJS N
patients NNS N
more JJR N
than IN N
80 CD N
achieved VBN N
substantial JJ N
control NN N
of IN N
their PRP$ N
symptoms NNS N
with IN N
budesonide NN N
The DT N
most RBS N
common JJ N
nasal NN N
and CC N
non-nasal JJ N
adverse JJ N
events NNS N
for IN N
both DT N
groups NNS N
were VBD N
epistaxis JJ N
and CC N
headache NN N
Turbuhaler NNP N
was VBD N
easier JJR N
to TO N
use VB N
and CC N
more RBR N
convenient JJ N
to TO N
carry VB N
had VBD N
less JJR N
of IN N
an DT N
unpleasant JJ N
taste NN N
and CC N
caused VBD N
less JJR N
nasal JJ N
irritation NN N
than IN N
the DT N
aqua JJ N
spray NN N
More JJR N
than IN N
twice RB N
as IN N
many JJ N
patients NNS N
preferred JJ N
Turbuhaler NNP N
to TO N
the DT N
aqua NN N
spray NN N
69 CD N
versus IN N
31 CD N
Improvement NN N
in IN N
quality NN N
of IN N
life NN N
from IN N
baseline NN N
to TO N
clinic VB N
visits NNS N
was VBD N
statistically RB N
significant JJ N
in IN N
both DT N
groups NNS N
CONCLUSION NNP N
Once RB N
daily JJ N
use NN N
of IN N
256 CD N
mg NN N
of IN N
budesonide NN N
aqua NN N
and CC N
400 CD N
mg NN N
of IN N
budesonide NN N
Turbuhaler NNP N
are VBP N
equally RB N
safe JJ N
and CC N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
SAR NNP 4_p
Patients NNS N
preferred VBD N
the DT N
budesonide NN N
powder NN N
formulation NN N
delivered VBD N
via IN N
Turbuhaler NNP N
two CD N
to TO N
one CD N
over IN N
the DT N
aqua JJ N
formulation NN N
-DOCSTART- -X- O O

Rationale NNP N
and CC N
design NN N
of IN N
RE-LY NNP N
randomized JJ N
evaluation NN N
of IN N
long-term JJ N
anticoagulant JJ N
therapy NN N
warfarin NN N
compared VBN N
with IN N
dabigatran NN N
Vitamin NNP N
K NNP N
antagonists NNS N
VKAs NNP N
are VBP N
effective JJ N
for IN N
stroke NN N
prevention NN N
in IN N
patients NNS N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
AF NNP 4_p
but CC N
are VBP N
difficult JJ N
to TO N
use VB N
Dabigatran NNP N
etexilate NN N
is VBZ N
a DT N
prodrug NN N
that WDT N
is VBZ N
rapidly RB N
converted VBN N
to TO N
the DT N
active JJ N
direct JJ N
thrombin NN N
inhibitor NN N
dabigatran NN N
It PRP N
is VBZ N
administered VBN N
in IN N
a DT N
fixed JJ N
dose NN N
without IN N
laboratory JJ N
monitoring NN N
and CC N
is VBZ N
being VBG N
compared VBN N
with IN N
warfarin NN N
international JJ N
normalized VBN N
ratio JJ N
2-3 JJ N
in IN N
the DT N
RE-LY JJ N
trial NN N
Two CD N
doses NNS N
of IN N
dabigatran NN N
110 CD N
and CC N
150 CD N
mg NNS N
BID NNP N
are VBP N
being VBG N
evaluated VBN N
RE-LY NNP N
is VBZ N
a DT N
phase NN N
3 CD N
prospective JJ N
randomized VBN N
open-label JJ N
multinational NN N
44 CD N
countries NNS N
trial NN N
of IN N
patients NNS N
with IN N
nonvalvular JJ N
AF NNP N
and CC N
at IN N
least JJS N
1 CD N
risk NN N
factor NN N
for IN N
stroke NN N
Recruitment NNP N
concluded VBD N
with IN N
a DT N
total NN N
of IN N
18,113 CD 3_p
patients NNS N
Patients NNS N
who WP N
were VBD N
VKA-naive NNP N
and CC N
experienced VBN N
are VBP N
included VBN N
in IN N
balanced JJ N
proportions NNS N
The DT N
primary JJ N
outcome NN N
is VBZ N
stroke VBN N
including VBG N
hemorrhagic NN N
or CC N
systemic JJ N
embolism NN N
Safety NNP N
outcomes NNS N
are VBP N
bleeding VBG N
liver JJ N
function NN N
abnormalities NNS N
and CC N
other JJ N
adverse JJ N
events NNS N
Adjudication NN N
of IN N
end NN N
points NNS N
is VBZ N
blinded VBN N
to TO N
drug NN N
assignment NN N
The DT N
trial NN N
is VBZ N
expected VBN N
to TO N
accrue VB N
a DT N
minimum NN N
of IN N
450 CD N
events NNS N
with IN N
a DT N
minimum JJ N
1-year JJ N
of IN N
follow-up JJ N
RE-LY NN N
is VBZ N
the DT N
largest JJS N
AF NNP N
stroke VBD N
prevention NN N
trial NN N
yet RB N
undertaken VBN N
It PRP N
is VBZ N
unique JJ N
because IN N
it PRP N
includes VBZ N
equal JJ N
numbers NNS N
of IN N
VKA-experienced NNP N
and CC N
naive JJ N
patients NNS N
and CC N
evaluates VBZ N
2 CD N
different JJ N
dosages NNS N
of IN N
dabigatran NN N
which WDT N
may MD N
allow VB N
tailoring NN N
of IN N
dosing VBG N
to TO N
individual JJ N
patient NN N
needs NNS N
The DT N
worldwide JJ N
site NN N
distribution NN N
and CC N
broad JJ N
range NN N
of IN N
stroke NN N
risk NN N
further RBR N
increase VB N
the DT N
general JJ N
applicability NN N
of IN N
the DT N
trial NN N
Results NNS N
are VBP N
expected VBN N
in IN N
2009 CD N
-DOCSTART- -X- O O

Double-blind NNP N
comparison NN N
of IN N
doxepin NN N
versus NN N
bupropion NN N
in IN N
outpatients NNS 4_p
with IN 4_p
a DT 4_p
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
A DT N
double-blind NN N
controlled VBN N
study NN N
comparing VBG N
the DT N
effects NNS N
of IN N
bupropion NN N
to TO N
doxepin VB N
in IN N
outpatients NNS 4_p
with IN 4_p
primary JJ 4_p
depression NN 4_p
was VBD N
conducted VBN N
to TO N
evaluate VB N
efficacy NN N
and CC N
safety NN N
differences NNS N
between IN N
the DT N
two CD N
drugs NNS N
Following VBG N
a DT N
7-day JJ N
placebo NN N
washout NN N
period NN N
patients NNS N
could MD N
be VB N
treated VBN N
for IN N
up RB N
to TO N
13 CD N
weeks NNS N
on IN N
either DT N
treatment NN N
Antidepressant JJ N
response NN N
was VBD N
assessed VBN N
by IN N
the DT N
Hamilton NNP N
Depression NNP N
and CC N
Anxiety NNP N
Scales NNP N
Clinical NNP N
Global NNP N
Severity NNP N
and CC N
Improvement NNP N
Ratings NNP N
and CC N
the DT N
Zung NNP N
Self-Rating NNP N
Depression NNP N
Scale NNP N
Comparable JJ N
efficacy NN N
between IN N
the DT N
compounds NNS N
was VBD N
found VBN N
across IN N
the DT N
13-week JJ N
study NN N
Doxepin NNP N
differed VBD N
from IN N
bupropion NN N
mainly RB N
on IN N
the DT N
sleep JJ N
factor NN N
of IN N
the DT N
Hamilton NNP N
Depression NNP N
Scale NNP N
with IN N
doxepin NN N
improving VBG N
sleep NN N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
bupropion NN N
Doxepin NNP N
produced VBD N
a DT N
greater JJR N
incidence NN N
of IN N
anticholinergic JJ N
side NN N
effects NNS N
including VBG N
dry JJ N
mouth NN N
constipation NN N
sleepiness NN N
and CC N
tiredness NN N
in IN N
comparison NN N
to TO N
bupropion NN N
Also RB N
increased VBD N
appetite NN N
and CC N
weight JJ N
gain NN N
were VBD N
consistent JJ N
side NN N
effects NNS N
of IN N
doxepin NN N
relative NN N
to TO N
bupropion NN N
-DOCSTART- -X- O O

Adherence NN N
to TO N
lifestyle VB N
recommendations NNS N
by IN N
patients NNS 4_p
with IN 4_p
depression NN 4_p
INTRODUCTION NNP N
There EX N
is VBZ N
an DT N
increasing VBG N
amount NN N
of IN N
evidence NN N
showing VBG N
that DT N
physical JJ N
activity NN N
and CC N
sun NN N
exposure NN N
are VBP N
effective JJ N
coadjuvant JJ N
treatments NNS N
for IN N
patients NNS 4_p
with IN 4_p
mild JJ 4_p
to TO 4_p
moderate VB 4_p
depression NN 4_p
However RB N
there EX N
is VBZ N
a DT N
lack NN N
of IN N
information NN N
regarding VBG N
patient NN N
's POS N
adherence NN N
to TO N
these DT N
recommendations NNS N
in IN N
daily JJ N
clinical JJ N
practice NN N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
study NN N
including VBG N
15 CD 3_p
depressive JJ 4_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
been VBN 4_p
under IN 4_p
antidepressant JJ 4_p
treatment NN 4_p
for IN 4_p
at IN 4_p
least JJS 4_p
one CD 4_p
month NN 4_p
They PRP N
wore VBD N
a DT N
wrist-watch-like JJ N
actimetry NN N
sensor NN N
to TO N
measure VB N
physical JJ N
activity NN N
and CC N
sun NN N
exposure NN N
24 CD N
hours NNS N
a DT N
day NN N
After IN N
one CD N
week NN N
of IN N
baseline NN N
assessment NN N
patients NNS N
were VBD N
randomised VBN N
into IN N
one CD N
of IN N
the DT N
two CD N
arms NNS N
of IN N
the DT N
study NN N
Patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
received VBD N
a DT N
brief JJ N
note NN N
in IN N
which WDT N
they PRP N
were VBD N
explicitly RB N
asked VBN N
to TO N
increase VB N
both DT N
their PRP$ N
physical JJ N
activity NN N
level NN N
and CC N
time NN N
of IN N
sun NN N
exposure NN N
while IN N
control NN N
group NN N
patients NNS N
did VBD N
not RB N
receive VB N
these DT N
explicit JJ N
recommendations NNS N
RESULTS NNP N
One CD N
week NN N
after IN N
recommendations NNS N
were VBD N
delivered VBN N
only RB N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
had VBD N
increased VBN N
time NN N
of IN N
sun NN N
exposure NN N
and CC N
physical JJ N
activity NN N
25.8 CD N
and CC N
14.3 CD N
respectively RB N
CONCLUSIONS NNP N
Depressive JJ 4_p
patients NNS 4_p
are VBP N
able JJ N
to TO N
follow VB N
prescribed JJ N
lifestyle JJ N
recommendations NNS N
in IN N
the DT N
short-term JJ N
-DOCSTART- -X- O O

Ascaris NNP N
and CC N
growth NN N
rates NNS N
a DT N
randomized JJ N
trial NN N
of IN N
treatment NN N
Three CD 3_p
hundred VBD 3_p
forty-one NN 3_p
Tanzanian JJ 4_p
preschool NN 1_p
children NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
levamisole VB N
or CC N
placebo VB N
treatment NN N
given VBN N
at IN N
three-month JJ N
intervals NNS N
Weights NNS N
and CC N
heights NNS N
were VBD N
measured VBN N
at IN N
the DT N
tri-monthly JJ N
treatment NN N
visits NNS N
for IN N
a DT N
period NN N
of IN N
one CD N
year NN N
Among IN N
the DT N
273 CD N
children NNS N
who WP N
were VBD N
seen VBN N
and CC N
weighed VBN N
at IN N
the DT N
one-year JJ N
follow-up JJ N
visit NN N
the DT N
rate NN N
of IN N
weight NN N
gain NN N
was VBD N
8 CD N
per IN N
cent NN N
greater JJR N
for IN N
those DT N
receiving VBG N
levamisole JJR N
than IN N
for IN N
placebo-treated JJ N
controls NNS N
p JJ N
.06 NNP N
In IN N
78 CD N
children NNS 1_p
known VBN N
to TO N
be VB N
infected VBN N
with IN N
Ascaris NNP N
at IN N
baseline NN N
the DT N
rate NN N
of IN N
weight NN N
gain NN N
was VBD N
21 CD N
per IN N
cent NN N
greater JJR N
in IN N
children NNS N
treated VBN N
with IN N
levamisole NN N
than IN N
in IN N
those DT N
receiving VBG N
placebo NN N
p JJ N
.03 NNP N
The DT N
rate NN N
of IN N
height NN N
gain NN N
was VBD N
no DT N
different JJ N
for IN N
treatment NN N
and CC N
placebo NN N
groups NNS N
-DOCSTART- -X- O O

Randomised VBN N
trial NN N
of IN N
text NN N
messaging NN N
on IN N
adherence NN N
to TO N
cardiovascular VB N
preventive JJ N
treatment NN N
INTERACT NNP N
trial NN N
BACKGROUND CC N
About IN N
one CD N
third NN N
of IN N
patients NNS N
prescribed VBN N
blood JJ N
pressure NN N
or CC N
lipid-lowering JJ N
drugs NNS N
for IN N
the DT N
prevention NN N
of IN N
coronary JJ N
heart NN N
disease NN N
and CC N
stroke NN N
do VBP N
not RB N
take VB N
their PRP$ N
medication NN N
as IN N
prescribed JJ N
We PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
to TO N
evaluate VB N
text JJ N
messaging NN N
as IN N
a DT N
means NN N
of IN N
improving VBG N
adherence NN N
to TO N
cardiovascular VB N
disease NN N
preventive JJ N
treatment NN N
METHODS NNP N
303 CD 3_p
patients NNS 4_p
taking VBG 4_p
blood NN 4_p
pressure NN 4_p
and/or IN 4_p
lipid-lowering JJ 4_p
medications NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
being VBG N
sent VBN N
text NN N
messages NNS N
Text NNP N
group NN N
151 CD N
or CC N
not RB N
being VBG N
sent VBN N
them PRP N
No NNP N
text NN N
group NN N
152 CD N
Texts NNP N
were VBD N
sent VBN N
daily RB N
for IN N
2 CD N
weeks NNS N
alternate JJ N
days NNS N
for IN N
2 CD N
weeks NNS N
and CC N
weekly JJ N
thereafter NN N
for IN N
22 CD N
weeks NNS N
6 CD N
months NNS N
overall JJ N
using VBG N
an DT N
automated VBN N
computer NN N
programme NN N
Patients NNS N
were VBD N
asked VBN N
to TO N
respond VB N
on IN N
whether IN N
they PRP N
had VBD N
taken VBN N
their PRP$ N
medication NN N
whether IN N
the DT N
text NN N
reminded VBD N
them PRP N
to TO N
do VB N
so RB N
if IN N
they PRP N
had VBD N
forgotten VBN N
and CC N
if IN N
they PRP N
had VBD N
not RB N
taken VBN N
their PRP$ N
medication NN N
to TO N
determine VB N
if IN N
there EX N
was VBD N
a DT N
reason NN N
for IN N
not RB N
doing VBG N
so RB N
At IN N
6 CD N
months NNS N
use NN N
of IN N
medication NN N
was VBD N
assessed VBN N
RESULTS NNP N
Two CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up NN N
providing VBG N
data NNS N
on IN N
301 CD N
for IN N
analysis NN N
In IN N
the DT N
No NNP N
text NN N
group NN N
38/151 CD N
25 CD N
took VBD N
less JJR N
than IN N
80 CD N
of IN N
the DT N
prescribed JJ N
regimen NNS N
ie NN N
stopped VBD N
medication NN N
completely RB N
or CC N
took VBD N
it PRP N
on IN N
fewer JJR N
than IN N
22 CD N
of IN N
the DT N
last JJ N
28 CD N
days NNS N
of IN N
follow-up NN N
compared VBN N
to TO N
14/150 CD N
patients NNS N
9 CD N
in IN N
the DT N
Text NNP N
group NN N
an DT N
improvement NN N
in IN N
adherence NN N
affecting VBG N
16 CD N
per IN N
100 CD N
patients NNS N
95 CD N
CI NNP N
7 CD N
to TO N
24 CD N
p JJ N
0.001 CD N
The DT N
texts NN N
reminded VBD N
98/151 CD N
patients NNS N
65 CD N
to TO N
take VB N
medication NN N
on IN N
at IN N
least JJS N
one CD N
occasion NN N
and CC N
lead NN N
to TO N
20/151 CD N
13 CD N
who WP N
stopped VBD N
taking VBG N
medication NN N
because IN N
of IN N
concern NN N
over IN N
efficacy NN N
or CC N
side-effects NNS N
resuming VBG N
treatment NN N
CONCLUSIONS NNP N
In IN N
patients NNS N
taking VBG 4_p
blood NN 4_p
pressure NN 4_p
or CC 4_p
lipid-lowering JJ 4_p
treatment NN 4_p
for IN 4_p
the DT 4_p
prevention NN 4_p
of IN 4_p
cardiovascular JJ 4_p
disease NN 4_p
text NN N
messaging NN N
improved JJ N
medication NN N
adherence NN N
compared VBN N
with IN N
no DT N
text NN N
messaging NN N
TRIAL NNP N
REGISTRATION NNP N
Controlled-Trials.com NNP N
ISRCTN74757601 NNP N
-DOCSTART- -X- O O

Epidemiology NN N
of IN N
stroke NN N
Importance NN N
of IN N
preventive JJ N
pharmacological JJ N
strategies NNS N
in IN N
elderly JJ 1_p
patients NNS 1_p
and CC N
associated JJ N
costs NNS N
Stroke NNP N
is VBZ N
a DT N
major JJ N
cause NN N
of IN N
death NN N
and CC N
disability NN N
in IN N
developed JJ N
countries NNS N
The DT N
incidence NN N
of IN N
stroke NN N
increases NNS N
exponentially RB N
with IN N
age NN N
yet RB N
traditionally RB N
many JJ N
medical JJ N
practitioners NNS N
have VBP N
been VBN N
reluctant JJ N
to TO N
treat VB N
hypertension NN N
in IN N
older JJR 1_p
patients NNS 1_p
Since IN N
1991 CD N
the DT N
results NNS N
of IN N
3 CD N
major JJ N
trials NNS N
-- : N
the DT N
British JJ N
Medical NNP N
Research NNP N
Council NNP N
MRC NNP N
trial NN N
of IN N
treatment NN N
in IN N
older JJR N
adults NNS N
the DT N
Swedish JJ N
Trial NNP N
in IN N
Old NNP 4_p
Patients NNPS 4_p
with IN 4_p
Hypertension NNP 4_p
STOP-Hypertension NNP N
and CC N
the DT N
Systolic NNP N
Hypertension NNP N
in IN N
the DT N
Elderly JJ N
Program NNP N
SHEP NNP N
-- : N
have VBP N
conclusively RB N
established VBN N
the DT N
benefits NNS N
of IN N
treating VBG N
older JJR 4_p
patients NNS 4_p
60 CD 4_p
years NNS 4_p
with IN 4_p
both DT 4_p
diastolic JJ 4_p
and CC 4_p
isolated JJ 4_p
systolic JJ 4_p
hypertension NN 4_p
International NNP N
guidelines NNS N
for IN N
the DT N
management NN N
of IN N
hypertension NN N
-- : N
including VBG N
the DT N
Fifth NNP N
Report NNP N
of IN N
the DT N
Joint NNP N
National NNP N
Committee NNP N
the DT N
1993 CD N
report NN N
of IN N
the DT N
World NNP N
Health NNP N
Organization NNP N
and CC N
the DT N
International NNP N
Society NNP N
of IN N
Hypertension NNP N
and CC N
the DT N
second JJ N
report NN N
of IN N
the DT N
British JJ N
Hypertension NNP N
Society NNP N
Working NNP N
Party NNP N
-- : N
have VBP N
all DT N
been VBN N
modified VBN N
to TO N
reflect VB N
the DT N
emerging VBG N
evidence NN N
concerning VBG N
the DT N
benefits NNS N
of IN N
treating VBG N
older JJR N
patients NNS N
Cost-effectiveness JJ N
data NNS N
are VBP N
similarly RB N
in IN N
accord NN N
with IN N
giving VBG N
high JJ N
priority NN N
to TO N
the DT N
treatment NN N
of IN N
older JJR 4_p
individuals NNS 4_p
with IN 4_p
hypertension NN 4_p
-DOCSTART- -X- O O

Group NNP N
cognitive JJ N
behavior NN N
therapy NN N
for IN N
children NNS 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC 4_p
anxiety NN 4_p
a DT N
randomized JJ N
trial NN N
BACKGROUND NNP N
Children NNP N
with IN N
high-functioning JJ N
autism NN N
spectrum NN N
disorders NNS N
ASD NNP N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
developing VBG N
significant JJ N
anxiety NN N
Anxiety NN N
can MD N
adversely RB N
impact VB N
functioning VBG N
across IN N
school NN N
home NN N
and CC N
community NN N
environments NNS N
Cognitive JJ N
behavioral JJ N
therapies NNS N
CBT NNP N
are VBP N
frequently RB N
used VBN N
with IN N
success NN N
for IN N
children NNS N
with IN N
anxiety NN N
symptoms NNS N
Modified NNP N
CBT NNP N
interventions NNS N
for IN N
anxiety NN N
in IN N
children NNS N
with IN N
ASD NNP N
have VBP N
also RB N
yielded VBN N
promising JJ N
results NNS N
METHODS NNP N
Fifty NNP 3_p
children NNS 1_p
with IN N
high-functioning JJ 4_p
ASD NNP 4_p
and CC 4_p
anxiety NN 4_p
were VBD N
randomizedto JJ N
group NN N
CBT NNP N
or CC N
treatment-as-usual JJ N
TAU NNP N
for IN N
12 CD N
weeks NNS N
Independent NNP N
clinical JJ N
evaluators NNS N
blind NN N
to TO N
condition NN N
completed VBN N
structured JJ N
interviews NNS N
Anxiety NNP N
Disorders NNP N
Interview NNP N
Schedule NNP N
– NNP N
Parent NNP N
Version NNP N
ADIS-P NNP N
pre- NN N
and CC N
post-intervention NN N
condition NN N
RESULTS NNP N
Forty-seven JJ 3_p
children NNS 1_p
completed VBN N
either CC N
the DT N
CBT NNP N
or CC N
TAU NNP N
condition NN N
Results NNS N
indicated VBD N
markedly RB N
better RBR N
outcomes NNS N
for IN N
the DT N
CBT NNP N
group NN N
Significant JJ N
differences NNS N
by IN N
group NN N
were VBD N
noted VBN N
in IN N
Clinician JJ N
Severity NNP N
Ratings NNP N
diagnostic JJ N
status NN N
and CC N
clinician JJ N
ratings NNS N
of IN N
global JJ N
improvement NN N
In IN N
the DT N
intent-to-treat JJ N
sample NN N
10 CD N
of IN N
20 CD N
children NNS N
50 CD N
in IN N
the DT N
CBT NNP N
group NN N
had VBD N
a DT N
clinically RB N
meaningful JJ N
positive JJ N
treatment NN N
response NN N
compared VBN N
to TO N
2 CD N
of IN N
23 CD N
children NNS N
8.7 CD N
in IN N
the DT N
TAU NNP N
group NN N
CONCLUSIONS NNP N
Initial JJ N
results NNS N
from IN N
this DT N
randomized VBN N
designed VBN N
treatment NN N
study NN N
suggest VBP N
that IN N
agroup NN N
CBT NNP N
intervention NN N
specifically RB N
developed VBD N
for IN N
children NNS N
with IN N
ASD NNP N
may MD N
be VB N
effective JJ N
in IN N
decreasing VBG N
anxiety NN N
Limitations NNS N
of IN N
this DT N
study NN N
include VBP N
small JJ N
sample JJ N
size NN N
lack NN N
of IN N
an DT N
attention NN N
control NN N
group NN N
and CC N
use NN N
of IN N
outcome NN N
measures NNS N
normed VBN N
with IN N
typically RB N
developing VBG N
children NNS N
-DOCSTART- -X- O O

Bacteremia NNP N
due JJ N
to TO N
Bacteroides NNP N
fragilis NN N
after IN N
elective JJ N
appendectomy NN N
in IN N
renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
Bacteremia NNP N
caused VBN N
by IN N
Bacteroides NNP N
fragilis NN N
occurred VBD N
in IN N
four CD N
of IN N
75 CD 3_p
children NNS 1_p
after IN 4_p
renal JJ 4_p
transplantation NN 4_p
and CC N
B. NNP N
fragilis NN N
was VBD N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
postoperative JJ N
bacteremia NN N
Bacteroides NNP N
bacteremia NN N
was VBD N
significantly RB N
associated VBN N
with IN N
performance NN N
of IN N
elective JJ N
appendectomy NN N
at IN N
the DT N
time NN N
of IN N
transplantation NN N
P NNP N
less JJR N
than IN N
0.01 CD N
and CC N
with IN N
profound JJ N
lymphocytopenia NN N
P NNP N
0.01 CD N
No DT N
patient NN N
received VBD N
antibiotics NNS N
at IN N
the DT N
time NN N
of IN N
surgery NN N
or CC N
prior RB N
to TO N
the DT N
first JJ N
positive JJ N
blood NN N
culture NN N
yet RB N
B. NNP N
fragilis NN N
was VBD N
the DT N
single JJ N
organism NN N
isolated VBN N
from IN N
blood NN N
and CC N
abscesses NNS N
in IN N
these DT N
patients NNS N
A DT N
role NN N
for IN N
lymphocytes NNS N
in IN N
containment NN N
of IN N
B. NNP N
fragilis NN N
has VBZ N
not RB N
been VBN N
suggested VBN N
previously RB N
although IN N
unexplained JJ N
occurrence NN N
of IN N
bacteroides NNS N
bacteremia VBP N
in IN N
immunocompromised JJ N
patients NNS N
has VBZ N
occasionally RB N
been VBN N
reported VBN N
Lymphocytes VBZ N
themselves PRP N
may MD N
be VB N
important JJ N
in IN N
this DT N
host-bacterium JJ N
interaction NN N
or CC N
lymphocytopenia NN N
may MD N
be VB N
the DT N
marker NN N
for IN N
a DT N
more RBR N
generalized JJ N
deficiency NN N
in IN N
host NN N
defenses NNS N
-DOCSTART- -X- O O

Safety NN N
and CC N
preliminary JJ N
immunogenicity NN N
of IN N
Cuban NNP N
pneumococcal JJ N
conjugate NN N
vaccine NN N
candidate NN N
in IN N
healthy JJ 4_p
children NNS 4_p
a DT N
randomized JJ N
phase NN N
I PRP N
clinical JJ N
trial NN N
A DT N
new JJ N
heptavalent NN N
conjugate NN N
vaccine NN N
PCV7-TT NNP N
is VBZ N
under IN N
development NN N
in IN N
Cuba NNP N
PCV7-TT NNP N
contains VBZ N
2 CD N
μg NN N
of IN N
serotypes NNS N
1 CD N
5 CD N
14 CD N
18C CD N
19F CD N
23F CD N
and CC N
4 CD N
μg NN N
of IN N
6B CD N
each DT N
one CD N
conjugated VBN N
to TO N
tetanus VB N
toxoid NN N
TT NNP N
This DT N
vaccine NN N
was VBD N
designed VBN N
with IN N
the DT N
serotypes NNS N
that WDT N
cause VBP N
most RBS N
invasive JJ N
pneumococcal JJ N
diseases NNS N
IPD NNP N
worldwide NN N
In IN N
the DT N
present JJ N
study NN N
we PRP N
investigated VBD N
the DT N
safety NN N
and CC N
explored VBD N
the DT N
immunogenicity NN N
of IN N
PCV7-TT NNP N
during IN N
a DT N
controlled VBN N
randomized VBN N
and CC N
double JJ N
blind NN N
clinical JJ N
trial NN N
phase NN N
I PRP N
in IN N
4-5-year-old JJ 1_p
children NNS 1_p
PCV7-TT NN N
was VBD N
well RB N
tolerated JJ N
and CC N
as RB N
safe JJ N
as IN N
Synflorix NNP N
used VBD N
as IN N
control NN N
vaccine NN N
Following VBG N
a DT N
single-dose JJ N
vaccination NN N
all DT N
individual JJ N
serotypes NNS N
included VBN N
in IN N
PCV7-TT NNP N
induced VBD N
statistically RB N
significant JJ N
increase NN N
of IN N
IgG NNP N
GMC NNP N
and CC N
OPA NNP N
GMT NNP N
These DT N
are VBP N
the DT N
first JJ N
clinical JJ N
results NNS N
of IN N
PCV7-TT NNP N
in IN N
children NNS N
and CC N
they PRP N
pave VBP N
the DT N
way NN N
toward IN N
next JJ N
clinical JJ N
trials NNS N
in IN N
children NNS N
and CC N
infants NNS N
This DT N
clinical JJ N
trial NN N
was VBD N
published VBN N
in IN N
the DT N
Cuban NNP N
Public NNP N
Register NNP N
of IN N
Clinical NNP N
Trials NNP N
with IN N
code NN N
RPCEC00000173 NNP N
-DOCSTART- -X- O O

Effect NN N
of IN N
the DT N
essential JJ N
oils NNS N
of IN N
garlic NN N
and CC N
onion NN N
on IN N
alimentary JJ N
hyperlipemia NN N
SUMMARY VB N
The DT N
effect NN N
of IN N
garlic NN N
and CC N
onion NN N
on IN N
alimentary JJ N
hyperlipemia NN N
induced VBN N
by IN N
feeding VBG N
100 CD N
g JJ N
butter NN N
has VBZ N
been VBN N
studied VBN N
in IN N
10 CD 3_p
healthy JJ 4_p
subjects NNS 4_p
The DT N
freshly RB N
extracted JJ N
juice NN N
of IN N
50 CD N
g NN N
of IN N
garlic NN N
or CC N
onion NN N
as RB N
well RB N
as IN N
an DT N
equivalent JJ N
amount NN N
of IN N
their PRP$ N
ether-extracted JJ N
essential JJ N
oils NNS N
was VBD N
administered VBN N
randomly RB N
on IN N
four CD N
different JJ N
days NNS N
during IN N
a DT N
one-week JJ N
period NN N
Garlic NNP N
and CC N
onion NN N
have VBP N
a DT N
significant JJ N
protective JJ N
action NN N
against IN N
fat-induced JJ N
increases NNS N
in IN N
serum NN N
cholesterol NN N
and CC N
plasma NN N
fibrinogen NN N
and CC N
decreases NNS N
in IN N
coagulation NN N
time NN N
and CC N
fibrinolytic JJ N
activity NN N
The DT N
essential JJ N
oil NN N
fraction NN N
which WDT N
contains VBZ N
all PDT N
the DT N
taste NN N
and CC N
odour NN N
exactly RB N
duplicated VBD N
the DT N
beneficial JJ N
effects NNS N
of IN N
whole JJ N
garlic NN N
and CC N
onion NN N
It PRP N
is VBZ N
therefore RB N
concluded VBD N
that IN N
the DT N
active JJ N
principle NN N
of IN N
garlic JJ N
and CC N
onion NN N
is VBZ N
the DT N
essential JJ N
oil NN N
which WDT N
chemically RB N
is VBZ N
a DT N
combination NN N
of IN N
sulphur-containing JJ N
compounds NNS N
mainly RB N
allyl VBZ N
propyl JJ N
disulphide NN N
and CC N
diallyl JJ N
disulphide NN N
-DOCSTART- -X- O O

Effect NN N
of IN N
duloxetine NN N
on IN N
pain NN N
function NN N
and CC N
quality NN N
of IN N
life NN N
among IN N
patients NNS 4_p
with IN 4_p
chemotherapy-induced JJ 4_p
painful JJ 4_p
peripheral JJ 4_p
neuropathy NN 4_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
IMPORTANCE NNP N
There EX N
are VBP N
no DT N
known JJ N
effective JJ N
treatments NNS N
for IN N
painful JJ N
chemotherapy-induced JJ N
peripheral JJ N
neuropathy NN N
OBJECTIVE UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
duloxetine NN N
60 CD N
mg JJ N
daily RB N
on IN N
average JJ N
pain NN N
severity NN N
DESIGN NNP N
SETTING NNP N
AND NNP N
PATIENTS NNP N
Randomized NNP N
double-blind NN N
placebo-controlled JJ N
crossover NN N
trial NN N
at IN N
8 CD N
National NNP N
Cancer NNP N
Institute NNP N
NCI NNP N
-funded VBD N
cooperative JJ N
research NN N
networks NNS N
that WDT N
enrolled VBD N
231 CD 3_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
25 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
being VBG N
treated VBN 4_p
at IN 4_p
community NN 4_p
and CC 4_p
academic JJ 4_p
settings NNS 4_p
between IN 4_p
April NNP 4_p
2008 CD 4_p
and CC 4_p
March NNP 4_p
2011 CD 4_p
Study NNP N
follow-up NN N
was VBD N
completed VBN N
July NNP N
2012 CD N
Stratified VBN N
by IN N
chemotherapeutic JJ N
drug NN N
and CC N
comorbid NN N
pain NN N
risk NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
duloxetine NN N
followed VBN N
by IN N
placebo NN N
or CC N
placebo NN N
followed VBN N
by IN N
duloxetine NN N
Eligibility NN N
required VBD N
that IN N
patients NNS N
have VBP N
grade VBN 4_p
1 CD 4_p
or CC 4_p
higher JJR 4_p
sensory NN 4_p
neuropathy JJ 4_p
according VBG 4_p
to TO 4_p
the DT 4_p
NCI NNP 4_p
Common NNP 4_p
Terminology NNP 4_p
Criteria NNP 4_p
for IN 4_p
Adverse NNP 4_p
Events NNS 4_p
and CC 4_p
at IN 4_p
least JJS 4_p
4 CD 4_p
on IN 4_p
a DT 4_p
scale NN 4_p
of IN 4_p
0 CD 4_p
to TO 4_p
10 CD 4_p
representing VBG 4_p
average JJ 4_p
chemotherapy-induced JJ 4_p
pain NN 4_p
after IN 4_p
paclitaxel NN 4_p
other JJ 4_p
taxane NN 4_p
or CC 4_p
oxaliplatin JJ 4_p
treatment NN 4_p
INTERVENTIONS VBZ N
The DT N
initial JJ N
treatment NN N
consisted VBN N
of IN N
taking VBG N
1 CD N
capsule JJ N
daily RB N
of IN N
either CC N
30 CD N
mg NN N
of IN N
duloxetine NN N
or CC N
placebo NN N
for IN N
the DT N
first JJ N
week NN N
and CC N
2 CD N
capsules NNS N
of IN N
either DT N
30 CD N
mg NN N
of IN N
duloxetine NN N
or CC N
placebo JJ N
daily JJ N
for IN N
4 CD N
additional JJ N
weeks NNS N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
hypothesis NN N
was VBD N
that IN N
duloxetine NN N
would MD N
be VB N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
decreasing VBG N
chemotherapy-induced JJ N
peripheral JJ N
neuropathic JJ N
pain NN N
Pain NNP N
severity NN N
was VBD N
assessed VBN N
using VBG N
the DT N
Brief JJ N
Pain NNP N
Inventory-Short NNP N
Form NNP N
average JJ N
pain NN N
item NN N
with IN N
0 CD N
representing VBG N
no DT N
pain NN N
and CC N
10 CD N
representing VBG N
as RB N
bad JJ N
as IN N
can MD N
be VB N
imagined VBN N
RESULTS JJ N
Individuals NNS N
receiving VBG N
duloxetine NN N
as IN N
their PRP$ N
initial JJ N
5-week JJ N
treatment NN N
reported VBD N
a DT N
mean JJ N
decrease NN N
in IN N
average JJ N
pain NN N
of IN N
1.06 CD N
95 CD N
CI NNP N
0.72-1.40 NNP N
vs VBZ N
0.34 CD N
95 CD N
CI NNP N
0.01-0.66 NNP N
among IN N
those DT N
who WP N
received VBD N
placebo NN N
P NNP N
.003 NNP N
effect NN N
size NN N
0.513 CD N
The DT N
observed JJ N
mean JJ N
difference NN N
in IN N
the DT N
average JJ N
pain NN N
score NN N
between IN N
duloxetine NN N
and CC N
placebo NN N
was VBD N
0.73 CD N
95 CD N
CI NNP N
0.26-1.20 NN N
Fifty-nine JJ N
percent NN N
of IN N
those DT N
initially RB N
receiving VBG N
duloxetine NN N
vs FW N
38 CD N
of IN N
those DT N
initially RB N
receiving VBG N
placebo NN N
reported VBD N
decreased JJ N
pain NN N
of IN N
any DT N
amount NN N
CONCLUSION NNP N
AND CC N
RELEVANCE NNP N
Among IN N
patients NNS 4_p
with IN 4_p
painful JJ 4_p
chemotherapy-induced JJ 4_p
peripheral JJ 4_p
neuropathy NN 4_p
the DT N
use NN N
of IN N
duloxetine NN N
compared VBN N
with IN N
placebo NN N
for IN N
5 CD N
weeks NNS N
resulted VBD N
in IN N
a DT N
greater JJR N
reduction NN N
in IN N
pain NN N
TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
NCT00489411 NN N
-DOCSTART- -X- O O

A DT N
multi-component JJ N
social JJ N
skills NNS N
intervention NN N
for IN N
children NNS 1_p
with IN N
Asperger NNP 4_p
syndrome NN 4_p
the DT N
Junior NNP N
Detective NNP N
Training NNP N
Program NNP N
BACKGROUND NNP N
The DT N
study NN N
aimed VBN N
to TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
a DT N
new JJ N
multi-component JJ N
social JJ N
skills NNS N
intervention NN N
for IN N
children NNS 1_p
with IN N
Asperger NNP 4_p
syndrome NN 4_p
AS IN 4_p
The DT N
Junior NNP N
Detective NNP N
Training NNP N
Program NNP N
This DT N
7-week JJ N
program NN N
included VBD N
a DT N
computer NN N
game NN N
small JJ N
group NN N
sessions NNS N
parent NN N
training NN N
sessions NNS N
and CC N
teacher NN N
handouts NNS N
METHOD NNP N
Forty-nine JJ 3_p
children NNS 4_p
with IN 4_p
AS NNP 4_p
were VBD N
recruited VBN N
to TO N
participate VB N
and CC N
randomly VB N
assigned VBN N
to TO N
intervention NN N
n JJ N
26 CD N
or CC N
wait-list JJ N
control NN N
n JJ N
23 CD N
conditions NNS N
RESULTS NNP N
Relative NNP N
to TO N
children NNS N
in IN N
the DT N
wait-list JJ N
group NN N
program NN N
participants NNS N
showed VBD N
greater JJR N
improvements NNS N
in IN N
social JJ N
skills NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
as IN N
indicated VBN N
by IN N
parent-report JJ N
measures NNS N
Teacher-report NNP N
data NNS N
also RB N
confirmed VBD N
that IN N
children NNS N
receiving VBG N
the DT N
intervention NN N
made VBD N
significant JJ N
improvements NNS N
in IN N
social JJ N
functioning NN N
from IN N
pre- JJ N
to TO N
post-treatment JJ N
Treatment NNP N
group NN N
participants NNS N
were VBD N
better RBR N
able JJ N
to TO N
suggest VB N
appropriate JJ N
emotion-management JJ N
strategies NNS N
for IN N
story NN N
characters NNS N
at IN N
post-intervention NN N
than IN N
at IN N
pre-intervention NN N
whereas NNS N
control VBP N
participants NNS N
were VBD N
not RB N
However RB N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
improvements NNS N
made VBN N
by IN N
children NNS N
in IN N
the DT N
intervention NN N
and CC N
control NN N
conditions NNS N
on IN N
facial JJ N
expression NN N
and CC N
body-posture NN N
recognition NN N
measures NNS N
Follow-up NNP N
data NN N
suggested VBD N
that IN N
treatment NN N
gains NNS N
were VBD N
maintained VBN N
by IN N
children NNS N
at IN N
5-months JJ N
post-intervention NN N
CONCLUSIONS VB N
The DT N
Junior NNP N
Detective NNP N
Training NNP N
Program NNP N
appeared VBD N
to TO N
be VB N
effective JJ N
in IN N
enhancing VBG N
the DT N
social JJ N
skills NNS N
and CC N
emotional JJ N
understanding NN N
of IN N
children NNS 4_p
with IN 4_p
AS NNP 4_p
Limitations NNS N
and CC N
suggestions NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
ionic JJ N
and CC N
nonionic JJ N
x-ray JJ N
contrast NN N
media NNS N
on IN N
myocardial JJ N
perfusion NN N
and CC N
myocardial JJ N
function NN N
The DT N
influence NN N
of IN N
injections NNS N
of IN N
Amidotrizoate NNP N
and CC N
Iopromide NNP N
into IN N
the DT N
left JJ N
coronary JJ N
artery NN N
on IN N
global JJ N
myocardial JJ N
perfusion NN N
and CC N
function NN N
pressures NNS N
in IN N
the DT N
left JJ N
ventricle NN N
heart NN N
rate NN N
as RB N
well RB N
as IN N
excitation NN N
formation NN N
and CC N
transmission NN N
was VBD N
studied VBN N
in IN N
16 CD 3_p
patients NNS 4_p
with IN 4_p
ischaemic JJ 4_p
heart NN 4_p
disease NN 4_p
No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
myocardial JJ N
perfusion NN N
measured VBN N
were VBD N
found VBN N
with IN N
xenon-133 JJ N
in IN N
this DT N
small JJ N
group NN N
between IN N
rest NN N
and CC N
dipyridamole JJ N
load NN N
for IN N
ionic JJ N
and CC N
non-ionic JJ N
contrast NN N
media NNS N
-DOCSTART- -X- O O

Neoton NNP N
and CC N
thrombolytic JJ N
therapy NN N
of IN N
myocardial JJ 4_p
infarction NN 4_p
AIM NNP N
To TO N
evaluate VB N
neoton JJ N
therapy NN N
effects NNS N
in IN N
acute JJ N
myocardial JJ N
infarction NN N
MI NNP N
on IN N
systolic JJ N
function NN N
of IN N
the DT N
left JJ N
ventricle NN N
arrhythmia NN N
and CC N
clinical JJ N
symptoms NNS N
in IN N
patients NNS 4_p
on IN 4_p
thrombolytic JJ 4_p
therapy NN 4_p
TLT NNP 4_p
MATERIAL NNP N
AND NNP N
METHODS NNP N
106 CD 3_p
males NNS 2_p
with IN N
Q-MI NNP 4_p
entered VBD N
the DT N
study NN N
47 CD N
received VBD N
treatment NN N
without IN N
TLT NNP N
and CC N
neoton NN N
30 CD N
patients NNS N
received VBD N
TLT NNP N
with IN N
streptokinase JJ N
preparations NNS N
29 CD N
patients NNS N
were VBD N
given VBN N
streptokinase JJ N
preparations NNS N
and CC N
neoton NN N
Left NNP N
ventricular JJ N
systolic JJ N
function NN N
was VBD N
measured VBN N
by IN N
echocardiography NN N
on IN N
day NN N
1 CD N
3 CD N
7 CD N
14 CD N
21 CD N
and CC N
28 CD N
arrhythmia NN N
was VBD N
analysed VBN N
at IN N
Holter NNP N
monitoring VBG N
in IN N
day NN N
1 CD N
and CC N
2 CD N
of IN N
MI NNP N
RESULTS NNP N
TLT NNP N
failed VBD N
to TO N
arrest VB N
progression NN N
of IN N
left JJ N
ventricular JJ N
dilation NN N
by IN N
the DT N
end NN N
of IN N
the DT N
hospital NN N
stay NN N
Patients NNS N
given VBN N
neoton NNS N
in IN N
acute JJ N
period NN N
of IN N
MI NNP N
had VBD N
no DT N
increase NN N
in IN N
the DT N
end NN N
systolic NN N
and CC N
diastolic JJ N
volumes NNS N
of IN N
the DT N
left JJ N
ventricle NN N
in IN N
the DT N
course NN N
of IN N
the DT N
first JJ N
months NNS N
after IN N
MI NNP N
onset NN N
Antiarrhythmic NNP N
action NN N
of IN N
neoton NN N
manifested VBN N
on IN N
MI NNP N
day NN N
2 CD N
CONCLUSION NNP N
Neoton NNP N
given VBN N
to TO N
MI NNP N
patients NNS N
receiving VBG N
TLT NNP N
prevents NNS N
progression NN N
of IN N
left JJ N
ventricular JJ N
systolic JJ N
dysfunction NN N
and CC N
establishment NN N
of IN N
predictors NNS N
of IN N
unfavourable JJ N
outcome NN N
-DOCSTART- -X- O O

Visual JJ N
and CC N
kinesthetic JJ N
locomotor NN N
imagery NN N
training NN N
integrated VBN N
with IN N
auditory JJ N
step NN N
rhythm NN N
for IN N
walking VBG N
performance NN N
of IN N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
stroke NN 4_p
OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
visual JJ N
and CC N
kinesthetic JJ N
locomotor NN N
imagery NN N
training NN N
on IN N
walking VBG N
performance NN N
and CC N
to TO N
determine VB N
the DT N
clinical JJ N
feasibility NN N
of IN N
incorporating VBG N
auditory JJ N
step NN N
rhythm NN N
into IN N
the DT N
training NN N
DESIGN NNP N
Randomized NNP N
crossover NN N
trial NN N
SETTING NNP N
Laboratory NNP N
of IN N
a DT N
Department NNP N
of IN N
Physical NNP N
Therapy NNP N
SUBJECTS NNP N
Fifteen NNP 3_p
subjects VBZ 4_p
with IN 4_p
post-stroke JJ 4_p
hemiparesis NN 4_p
INTERVENTION NNP N
Four NNP N
locomotor NN N
imagery NN N
trainings NNS N
on IN N
walking VBG N
performance NN N
visual JJ N
locomotor NN N
imagery NN N
training NN N
kinesthetic JJ N
locomotor NN N
imagery NN N
training NN N
visual JJ N
locomotor NN N
imagery NN N
training NN N
with IN N
auditory JJ N
step NN N
rhythm NN N
and CC N
kinesthetic JJ N
locomotor NN N
imagery NN N
training NN N
with IN N
auditory JJ N
step NN N
rhythm NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
timed JJ N
up-and-go JJ N
test NN N
and CC N
electromyographic JJ N
and CC N
kinematic JJ N
analyses NNS N
of IN N
the DT N
affected JJ N
lower JJR N
limb NN N
during IN N
one CD N
gait NN N
cycle NN N
RESULTS NNP N
After IN N
the DT N
interventions NNS N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
timed JJ N
up-and-go JJ N
test NN N
results NNS N
between IN N
the DT N
visual JJ N
locomotor NN N
imagery NN N
training NN N
25.69 CD N
± RB N
16.16 CD N
to TO N
23.97 CD N
± NNS N
14.30 CD N
and CC N
the DT N
kinesthetic JJ N
locomotor NN N
imagery NN N
training NN N
with IN N
auditory JJ N
step NN N
rhythm NN N
22.68 CD N
± RB N
12.35 CD N
to TO N
15.77 CD N
± NNS N
8.58 CD N
P NNP N
0.05 CD N
During IN N
the DT N
swing NN N
and CC N
stance NN N
phases NNS N
the DT N
kinesthetic JJ N
locomotor NN N
imagery NN N
training NN N
exhibited VBN N
significantly RB N
increased VBN N
activation NN N
in IN N
a DT N
greater JJR N
number NN N
of IN N
muscles NNS N
and CC N
increased VBD N
angular JJ N
displacement NN N
of IN N
the DT N
knee NN N
and CC N
ankle NN N
joints NNS N
compared VBN N
with IN N
the DT N
visual JJ N
locomotor NN N
imagery NN N
training NN N
and CC N
these DT N
effects NNS N
were VBD N
more RBR N
prominent JJ N
when WRB N
auditory JJ N
step NN N
rhythm NN N
was VBD N
integrated VBN N
into IN N
each DT N
form NN N
of IN N
locomotor NN N
imagery NN N
training NN N
The DT N
activation NN N
of IN N
the DT N
hamstring NN N
during IN N
the DT N
swing JJ N
phase NN N
and CC N
the DT N
gastrocnemius NN N
during IN N
the DT N
stance NN N
phase NN N
as RB N
well RB N
as IN N
kinematic JJ N
data NNS N
of IN N
the DT N
knee NN N
joint NN N
were VBD N
significantly RB N
different JJ N
for IN N
posttest JJS N
values NNS N
between IN N
the DT N
visual JJ N
locomotor NN N
imagery NN N
training NN N
and CC N
the DT N
kinesthetic JJ N
locomotor NN N
imagery NN N
training NN N
with IN N
auditory JJ N
step NN N
rhythm NN N
P NNP N
0.05 CD N
CONCLUSIONS VB N
The DT N
therapeutic JJ N
effect NN N
may MD N
be VB N
further RB N
enhanced VBN N
in IN N
the DT N
kinesthetic JJ N
locomotor NN N
imagery NN N
training NN N
than IN N
in IN N
the DT N
visual JJ N
locomotor NN N
imagery NN N
training NN N
The DT N
auditory JJ N
step NN N
rhythm VBZ N
together RB N
with IN N
the DT N
locomotor NN N
imagery NN N
training NN N
produces VBZ N
a DT N
greater JJR N
positive JJ N
effect NN N
in IN N
improving VBG N
the DT N
walking VBG N
performance NN N
of IN N
patients NNS N
with IN N
post-stroke JJ 4_p
hemiparesis NN 4_p
-DOCSTART- -X- O O

Bayesian JJ N
adaptive JJ N
trials NNS N
offer VBP N
advantages NNS N
in IN N
comparative JJ N
effectiveness NN N
trials NNS N
an DT N
example NN N
in IN N
status NN 4_p
epilepticus NN 4_p
OBJECTIVE IN N
We PRP N
present VBP N
a DT N
novel JJ N
Bayesian JJ N
adaptive JJ N
comparative NN N
effectiveness NN N
trial NN N
comparing VBG N
three CD N
treatments NNS N
for IN N
status NN N
epilepticus NN N
that WDT N
uses VBZ N
adaptive JJ N
randomization NN N
with IN N
potential JJ N
early JJ N
stopping NN N
STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
The DT N
trial NN N
will MD N
enroll VB N
720 CD 3_p
unique JJ N
patients NNS 4_p
in IN 4_p
emergency NN 4_p
departments NNS 4_p
and CC 4_p
uses VBZ 4_p
a DT 4_p
Bayesian JJ 4_p
adaptive JJ 4_p
design NN 4_p
RESULTS VB N
The DT N
trial NN N
design NN N
is VBZ N
compared VBN N
to TO N
a DT N
trial NN N
without IN N
adaptive JJ N
randomization NN N
and CC N
produces VBZ N
an DT N
efficient JJ N
trial NN N
in IN N
which WDT N
a DT N
higher JJR N
proportion NN N
of IN N
patients NNS N
are VBP N
likely JJ N
to TO N
be VB N
randomized VBN N
to TO N
the DT N
most RBS N
effective JJ N
treatment NN N
arm NN N
while IN N
generally RB N
using VBG N
fewer JJR N
total JJ N
patients NNS N
and CC N
offers VBZ N
higher JJR N
power NN N
than IN N
an DT N
analogous JJ N
trial NN N
with IN N
fixed JJ N
randomization NN N
when WRB N
identifying VBG N
a DT N
superior JJ N
treatment NN N
CONCLUSION NN N
When WRB N
one CD N
treatment NN N
is VBZ N
superior JJ N
to TO N
the DT N
other JJ N
two CD N
the DT N
trial NN N
design NN N
provides VBZ N
better RBR N
patient NN N
care NN N
higher JJR N
power NN N
and CC N
a DT N
lower JJR N
expected VBN N
sample JJ N
size NN N
-DOCSTART- -X- O O

Superior JJ N
visual JJ N
search NN N
in IN N
adults NNS 4_p
with IN 4_p
autism NN 4_p
Recent JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
children NNS N
with IN N
autism NN N
perform NN N
better RBR N
than IN N
matched VBN N
controls NNS N
on IN N
visual JJ N
search NN N
tasks NNS N
and CC N
that IN N
this DT N
stems VBZ N
from IN N
a DT N
superior JJ N
visual JJ N
discrimination NN N
ability NN N
This DT N
study NN N
assessed VBD N
whether IN N
these DT N
findings NNS N
generalize VBP N
from IN N
children NNS N
to TO N
adults NNS 4_p
with IN 4_p
autism NN 4_p
Experiments NNS N
1 CD N
and CC N
2 CD N
showed VBD N
that IN N
like IN N
children NNS N
adults NNS 4_p
with IN 4_p
autism NN 4_p
were VBD N
superior JJ N
to TO N
controls NNS N
at IN N
searching VBG N
for IN N
targets NNS N
Experiment NN N
3 CD N
showed VBD N
that IN N
increases NNS N
in IN N
target-distractor JJ N
similarity NN N
slowed VBD N
the DT N
visual JJ N
search NN N
performance NN N
of IN N
the DT N
control NN N
group NN N
significantly RB N
more RBR N
than IN N
that DT N
of IN N
the DT N
autism NN N
group NN N
suggesting VBG N
that IN N
the DT N
adults NNS N
with IN N
autism NN N
have VBP N
a DT N
superior JJ N
visual JJ N
discrimination NN N
ability NN N
Thus RB N
these DT N
experiments NNS N
replicate VBP N
in IN N
adults NNS N
previous JJ N
findings NNS N
in IN N
children NNS N
with IN N
autism NN N
Superior NNP N
unique JJ N
item NN N
detection NN N
in IN N
adults NNS N
with IN N
autism NN N
stemming VBG N
from IN N
enhanced VBN N
discrimination NN N
is VBZ N
discussed VBN N
in IN N
the DT N
light NN N
of IN N
the DT N
possible JJ N
role NN N
of IN N
stimulus JJ N
processing NN N
disturbances NNS N
in IN N
the DT N
disorder NN N
in IN N
general JJ N
-DOCSTART- -X- O O

Economic JJ N
evaluation NN N
of IN N
aquatic JJ N
exercise NN N
for IN N
persons NNS 4_p
with IN 4_p
osteoarthritis NN 4_p
OBJECTIVES NNP N
To TO N
estimate VB N
cost NN N
and CC N
outcomes NNS N
of IN N
the DT N
Arthritis NNP N
Foundation NNP N
aquatic JJ N
exercise NN N
classes NNS N
from IN N
the DT N
societal JJ N
perspective NN N
DESIGN NNP N
Randomized NNP N
trial NN N
of IN N
20-week JJ N
aquatic JJ N
classes NNS N
Cost NN N
per IN N
quality-adjusted JJ N
life NN N
year NN N
QALY NNP N
gained VBD N
was VBD N
estimated VBN N
using VBG N
trial NN N
data NNS N
Sample NNP N
size NN N
was VBD N
based VBN N
on IN N
80 CD N
power NN N
to TO N
reject VB N
the DT N
null JJ N
hypothesis NN N
that IN N
the DT N
cost/QALY NN N
gained VBD N
would MD N
not RB N
exceed VB N
50,000 CD N
SUBJECTS NNP N
AND NNP N
METHODS NNP N
Recruited VBD N
249 CD 3_p
adults NNS 1_p
from IN 4_p
Washington NNP 4_p
State NNP 4_p
aged VBD 1_p
55 CD 1_p
to TO 1_p
75 CD 1_p
with IN N
a DT N
doctor-confirmed JJ 4_p
diagnosis NN 4_p
of IN 4_p
osteoarthritis NN 4_p
to TO N
participate VB N
in IN N
aquatic JJ N
classes NNS N
The DT N
Quality NN N
of IN N
Well-Being NNP N
Scale NNP N
QWB NNP N
and CC N
Current NNP N
Health NNP N
Desirability NNP N
Rating NNP N
CHDR NNP N
were VBD N
used VBN N
for IN N
economic JJ N
evaluation NN N
supplemented VBN N
by IN N
the DT N
arthritis-specific JJ N
Health NNP N
Assessment NNP N
Questionnaire NNP N
HAQ NNP N
Center NNP N
for IN N
Epidemiologic NNP N
Studies-Depression NNP N
Scale NNP N
CES-D NNP N
and CC N
Perceived NNP N
Quality NNP N
of IN N
Life NNP N
Scale NNP N
PQOL NNP N
collected VBD N
at IN N
baseline NN N
and CC N
postclass NN N
Outcome NNP N
results NNS N
applied VBD N
to TO N
life NN N
expectancy NN N
tables NNS N
were VBD N
used VBN N
to TO N
estimate VB N
QALYs NNP N
Use NNP N
of IN N
health NN N
care NN N
facilities NNS N
was VBD N
assessed VBN N
from IN N
diaries/questionnaires NNS N
and CC N
Medicare NNP N
reimbursement NN N
rates NNS N
used VBD N
to TO N
estimate VB N
costs NNS N
Nonparametric NNP N
bootstrap NN N
sampling NN N
of IN N
costs/QALY NN N
ratios NNS N
established VBD N
the DT N
95 CD N
CI NNP N
around IN N
the DT N
estimates NNS N
RESULTS NNP N
Aquatic JJ N
exercisers NNS N
reported VBD N
equal JJ N
QWB NNP N
or CC N
better JJR N
CHDR NNP N
HAQ NNP N
PQOL NNP N
health-related JJ N
quality NN N
of IN N
life NN N
compared VBN N
with IN N
controls NNS N
Outcomes NNS N
improved VBN N
with IN N
regular JJ N
class NN N
attendance NN N
Costs/QALY NNP N
gained VBD N
discounted VBN N
at IN N
3 CD N
were VBD N
205,186 CD N
using VBG N
the DT N
QWB NNP N
and CC N
32,643 CD N
using VBG N
the DT N
CHRD NNP N
CONCLUSION NNP N
Aquatic NNP N
exercise NN N
exceeded VBD N
50,000 CD N
per IN N
QALY NN N
gained VBN N
using VBG N
the DT N
community-weighted JJ N
outcome NN N
but CC N
fell VBD N
below IN N
this DT N
arbitrary JJ N
budget NN N
constraint NN N
when WRB N
using VBG N
the DT N
participant-weighted JJ N
measure NN N
Confidence NN N
intervals NNS N
around IN N
these DT N
ratios NNS N
suggested VBD N
wide JJ N
variability NN N
of IN N
cost NN N
effectiveness NN N
of IN N
aquatic JJ N
exercise NN N
-DOCSTART- -X- O O

The DT N
treatment NN N
of IN N
asthma NN 4_p
in IN N
adults NNS 1_p
using VBG N
sodium NN N
cromoglycate NN N
pressurized VBN N
aerosol NN N
a DT N
double-blind NN N
controlled VBN N
trial NN N
Sodium NN N
cromoglycate NN N
formulated VBN N
as IN N
a DT N
pressurized JJ N
aerosol NN N
2 CD N
mg RB N
4-times JJ N
daily JJ N
and CC N
placebo NN N
were VBD N
compared VBN N
in IN N
31 CD 3_p
adult NN 1_p
asthmatic JJ 4_p
patients NNS N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
lasting VBG N
12 CD N
weeks NNS N
Sodium NNP N
cromoglycate NN N
was VBD N
superior JJ N
to TO N
placebo VB N
in IN N
improving VBG N
breathlessness NN N
at IN N
rest NN N
p IN N
less JJR N
than IN N
0.001 CD N
breathlessness NN N
on IN N
exertion NN N
p NN N
less JJR N
than IN N
0.05 CD N
and CC N
the DT N
quality NN N
of IN N
sleep NN N
p NN N
less JJR N
than IN N
0.001 CD N
and CC N
also RB N
in IN N
improving VBG N
the DT N
morning NN N
peak NN N
expiratory NN N
flow NN N
rate NN N
value NN N
p IN N
less JJR N
than IN N
0.05 CD N
Both CC N
the DT N
patients NNS N
p NN N
less JJR N
than IN N
0.05 CD N
and CC N
the DT N
clinicians NNS N
p NN N
less JJR N
than IN N
0.01 CD N
treatment NN N
opinions NNS N
and CC N
their PRP$ N
treatment NN N
preferences NNS N
p NN N
less JJR N
than IN N
0.05 CD N
favoured VBD N
sodium NN N
cromoglycate NN N
Moreover RB N
usage NN N
of IN N
bronchodilators NNS N
theophylline NN N
and CC N
aerosol JJ N
beta-stimulants NNS N
combined VBN N
declined VBD N
significantly RB N
p NN N
less JJR N
than IN N
0.001 CD N
during IN N
sodium NN N
cromoglycate NN N
treatment NN N
compared VBN N
to TO N
placebo VB N
No DT N
side-effects NNS N
were VBD N
reported VBN N
The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
sodium NN N
cromoglycate NN N
delivered VBN N
by IN N
pressurized JJ N
aerosol NN N
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB N
not RB N
only RB N
in IN N
improving VBG N
asthmatic JJ N
symptoms NNS N
but CC N
also RB N
in IN N
reducing VBG N
the DT N
amount NN N
of IN N
concomitant JJ N
bronchodilator NN N
therapy NN N
required VBN N
-DOCSTART- -X- O O

Intrathecal JJ N
morphine NN N
suppresses NNS N
NK NNP N
cell NN N
activity NN N
following VBG N
abdominal JJ N
surgery NN N
PURPOSE VB N
The DT N
effects NNS N
of IN N
morphine NN N
on IN N
natural JJ N
killer NN N
NK NNP N
cell NN N
activity NN N
were VBD N
investigated VBN N
in IN N
patients NNS N
who WP N
underwent JJ 4_p
hysterectomy NN 4_p
METHODS NNP N
Forty NNP 3_p
patients NNS 3_p
were VBD 3_p
divided VBN 3_p
into IN 3_p
four CD 3_p
groups NNS 3_p
of IN 3_p
ten NN 3_p
The DT N
groups NNS N
received VBD N
intrathecal JJ N
0.5 CD N
mg NN N
morphine NN N
Group NNP N
IT0.5 NNP N
intrathecal JJ N
0.1 CD N
mg NN N
morphine NN N
Group NNP N
IT0.1 NNP N
or CC N
10 CD N
mg NNS N
morphine JJ N
i.v NN N
Group NNP N
IV NNP N
The DT N
remaining VBG N
ten JJ N
patients NNS N
served VBD N
as IN N
controls NNS N
and CC N
received VBN N
inhalation NN N
anesthesia NN N
alone RB N
Group NNP N
C NNP N
Blood NN N
samples NNS N
were VBD N
withdrawn VBN N
before RB N
and CC N
two CD N
hours NNS N
after IN N
surgery NN N
and CC N
on IN N
postoperative JJ N
days NNS N
one CD N
and CC N
two CD N
to TO N
determine VB N
the DT N
blood NN N
NK NNP N
cell NN N
activity NN N
using VBG N
a DT N
chromium NN N
release NN N
assay VBP N
with IN N
K562 NNP N
cells NNS N
as IN N
targets NNS N
plasma JJ N
catecholamines NNS N
and CC N
cortisol NN N
levels NNS N
The DT N
postoperative JJ N
pain NN N
score NN N
and CC N
side NN N
effects NNS N
were VBD N
studied VBN N
in IN N
the DT N
four CD N
groups NNS N
RESULTS NNP N
In IN N
Group NNP N
IT0.5 NNP N
the DT N
NK NNP N
cell NN N
activity NN N
was VBD N
lower JJR N
on IN N
postoperative JJ N
day NN N
1 CD N
23.9 CD N
+/- JJ N
8.4 CD N
than IN N
the DT N
baseline NN N
level NN N
45.7 CD N
+/- JJ N
13 CD N
before IN N
surgery NN N
and CC N
recovered VBD N
on IN N
postoperative JJ N
day NN N
2 CD N
In IN N
Groups NNP N
IT0.1 NNP N
C NNP N
and CC N
IV NNP N
the DT N
NK NNP N
cell NN N
activities NNS N
showed VBD N
no DT N
significant JJ N
changes NNS N
In IN N
all DT N
four CD N
groups NNS N
neither CC N
plasma JJ N
adrenaline NN N
nor CC N
noradrenaline JJ N
concentrations NNS N
changed VBD N
In IN N
all DT N
four CD N
groups NNS N
the DT N
plasma NN N
cortisol NN N
levels NNS N
increased VBN N
after IN N
surgery NN N
on IN N
postoperative JJ N
days NNS N
1 CD N
and CC N
2 CD N
The DT N
pain NN N
score NN N
was VBD N
lower JJR N
two CD N
hours NNS N
after IN N
surgery NN N
and CC N
on IN N
postoperative JJ N
day NN N
1 CD N
in IN N
Group NNP N
IT0.5 NNP N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
long-lasting JJ N
analgesic JJ N
effects NNS N
of IN N
intrathecal JJ N
0.5 CD N
mg JJ N
morphine NN N
suppress NN N
the DT N
immune JJ N
response NN N
following VBG N
abdominal JJ N
surgery NN N
